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Abstract 
 
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) has two stages to its life 
cycle; latency and lytic replication. KSHV latent infection is associated with the 
B-cell tumour, Primary Effusion Lymphoma (PEL). During latency the viral 
episome is maintained, few viral genes are expressed and no infectious virions 
are produced. The switch between phases is controlled by the viral transcription 
factor, RTA encoded by ORF50. Lytic replication, which results in the 
production of progeny virions, can be triggered by a variety of causes 
suggesting KSHV has the ability to reactivate in response to a multitude of 
scenarios. However, many of the stimuli described, to date, have no clear 
physiological relevance. 
 
This thesis investigates how cellular transcription factors can induce the KSHV 
lytic cycle. Firstly, a model system for monitoring KSHV lytic replication is 
developed and characterised. This system is then employed to demonstrate 
how the cellular transcription factor XBP-1s is able to induce KSHV reactivation. 
XBP-1 is responsible for the terminal differentiation of B-cells into plasma cells 
(PCs) and is a major regulator of the unfolded protein response (UPR). PEL do 
not express the transcription factor X-box binding protein-1 (XBP-1). When 
spliced active XBP-1s is supplied, PEL cells differentiate towards a PC and 
induce KSHV lytic replication. B-cell terminal differentiation is therefore a 
physiological trigger of KSHV lytic reactivation. To understand the role of host 
cell factors in this interaction further, the gene expression changes that occur 
when XBP-1s is supplied to PEL are also examined. Finally, we investigate the 
specific roles of XBP-1s and HIF-1α in the KSHV reactivation seen in response 
to hypoxia. We conclude that both B-cell differentiation and hypoxia are 
physiologically relevant triggers for KSHV lytic cycle induction, highlighting 
some of the many complex interactions between the virus and its host.  
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MCP Major capsid protein 
MFI Mean fluorescence intensity 
MHC Major histocompatibiity complex 
MHV-68 Murine gammaherpesvirus 68 
MIR Modulators of immune recognition 
mRNA Messenger RNA 
miRNA Micro RNA 
MITF Micropthalmia-associated transcription factor  
MK2 MAP K 2 
MM Multiple myeloma 
MOI Multiplicity of infection 
MTA mRNA transcript accumulation protein 
MTA3 Metastasis-associated 1 family member 3  
mTOR Mammalian target of Rapamycin 
MuHV-4 Murine herpesvirus 4 
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MVECs Microvascular endothelial cells 
MZ Marginal zone 
N2 Nitrogen 
NaBut Sodium butyrate 
NADPH Nicotinamide adenine dinucleotide phosphate 
NFκB Nuclear factor kappa B 
NFKBIZ 
Nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, zeta 
NHL Non-Hodgkin lymphoma 
NLS Nuclear localisation signal 
nm nanometre 
NO Nitric oxide 
NPC Nuclear pore complex 
NRF2 Nuclear factor erythroid 2 (NF-E2)-related factor 2  
N-TAD N-terminal transcriptional activation domain 
O2 Oxygen 
OAS 2'-5' oligoadenylate synthase 
Oct Octamer binding protein 
ODD Oxygen dependent degradation domain 
ORF Open reading frame 
Ori-Lyt Origin of lytic replication 
P/S Penicillin and streptomycin 
PAc Puromycin glycol 
PALS Periarteriolar lymphoid sheath 
PAN Polyadenylated nuclear transcript 
PARP Poly (ADP-Ribose) polymerase 
PAS Per-Arnt-Sim domain 
PAX5 Paired box protein 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PDI Protein disulphide isomerase 
PEG Polyethylene glycol 
PEL Primary effusion lymphoma 
PERK PKR-like ER kinase 
PF-8 Processivity factor 8 
PHD Prolyl hydroxylase 
PI3K Phosphatidylinositol-3-kinase 
PKA Protein kinase A 
PKC Protein kinase C 
PKR Double-stranded DNA dependent protein kinase 
PLDN Pallidin homolog 
PP1 Protein phosphatase 1 
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PPIB Peptidyl isomerise B 
Prdm1 Positive-regulatory-domain-containing 1 
pre-B-cells Precursor B-cell 
Pre-BCR Pre-B-cell receptor complex 
Pre-mRNA Precursor mRNA 
Pre-miRNA Precursor miRNA 
Pro-B-cells Progenitor B-cell 
PTB Polypyrimidine tract binding protein 
PTEN Phosphatase and tensin homolog 
PTP-1B Protein tyrosine phosphatise 1B 
RACK Receptor of activated protein kinase C 
RAG Recombinase-activating gene 
RAP Receptor associated protein 
Rb Retinoblastoma 
Rbl2 Rb-like protein 2 
RBP-Jκ Recombination-signal binding protein Ig Jκ region 
RDA Representational difference analysis 
redox Reduction-oxidation 
rev Reverse  
RFHV Retroperitoneal fibromatosis-associated herpesvirus  
RGD Arginine glycine aspartate domain 
RIG-I Retinoic acid inducible gene 1 
RIN RNA integrity number 
RIP Receptor Interacting protein 
RLU Relative light unit 
RNA Ribonucleic acid 
RNAi RNA interference 
RNase Ribonuclease 
ROS Reactive oxygen species 
rpm Revolutions per minute 
RPMI Roswell Park Memorial Institute 
RPN1 Ribophorin 1 
RRE RTA response element 
RRV Rhesus Rhadinovirus 
RT Reverse transcriptase 
RTA Regulator of transcription activation 
S1P Site 1 protease 
S2P Site 2 protease 
SDF-1 Stromal cell-derived factor-1 
SDR Thioltransferase dehydrogenase/reductase 
SDS Sodium dodecyl sulphate 
SFFV Spleen focus-forming virus 
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SHM Somatic Hypermutation 
shRNA Short hairpin RNA 
SIN Self-inactivating 
siRNA Small/short interfering RNAs 
SLC Surrogate light chain 
SNP Single nucleotide polymorphism 
SOX  Shutoff and exonuclease 
SP-1 Specificity protein 1  
SPC Signal peptidase complex 
SRP Signal recognition protein 
ssDNA Salmon sperm DNA 
SSR Signal sequence receptor 
STAT Signal transducer and activator of transcription 
SYK Spleen tyrosine kinase 
TAE Tris-acetate-EDTA 
Tat HIV tat 
TBE Tris borate EDTA 
TBS Tris buffered saline 
TBST TBS tween  
TCR T-cell receptor 
TdT Terminal deoxynucleotide transferase 
TE Tris-EDTA 
Th T- helper cell 
TLR Toll-like receptor 
TNF Tumour necrosis factor 
Topo Topoisomerase 
TPA 12-0-tetradecoylphorbol 13-acetate 
TR Terminal repeats 
TRAF Tumour necrosis factor receptor-associated factor 
TRAM1 Translocation associated membrane protein 1 
TRIM Tripartite motif containing protein 
tRNA Transfer RNA 
Ub Ubiquitin 
UC Ulcerative Colitis 
UCP Ub carrier protein 
UDG Uracil DNA glycosidase 
UK United Kingdom 
UPR Unfolded protein response 
UPRE UPR element 
USA United States of America 
UTR Untranslated region 
UV Ultra-violet 
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V Ig variable region 
V1/2 Variable region 1/2 
vBcl-2 Viral Bcl-2 
v-Cyc Viral cyclin 
VDP Vesicle docking protein 
VEGF Vascular endothelial growth factor 
vFLIP Viral FLICE inhibitory protein 
vGPCR Viral G-protein coupled receptor 
VHL Von Hippel Lindau 
vIL-6 Viral IL-6 
vIRF Viral interferon regulatory factor 
vMIP Viral macrophage inflammatory protein 
vOX-2 Viral OX-2 
VZV Varicella-Zoster virus 
WPRE 
Woodchuck hepatitis virus post-transcriptional regulatory 
element  
XBP-1 X-box binding protein-1 
XBP-1s Spliced XBP-1 
XBP-1u Unspliced XBP-1 
xCT Cysteine/glutamate transporter 
XRE XBP-1 response element 
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1 Introduction 
 
Viruses are ultramicroscopic, obligate intracellular parasites and therefore, by 
definition, are reliant on and intricately associated with the host cell for their 
replication. Through co-evolution, most aspects of virus biology are shaped by 
its interaction with the host, to allow continued success of these host dependent 
microorganisms. However, in the past, a new virus discovery was often followed 
by intense focus on disease association and the virus itself, often in isolation of 
the host, with emphasis given to the virus structure and viral genes encoded. 
Later, more in depth study revealed many important host-pathogen interactions 
including the interferon response and the use of cellular receptors for virus 
entry. More recently, the development and application of systems biology and 
genomic approaches have allowed these interactions to be investigated further 
(reviewed in (Peng et al., 2009) (Bailer and Haas, 2009)). These integrative 
methods can provide a multidimensional view of virus-host interactions. 
Problems to overcome include the development of models to make sufficiently 
accurate interaction predictions and the requirement of interdisciplinary 
collaborations. Despite this, these high-throughput techniques highlight the 
importance of studying viruses in the context of host infection. Studies have 
already demonstrated that different viruses adopt similar core interactions in 
order to by-pass or hi-jack the cellular machinery and responses (Fossum et al., 
2009). We have also seen how these interactions can inadvertently cause 
disease, for example the human herpesvirus Kaposi’s sarcoma-associated virus 
(see section 1.1.8) (Moore and Chang, 2003) (Dalton-Griffin and Kellam, 2009). 
Consequently, understanding virus-host interactions and their complexities has 
far reaching implications for translational research and drug discovery.   
 
1.1 Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) 
Kaposi’s Sarcoma-associated Herpesvirus (KSHV) (human herpesvirus 8; 
HHV8) is the aetiological agent of Kaposi’s Sarcoma (KS) (Chang et al., 1994), 
a malignancy that accounts for 10 % of all cancers in areas of sub-Saharan 
Africa and is the most common cause of cancer in African men (Schwartz et al., 
2008) (Hengge et al., 2002) (Parkin et al., 1999). Additionally, the B-cell 
lymphoproliferative disease primary effusion lymphoma (PEL) is also associated 
with KSHV infection (Cesarman et al., 1995), and represents 4 % of all acquired 
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immunodeficiency disease (AID) related non-Hodgkin lymphomas (Carbone and 
Gloghini, 2008).  KSHV is thus the most common cause of cancer among those 
with untreated HIV infection (Beral et al., 1990) (Boshoff and Weiss, 2002) 
(Casper and Wald, 2007). These diseases are most likely caused, 
unintentionally, by the mechanisms employed by KSHV to evade the host 
immune system and establish latency. These interactions, although necessary 
for virus propagation, can lead to cell proliferation and tumorigenesis in a 
susceptible individual. The entire life cycle of KSHV is intertwined with its host 
including both latent and lytic stages as well as, importantly for the topic of this 
thesis, the switch between the two phases, reactivation (Hayward, 1999).  
 
KSHV was discovered in 1994 by Chang et. al. using the technique of 
representational difference analysis (RDA) (Chang et al., 1994). This study 
indentified a potential infectious aetiology for the tumour of endothelial origin, 
Kaposi Sarcoma, originally described by Mauritz Kaposi in 1872 as an 
‘idiopathic multiple pigmented sarcoma of the skin’ (Kaposi, 1872). KSHV or 
human herpesvirus 8 (HHV8) is the eighth and most recently identified human 
herpesvirus.  
 
1.1.1 Herpesviruses 
There are currently 90 species of herpesviruses (order - Herpesvirales) 
recognised (www.ICTVonline.org), all are large double stranded DNA viruses 
with genomes typically between (125-290kb) and with a characteristic virion 
structure (Davison et al., 2009). These viruses are highly adapted to their host, 
often through millions of years of co-evolution (Hayward, 1999) and can be 
divided into three distinct family groups depending on the host range (McGeoch 
et al., 2006). The first group, Herpesviridae, contains those viruses infecting 
mammals, birds and reptiles naturally, the second group, Alloherpesviridae, 
infect amphibians and fish. Finally, the third group, Malacoherpesviridae, 
contains a single virus that infects the invertebrate bivalve molluscs (Davison et 
al., 2005). Herpesviruses have been historically identified by biological criteria, 
including cell tropism and replication cycle. As technology progressed, 
information concerning virus morphology and component parts became 
available and facilitated further categorisation. These details are used to divide 
the Herpesviridae into three subfamilies Alpha-, Beta-, and 
 25
Gammaherpesvirinae (Roizman et al., 1981) (McGeoch et al., 2006). 
Classification is now carried out using the additional information provided by 
sequence-based phylogeny, and new genera have been added to the 
Herpesviridae family. This update of taxonomy includes the addition of two new 
genera to the Gammaherpesvirinae subfamily as well as new taxa to the 
Alloherpesviridae group (Davison et al., 2009) (reviewed in (Davison, 2010)).  
 
The gamma-herpesviruses are characterised by a limited host range, 
lymphocyte tropism and sequence homology. KSHV is a gamma-2-herpesvirus 
(γ2-) and is the first member of the genus Rhadinovirus known to infect humans 
(Moore et al., 1996a) (Neipel et al., 1998). Rhadinoviruses have also been 
discovered in several animal species, including cattle, mice and primates 
(Rovnak et al., 1998) (Efstathiou et al., 1990). Phylogenetic analysis of the 
primate virus genomes has led to the identification of three separate 
Rhadinovirus lineages. Members of the first lineage are T-lymphotropic viruses 
infecting New World monkeys, including the archetypal Rhadinovirus, 
herpesvirus saimiri (HVS) and the closely related ateles herpesvirus (HVA). 
These viruses infect squirrel monkeys (Saimiri sciureus) and spider monkeys 
(Ateles geoffryi) respectively (reviewed in (Ensser and Fleckenstein, 2005)). 
Rhadinoviruses have also been identified in Old World primates such as 
chimpanzees (Greensill et al., 2000a), gorillas (Lacoste et al., 2000) and 
gibbons (Duprez et al., 2004). With the discovery of further primate 
Rhadinovirus genomes in African green monkeys (Greensill et al., 2000b) and 
Macaques (Desrosiers et al., 1997) it has been shown that there are two distinct 
lineages within the Rhadinoviruses that infect Old World monkeys. The first 
genogroup, RV1, is represented by KSHV and the retroperitoneal fibromatosis-
associated herpesvirus (RFHV) that can cause a rare disease in Macaques, 
reminiscent of KS (Rose et al., 1997) (Bruce et al., 2006). The second group, 
RV2, contains the rhesus Rhadinovirus (RRV) and the novel gibbon virus 
HyloRHV2, no human virus has yet been found in this sub-group (Rose et.al. 
KSHV International Conference 2009). The most closely related human virus to 
KSHV is Epstein-Barr virus (EBV) from the Lymphocryptovirus genus.  
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1.1.2 Human Herpesviruses 
Currently, there are eight identified human herpesviruses, all of which are 
associated with human disease (Table 1-1). Despite a considerable proportion 
of the population being infected with one or more herpesviruses, disease is 
usually only seen in the immunocompromised.  
 
Table 1-1 Human Herpesviruses and their disease associations 
Sub-
family 
Human 
herpesvirus 
Common name Disease associations 
α HHV-1 Herpes-simplex virus (HSV)-1 Oropharangeal herpes (cold sores) 
Genital herpes 
α HHV-2 Herpes-simplex virus (HSV)-2 Genital herpes 
α HHV-3 Varicella-Zoster virus (VZV) Varicella (chickenpox) 
Zoster (shingles) 
γ HHV-4 Epstein-Barr virus (EBV) Infectious mononucleosis 
Nasopharyngeal carcinoma 
Burkitt’s lymphoma 
Classical Hodgkin’s lymphoma 
β HHV-5 Human cytomegalovirus 
(HCMV) 
CMV-mononucleosis 
CMV disease 
β HHV-6a 
HHV-6b 
 Exanthem subitum (sixth disease) 
Roseola infantum 
Encephalitis 
β HHV-7  Exanthem subitum (sixth disease) 
Encephalitis 
γ HHV-8 Kaposi’s sarcoma-associated 
herpesvirus (KSHV) 
Kaposi’s sarcoma 
Primary effusion lymphoma 
Multicentric Castleman’s disease 
 
1.1.3 KSHV genome 
KSHV has a double stranded DNA (dsDNA) genome of 165 to 170 kilo bases 
(kb) (Renne et al., 1996a), consisting of a long unique region (LUR) 
approximately 140-145 kb in length which encodes all viral open-reading frames 
(vORFs) (Figure 1-1) (Russo et al., 1996). The LUR is flanked at each end by a 
series of non-coding GC-rich terminal repeats (TRs), which are 801 base pairs 
(bp) long. On average, isolates contain 20-25 (kb) of total TR DNA; however the 
number of repeats can range between 16-75; accounting for the variation seen 
in genome size between KSHV isolates (Lagunoff and Ganem, 1997). The 
genome exists as a circular dsDNA episome during latent KSHV infection 
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however, during lytic replication linear dsDNA genome is detected in 
reactivating cells and virions; by Gardella gel analysis (Renne et al., 1996a).  
 
Comparison of the genome organisation and gene content of five gamma-
herpesviruses, including KSHV, identified four major blocks of conserved genes 
(Nicholas et al., 1998). These genes are predominantly involved in replication or 
are structural components of the virus and many are also conserved in the 
alpha and beta-herpesviruses (Alba et al., 2001). There is also a high degree of 
similarity between the KSHV genome and the genomes of the primate viruses, 
retroperitoneal fibromatosis-associated herpesvirus (RFHV) and rhesus monkey 
Rhadinovirus (RRV). However, at the time of KSHV genome annotation the 
closest sequenced virus of the Rhadinovirus subfamily was herpesvirus saimiri 
(HVS). Therefore, many of KSHV’s >90 ORFs were named using the logical 
HVS nomenclature. Any ORF with no homology to a HVS gene was assigned a 
K followed by a number in consecutive order relating to its location.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 The KSHV Genome 
The KSHV genome is around 170 kb and consists of a ~140 kb long unique coding region 
(LUR) flanked by multiple GC rich ~800bp terminal repeats (TR, shown as red boxes). Distance 
along the LUR is shown in kb. Upon infection, the Kaposi’s sarcoma-associated herpesvirus 
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(KSHV) genome is delivered to the nucleus where it circularises into an episome. The TR 
regions are used to anchor KSHV episomes to the host chromatin and are therefore essential 
for latent replication. KSHV also contains two origins of lytic replication (Ori-Lyt-L and Ori-Lyt-R, 
(orange lines). During the latent programme, a small number of proteins are expressed (green 
arrows). ORFs encoded on the forward strand i.e. left-to-right are shown in black, while genes 
encoded on the opposite strand are shown in red. The position of the mIR cluster is shown by 
the blue line and shown in more detail in Figure 1-5. Adapted from (Cotter and Robertson, 
2002). 
 
Since this first characterisation additional ORFs have been described. The 
divergent regions of the KSHV genome contain more than 20 unique genes, 
and approximately a quarter of KSHV genes encode several proteins due to 
differential splicing or alternative promoter usage (Zheng, 2003). Several KSHV 
ORFs code for genes that have significant homology to cellular genes 
(Holzerlandt et al., 2002). These genes appear to have been ‘pirated’ by KSHV 
in order to manipulate host processes, for example a cyclin D2 homologue, v-
cyclin, ensures cell cycle progression (Cesarman et al., 1996) (see section 
1.1.12.3). More recently, the KSHV genome has been shown to produce non-
coding RNA, including a set of viral micro-RNAs which are expressed during 
latency (Cai et al., 2005) (Pfeffer et al., 2005) (Samols et al., 2005) (see section 
1.1.12.7) and the 1077 bp polyadenylated nuclear RNA (PAN) produced during 
lytic replication (Conrad and Steitz, 2005) (Sun et al., 1996). 
 
1.1.3.1 KSHV strain diversity 
Four major variants of KSHV have been identified by examining the levels of 
genetic variation between KSHV isolates from various locations around the 
World (Zong et al., 1999). Large parts of the KSHV genome are highly 
conserved, however several regions were shown to be highly variable primarily 
the ORFs K1 and K15. Analysis of the sequence variability of the K1 gene has 
facilitated the classification of KSHV isolates into the sub-types A, B, C, D and E 
(Hayward and Zong, 2007). General genome variation between clades is 
around 3 % however up to 15-30 % variation is seen in K1 at the nucleotide 
level, particularly in two hypervariable regions (V1 and V2) where as much as 
60 % variation is reported (Zong et al., 1999) (Zong et al., 2002). It is not clear 
what selection pressure is driving this sequence variation. However, epitopes 
for cytotoxic T-cells (CTLs) are present in the V1 region indicating CTL evasion 
may contribute to K1 evolution (Stebbing et al., 2003). Also the ability to interact 
with host intracellular signalling may be involved, as the immune-receptor 
tyrosine-based activation motif (ITAM)-like sequence in the cytoplasmic region 
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of K1 shows strong divergence between clades (Hughes and Hughes, 2007). 
Importantly, variants are stable within an individual host i.e. multiple clones 
sequenced from a single patient are identical. Sub-type correlates with 
geographical/ethnic origin of the host. Clades A and C are predominantly 
isolated from infected individuals in Europe, the United States, Asia and the 
Middle East, sub-group B strains are found principally in sub-Saharan Africa, 
while D and E strains are located primarily in south Asia, Australia, the Pacific 
and Brazilian Amerindians (Zong et al., 1999) (Cook et al., 1999) (Meng et al., 
1999) (McGeoch and Davison, 1999) (Biggar et al., 2000). From this information 
it can be inferred that KSHV is an ancient human virus which arose in Africa. 
The separation of sub-groups resulted from the isolation and founder effects 
associated with the several migrations of people from Africa (Hayward, 1999).  
 
Further diversity has been discovered in the region surrounding ORFK15. 
Variants are known as P (or prototype) or M (or minority) (Poole et al., 1999) 
and more recently two further variations were seen and designated N and Q 
(Zong et al., 2002). Only two of the KSHV sub-types, A and C, have these 
variations that are thought to arise from a recombination event with an unknown 
progenitor herpesvirus, which occurred after the first two waves of emigration 
from Africa (Zong et al., 1999).  
 
1.1.4 KSHV virion structure 
Herpesvirus architecture is distinct from all other viruses. The linear double 
stranded DNA genome is packaged as a torus, and encased in an icosahedral 
capsid composed of 162 capsomeres resulting in a diameter of 115-130 nm 
(Furlong et al., 1972) (Wu et al., 2000a). Surrounding the nucleocapsid is the 
tegument, an organised layer composed of various protein species that appears 
to mirror the shape of the capsid (Zhou et al., 1999). The outer layer of the virus 
is a lipid bilayer envelope, embedded with viral proteins that are usually 
glycosylated (Skepper et al., 2001) (see Figure 1-2).  
 
Recent examination of the protein composition of the KSHV virion has revealed 
that both host and viral proteins are incorporated into the tegument during viral 
egress (Bechtel et al., 2005b) (Zhu et al., 2005). These proteins include the viral 
transactivator of lytic replication, RTA, and are thought to be responsible for the 
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very early events of virus infection. Host proteins found in the virion included the 
abundant chaperone Hsp90, actin and tubulin. Whether any protein is actively 
incorporated or simply included during the budding and envelopment process, 
remains to be determined. This may also apply to the 11 viral messenger RNAs 
(mRNAs) also shown to be present in the KSHV virion (Bechtel et al., 2005a). 
However, one incorporated transcript ORF17, encoding viral protease, was 
detected in the cytosol at lower levels than other un-incorporated controls; 
indicating a possible selective mechanism of inclusion. At least one of the 
transcripts, ORF59, was also shown to be translated. Many of the products of 
these RNAs have anti-apoptotic and immune-modulatory functions that can 
adapt the host cell environment for infection. The presence of RTA protein and 
viral mRNA, encoding predominantly lytic products, in the virion could 
potentially explain the burst of viral lytic genes seen immediately after infection 
(Krishnan et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 Morphology of the KSHV virion 
(A) Cartoon of a herpesvirus virion structure. KSHV shares the same morphology and structure 
as other members of the herpesvirus family. Herpesviruses are surrounded by a lipid membrane 
(envelope), which is studded with virus glycoproteins (not shown to scale). Within this is a 
protein layer known as the tegument. The final layer is the capsid, an icosahedral protein shell 
that contains the virus genome packaged as linear double stranded DNA. Taken from 
stdgen.northwestern.edu.(B) Radially coloured surface representation of an averaged KSHV 
capsid showing the characteristic herpesvirus capsomers, including an ‘‘umbilical’’ portal, 11 
pentons and 150 hexons. Adapted from (Deng et al., 2008).  Bar, 200 Å.  
 
The KSHV capsid was revealed by cryo-electron microscopy (cryoEM) 
reconstruction to have a T-16 icosahedral structure with 20 triangular faces. The 
capsomers are composed of hexamers (hexons) and pentamers (pentons) of 
the major capsid protein (MCP/ORF25). A capsid is comprised of 150 hexons 
and 12 pentons, connected by 320 triplexes composed of an ORF62 monomer 
and a ORF26 dimer arranged in a lattice (Figure 1-2 B) (Wu et al., 2000a). 
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Recently, studies using cryo-electron topography (cryoET) have allowed the 
study of individual KSHV capsids to obtain structural information that is not 
averaged over a population (Deng et al., 2008). Comparison of the structures 
and their scaffold cores have led to a mechanistic model for herpesviral capsid 
assembly and maturation (see section 1.1.5). 
 
1.1.5 KSHV assembly and maturation 
The crucial steps in herpesvirus morphogenesis have been predominantly 
studied in viruses such as herpes simplex virus (HSV). However, within the 
family Herpesviridae the alpha, beta and gamma subfamilies have similar virion 
morphology suggesting virion assembly and maturation occurs via comparable 
mechanisms (Mettenleiter, 2004) (detailed review in (Mettenleiter et al., 2009)). 
Despite this there is considerable variation between the herpesviruses and 
further work is required to determine the exact mechanism for each virus that 
will incorporate the unique genes and their specific functions. Herpesviruses 
have complicated and highly structured virus particles which include both viral 
and cellular proteins (see section 1.1.4) (Bechtel et al., 2005b) (Bechtel et al., 
2005a) (Zhu et al., 2005). A study of the protein-protein interactions between 
virion-associated KSHV proteins identified a total of 37 interactions between 
capsid and tegument proteins and between tegument proteins, as well as 
between tegument and glycoproteins; providing evidence that the virus particle 
is constructed through highly specific interactions (Rozen et al., 2008).  
 
The first step in general herpesvirus virion assembly is nucleocapsid formation, 
an autocatalytic process that occurs in the nucleus. Capsid proteins build 
around scaffold proteins to form a pro-capsid (Newcomb et al., 1996). The 
procapsid then undergoes angularisation, catalysed by viral proteases, which 
results in a capsid with T-16 icosahedral symmetry (Trus et al., 1996). Distinct 
capsid intermediates can be seen using cryo-EM technology, profiling the 
mechanism of viral capsid assembly and maturation (Deng et al., 2008). Newly 
replicated herpesviral DNA is then cleaved and encapsulated through a portal 
channel, a process similar to that of dsDNA bacteriophage packaging 
(Newcomb et al., 2001) (Deng et al., 2007).  
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Herpesvirions complete their morphogenesis via acquisition of tegument and a 
‘two-step envelopment’ process (Skepper et al., 2001). The first step is nuclear 
egress and is governed by highly conserved proteins; this involves primary 
envelopment of the capsid via budding through the inner nuclear membrane 
(Fuchs et al., 2002) (Gonnella et al., 2005). Capsids then gain access to the 
cytoplasm via budding through the outer nuclear membrane ‘de-envelopment’. 
Processes that occur in the cytoplasm are less well conserved and are complex 
due to the large number of proteins involved, in addition to a degree of 
redundancy. Tegumentation occurs via the interaction of viral proteins at two 
sites, proximal to the capsid and at the future envelopment site, which combine 
to form a highly ordered network surrounding the capsid (Mettenleiter, 2006). 
The composition of tegument varies and major changes can occur without 
significant cost to infectivity.  Finally, secondary envelopment through the trans-
Golgi network is driven by protein interactions between the two ‘subassemblies’ 
of tegument. At this stage glycoproteins are acquired leading to the formation of 
a mature virus particle, which fuses with the plasma membrane and is released 
(Turcotte et al., 2005). Herpesvirus virion assembly therefore occurs in both the 
nucleus and the cytoplasm and consists of two distinct budding and fusion 
events. The first at the nuclear membrane and the second though the trans-
Golgi network to the plasma membrane and out of the cell.  
 
1.1.6 Cell tropism 
Gamma-herpesviruses are lymphotropic (Neipel et al., 1998). KSHV DNA has 
been detected in CD19+ B-cells and is associated with two B-cell 
lymphoproliferative diseases, PEL and MCD (see section 1.1.8) (Ambroziak et 
al., 1995) (Harrington et al., 1996) (Mesri et al., 1996) (Campbell et al., 2005) 
(Dupin et al., 1999). KSHV infection has also been found in peripheral blood 
monocytes as well as the infiltrating monocytes and endothelial (spindle) cells of 
KS lesions (Blasig et al., 1997) (Monini et al., 1999) (Boshoff et al., 1995). 
However, infection of primary or transformed B-cells in vitro is very inefficient 
(Renne et al., 1998) (Blackbourn et al., 2000b) (Bechtel et al., 2003) (Mesri et 
al., 1996) (Kliche et al., 1998) (Gasperini et al., 2005). The reason for the lack of 
infectivity of B-cells in vitro is not understood as B-cells are the principal KSHV 
infected cell in peripheral blood. However, a recent study has indicated the 
requirement of an activated phenotype and the expression of potential co-
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receptors such as the dendritic-cell (DC)-specific intercellular adhesion 
molecule 3-grabbing non-integrin (DC-SIGN; CD209) for B-cell infection 
(Rappocciolo et al., 2008).   
 
Recently, oral epithelial cells have been proposed as a target cell for primary 
KSHV infection (Duus et al., 2004). Further study using models for keratinocyte 
differentiation have shown that, like other viruses such as human papillomavirus 
(HPV), KSHV lytic-gene expression is activated in response to epithelial 
differentiation and results in the production of infectious virions at the epithelial 
surface. KSHV DNA and infectious virions have also been found in the saliva 
indicating saliva exchange as an important route of KSHV transmission 
(Boldogh et al., 1996) (Pauk et al., 2000) (Vieira et al., 1997) (see section 
1.1.7). KSHV lytic reactivation has been linked to B-cell differentiation into 
plasma cells via the transcription factor XBP-1; if this occurs at the oral mucosal 
surfaces then KSHV may be shed into saliva and spread to the epithelium 
(Wilson et al., 2007). This suggests that B-cells are the latent reservoir for 
KSHV infection in vivo, when triggered to differentiate KSHV is produced and 
infects the oral mucosa and the lymphoid tissue of the Waldeyer’s ring; leading 
to virus shedding into the saliva (Longworth and Laimins, 2004) (Johnson et al., 
2005a) (Pauk et al., 2000) (Chagas et al., 2006). Most cases of primary KSHV 
infection are asymptomatic and recognised only by the presence of antibody to 
viral proteins. The initial infection of children and immunocompromised adults 
however, often leads to a burst of viraemia, which can cause a febrile illness 
and lymphadenopathy (Wang et al., 2001b) (Kasolo et al., 1997).  
 
In vitro, KSHV infects more than 20 cell types of both human and non-human 
origin, including those known to be infected in vivo, and a range of adherent cell 
lines including human fibroblasts, 293 cells, microvascular endothelial cells 
(MVECs), human umbilical vein endothelial cells (HUVECs), rat endothelial cells 
and mouse fibroblasts (Blackbourn et al., 2000b) (Renne et al., 1998) (Bechtel 
et al., 2003) (Flore et al., 1998). Infection of these cells predominantly leads to 
latency, and many cell lines can be cultured for a significant period of time 
(Vieira et al., 2001) (Vieira and O'Hearn, 2004). In general, KSHV in established 
cell lines responds only weakly to reactivation stimuli. Therefore, these cell lines 
cannot be used to produce high titre KSHV virus. However, addition of the viral 
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regulator of transcription activation (RTA) does lead to lytic replication in many 
of these cell lines, indicating the block to reactivation in these cell lines is at the 
induction of expression of RTA (Bechtel et al., 2003).  Of the many cell types 
infected MVECs have proven the most useful as an experimental system. This 
is due to the fact that MVECs are thought to be a precursor cell type for KS 
lesions, and they are frequently latently infected with a small spontaneous lytic 
population, a situation similar to in vivo conditions (Ciufo et al., 2001).  
 
Despite the potential of the MVEC system and PEL cell lines (see section 
1.1.8.2), the study of lytic replication, immune responses and pathology are still 
impeded by the lack of lytic replication in vitro and the absence of an animal 
model for KSHV infection and its associated diseases (Renne et al., 1998) 
(Mutlu et al., 2007) (reviewed in (Chang et al., 2009) (Parsons et al., 2006)). A 
recent study has shown successful infection of a new world primate, the 
common marmoset, and has identified persistent infection as well as possibly 
KS-like disease (Chang et al., 2009). This will facilitate further investigation into 
host-viral interactions in the context of an intact host immunity.  
 
1.1.7 Epidemiology and transmission 
KSHV prevalence can be divided by geographic location and by HIV risk groups 
(reviewed in (Bagni and Whitby, 2009)). In regions such as North America, 
North Europe and Asia the prevalence of KSHV in the population is low, 
between 1- 7 % (Gao et al., 1996b) (Pellett et al., 2003) (Simpson et al., 1996). 
Intermediate levels of KSHV prevalence of around 5-25 % are seen in the 
Mediterranean, Middle East and the Caribbean (Calabro et al., 1998) (Serraino 
et al., 2001). The highest levels of KSHV seropositivity are seen in sub-Saharan 
Africa and the Amazon basin where greater than 50 % of the population are 
thought to be infected (Sitas and Newton, 2001) (Engels et al., 2000). The 
incidence of Kaposi Sarcoma (KS) is correlated with KSHV seroprevalence. The 
transmission and risk factors for KSHV infection are not completely understood, 
however the different epidemiology in these regions indicates two major routes 
of infection, sexual and non-sexual contact.  
 
In low-prevalence areas, including Western Europe and the USA, sexual 
transmission is thought to be the predominant route of transmission. In these 
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regions children, before sexual maturity, are seronegative while the risk of 
conversion increases with age. KSHV is frequent in homosexual men and 
peaked during the AIDS epidemic, where seroprevalence was reported to be 
between 25-60 % (Simpson et al., 1996) (Chatlynne et al., 1998) (Dukers et al., 
2000). A clear link between the number of sexual partners and risk of KSHV 
indicates transmission via sexual contact in this group (Martin et al., 1998) 
(Martro et al., 2007). Interestingly, in low-prevalence areas seroprevalence in 
women is lower than in men, highlighting heterosexual practices as an 
inefficient route of KSHV transmission (Kedes et al., 1997a) (Smith et al., 1999) 
(Engels et al., 2007) (de Sanjose et al., 2009). Parenteral transmission appears 
to play a small part in KSHV epidemiology as the prevalence is much lower than 
other viruses that are known to be transmitted via this route, HIV, HBV, HCV 
(Renwick et al., 2002) (Atkinson et al., 2003) (Zavitsanou et al., 2010). Cases of 
KSHV infection in the recipients of blood transfusions have been reported, 
suggesting donors should be screened (Hladik et al., 2006). However, due to 
limited resources depleting blood of leukocytes or storing the blood before use 
would reduce the risk of transmission. An increased risk of developing KS is 
associated with transplantation, this is primarily due to reactivation of KSHV in 
immune-suppressed KSHV positive recipients, but can be caused by 
transmission from seropositive donor to seronegative recipient (Luppi et al., 
2000) (Cattani et al., 2001) (Barozzi et al., 2003) (Frances et al., 2009).  
 
In the high-prevalence areas such as sub-Saharan Africa and the Amazon 
basin, the epidemiology is starkly different with infection occurring more often at 
childhood, and with equal seroprevalence amongst adult men and women 
(Sarmati, 2004) (Klaskala et al., 2005). The high numbers of childhood infection 
highlights a non-sexual route of transmission, presumably through salivary 
exchange as there is no evidence for transmission through breast milk and 
congenital infection occurs rarely (Brayfield et al., 2004) (Mantina et al., 2001). 
In children KSHV is therefore acquired horizontally via intra-familial contact 
(Plancoulaine et al., 2000) (Dedicoat et al., 2004) (Malope et al., 2007). It was 
also shown that HIV co-infection leads to a highly significant increased risk of 
childhood KSHV infection (Minhas et al., 2008). Seroprevalence rises gradually 
after puberty to mid-adulthood, reflective of poor heterosexual transmission 
(Baeten et al., 2002) (Eltom et al., 2002). KSHV is however found at low levels 
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in genital secretions suggesting that heterosexual transmission is possible 
although highly debated (Calabro et al., 1999) (Howard et al., 1997) (Diamond 
et al., 1997) (Taylor et al., 2004).  
 
The majority of herpesviruses are transmitted via saliva and are acquired early 
in childhood leading to a large proportion of seropostive adults. KSHV virions 
are most readily detected in the saliva indicating a role in transmission (Pauk et 
al., 2000) (Vieira et al., 1997). Despite this, the prevalence of KSHV in some 
areas is far lower than other herpesviruses EBV, HCMV, HHV6 and 7, which 
are almost ubiquitous in the adult human population (reviewed in (Iscovich et 
al., 2000)). An exception is in South America among the Amerindians where 
KSHV is hyper-endemic, with 79 % of the population infected likely through oral-
transmission routes (de Souza et al., 2007). Non-Amerindians living in the same 
region displayed only 6 % seropositivity indicating that the factors contributing to 
KSHV transmission in this population are more associated with behaviour or 
genetic susceptibility to infection rather than environmental factors. However, 
the vast geographical differences in KSHV prevalence must be in part due to 
environmental co-factors. Studies in Italy and northern Sweden suggest that 
biting insects may play a role in transmission, as insect bites may be licked in 
order to sooth pain, exposing the wound to infected saliva (Coluzzi et al., 2002) 
(Ascoli et al., 2006). A Ugandan study reported the source of water as a risk 
factor for KSHV infection among other socioeconomic factors (Mbulaiteye et al., 
2005). Finally, a screen of naturally occurring compounds for their ability to 
induce KSHV reactivation led to the identification of plant products used in 
traditional medicines by some cultures; thus exposure may increase shedding 
(Whitby et al., 2007). Together these findings indicate that the transmission of 
KSHV is dependent on a combination of both environmental and genetic 
factors.  
 
1.1.8 KSHV-associated disease 
Diseases associated with KSHV infection occur predominantly in the immune-
suppressed and is important to remember that KSHV infection most frequently 
occurs without causing disease. 
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1.1.8.1 Kaposi Sarcoma (KS) 
Kaposi Sarcoma (KS) is a highly vascular, non-classical tumour, composed 
predominantly of KSHV-infected cells; the spindle cells (Boshoff et al., 1995) 
(Ensoli et al., 2001a) (Schwartz et al., 2008) (Gessain and Duprez, 2005). 
These spindle cells are named according to their morphology, can be 
oligoclonal and are of endothelial origin but poorly differentiated (Gill et al., 
1998) (Judde et al., 2000) (Duprez et al., 2007). KS spindle cells express 
molecular markers of two closely related cell types; including CD31 and CD36 
present on blood vessel endothelial cells (BECs), as well as markers of 
lymphatic endothelial cells (LECs), VEGF-R3 and podoplanin, making it difficult 
to identify the precursor cell type of KS (Regezi et al., 1993) (Dupin et al., 1999) 
(Beckstead et al., 1985) (Staskus et al., 1997) (Weninger et al., 1999). More 
recently, studies have reported that the spindle cells of KS-lesions have a 
similar gene expression profile to LECs (Wang et al., 2004a). In addition latent 
KSHV infection of BECs has been shown to cause reprogramming and the 
induction of lymphatic lineage-specific genes (Carroll et al., 2004) (Hong et al., 
2004b) (Hansen et al., 2010).  
 
KS is also characterised by the presence of infiltrating macrophages, plasma 
cells and T-lymphocytes. Lesions are interspersed with slit-like neovascular 
spaces, which are not lined by smooth muscle or pericytes and are therefore 
susceptible to leakage (Dupin et al., 1999). Clinically, KS presents as reddish 
brown lesions of the dermis, found cutaneously, mucosally or viscerally. The 
colour is due to the breakdown of erythrocytes that enter the lesion via the weak 
neo-vasculature. KS development can be staged into 6 overlapping forms: 
patch, plaque, nodular, lymphadenopathic, infiltrative and florid (Wen and 
Damania, 2009). As the lesion progresses, the ‘driving’ KSHV infected spindle 
cells gradually predominate, indicating a growth/survival advantage (Boshoff et 
al., 1995) (Staskus et al., 1997) (Dupin et al., 1999).  KS derived cells do not 
display all the traits of transformed cells. In general, they lack aneuploidy, 
cannot grow in soft agar and when injected into nude mice do not form tumours, 
but survive briefly to encourage neovascularisation (Salahuddin et al., 1988). 
These cells also continue to require exogenous factors for growth (Ensoli and 
Sturzl, 1998) (Marchio et al., 1999). Intriguingly, many viral lytic pro-
inflammatory and angiogenic gene products may be involved in the paracrine 
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stimulation of sarcomagenesis (reviewed in (Hayward, 2003)).  This highlights 
the importance of a small spontaneous lytic population of KSHV infected cells in 
KS (Parravicini et al., 2000) (Katano et al., 2000).  
 
KSHV was identified from KS biopsies in 1994; since then the evidence for its 
involvement in KS development has been obtained (Chang et al., 1994). Firstly, 
KSHV viral DNA and antigens have been found in nearly all KS spindle cells but 
are absent in surrounding healthy tissues (Boshoff et al., 1995) (Huang et al., 
1995) (Moore and Chang, 1995) (Dupin et al., 1999).  Secondly, KSHV infection 
occurs prior to onset of AIDS-KS and viral load can be used to predict risk of KS 
development (Moore et al., 1996b) (Whitby et al., 1995) (Renwick et al., 1998). 
Thirdly, prophylactic treatment with anti-herpetics (e.g. ganciclovir) can reduce 
the risk of developing KS (Martin et al., 1999) (Robles et al., 1999) (Casper and 
Wald, 2007). In addition the KSHV present in advanced lesions is monoclonal 
indicating that infection occurs before sarcomagenesis (Judde et al., 2000). 
Finally, the expression of the viral homolog of a G-protein coupled receptor 
(GPCR) in mouse endothelial cells, in vivo, causes angioproliferative tumours 
reminiscent of KS, highlighting the oncogenic potential of KSHV encoded genes 
(Montaner et al., 2003). The role of KSHV in KS development is complex and 
involves both latent and lytic genes, many of which are pirated versions of 
cellular genes. The oncogenic potential of latently encoded genes can lead to a 
cellular growth advantage, which in combination with paracrine signals 
expressed during the lytic cycle can cause hyperproliferation and transformation  
(see sections 1.1.12 and 1.1.13 (reviewed in (Schulz, 2006) (Ganem, 2006) 
(Martin and Gutkind, 2008) (Ganem, 2010)).  
 
Lytic gene involvement in KSHV-associated disease pathogenesis is further 
complicated by the cytotoxicity of lytic replication. Therefore, if a gene is to 
contribute to disease progression, for example via a paracrine mechanism such 
as vGPCR upregulation of VEGF, then substantial lytic replication would be 
required. This is in fact what is seen as higher viral loads are detected in those 
with disease (Campbell et al., 2000) (Quinlivan et al., 2002). It is also necessary 
to circumvent the shut off of host gene expression mediated by another KSHV 
lytic gene product SOX, although this is not thought to be complete (see section 
1.1.13). 
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On the basis of epidemiology KS can be divided into four distinct forms: 
classic/sporadic, endemic/African, AIDS-related/epidemic and post-
transplant/iatrogenic (reviewed in (Schwartz et al., 2008)). Moritz Kaposi first 
identified classic KS in 1872. This form occurs predominantly in the elderly male 
population of the Mediterranean, Eastern Europe and Arab nations as well as 
those of Jewish ancestory.  This indolent form usually presents as lesions in the 
lower and upper extremities without lymph node and internal organ involvement 
(Iscovich et al., 2000). Endemic KS is also known as African KS because it is 
commonly seen in Central and East African countries. This type of KS can be 
indolent or aggressive (lymphadenopathic), although the latter is more often 
found in children and has high fatality rates. The most frequent and aggressive 
form of KS is AIDS-related and can include lymph node and visceral spreading. 
High HIV viral load has been associated with increased KS risk, while the 
number of KS cases reported after the initiation of highly active antiretroviral 
therapy (HAART) decreased (Gates and Kaplan, 2002b) (Gates and Kaplan, 
2002a). KS regression is also seen after HAART (Cattelan et al., 2001). Due to 
the strong association with HIV infection and AIDS outlined above, KS was 
identified as an AIDS-defining illness in the mid 1980s (Mbulaiteye et al., 2003). 
The role HIV infection plays in KS development is unclear, the HIV tat protein 
has been shown to encourage KS development as well as inducing KSHV lytic 
replication, possibly disseminating virus to endothelial cells, again increasing 
risk of KS (Harrington et al., 1997) (Varthakavi et al., 2002). HIV-associated 
immunodeficiency may also play a key role, as this inhibits the host’s ability to 
control KSHV lytic replication, again increasing the number of endothelial cells 
infected. This assumption is supported by the final type of KS, post-transplant, 
which is also associated with immune-suppression, although drug-induced, and 
can originate from KSHV infected donor cells (Barozzi et al., 2003). This link to 
immunodeficiency also highlights another important aspect of KS, in that KSHV 
is necessary but not sufficient for KS development and cofactors are also 
required (Calabro et al., 1998). The fact that the risk of KS is low even in areas 
of high prevalence illustrates this point. For example, most of the KS cases 
reported in Africa are in East and Central regions despite high seroprevalence 
in other areas (Cook-Mozaffari et al., 1998).   
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1.1.8.2 Primary Effusion Lymphoma (PEL) 
PEL is a rare and aggressive form of non-Hodgkin lymphoma (NHL) associated 
with KSHV infection, and found predominantly in late stage AIDS patients 
(Cesarman et al., 1995) (Nador et al., 1996) (Knowles, 2003) (reviewed in 
(Carbone et al., 2010)). The disease is primarily characterised by a 
lymphomatous effusion in the serous cavities including the pericardium, 
pleurum and peritoneum, however lymph node and solid organ involvement is 
sometimes seen (Chadburn et al., 2004) (Carbone et al., 2005). Although most 
cases are observed in the AIDS-related immune-deficient environment, AIDS-
unrelated cases have been reported and are clinically identical but tend to 
develop later in life (Carbone et al., 1996). PEL has also been found in 
association with iatrogenic immune-suppression linked to solid organ transplant 
(Kapelushnik et al., 2001) (Boulanger et al., 2008).  
 
The origin of PEL cells was difficult to determine due to the absence of classical 
B-cell markers such as CD19, however analysis of immunoglobulin (Ig) 
rearrangements confirmed not only a B-cell origin but also that PEL is a clonal 
malignancy, suggesting latent infection occurs before PEL develops (Nador et 
al., 1996). PEL predominantly have somatically hypermutated Ig genes 
indicating a post-germinal centre origin (Matolcsy et al., 1998) (Arvanitakis et 
al., 1996) (see section 1.4.2). PEL cells do not have Ig on their surface or 
produce Ig for secretion, partly due to the absence of B-cell specific members of 
the POU family of transcription factors, Oct-2 and OCA-B (Di Bartolo et al., 
2009). PEL do express B-lymphocyte induced maturation protein-1 (BLIMP-1) 
and the cleaved form of activating transcription factor-6 (ATF-6) but express the 
inactive form of the transcription factor, X-box binding protein-1 (XBP-1) (see 
section 1.4.4). This transcription factor profile indicates that PEL represent a 
pre-terminal, plasmablastic stage of B-cell differentiation, which has been 
previously indicated by gene expression profiling (Wilson et al., 2007) (Jenner 
et al., 2003) (Klein et al., 2003) (Carbone et al., 2001) (see section 1.4.5). PEL 
cells express syndecan-1 (CD138), a marker of pre B-cells and plasma cells 
which is not expressed on any other lymphomatous effusion and can therefore 
be used for clinical diagnosis (Gaidano et al., 1997).  
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Evidence for the contributing role of KSHV in PEL development is attributed to 
the identification of approximately 2-200 viral DNA episomes in all PEL cells 
(Cesarman et al., 1995) (Dupin et al., 1999). EBV is also reported in 70 % of 
PEL cases and may be involved in tumour progression after the germinal centre 
reaction, although little or no expression of EBV transforming genes are 
detected in PEL (Horenstein et al., 1997) (Szekely et al., 1998) (Gaidano et al., 
2000). Comparisons of the gene expression profiles of PEL with KSHV negative 
lymphomas identify many differentially expressed genes, while comparisons of 
EBV positive and negative PEL have shown only subtle differences (Hamoudi et 
al., 2004) (Klein et al., 2003) (Fan et al., 2005). This work identifies the 
dominant role of KSHV in PEL. PEL cell survival has been shown to depend on 
the expression of KSHV latent genes, again highlighting the association 
between KSHV infection and this disease (Guasparri et al., 2004) (Godfrey et 
al., 2005) (Wies et al., 2008). Despite this clear correlation PEL occurs very 
rarely even in endemic KSHV areas. Cases of KSHV negative, EBV negative 
PEL have been reported and can be associated with HCV and liver cirrhosis 
(Kobayashi et al., 2007) (Hara et al., 2001).  
 
KSHV is therefore a risk factor for PEL development and like other DNA tumour 
viruses, further transforming events must occur. In PEL, the BCL-6 gene is 
often mutated and chromosome abnormalities are also seen such as trisomy 7 
and 12, however; no abnormality is common to all cases indicating the 
importance of KSHV infection (Gaidano et al., 1999) (Gaidano et al., 2000) 
(Wilson et al., 2002). The immune-system also has a key role in controlling this 
disease as HIV patients on HAART have a better clinical prognosis, and 
efficient tumour formation is observed when PEL cells are supplied to nude 
mice (Boulanger et al., 2005) (Picchio et al., 1997).  
 
How KSHV directly contributes to this B-cell malignancy is not completely 
understood, and as yet infection of primary B-cells is inefficient and does not 
lead to transformation (see sections 1.1.12 and 1.1.13) (reviewed in (Schulz, 
2006)) (Rappocciolo et al., 2008). However, PEL cells readily grow in culture 
providing the first and most robust system for studying KSHV infection 
(Arvanitakis et al., 1996) (Gaidano et al., 1996) (Renne et al., 1996a) (Renne et 
al., 1996b) (Boshoff et al., 1998). In this system KSHV is predominantly latent 
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(see section 1.1.12) with less than 1 % of cells entering the lytic cycle, unless 
induced to reactivate, and has therefore been fundamental in facilitating the 
study of KSHV (Miller et al., 1997) (Shaw et al., 2000) (Parravicini et al., 2000) 
(Katano et al., 2000).  
 
1.1.8.3 Multicentric Castleman’s Disease (MCD) 
MCD is an unusual lymphoproliferative disorder of plasmablast cells 
characterised by lymphadenopathy, splenomegaly, fever and weight loss 
(reviewed in (Waterston and Bower, 2004) (Stebbing et al., 2008)). The plasma 
cell variant of MCD occurs predominantly in AIDS patients and is frequently 
linked to KSHV infection (Soulier et al., 1995) (Dupin et al., 2000). KSHV DNA 
is detected predominantly in plasmablasts located in the mantle zone regions of 
germinal centres in all HIV-associated cases of MCD and between 40-50 % of 
those unrelated to HIV infection (Soulier et al., 1995) (Luppi et al., 1996) (Dupin 
et al., 1999) (Parravicini et al., 2000). HAART in combination with 
chemotherapy has lengthened the life expectancy of MCD patients, probably 
more indicative of fewer opportunistic infections rather than an effect on MCD 
as chemotherapy is required to prevent reoccurrence of MCD (Aaron et al., 
2002).  
 
The KSHV positive cells are lambda light chain restricted, for as yet unknown 
reasons, but are polyclonal as monitored by the Ig rearrangements as well as 
KSHV TR regions (Du et al., 2001) (Judde et al., 2000). KSHV positive 
plasmablasts are not co-infected with EBV, and probably result from KSHV 
infection of naive B-cells (Murray et al., 1995) (Dupin et al., 1999) (Du et al., 
2001) (Chadburn et al., 2008). KSHV viral load and cytokines, for example vIL-
6, have also been reported to contribute to the disease state, MCD 
(Oksenhendler et al., 2000). A proportion of KSHV infected cells of MCD 
undergo lytic replication and may be responsible for the pathology and severity 
of the disease (Parravicini et al., 2000) (Katano et al., 2000) (reviewed in 
(Schulz, 2006)). The use of anti-virals has led to a reduced frequency of acute 
symptoms in MCD patients again linking KSHV to the pathogenesis of this 
disease (Casper et al., 2004). When used in combination with rituximab 
treatment, which depletes CD20 B-cells, a possible increase in remission of 
MCD may be seen (Gerard et al., 2007). 
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1.1.8.4 KSHV-associated disease treatment 
The predominantly latent KSHV infection of KS and PEL tumour cells prevents 
the use of anti-herpetics that target lytic replication (Boshoff et al., 1995) (Dupin 
et al., 1999) (reviewed in (Klass and Offermann, 2005)). In contrast, the KSHV 
lytic population of the cells in MCD is far higher, and treatment with anti-virals 
has proved successful (Parravicini et al., 2000) (Casper et al., 2004). Therefore, 
as described with KS, inducing lytic replication in PEL cells could make anti-
herpetic drugs, such as ganciclovir, useful therapeutic agents in treating this 
neoplasm (Martin et al., 1999). The inhibition of lytic replication may also be 
fundamental in reducing the risk of disease. Lytic replication in infected B-cells 
is thought to be required for transmission to endothelial cells, which may initiate 
KS development (Whitby et al., 1995) (Song et al., 2004). Since the 
pathogenesis associated with KSHV-related disease, especially in KS, has 
been linked to lytic gene products, this may also be challenged by a therapy to 
inhibit lytic replication (Montaner et al., 2003).  The potential of exploiting the 
lytic cycle as a therapeutic target indicates the importance of indentifying the 
stimuli that cause KSHV reactivation. A better comprehension of host-virus 
interactions may lead to new strategies for controlling and perhaps eliminating 
the KSHV latent infection associated with malignancies.   
 
A drug for possible use in the treatment of PEL is valproic acid (or valproate), a 
histone deacetylase inhibitor commonly used in the treatment of seizures and 
other neurological disorders. Valproate can reactivate latent KSHV at 
concentrations similar to plasma concentration after chronic oral treatment 
(Shaw et al., 2000). Used in combination with ganciclovir, valproate can block 
KSHV lytic replication and induce apoptosis of PEL cells in vitro (Klass et al., 
2005). The clinical use of this strategy has also been demonstrated in a patient 
suffering from post-transplant lymphoproliferative disease, a B-cell neoplasm 
associated with EBV. Arginine-butyrate was used to induce EBV lytic 
replication, which was then blocked by the administration of ganciclovir; 
resulting in substantial tumour necrosis (Mentzer et al., 1998). Another potential 
therapy is the use of the proteasome inhibitor, Bortezomib (valcade). 
Bortezomib is an anti-tumour drug shown to be effective against many 
hematologic malignancies and has been approved for the treatment of multiple 
myeloma (Hideshima et al., 2001). By inhibiting the degradation of proteins by 
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the proteasome bortezomib increases the cellular levels of many proteins; 
modulating the functions of the pathways dependent on these proteins. For 
example, the inhibitor of NF-κB activity, IκB is no longer degraded causing NF-
κB inhibition. Accumulation of protein also induces ER stress and the UPR 
however, bortezomib interferes with the normal processing of XBP-1 by IRE-1; 
see section 1.3 (Lee et al., 2003a).  Recently, it has been demonstrated that 
bortezomib has an anti-tumour activity on PEL (An et al., 2004). Its activity here 
could possibly be due to the stabilisation of XBP-1u which has been shown to 
induce limited KSHV reactivation (Wilson et al., 2007).  
 
1.1.9 KSHV life cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 General life cycle of KSHV 
Upon entering a cell the viral genome forms an episome. Herpesviruses can enter one of two 
pathways of replication; latent replication, during which the virus genome copied by host DNA 
replication machinery during the cell cycle, or lytic replication, during which the genome is 
copied by virus-encoded DNA replication proteins and packaged into progeny virions. 
Herpesviruses can also reactivate from latency to enter lytic replication, although the 
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mechanism by which this occurs is poorly understood. Virus replication results in cell lysis and 
the progeny virions are able to infect more cells or be transmitted to a new host. 
 
KSHV adopts the typical life cycle of a herpesvirus depicted in Figure 1-3. Upon 
infection, the genome is delivered to the nucleus where it is maintained as a 
circular episome. KSHV, like all other herpesviruses, can enter one of two 
phases; either the pathway of latent infection or lytic infection in order to 
produce progeny virions. During latency the majority of the genome is silenced, 
and selective promoter regions, for example ORF50, are heavily methylated 
potentially to maintain latency (Chen et al., 2001). Reactivation, the switch from 
latency to lytic replication, can be induced by many exogenous signals. 
However, it is those signals that are relevant to in vivo infections that are critical 
in understanding how the virus and host interact (see section 1.1.14). Lytic 
replication is the ordered expression of the whole genome in temporally 
regulated transcriptional cascade (Jenner et al., 2001). Genes are grouped 
according to their timing of expression. Finally, linear DNA genomes are 
packaged into nascent viral capsids, tegument is acquired just prior to budding, 
an event which provides the envelope of host-derived membrane. New virions 
are released in a lytic burst and can go onto infect other cells within a host or 
transmit to a new host (Figure 1-3).  
 
1.1.10 Virus Entry  
KSHV entry is a multi-stage, complex process recently reviewed by Chandran 
(Chandran, 2009). The initial attachment of KSHV to the cell surface is 
mediated by the interaction of viral envelope glycoproteins gB, K8.1, gH and 
KSHV complement control protein (KCP) with the cellular glycosaminoglycan, 
heparin sulphate, on the host plasma membrane (Akula et al., 2001a) (Wang et 
al., 2001a) (Birkmann et al., 2001) (Hahn et al., 2009) (Spiller et al., 2006). This 
mechanism of concentrating virus at the cell surface, prior to entry, increases 
infection efficiency and is employed by many herpesviruses including HSV and 
EBV (O'Donnell and Shukla, 2008) (Tanner et al., 1987). However, the fact that 
infectivity is not completely blocked by the addition of heparin sulphate binding 
competitors suggests that this adsorption step is not essential (Akula et al., 
2001b) (Luna et al., 2004).  
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The KSHV envelope embedded glycoproteins; gB, gH and gL have been shown 
to mediate virus entry in transient expression studies (Pertel, 2002). 
Glycoprotein, gB, has been shown to bind to integrin α3β1 via an arginine-
glycine-aspartate (RGD) integrin binding motif (Akula et al., 2002). However 
blocking this interaction with antibodies to α3β1 did not abolish infectivity, 
suggesting that integrins are not the only host receptor involved in KSHV entry 
(Akula et al., 2002) (Inoue et al., 2003). Also, different combinations of integrins 
are expressed by different cell-types indicating a cell-type dependent receptor 
usage. Other studies have also implicated αVβ3 and αVβ3 integrins and the 
binding of gH/gL to syndecans in adherent cell infection (Garrigues et al., 2008) 
(Hahn et al., 2009).  
 
A cDNA screen for cellular receptors that facilitate KSHV entry to an otherwise 
non-permissive cell, revealed the cysteine/glutamate transporter (xCT), which is 
known to form a cell surface complex that includes CD98 (Kaleeba and Berger, 
2006) (Wagner et al., 2001). CD98 is multifunctional molecule identified in 
association with integrin α3 as fusion regulation protein 1 (FRP-1) (Deves and 
Boyd, 2000) (Ohgimoto et al., 1995). Studies in HMVEC-d demonstrate that 
KSHV infection induced the formation of a multi-molecular complex containing 
α3β1, αVβ3 and αVβ3 integrins and CD98/xCT (Veettil et al., 2008). However, 
xCT mRNA was not detected in non-activated primary B-cells a known target of 
KSHV (Kaleeba and Berger, 2006) and the role of integrins in non-adherent cell 
infection is not clear. KSHV therefore may interact with one set of receptors in 
adherent cells and may use an alternative receptor(s) in non-adherent cells. 
Indeed, for the infection of human primary myeloid DCs, macrophages, and B 
cells, KSHV has been shown to use DC-SIGN, as a receptor (Rappocciolo et 
al., 2008). Receptor engagement instigates membrane fusion, delivering 
nucleocapsid to the cytoplasm. This occurs either at the plasma membrane or 
endosomal membranes in a cell-type dependent way (Akula et al., 2003) 
(Raghu et al., 2009).  
 
Importantly, virus-cell binding has been shown to activate existing integrin-
associated host cell signalling pathways, to augment the cellular environment 
so that it supports establishment of infection. Pathways include focal adhesion 
kinase (FAK), Src, phosphatidylinositol 3-kinase (PI3-K), protein kinase C-ζ 
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(PKC), Rho-GTPases, mitogen-activated protein kinase (MEK), extracellular 
signal-regulated kinase (ERK1/2), and nuclear factor kappa B (NF-κB)., which 
are required for the internalization of viral DNA, modulation of cytoskeleton, 
transport of capsid the microtubules using dynein motors (reviewed in (Lyman 
and Enquist, 2009)), nuclear delivery of viral DNA as well as the initiation of viral 
and host gene expression (Akula et al., 2002) (Naranatt et al., 2003) (Naranatt 
et al., 2005) (Raghu et al., 2007) (Sadagopan et al., 2007) (Sharma-Walia et al., 
2005) (Veettil et al., 2006) (Pan et al., 2006). Activation of cell signalling is 
independent of viral replication as UV-irradiated inactive virus also induces the 
same responses.  
 
The viral capsids of herpesviruses are too large to enter the nucleus via the 
nuclear pore complex (NPC). Genomic DNA is therefore actively injected into 
the nucleus from the nucleocapsid docked to the cytosolic face of the NPC, this 
is dependent on the presence of importin-β (reviewed in (Greber and Fassati, 
2003)). Following delivery the linear genome is circularised, a process thought 
to depend on host enzymes. Once this is achieved the virus can enter either a 
latent or lytic transcriptional program. 
 
1.1.11 Establishing Latency 
Latency is a feature of all herpesviruses which allows persistent infection of the 
host. During latency the expression of viral genes from the viral episome 
tethered to host chromatin is restricted. This limits the number of viral protein 
epitopes presented to the immune system, allowing the virus to avoid detection. 
How the virus is directed into latency rather than the lytic gene expression 
programme is intensely studied. In alpha-herpesviruses this depends on the 
cellular environment encountered upon infection. HSV-1 infection of oral 
mucosal epithelium results in lytic replication, however infection of sensory 
neurons leads to HSV-1 latency (Bastian et al., 1972). This strongly suggests 
that host cell factors actively influence the establishment of latent or lytic 
infection. 
 
Latency has been identified as the ‘default’ pathway following failed lytic cycle 
initiation i.e. immediate early gene expression is blocked (Samaniego et al., 
1998). In the case of KSHV, the expression of a number of lytic transcripts and 
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proteins occurs transiently in the first 12 hours of infection, known as the 
abortive lytic gene expression programme, before the latency programme 
succeeds at 24 hours (Krishnan et al., 2004). This intermediate stage, does not 
represent full lytic cycle as only 29 lytic products were detected, including 
members from all stages, early to late. The presence of some of these gene 
products can be partly explained by the discovery that 11 virally encoded lytic 
mRNAs are incorporated into the tegument of newly made virions (see section 
1.1.4) (Bechtel et al., 2005a). RTA, the lytic switch protein was also shown, by 
one study, to be incorporated into the virus particle, possibly at low levels 
(Bechtel et al., 2005b). However, the presence of RTA should induce the full 
lytic cycle not the partial and disorganised lytic cycle observed (Sun et al., 1999) 
(West and Wood, 2003). It is possible that the viral gene expression seen may 
relate to the incomplete maturation and histone association of virion DNA 
(Stedman et al., 2004). Despite the lack of mechanism for the restricted lytic 
gene expression prior to latency it is thought that the immune-modulatory and 
anti-apoptotic functions of the genes expressed are required for the progression 
of infection (Krishnan et al., 2004). Whether the concurrent expression of lytic 
and latent transcripts transiently occurs in the de novo infection of all cell types 
is yet to be determined.  
 
1.1.12 Latency 
During latency, the viral episome is maintained through successive generations 
but no viral progeny are produced. The majority of information on KSHV latent 
gene expression comes from studies with PEL cell lines. This is due to the fact 
that these cells stably maintain the viral episome and latent viral transcripts are 
present in all cells. However, the KSHV latent expression profile observed in 
these cells may not represent all possible forms of latency; as indicated by the 
viral interferon regulatory factor – 3 (vIRF3/LANA2), which is detected in PEL 
cells but is absent from latently infected KS spindle cells (Rivas et al., 2001). In 
general, despite the potential of KSHV to have various latency programmes 
similar to the closely related EBV, the viral gene products associated with KSHV 
latency in PEL have been confirmed in other latency models.  The similarity in 
the gene expression profiles of KSHV-associated diseases KS, PEL and MCD 
also indicate a predominant latency programme (Schulz, 2006).  These genes 
are important for the establishment and maintenance of latency and also have 
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roles in the tumourigenesis associated with KSHV (reviewed in (Moore and 
Chang, 2003)).  
 
1.1.12.1 KSHV latency-associated region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4 Transcription of the latency-associated region of the KSHV genome 
The KSHV latency-associated region encodes four proteins, indicated by black boxes, as well 
as 11 miRNAs (white boxes) and is flanked by lytic genes (grey boxes). (A) Previously reported 
promoters, splice sites, and poly(A) addition sites are indicated. Lytic promoters are indicated by 
black arrows and latent promoters by white/red arrows. Novel KSHV transcripts identified in this 
report are shown in (B). Sequence coordinates are derived from the KSHV genome sequence 
obtained from BC-1 cells (GenBank accession number NC_003409). Adapted from (Cai and 
Cullen, 2006). 
 
During latency, KSHV gene expression is restricted to the latency-associated 
region located between ORFK12 and ORF74 (Figure 1-4). This region encodes 
four genes as well as the set of viral microRNAs (miRNA) in the same 
orientation, indicating their production from one primary precursor miRNA 
(Samols et al., 2005). Within this region at least two promoters are active, 
leading to the production of a group of transcripts, latency-associated 
transcripts (LATs) (Figure 1-4) (Talbot et al., 1999) (Pearce et al., 2005) (Cai 
and Cullen, 2006). The first promoter is located upstream of ORF73, the coding 
region for the latent nuclear antigen (LANA) (Figure 1-4 – red arrows). The 
LANA promoter is constitutively active in many cell types, upregulated in S-
phase of the cell-cycle and found to function primarily in B-cells in transgenic 
mice studies (Dittmer et al., 1998) (Sarid et al., 1999) (Jeong et al., 2002a). 
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Studies also demonstrate the potential for LANA to act on the LANA promoter 
indicating an auto-regulatory mechanism (Renne et al., 2001) (Jeong et al., 
2004). The LANA promoter has also been shown to be transactivated by the 
lytic switch protein RTA, suggesting a role for RTA in establishing latency during 
de novo infection (Lan et al., 2005b). Transcription from the LANA promoter 
leads to the expression of ORF73 (LANA), ORF72 viral Fas-associated death 
domain (FADD) interleukin-1β-converting enzyme (FLICE) inhibitory protein 
(vFLIP) and ORF71 viral cyclin (v-cyc); via the differential splicing of 
polycistronic mRNAs and internal translation initiation sites (Figure 1-4) (Kedes 
et al., 1997b) (Grundhoff and Ganem, 2001) (Low et al., 2001) (Cesarman et 
al., 1996) (Bieleski and Talbot, 2001).  
 
A second KSHV latent promoter transcribes an unspliced 1.3 kb mRNA which 
encodes the KSHV kaposin proteins (Figure 1-4 A - black arrow). The kaposins 
are translated from overlapping open reading frames that include the K12 
sequence as well as two adjacent direct repeat elements, DR1 and DR2 (Figure 
1-4 A) (Sadler et al., 1999). This mRNA also contains the viral miR-K10 miRNA. 
The remaining viral miRNAs are present within the intron of the latent kaposin 
pre-mRNA transcripts which initiate from a promoter located downstream of 
ORF72, as well as from the LANA promoter (Figure 1-4 A and B – white arrows 
and B –  red arrows) (Li et al., 2002) (Cai and Cullen, 2006) (Pearce et al., 
2005). The start site for the promoter denoted by the white arrow is more 
accurately defined by the position shown in Figure 1-4 B. Transcripts that 
terminate early from the promoter in the green circle potentially encode ORF71 
and 72. The reason for having two promoters (red and white) that give rise to 
similar transcripts is not clear but may indicate cell-type differential regulation. 
The viral miRNAs are thought to be derived from the pre-mRNA by Drosha-
mediated processing. Lastly, a transcript that originates from a novel promoter, 
LTi, has been demonstrated as RTA responsive; again potentially indicating a 
role for RTA in establishing latency (Figure 1-4 – black arrow in blue circle) 
(Matsumura et al., 2005).  
 
1.1.12.2 Latency-associated nuclear antigen (LANA) 
KSHV ORF73 encodes the major latent protein LANA, translated from the 
tricistronic latency-associated transcript (LAT) (Kellam et al., 1997) (Kedes et 
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al., 1997b). LANA is a large (222-234 kDa) multi-functional protein known to 
interact with various cellular and viral proteins (Rainbow et al., 1997) (Verma et 
al., 2007). LANA has been detected in the nucleus of KSHV infected cells and 
in all forms of KSHV-associated malignancies (Dupin et al., 1999) (Gao et al., 
1996a). The protein can be divided into three domains a C-terminal basic region 
involved in DNA-binding, a central repeat region of acidic amino acids and an 
N-terminal domain responsible for chromatin attachment and co-repressor 
recruitment (Lan et al., 2005a). A key function of LANA is the establishment and 
maintenance of the viral episome in the nucleus. LANA is involved in promoting 
semi-conservative replication of the circularised KSHV genome by binding to 
terminal repeat regions and recruiting host cellular DNA replication machinery 
(Garber et al., 2002) (Grundhoff and Ganem, 2003) (Lim et al., 2002). To 
ensure segregation of the viral genome into daughter cells during mitosis, LANA 
is also required to tether viral episomes to the host chromatin through binding to 
histones (Cotter and Robertson, 1999) (Ballestas et al., 1999) (Ballestas and 
Kaye, 2001) (Cotter et al., 2001) (Piolot et al., 2001) (Hu et al., 2002) (Ye et al., 
2004) (Barbera et al., 2006). However, LANA is not sufficient for this process, 
this is demonstrated by the many failed attempts to culture KS spindle cell 
derived cell lines that maintain the episome (Flamand et al., 1996) (Dictor et al., 
1996) (Grundhoff and Ganem, 2004). Therefore, stable latency is a multistage 
process that occurs with different efficiency in different cell types, requires cis-
acting epigenetic changes and may rely on lytic replication to sustain a latently 
infected population of cells (Grundhoff and Ganem, 2004) (Pantry and 
Medveczky, 2009). 
 
In addition to its role in KSHV plasmid replication and maintenance LANA has 
been implicated in the perturbation of several cellular pathways that regulate 
cell proliferation and survival. Expression of LANA under its own B-cell specific 
promoter in transgenic mice leads to splenic follicular hyperplasia and increased 
germinal centre formation (Fakhari et al., 2006). B-cell lymphomas, that did not 
resemble PEL, were seen at later stages highlighting the role of LANA in 
tumourigenesis. LANA physically binds to and represses p53-mediated 
transcription and apoptosis, promoting cell survival (Friborg et al., 1999). LANA 
also promotes cell cycle progression by binding to and inactivating the tumour 
suppressor retinoblastoma (Rb), increasing the expression of E2F dependent 
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genes. In combination with activate H-ras, LANA also led to the transformation 
of rat embryonic fibroblasts (Radkov et al., 2000). Via interactions with glycogen 
synthase kinase 3β (GSK-3β) LANA repositions the kinase to the nucleus 
where it can no longer degrade β-catenin in the cytoplasm (Krithivas et al., 
2002) (Fujimuro and Hayward, 2003). The resulting accumulation of β-catenin 
can associate with lymphoid enhancing factor (LEF) and enter the nucleus to 
activate transcription of genes involved in cell cycle and oncogenesis, for 
example MYC. LANA was also shown to increase the expression of human 
telomerase reverse transcriptase (hTERT), prolonging the life span of primary 
cultured endothelial cells (Watanabe et al., 2003).  
 
Many host and viral gene expression levels are manipulated by LANA 
expression (Renne et al., 2001). LANA primarily represses transcription by 
direct binding to DNA (Garber et al., 2002) and recruitment of the mSin3 co-
repressor complex (Krithivas et al., 2000). Repression is achieved by binding 
and inhibiting the histone acetyl transferase (HAT) activity of the CREB binding 
protein (CBP) (Lim et al., 2001). LANA can directly inactivate transcriptional 
activators such as ATF4 (Lim et al., 2000). Finally, LANA has been shown to 
interact with the host recombination signal binding protein (RBP)-Jκ and target it 
to the promoter regions of lytic genes to mediate repression (Lan et al., 2005a). 
LANA therefore has important roles in viral genome maintenance, cell 
proliferation and survival as well as the repression of lytic transcripts, and is 
therefore critical for KSHV persistence.  
 
1.1.12.3 v-Cyclin 
Viral cyclin (v-cyclin) is the gene product of ORF72, translated from the 
abundant bicistronic LAT that also encodes ORF71. ORF72 is a viral 
homologue of cellular D-cyclin, which binds to and activates cyclin dependent 
kinase 6 (cdk6) as well as cdk4 to a lesser extent (Li et al., 1997). The v-
cyclin/cdk6 complex is resistant to cdk inhibitors (cdki) and can phosphorylate a 
wider range of targets than its cellular counterpart including Rb, Histone H1 and 
the cdk inhibitor (cdki), p27 (Kip1), which is then targeted for degradation in 
cultured cells (Cesarman et al., 1996) (Chang et al., 1996) (Godden-Kent et al., 
1997) (Ellis et al., 1999). This evidence indicates that v-cyclin is involved in 
promoting proliferation in KSHV infected cells. However, PEL cells have a high 
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level of the p27 and continue to proliferate (Carbone et al., 2000) (Jarviluoma et 
al., 2004) (Sarek et al., 2006) (reviewed in (Verschuren et al., 2004b)). In 
addition the cellular microRNAs miR-221 and miR-222 that are known to target 
p27, are absent in PEL indicating a more complex level of cell cycle regulation 
during latency (Visone et al., 2007) (Eve Coulter: personal communication). 
 
Studies of v-cyclin are hampered by the inability to form stable cell lines 
overexpressing the protein (Ojala et al., 1999). Apoptosis is triggered in these 
cells due to v-cyclin/cdk6 inactivation of the anti-apoptotic factor, Bcl-2, adding a 
further layer of complexity to how v-cyclin can induce cell proliferation in vivo 
(Ojala et al., 2000). The oncogenic potential of v-cyclin has, however, been 
demonstrated in p53-/- transgenic mice that develop lymphomas, indicating the 
importance of LANA mediated inhibition of p53 in KSHV associated malignancy 
progression (Verschuren et al., 2002) (Verschuren et al., 2004a). 
 
1.1.12.4 v-FLIP 
ORF71 encodes the KSHV homologue of cellular Fas-associated death domain 
(FADD) interleukin-1β-converting enzyme (FLICE) inhibitory protein (FLIP). 
However, whether this protein functions to prevent FADD dependent caspase 8 
recruitment to the death-inducing signalling complex (DISC), blocking apoptosis 
is unclear (Chaudhary et al., 2000). Several studies indicate that v-FLIP can 
directly interfere with the Fas-mediated apoptosis pathway, but this was not 
confirmed in later studies (Belanger et al., 2001) (Djerbi et al., 1999) (Chugh et 
al., 2005). A consistent observation, however, is the upregulation of the 
transcription factor, NF-κB (Chaudhary et al., 1999) (Matta et al., 2003). PEL 
cells have a constitutively active NF-κB pathway which has been attributed to 
the v-FLIP mediated activation of the IKK complex, leading to the 
phosphorylation of IκB and release of active NF-κB (Liu et al., 2002) (Field et 
al., 2003). This contributes to the proliferation of PEL cells, as knock down of v-
FLIP in PEL cell lines or the inhibition of the proteasome blocking IκB 
degradation leads to cell death (Guasparri et al., 2004) (Matta and Chaudhary, 
2005). NF-κB is also important in activation of the inflammatory response. This 
seems contradictory during latent infection, but may have relevance to KSHV-
associated disease pathology (Li et al., 2005). Overexpression of v-FLIP in B-
cells from transgenic mice led to increased responsiveness to mitogenic signal 
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as well as lymphoma development (Chugh et al., 2005). Forced expression in 
rodent fibroblasts also led to transformation, possibly indicating a role for v-FLIP 
interactions with tumour necrosis receptor-associated factor 2 (TRAF2) and 
receptor interacting protein (RIP) as well as activation of the JNK pathway (Sun 
et al., 2003) (An et al., 2003). v-FLIP inhibits lytic replication via inhibition of the 
AP-1 pathway indicating its role in the maintenance of latency in certain KSHV 
infected cell-types (Brown et al., 2003) (Ye et al., 2008) (Grossmann and 
Ganem, 2008). 
 
1.1.12.5 Kaposins 
The kaposin locus (K12 and surrounding direct repeat regions) encodes for at 
least 3 proteins via differential translation (Sadler et al., 1999). Kaposin A is a 
hydrophobic protein that localises to both surface and intracellular membranes 
(Tomkowicz et al., 2002). Overexpression in immortalised Rat-1 fibroblasts 
induced morphological transformation and highly vascular undifferentiated 
sarcomas, indicating a role in the deregulation of cell growth (Muralidhar et al., 
1998). These changes are thought to be mediated via the interaction with 
cytohesin 1, a guanine exchange factor (GEF) for alternate reading frame (ARF) 
GTPases and a cell adhesion regulator (Kliche et al., 2001). Kaposin B is a 
small soluble protein localised to the nucleus, thought to act as a scaffold or 
adaptor protein. It causes the upregulation of various cytokines including IL6, 
tumour necrosis factor (TNF) and granulocyte-macrophage colony stimulating 
factor (GM-CSF) among others. This is achieved by the stabilisation of a class 
of cellular mRNAs containing AU-rich regions (i.e. cytokines); via the binding 
and activation of the mitogen-activated protein (MAP) kinase 2 (MK2) 
(McCormick and Ganem, 2005). Kaposin B represents another latent KSHV 
protein involved in inducing the inflammatory response. This, as discussed 
before, appears counterintuitive as viruses attempt to avoid the immune system, 
however; this response may be required to maintain latency in vivo or used to 
recruit susceptible cells to the site of infection, facilitating spread of the virus.  
Kaposin C shares a common repeat amino acid sequence with kaposin B and is 
therefore a trans-membrane fusion protein.  
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1.1.12.6 LANA2/vIRF3 
The KSHV genome encodes four viral homologues of cellular interferon 
regulatory proteins (vIRFs) which cluster in one region; suggestive of ancestral 
gene duplication probably after acquisition from the host. The IRFs are a family 
of transcription factors involved in regulating the interferon response (Barnes et 
al., 2002). Viral IRFs therefore contribute to immune-evasion and are lytic 
proteins except for K10.5 or LANA2 (vIRF3); which is expressed predominantly 
during latency, but can be induced during lytic reactivation (Lubyova and Pitha, 
2000). LANA2 is expressed exclusively in PEL and MCD, indicating the 
potential of different KSHV latency programs (Rivas et al., 2001), and has been 
shown to be essential for PEL cell survival (Wies et al., 2008). This nuclear 
protein has a role in the disruption of cellular IRF-7, IRF-3  and IRF-5 mediated 
signalling and cellular PKR signalling (Esteban et al., 2003) (Joo et al., 2007) 
(Wies et al., 2009). However, like some cellular IRFs for example IRF4, LANA2 
also has a role in cell growth and regulation and has been shown to inhibit p53 
and NF-κB as well as stimulate MYC expression. This highlights the importance 
of LANA2 in KSHV pathogenesis and cell proliferation (Rivas et al., 2001) (Seo 
et al., 2004) (Lubyova et al., 2007). 
 
1.1.12.7 Viral miRNA 
MicroRNAs (miRNA) are a family of recently discovered non-coding RNAs, 
which are approximately 21-22 nucleotides in length and play an important part 
in post-transcriptional gene regulation (reviewed in (Bartel, 2004)). This is a 
highly conserved mechanism of regulating gene expression and several 
herpesviruses have been shown to also express viral miRNAs (Pfeffer et al., 
2005) (Swaminathan, 2008) (Umbach and Cullen, 2009). During KSHV latency, 
18 mature miRNAs are processed from 12 pre-miRNAs, 14 of which are present 
in the same genome region, or cluster, and are expressed from a single 
precursor mRNA (see section 1.1.12.1) (Cai et al., 2005) (Pfeffer et al., 2005) 
(Samols et al., 2005) (Grundhoff et al., 2006) (Umbach and Cullen, 2010). The 
cellular targets of these viral miRNAs can be predicted by looking for binding 
sequences in the 3’UTR of cellular mRNAs. However, few potential targets have 
been experimentally confirmed as yet (reviewed in (Bartel, 2009)). Despite this, 
viral miRNAs are predominantly involved with regulating lytic reactivation, 
apoptosis, immune evasion, cellular differentiation and reprogramming 
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(reviewed in (Umbach and Cullen, 2009)) (Hansen et al., 2010). In one 
instance, KSHV-miR-K12-11 has been shown to function as an orthologue 
(shares 100 % seed sequence homology) of cellular miR-155, which is in fact 
absent from PEL cells (Gottwein et al., 2007) (Skalsky et al., 2007). This 
suggests a viral miRNA is able to target the same mRNAs as cellular miR-155, 
including the transcriptional repressor BACH-1, and regulate the same 
processes such as germinal centre development and the generation of antigen-
specific switched antibody-producing cells (Calame, 2007). However, 
overexpression of miR-155 triggers the development of B cell malignancies, and 
is abundantly expressed in diffuse large B-cell lymphomas (DLBCLs) (Kluiver et 
al., 2005).  
 
Most recently, a specific role for KSHV miRNAs in the regulation of the switch 
between latent and lytic replication phases has been established. KSHV miR-
K9* has been shown to target the 3’UTR of the immediate early viral RTA 
protein, necessary and sufficient for lytic reactivation (Bellare and Ganem, 
2009) (Lukac et al., 1998) (Xu et al., 2005). The ectopic expression of miR-K9* 
reduced the expression of a luciferase reporter driven by the RTA 3’UTR, and 
expression of an antagonist to miR-K9* in a KSHV latent cell system led to 
increased lytic replication (Bellare and Ganem, 2009). This viral miRNA 
therefore acts to maintain latency. Previous studies of miR-K5 and its cellular 
target Bcl-2-associated transcription factor 1, BCLAF-1, showed an increase in 
sensitivity to lytic reactivation (Ziegelbauer et al., 2009). Additionally, another 
KSHV miRNA, miR-K1 has been shown to target IκBα, an inhibitor of the NF-κB 
pathway, which leads to increased NF-κB activity and increased lytic replication 
(Lei et al., 2010). Finally, KSHV miR-K12-5 maintains latency by reducing levels 
of mRNA encoding RTA, while the KSHV miR-K12-4-5-p was found to target a 
Retinoblastoma-like protein 2 (Rbl2) a repressor of the DNA methyltransferases 
(DNMT) 3a and b, making global epigenetic changes (Lu et al., 2010). The 
various examples of viral miRNA regulation of lytic replication, outlined above, 
suggest that they all act to ‘fine tune’ the level of reactivation, a vital and already 
highly controlled process (see section 1.1.14), allowing the virus to intricately 
respond to the changing cellular environment.  These results demonstrate that 
the gene expression profile of a cell infected with an oncogenic miRNA 
expressing virus, like KSHV, is dependent on both the virus and host miRNA 
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expression, introducing yet another layer of virus-host interaction (Umbach and 
Cullen, 2010).  
 
1.1.13 KSHV Lytic cycle 
Within the predominantly latent population of KS spindle cells around 3 % of 
cells express markers of lytic replication (Parravicini et al., 2000) (Katano et al., 
2000). This small proportion of cells is thought to contribute to the pathogenesis 
of KS in two main ways. Firstly, the retention of KSHV genomes in dividing 
cells, other than B-cells, is inefficient and therefore re-infection of endothelial 
cells is required for viral persistence (Grundhoff and Ganem, 2004). Secondly, 
many of the genes expressed during the lytic cycle induce the expression of 
host cellular cytokines which are responsible for the angiogenesis and cell 
proliferation seen in KS. The chemokine receptor homologue vGPCR which 
induces the expression of VEGF is an example of this (Arvanitakis et al., 1997) 
(Montaner et al., 2003). 
 
Table 1-2 Classification of KSHV lytic genes 
Class Symbol Definition 
Immediate-early 
(IE) 
 Expression requires no new viral protein synthesis 
(transcription insensitive to cycloheximide). 
Delayed-early 
(DE) 
 Expression is independent of virus DNA synthesis 
(transcription prevented by cycloheximide but insensitive to 
DNA synthesis inhibitors). Depend on IE gene function.  
Partial-late (L)  Expression is increased by viral DNA synthesis (transcription 
prevented by cycloheximide and reduced by DNA synthesis 
inhibitors. 
True-late (L)  Expression requires viral DNA synthesis (transcription blocked 
by cycloheximide or DNA synthesis inhibitors). 
 
Lytic replication results in the production of new viruses and therefore involves 
viral DNA replication by the virus-encoded replication machinery, packaging of 
virus genomes into newly assembled capsids and subsequent maturation into a 
viral particle (see sections1.1.13.1 and 1.1.5). This occurs via a highly regulated 
and temporally ordered gene expression cascade that is initiated by the viral 
lytic switch protein, RTA (see section 1.1.14). Genes expressed during the lytic 
cycle can be grouped based on their timing and their expression in response to 
protein synthesis and DNA replication inhibitors (Zhu et al., 1999) (Saveliev et 
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al., 2002) (Lu et al., 2004a) (see Table 1-2). The immediate early (IE) genes are 
regulatory and include ORF50 encoding RTA, which transactivates the 
promoters of the delayed early genes (DE). Many DE genes have enzymatic 
functions, for example DNA polymerase, or are accessory proteins, such as the 
polymerase processivity factor. DE genes are primarily involved in viral DNA 
replication and protein production. Functions of KSHV DE genes also include 
regulation of gene expression for example, the mRNA transcript accumulation 
(MTA) protein (Kirshner et al., 2000). Immune evasion is another important 
function of DE genes (reviewed in (Coscoy, 2007)) for example: the modulators 
of immune recognition (MIR1/2) and the membrane bound E3-ubiquitin ligases 
(encoded by ORFK3 and -K5), which evade CTL recognition by removing MHC 
class I from the surface of infected cells via endocytosis and subsequent 
endosmomal degradation (Coscoy and Ganem, 2000) (Coscoy et al., 2001). K5 
has also been shown to downregulate BST2/tetherin from the cell surface; 
facilitating virus release from cell membranes (Mansouri et al., 2009) (Pardieu 
et al., 2010). KSHV also encodes several viral homologues of interferon 
regulatory factors (vIRFs) which are capable of opposing the function of cellular 
IRFs and suppress interferon responses (reviewed in (Lee et al., 2009)).  
Remaining functions of DE genes include the anti-apoptotic role of the viral 
homolog of Bcl-2 (v-Bcl-2) (Sarid et al., 1997), selective accelerated turnover of 
host mRNA mediated by ORF37, shutoff exonuclease (SOX) (Glaunsinger et 
al., 2005), and the modulation of signal transduction carried out by various 
virally encoded proteins including K1. K1 encodes a type I transmembrane 
protein with an immunoreceptor tyrosine-based activation motif (ITAM) and 
mimics a constitutively active B-cell antigen receptor (Lee et al., 1998) 
(Lagunoff et al., 1999). ORFK2 encodes a viral homologue of cellular interleukin 
6 (vIL-6), this protein triggers JAK/STAT signalling leading to the upregulation of 
VEGF (Molden et al., 1997). Other virally encoded chemokines, the 
macrophage inflammatory proteins (vMIPs), are involved in polarisation of the 
immune response away from the Th1 driven anti-viral response (Choi and 
Nicholas, 2008). Another KSHV protein known to induce VEGF is the  
constitutively active homologue of the cellular IL-8 receptor, G-protein coupled 
receptor (ORF74/vGPCR), which has a broad range of signalling activity leading 
to proliferation and angiogenesis (Cannon et al., 2003). Finally, the late genes 
(L) are transcribed following DNA replication and provide the structural genes 
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for virus assembly for example, the major capsid protein (MCP) (Chang and 
Ganem, 2000) (Jenner et al., 2001). 
 
Cell cycle arrest at the G1/S boundary is associated with lytic infection by 
herpesviruses, including KSHV, where the replication associated protein (RAP) 
or K-bZIP/K8 is mechanistically involved (Wu et al., 2002) (Izumiya et al., 
2003b). K-bZIP increases the accumulation of C/EBP-α leading to cell cycle 
arrest via the upregulation of the cdk inhibitor p21 and the inhibition of E2F 
expression (Wu et al., 2003). K-bZIP is also able to directly bind to 
cdk2/cyclinA/E complexes, which causes impaired kinase activity (Izumiya et 
al., 2003b).  This block to the cell cycle prevents cellular DNA synthesis, 
reducing competition for nucleotide pools and increasing the access to sub-
nuclear compartments required for replication.  
 
1.1.13.1 KSHV lytic DNA replication 
Information on KSHV lytic DNA replication is derived from studies of other 
herpesviruses including EBV and HSV, whose DNA replication had been 
reconstructed in vitro (Boehmer and Lehman, 1997). DNA replication involves a 
multi-subunit complex composed of the catalytic and accessory proteins 
required for DNA synthesis from a cis-acting replication origin. KSHV encodes 
homologues of the six components of the core machinery of viral DNA 
replication, viral DNA polymerase (ORF9), primase (ORF56), polymerase 
processivity factor (ORF59), primase-associated factor (ORF40/41), helicase 
(ORF44) and single stranded binding protein (ORF6) in abundance. These 
proteins when co-expressed in the absence of viral genome form a stable 
complex in the nucleus (Wu et al., 2001a). KSHV-encoded K8 (ORFK8/K-bZIP) 
protein, which is a distant evolutionary homologue to EBV ZTA, was also 
incorporated into these structures. Once genomic template is present, DNA 
replication will occur via a rolling circle mechanism in a replication compartment 
usually found in the vicinity of a host ND10 body, a site of viral DNA 
accumulation (Ishov and Maul, 1996). The multimeric genomes produced 
require processing into linear monomers before packaging into nascent capsids.  
 
KSHV has two origins of lytic replication (Ori-Lyt) which have close sequence 
homology. The left hand origin (Ori-Lyt-L) is located between ORFK4.2 and -K5 
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and the right hand origin (Ori-Lyt-R) is found between ORFK12 and ORF71 
(AuCoin et al., 2002) (see Figure 1-1). Ori-Lyt-L is sufficient for viral genome 
propagation whereas Ori-Lyt-R, on its own, is unable to direct amplification of 
viral DNA (Xu et al., 2006). For an origin of replication to be functional, four 
critical elements are required, four pairs of C/EBPα binding sites, an 18 bp AT-
rich palindrome, a 32 bp sequence of as yet unknown function and a high 
affinity binding site for RTA near a TATA box (AuCoin et al., 2004) (Wang et al., 
2004c). RTA and K-bZIP are required for DNA replication from the Ori-Lyt, and 
RBP-J is needed to overcome LANA mediated repression of DNA replication 
(AuCoin et al., 2004) (Wang et al., 2004c) (Wang et al., 2006) (Lefort and 
Flamand, 2009) (Rossetto et al., 2009) (see section 1.1.14.). Herpesviruses 
also encode proteins involved in DNA repair and nucleotide metabolism which 
are essential for in vivo replication (Coleman et al., 2003). Various cellular 
proteins are involved in KSHV DNA replication including topoisomerase (Topo) I 
and II, which are essential (Wang et al., 2008). 
 
1.1.14 Reactivation from latency 
An important aspect of the definition of latency is the ability to reactivate and 
produce progeny virions. This is required for viral persistence, transmission and 
disease pathogenesis and therefore is studied intensely for the discovery of 
therapeutic targets. The process of switching from latent, non-productive 
infection to lytic replication is known as reactivation. In KSHV this is governed 
by ORF50 that encodes the immediate early regulator of transcription activation, 
RTA (Zhu et al., 1999).  Ectopic expression of RTA is sufficient to induce 
reactivation in latently infected cells, and removal of RTA or inhibition of its 
function prevents spontaneous and chemically induced reactivation (Gradoville 
et al., 2000) (Lukac et al., 1998) (Sun et al., 1998) (Lukac et al., 1999) (Xu et 
al., 2005). RTA in combination with other viral and cellular transcription factors 
(see Table 1-3) (Wang et al., 2001c) is able to transactivate its own promoter 
and those of many viral and cellular genes, initiating a highly regulated gene 
expression cascade that results in the manufacture of new virions (see section 
1.1.13) (Deng et al., 2000) (reviewed in (West and Wood, 2003)). RTA is known 
as a KSHV ‘molecular switch’ that controls reactivation. Factors affecting the 
expression of this protein therefore impact on the balance between KSHV lytic 
and latent replication (see Table 1-3 and Table 1-4).  
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RTA is transcribed from the major 3.6 kb transcript of the ORF50 region. Minor, 
smaller RNA species are also transcribed from this region and are 
complementary in sequence to RTA mRNA. They are expressed during 
reactivation but do not appear to encode any viral proteins, their role in lytic 
replication is therefore unclear (Lukac et al., 1999) (Zhu et al., 1999) (Saveliev 
et al., 2002). The RTA protein is organised in the same manner as other 
general viral transcriptional activators. Similar to its functional homolog in EBV, 
RTA has an N-terminal DNA-binding domain and a potent transcriptional 
activator at the C-terminus (Manet et al., 1991) (Hardwick et al., 1992) (Lukac et 
al., 1999). Deletion of the C-terminal amino acids 531-691 removes the 
transactivation domain and creates a dominant negative (dn) mutant RTA 
(Lukac et al., 1999) (discussed further in Chapter 5). An N-terminal proline-rich, 
leucine heptapeptide repeat (LR) region is important for RTA multimerisation 
and RTA is thought to function most efficiently as a tetramer (Bu et al., 2007).  
 
RTA can transactivate either by direct binding to RTA response elements 
(RRE), which have limited consensus, or via cooperative interactions with 
partners such as RBP-J (Song et al., 2001) (Liao et al., 2003a) (Ziegelbauer et 
al., 2006) (Persson and Wilson, 2010). RTA is also highly phosphorylated but 
the function of this post-translational modification has not yet been identified 
(Lukac et al., 1999).   
 
Numerous factors control the expression of RTA and therefore KSHV lytic 
replication. These include both epigenetic modifications (Pantry and 
Medveczky, 2009) as well as cellular signalling pathways and these are outlined 
in Table 1-3 and Table 1-4 below.  Over 20 stimuli are reported to disrupt RTA 
regulation and cause KSHV reactivation; however the physiological relevance of 
many of these stimuli is yet to be explained (see Table 1-3). Many are also 
involved in RTA transcriptional regulation of other viral and cellular proteins and 
are therefore important for lytic replication.  
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Table 1-3 Factors reported to induce RTA expression and RTA dependent lytic gene expression 
Factor Mechanism Reference 
   
12-O-tetradecanoyl 
phorbol-13-acetate 
(TPA) 
 
Requires activation of protein kinase C (Deutsch 
et al., 2004) and requires activating protein 1 (AP-
1) (Wang et al., 2004b). Role for MAPK pathways. 
(Renne et al., 1996b) 
(Moore et al., 1996a)  
(Cohen et al., 2006) 
Sodium butyrate The ORF50 promoter is present in a region of 
densely packed chromatin. Sodium butyrate 
inhibits histone deacetylases causing chromatin 
remodelling of ORF50 promoter via recruitment of 
Ini1/Snf5 (Lu et al., 2003) and recruitment of Sp1 
and Sp3 complexes (Ye et al., 2005) 
 
(Miller et al., 1997) 
(Miller et al., 1996) 
Ionomycin Mobilises Ca2+ and reactivation is dependent on 
calcineurin (Zoeteweij et al., 2001) 
 
(Chang et al., 2000) 
Thapsigargin Mobilises Ca2+ and reactivation is dependent on 
calcineurin (Zoeteweij et al., 2001) 
 
(Zoeteweij et al., 2001) 
5-azacytidine The ORF50 promoter is heavy methylated in a 
asymptomatic individuals (Chen et al., 2001). 
Demethylating agents therefore modify the 
chromatin facilitating reactivation 
 
(Chen et al., 2001) 
Prostratin A non-tumour-promoting phorbol ester (Brown et al., 2005) 
   
Bortezomib 
 
Proteasome inhibitor (Brown et al., 2005) 
Valproic acid Inhibits histone deacetylases (Shaw et al., 2000) 
   
Trichostatin A 
 
Inhibits histone deacetylases (Lu et al., 2003) 
Hydrocortisone 
 
Direct activation of KSHV lytic gene transcription (Hudnall et al., 1999) 
Hypoxia Hypoxia inducible factors (HIFs) activate the 
ORF50 promoter  (Haque et al., 2003) 
 
(Davis et al., 2001)
(Cai et al., 2006a) 
Epithelial 
differentiation 
 
 
 
(Johnson et al., 2005a) 
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Plasma cell 
differentiation 
 
XBP-1 transactivates the ORF50 promoter (Wilson et al., 2007) 
(Sun and Thorley-
Lawson, 2007) (Yu et 
al., 2007b) (Liang et 
al., 2009) (Siegel et al., 
2010) 
   
Catecholamine 
neurotransmitters 
Physiological levels of epinephrine and 
norepinephrine act via Β adrenergic activation of 
protein kinase A (PKA) 
(Chang et al., 2005) 
 
Dopamine receptor 
targets 
 
 
Via activation of protein kinase A (PKA) and 
mitogen-activated protein kinase (MAPK) 
signalling pathways 
 
 
(Lee et al., 2008) 
 
 
MAPK 
 
Ras/Raf/MEK/ERK, JNK and p38: Ets-1 and AP-1 
mediated transactivation of KSHV ORF50 (Pan et 
al., 2006) 
 
(Yu et al., 2007b) (Xie 
et al., 2008) 
 
Inflammatory 
cytokines 
 
Including Interferon-, Oncostatin M, Hepatocyte 
growth factor/ scatter factor and Interleukin-6, 
possibly via the action of the cellular Kinase Pim-1 
(Cheng et al., 2009b) 
 
(Blackbourn et al., 
2000a) (Chang et al., 
2000) 
(Mercader et al., 2000) 
(Monini et al., 1999) 
 
Pim-1/Pim3 
kinases  
Phosphorylation of LANA counteracts its inhibition 
of transcription from the TR region 
(Cheng et al., 2009b) 
 
TLR signalling 
 
 
Activation of toll like receptor (TLR) 7/8 
 
(Gregory et al., 2009) 
HIV-1 tat  Via JAK/STAT signalling (Zeng et al., 2007) (Harrington et al., 
1997) 
 
KSHV RTA 
 
 
Auto activates RTA expression (Deng et al., 2000) 
 
(Lukac et al., 1998) 
K-bZIP/K8 Knock down K-bZIP see loss of ORF 50 transcript 
in PEL cells 
(Lefort and Flamand, 
2009) 
   
ORF57/MTA Ability to transactivate promoters, either alone or 
synergistically with RTA, is cell and promoter 
specific. Does not induce reactivation alone 
(Malik et al., 2004)
(Palmeri et al., 2007) 
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RTA homologues 
 
HVS, MHV68, RRV via direct transactivation of 
ORF50 
(Goodwin et al., 2001) 
(Damania et al., 2004) 
 
Co-infection 
 
 
HHV6, HSV-1, HIV-1 and HCMV in human 
fibroblasts but not in PEL 
 
(Lu et al., 2005) (Qin et 
al., 2008) (Merat et al., 
2002) (Vieira et al., 
2001) (Cheng et al., 
2009a) 
   
cJun Via direct transactivation of  the ORF50 promoter  (Gwack et al., 2001) 
   
cFOS-cJUN 
heterodimer/ 
activating protein 1 
(AP-1) 
Via direct transactivation of  the ORF50 promoter 
and cooperates with RTA 
(Wang et al., 2004b)  
   
CCAAT/ Enhancer-
binding protein- 
(C/EBP) 
Exogenously expressed C/EBP can induce RTA 
expression and cooperates with RTA  
 
(Wang et al., 2003b)
(Wang et al., 2003a) 
 
Recombination 
signal-binding 
protein 1 for J-
kappa (RBP-
J)/CSL 
 
 
RTA interacts with the primary target of the Notch 
signalling pathway to direct RTA to target 
promoters. The strong transactivator domain of 
RTA overrides the repressive function RBP-J by 
displacing repressive complexes and recruiting 
coactivator complexes 
 
(Liang et al., 2002) 
(Persson and Wilson, 
2010) 
   
Intracellular domain 
of Notch1 (ICN) 
Ectopic expression induces KSHV lytic replication 
and requires RBP-J binding sites in the ORF50 
promoter 
(Lan et al., 2006)  
   
MGC2663/ KSHV-
RTA binding 
protein (K-RBP) 
Synergises with RTA weakly enhancing RTA-
mediated transactivation 
(Wang et al., 2001c)  
   
Octamer-binding 
protein 1 (Oct-1) 
Binds octamer sequences in the ORF50 promoter 
and enhances RTA-mediated transactivation. Also 
cooperates with RTA. 
 (Sakakibara et al., 
2001) (Carroll et al., 
2007) 
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cAMP response 
element (CRE)-
binding protein 
(CBP) 
Via direct transactivation of  the ORF50 promoter 
and via histone acetyl transferase (HAT) activity 
transforms the chromatin into a more accessible 
state 
(Lu et al., 2003) 
(Gwack et al., 2001) 
 
In addition to the factors that induce directly or cooperate with RTA to facilitate 
reactivation many factors have been identified that repress RTA functions (see 
Table 1-4). Many of these factors are therefore important for the maintenance of 
latency. For example, LANA which interacts with and inhibits many of the 
factors designated as inducers or co-operators of RTA.  
 
Table 1-4 Factors reported to negatively regulate RTA 
Factor Mechanism  Reference 
RBP-J/CSL Interacts with LANA to mediate ORF50 
repression 
 
(Lan et al., 2005a) 
K-bZIP/K8 Interacts with RTA and represses RTA-mediated 
transactivation of K8 promoter. Interacts with 
CBP repressing AP-1 mediated transactivation  
 
(Liao et al., 2003b) 
(Hwang et al., 2001) 
(Izumiya et al., 2003a) 
MGC2663/ KSHV-
RTA binding protein 
(K-RBP) 
K-RBP was found to repress RTA-mediated 
transactivation, however RTA can promote K-
RBP degradation  
(Yang and Wood, 
2007)  (Yang et al., 
2008) 
   
LANA Interferes with RTA mediated promoter 
activation through interactions with, RTA,  RBP-
J, ICN and CBP 
 
(Lan et al., 2004) (Lan 
et al., 2005a) (Lan et 
al., 2006) (Lim et al., 
2001) 
   
Histone 
deacetylase -1 
(HDAC1) 
Interacts with the ORF50 promoter and 
mediates repression 
 
(Gwack et al., 2001) 
(Lu et al., 2003) 
   
Nuclear factor 
kappa B (NF-κB) 
Inhibits RTA mediated transactivation in a 
context dependent manner 
(Brown et al., 2003) 
(Grossmann and 
Ganem, 2008) 
(Izumiya et al., 2009) 
(Lei et al., 2010) 
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KSHV reactivation is a complex and highly regulated process. The balance 
between latency and lytic replication is therefore highly sensitive and can be 
seen as equilibrium between the induction and repression of lytic gene 
expression, controlled by the expression of RTA. The ability of RTA to respond 
to a multitude of different stimuli in vitro indicates the capacity of KSHV to 
reactivate in response to many different scenarios in vivo. Alternatively, the 
effect of many negative regulators suggests that the KSHV lytic cycle is robustly 
buffered against inappropriate lytic reactivation. This implies that the most 
important pathways, that induce reactivation from latency, are those that are 
physiologically relevant to KSHV infection and the associated diseases. These, 
triggers of lytic replication, represent potential targets for therapy and disease 
intervention.   
 
Interferon 
regulatory factor 7 
(IRF7) 
Competes with RTA for binding to the RTA 
response element in the ORF57 promoter 
(Wang et al., 2005a) 
   
Hairy/E(spl)-related 
with YRPW (Hey1) 
Induced by RTA, Hey1 represses the ORF50 
promoter  
(Yada et al., 2006) 
   
Poly(ADP-ribose) 
polymerase 1 
(PARP-1) 
Efficiently transfer of poly(ADP-ribose) to RTA 
causing repression  
(Gwack et al., 2003) 
 
 
   
Ste20-like kinase 
(hKFC) 
Efficiently transfer of phosphate units to RTA  
causing repression 
(Gwack et al., 2003) 
   
Phosphatidylinositol  
3-kinase (PI3K)-Akt 
Suppresses the activity of RTA. Inhibitors of the 
pathway enhances response to TPA 
(Peng et al., 2010) 
   
Octamer-binding 
protein 2 (Oct-2)  
Competes with Oct-1 for the octamer binding 
motif present in the ORF50 promoter 
(Di Bartolo et al., 
2009) 
 
KSHV microRNAs Direct targeting of 3’ UTR of RTA and increases 
methyltransferase activity. Provides ‘fine-tuning’ 
regulation of RTA expression 
(Bellare and Ganem, 
2009) (Lu et al., 2010) 
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1.1.14.1 A comparison with EBV reactivation from Latency 
In contrast to KSHV, where RTA is both necessary and sufficient for lytic 
reactivation, activation of the EBV lytic cycle is mediated by two viral proteins 
proteins. However, analogously to RTA the expression of immediate early viral 
protein BZLF-1 (ZTA) is a primary event sufficient to trigger the entire EBV lytic 
cascade (Countryman and Miller, 1985). BZLF-1 is a bZIP transcription factor 
related to KSHV ORFK8/K-bZIP but is a functional homology of KSHV RTA 
(Sinclair, 2003) (Chang et al., 1990).  Like RTA, BZLF-1 is able to autoactivate 
its own promoter as well as a subset of EBV genes including the second viral 
protein important for EBV reactivation, BRLF-1 (RTA), through ZTA response 
elements (ZREs) (Hardwick et al., 1988) (Speck et al., 1997). BZLF-1 
transactivation of BRLF-1 is thought to be enhanced by promoter methylation, a 
feature that KSHV RTA is as yet not known to do (Bhende et al., 2004). 
Phosphorylation of BZLF-1 has also been shown to enhance transactivation 
capabilities, a trait thought to be important for RTA (Kolman et al., 1993) (Chang 
et al., 2005). The expression of BRLF-1 requires protein synthesis and therefore 
can not be classified as immediate early (Amon et al., 2004). However, BRLF-1 
plays an important cooperative role alongside BZLF-1 in transactivation of viral 
genes in the next stage of lytic replication (Quinlivan et al., 1993). During 
latency the BZLF-1 promoter (Zp) is inactivated by repressive chromatin 
structure that can be released by histone acetylation for example as a result of 
BCR signalling, a mechanism of reactivation that is also used in KSHV 
reactivation (Jenkins et al., 2000) (Bryant and Farrell, 2002).  
 
1.2 Cellular stress 
Hans Selye first described physiological stress and suggested a ‘common 
response of the body to a variety of insults and “stressful” conditions’. Cellular 
stress has since been defined as a ‘variety of processes that are triggered by an 
acute or chronic shift from the usual cellular conditions and homeostasis that 
aim to counteract the insult, repair the damage and eventually protect the cell or 
organism’ (Barouki and Sitia, 2007). This definition indicates that there are 
many conditions that alter the cellular environment and activate a variety of 
responses required for cell adaptation and recovery.  
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Cellular stress may be caused by exogenous factors such as extremes of 
temperature, radiation, hypoxia, nutrient deprivation, free radicals, 
toxins/chemicals and pathogen infection. There are also endogenous sources of 
cell stress, for example the disruption of protein folding in the endoplasmic 
reticulum (ER) during plasma cell differentiation, which leads to ER stress 
termed ‘physiological stress’ (Rutkowski and Kaufman, 2004). In some 
instances the same cellular stress response can be induced by both exogenous 
and endogenous factors to different levels of effect and control. However, the 
cell is able to distinguish between these situations and respond accordingly with 
highly regulated response programmes. For example, the unfolded protein 
response (UPR) is the cellular stress response to ER stress (see section 1.3). 
This adaptive response may be elicited by a temporary environmental insult, for 
example hypoxia, which requires activation of the UPR to allow cells to recover 
or remove cells with irrevocable damage. However, chronic ER stress occurs in 
professional secretory cells, such as plasma cells, hepatocytes and β-cells of 
the pancreas. Here the UPR is physiologically activated to facilitate 
development and survival of these cell types that have a high secretory 
capacity. Therefore, classical regulation of the UPR (described in section 1.3) 
provides general cellular protection to acute ER stress. However, each pathway 
has diverse roles within the response and can be selectively activated in 
different tissues to provide a tailored response to various physiological and 
pathological induced stresses (reviewed in (Wu and Kaufman, 2006)). The 
physiological role of the UPR in development and function is best understood in 
the context of professional secretory cells and in cancer progression (see 
sections 1.4 and 1.5). Virus infection not only contributes to cellular stress but 
due to their dependence on the host cell, viruses are consequently also 
susceptible to the many cellular stresses encountered. How the virus life cycle 
reacts to the various changes that occur within the host cell, in response to 
cellular stress, highlights an important aspect of virus-host interaction. This 
aspect is investigated by this thesis, in the context of physiological stresses that 
can trigger reactivation of latent virus from infected cells.   
 
1.3 The unfolded protein response 
The unfolded protein response (UPR) is an evolutionarily conserved integrated 
signal transduction pathway that mediates the adaptation to protein-folding 
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stress (reviewed in (Ron and Walter, 2007)). The endoplasmic reticulum (ER) 
receives newly synthesised polypeptide chains destined for secretion or the 
cell-surface, and provides an optimum environment for the correct folding and 
assembly, allowing these proteins to mature. However, the nascent protein load 
of the ER varies, sometimes rapidly, in response to an array of insults including 
exposure to pharmacological agents that disturb protein folding, genetic 
mutation of ER chaperones or chaperone substrates, failure of post-
translational modifications, alterations to the reduction-oxidation (redox) balance 
of the ER, changes in calcium concentration, pathogen infection, nutrient 
deprivation, as well as normal differentiation and function of professional 
secretory cells. ER stress occurs when the amount of unfolded protein in the ER 
is greater than the capacity of the cellular machinery to deal with this protein 
load. The cellular response is to restore homeostasis by increasing the protein-
folding capacity of the ER and to trigger apoptosis when the system remains 
overwhelmed. This is coordinated by the UPR which: (i) reduces the amount of 
newly synthesised protein delivered to the ER; (ii) upregulates the expression of 
chaperones and foldases as well as proteins involved in ER entry and 
degradation pathways; (iii) induces the expansion of the secretory apparatus 
involving lipid biogenesis and increases vesicle trafficking; (iv) regulates cell 
cycle progression, autophagy and apoptosis (reviewed in (Schroder and 
Kaufman, 2005)). Many diseases are associated with chronic ER stress 
including neurodegenerative disorders (reviewed in (Matus et al., 2008)), cancer 
(reviewed in (Moenner et al., 2007)), inflammation and autoimmunity (reviewed 
in (Todd et al., 2008)) (Yoshida, 2007) and diabetes (reviewed in (Lipson et al., 
2006)). Recent studies have linked insulin signalling via the PI3K pathway 
directly to the UPR via the interaction of a PI3K regulatory subunit and X-box 
binding protein-1 (XBP-1); see section 1.3.3.1 (Winnay et al., 2010). This 
interaction is required for the nuclear translocation of XBP-1 and adaptation to 
metabolic induced ER-stress, thereby preventing the development of insulin 
resistance (Park et al., 2010). Therefore, uncovering the mechanisms of UPR 
regulation in these disease states allows further insight into the response and 
may uncover novel therapeutic strategies.  
 
The UPR was originally discovered in budding yeast cells as a single pathway 
mediated by inositol-requiring kinase/endonuclease-1 (IRE-1), a type 1 ER-
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resident transmembrane protein (reviewed in (Patil and Walter, 2001)). Higher-
order eukaryotic organisms have evolved a more complex UPR with three 
separate branches. Signalling is initiated by three distinct ER integral 
membrane proteins, activating transcription factor-6 (ATF6), protein kinase RNA 
(PKR)-like ER kinase (PERK) and the conserved IRE-1α (see Figure 1-5). The 
UPR in mammalian systems is however highly coordinated and there is a 
degree of cross-talk between the pathways which includes redundancy, positive 
reinforcement and negative feedback (reviewed in (Ron and Walter, 2007)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 The mammalian unfolded protein response 
During unstressed conditions (top panel), BiP binds to and inhibits the three endoplasmic 
reticulum (ER)-proximal unfolded-protein response (UPR) transmembrane proteins: activating 
transcription factor 6 (ATF6), inositol-requiring transmembrane kinase/endonuclease 1 (IRE1) 
and pancreatic ER kinase (PERK). ER stress is averted as long as newly synthesized proteins 
fold properly as they transit into the ER lumen through SEC61 channel proteins. When unfolded 
proteins accumulate during stress (bottom panel), BiP is recruited away from ATF6, IRE1 and 
PERK. This has the potential to activate the different UPR signalling axes. A | The release of 
BiP exposes a Golgi-localization sequence (GLS) within ATF6 (Aa), targeting the molecule for 
the Golgi. In the Golgi, ATF6 is sequentially cleaved by site-1 protease (S1P) and S2P (Ab). 
This releases the ATF6 fragment (ATF6f) transcription factor, which translocates to the nucleus, 
binds to ER-stress response elements (ERSE) and induces transcription of several genes, 
including BIP, CHOP (CCAAT/enhancer-binding protein, homologous protein) and X-box 
binding protein 1 (XBP-1) (Ac). (B) The release of BiP from IRE1 allows for homodimerisation 
and activation of IRE1 through autophosphorylation. Unfolded proteins themselves may also 
directly activate IRE1 (Ba). Phosphorylated IRE1 possesses endoribonuclease activity that 
excises a 26 base pair fragment from unspliced XBP-1 mRNA and, following religation by a 
putative tRNA ligase, forms spliced XBP-1s mRNA (Bb). XBP-1s protein translocates to the 
nucleus, where it binds to UPR elements (UPREs) and activates many genes that are crucial for 
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secretory function. One of these gene products, p58IPK, inhibits PERK activity. Although XBP-1u 
protein is short-lived, it can impair XBP1s transcriptional function (Bc). In addition to its 
endoribonuclease activity, phosphorylated IRE1 also leads to activation of JUN N-terminal 
kinase (JNK), through TRAF2 (tumour-necrosis factor (TNF)-receptor-associated factor 2) and 
ASK1 (apoptosis signal-regulating kinase 1; not shown), which can promote cell survival by 
inducing autophagy or can lead to programmed cell death through caspase-12-mediated 
apoptosis pathways (Bd). C | Much like IRE1, PERK is activated by autophosphorylation 
following the release of BiP. Phosphorylated PERK also phosphorylates eukaryotic translation-
initiation factor-2α (eIF-2α), causing translational arrest of most proteins and subsequent cell 
cycle growth arrest (Ca). However, ATF4 mRNA escapes translational suppression because it 
possesses upstream open reading frames (ORFs) (Cb). ATF4 translocates to the nucleus, 
where it activates a third set of UPR target genes (Cc). These include GADD34 (growth-arrest 
DNA damage gene 34), which feedbacks to inhibit PERK, and CHOP, which can induce 
apoptosis in cells with irrecoverable levels of ER stress. Although each UPR pathway induces 
different target genes, in total they allow a cell to combat the endogenous stress of unfolded 
proteins by shutting off the synthesis of new proteins. They also enable a cell to export existing 
proteins by increasing the secretory capacity of the cell, ERAD, ER-associated degradation. 
Taken from (Todd et al., 2008). 
 
In the absence of stress, the ER-lumenal domains of these signal transducers 
are bound by the IgH binding protein, BiP/GRP78, and held in an inactive state 
(Bertolotti et al., 2000) (see Figure 1-5 top panel). However BiP, an ER 
chaperone, has an affinity for hydrophobic motifs that are normally found on the 
interior of properly folded proteins. The presence of unfolded protein in the ER 
titrates BiP away from the UPR signalling initiators, allowing signals to be 
relayed to the effector regions in the cytosol (Schroder and Kaufman, 2005) 
(see Figure 1-5 bottom panel).  IRE-1α and PERK closely resemble each other 
and have serine/threonine kinase cytoplasmic domains (Bertolotti et al., 2000). 
ER stress induces lumenal-domain-directed homodimerisation, 
autophosphorylation and activation of IRE-1α and PERK (see Figure 1-5 Ba and 
Ca). ATF6 in response to ER stress is transported to the Golgi, where it is 
cleaved by proteases (S1P and S2P) (see Figure 1-5 Aa and Ab). This releases 
the N-terminal fragment of ATF6 which translocates to the nucleus and 
activates transcription of target genes (Ye et al., 2000) (see Figure 1-5 Ac). 
 
Structural analysis has revealed that the lumenal domain of yeast IRE-1α is 
able to detect unfolded proteins directly (Credle et al., 2005). Despite this, 
overexpression of BiP attenuates transducer activity suggesting a possible 
hybrid mechanism of unfolded protein recognition (Kimata et al., 2007). 
However, this may not apply to mammalian IRE-1α, as a recent study showed 
that mutant IRE-1α, which is unable to bind BiP, is active in the absence of 
unfolded protein (Oikawa et al., 2009). ATF6 has also been reported to sense 
ER stress via an alternative mechanism, possibly in response to nutrient 
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deprivation. Glycosylated ATF6 interacts with calreticulin, anchoring ATF6 to 
the ER, whereas underglycosylated ATF6 traffics to the Golgi (Hong et al., 
2004a). This links the UPR to ER quality control strategies mediated by calnexin 
and calreticulin (reviewed in (Kleizen and Braakman, 2004)). These alternative 
mechanisms of sensing unfolded protein may also explain the selective 
activation of the branches of the UPR seen in certain instances for example 
plasma cell differentiation (discussed further 1.4.4) (Ma et al., 2010). 
 
1.3.1 PERK 
The PERK dependent pathway of the UPR is activated most rapidly in response 
to ER stress and mediates translational repression via the phosphorylation of 
eukaryotic initiation factor-2α (eIF-2α) (Harding et al., 1999) (see Figure 1-5 
Ca). This immediate response acts to prevent any further accumulation of 
protein in the ER. This causes a reduction in the level of proteins that are 
continually expressed and turned over, for example cyclin D1, resulting in G1 
cell-cycle arrest in cells experiencing ER-stress (Tomida et al., 1996). However, 
this translational arrest is not complete, for example, the translation of ATF4 
actually requires eIF-2α phosphorylation and ATF4 is important for the recovery 
from several cellular stresses (see Figure 1-5 Cb). (Harding et al., 2000) 
(Harding et al., 2003) (Lu et al., 2004b) (Clemens, 2001). ATF4 upregulates 
genes involved in amino acid synthesis, redox metabolism (Harding et al., 2003) 
as well as the growth-arrest DNA damage gene 34 (GADD34), which enhances 
the dephosphorylation of eIF-2α by protein phosphatise 1 (PP1). ATF4 can 
thereby act as a negative regulator of PERK-mediated inhibition of translation, 
allowing the expression of the proteins required for ER recovery (see Figure 1-5 
Cc) (Novoa et al., 2003). ATF4 and ATF6 also drive the expression of the 
proapoptotic transcription factor, CCAAT/enhancer binding protein, homologous 
protein (CHOP), which inhibits transcription of Bcl-2 (Zinszner et al., 1998). This 
factor may play an important role in switching the UPR from prosurvival to 
apoptotic signalling (Rutkowski et al., 2006). Finally, PERK is also responsible 
for the phosphorylation and activation of NF-E2-related factor-2 (NRF2), which 
acts on genes important for maintaining the redox homeostasis of the ER 
(Cullinan and Diehl, 2004).  
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1.3.2 ATF6 
The second wave of the UPR is mediated by ATF6, of which there are two 
paralogues in mammals, ATF6α and ATF6β (Haze et al., 1999). ATF6β has a 
minimal role in the UPR (Thuerauf et al., 2004). ATF6α is a type II 
transmembrane protein, containing a cytosolic bZIP transcription factor domain 
and therefore has the potential to homo- and hetero-dimerise with other 
members of the bZIP transcription factor family (Newman and Keating, 2003). 
ATF6α activates transcription from the promoter of genes containing ER-stress 
response elements (ERSEs) (see Figure 1-5 Ac). These genes include 
chaperones required for efficient protein folding, for example BiP and protein di-
sulphide isomerase (PDI) that increase the folding capacity of the ER as well as 
genes involved in ER-associated protein degradation (ERAD) (Okada et al., 
2002) (Yamamoto et al., 2007). ERAD is the process of retro-translocation of 
unfolded proteins from the ER lumen into the cytosol for degradation by the 
proteasome. ATF6 has also been reported to play a role in ER expansion and 
lipid biosynthesis (Bommiasamy et al., 2009).  
 
Several tissue specific regulators of the UPR have been identified with 
homology to ATF6. These ER-anchored transcription factors are likely to be 
activated in a similar manner to ATF6, and integrate the function of the UPR 
into a range of physiological systems. For example, liver-specific cyclic-AMP 
responsive element binding protein - hepatocyte (CREBH) is regulated by ER-
stress mediated proteolysis but does not act as a typical UPR-transactivator 
(Omori et al., 2001). CREBH and ATF6 function to activate the systemic 
inflammatory component of innate immunity, the acute phase response (APR), 
and therefore link ER stress to liver secretion of inflammatory proteins and the 
innate immune system (Zhang et al., 2006).  
 
1.3.3 IRE-1 
ER stress leads to the activation of both the kinase and endonuclease domains 
of the ubiquitously expressed IRE-1α isoform (reviewed in (Hetz and Glimcher, 
2009)). IRE-1α can then bind to the tumour-necrosis factor (TNF)-receptor-
associated factor-2 (TRAF2) which activates JNK signalling via  apoptosis 
signal-regulating kinase-1 (ASK-1) (Urano et al., 2000) (Nishitoh et al., 2002) 
(see Figure 1-5 Bd). This signalling can activate autophagy, a survival 
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mechanism that can remove damaged organelles and aggregated proteins 
(Ogata et al., 2006) (Bernales et al., 2006). JNK activation can also induce 
apoptosis of those cells that are unable to recover from ER stress, an effect 
mediated by caspase 12 (Yoneda et al., 2001). IRE-1α activity is also 
modulated by BAX, BAK and ‘BH3 only’, members of the B-cell lymphoma 2 
(Bcl-2) family of cell death regulators, again connecting the UPR to apoptosis 
(Hetz et al., 2006) (Klee et al., 2009). These proteins are thought to act as 
determinants of cell fate depending on the level of ER stress experienced. 
Severe ER stress leads to a conformational change of these proteins, calcium 
release from the ER and subsequent cytochrome C release from mitochondria, 
initiating the caspase cascade resulting in apoptosis (reviewed in (Rao et al., 
2004)). A protein tyrosine phosphatase 1B (PTP-1B) is also involved in IRE-1α 
function. Absence of PTP-1B reduces ER-stress induced apoptosis, JNK 
activation and XBP-1 splicing (Gu et al., 2004). IRE-1α also modulates other 
‘alarm sensing’ pathways including p38, ERK and NF-κB (Nguyen et al., 2004) 
(Hu et al., 2006). The outcome of IRE-1α activation is thought to be ‘fine-tuned’ 
by its association with different adaptors and modulatory proteins, outlined 
above. This signalling platform has been referred to as the ‘IRE-1α interactome’ 
or UPRosome, and its function depends on the cell type and the nature of the 
stress encountered (Hetz and Glimcher, 2009).  
 
Recently, a direct role for IRE-1α in the degradation of mRNA has been 
described as part of an attempt to reprogramme translation towards UPR-
induced genes (Hollien et al., 2009) (Han et al., 2009). This function of the 
endoribonuclease domain of IRE-1α has been proposed to relieve the ER of 
proteins that are challenging to fold, but may also target mRNA that encodes 
chaperones and can lead to apoptosis. This highlights the biphasic response of 
the UPR; firstly to attempt recovery and secondly to mediate cell death where 
homeostasis cannot be restored. 
 
The complete transcriptional response mediated by IRE-1α is delayed in 
comparison to that of ATF4 and ATF6 (Yoshida et al., 2003). This is due to the 
low expression of the substrate for the IRE-1α endonuclease domain, X-box 
binding protein 1 (XBP-1) mRNA (Nekrutenko and He, 2006). The expression of 
XBP-1, a bZIP transcription factor, is only increased in response to ER-stress 
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partly via the ATF6 pathway (Yoshida et al., 2001) (Lee et al., 2002) 
(Yamamoto et al., 2007). Therefore, after the induction of the initial phase of the 
UPR, IRE-1α is able to cleave a 26 nucleotide unconventional intron from XBP-
1 mRNA (see Figure 1-5 Bb). XBP-1 mRNA is thought to be targeted to IRE-1α 
by XBP-1 unspliced (XBP-1u) protein, which associates with the ER membrane 
and recruits XBP-1u transcript (Yanagitani et al., 2009) IRE-1α mediated 
splicing results in a open reading frame-shift and a transcript that encodes a 
371 amino acid, 54 kDa, spliced XBP-1 (XBP-1s) bZIP isoform that has a potent 
C-terminal transactivation domain (Calfon et al., 2002) (Lee et al., 2002) (see 
Figure 1-5 Bc).  
 
1.3.3.1 XBP-1 
XBP-1 is a critical effector of the UPR and regulates many of the genes required 
for ER homeostasis, including chaperones and components of ERAD, and is 
also involved in ER membrane biogenesis (Lee et al., 2003b) (Shaffer et al., 
2004) (Sriburi et al., 2004). One of the targets of XBP-1, p58IPK, is a negative 
regulator of PERK-mediated translation repression; highlighting the crosstalk 
between the UPR axes (see Figure 1-5 Bc) (Yan et al., 2002). This cross talk is 
also evident in the bZIP heterodimerisation between XBP-1s and ATF6: with 
many of their target genes overlapping (Newman and Keating, 2003) (Lee et al., 
2003b) (Yamamoto et al., 2007). Unspliced XBP-1 (XBP-1u) mRNA is 
translated to yield a 261 amino acid, 33 kDa, XBP-1u isoform which lacks the 
transactivation domain and undergoes rapid degradation (Lee et al., 2003a) 
(Tirosh et al., 2006). It has been reported that XBP-1u may act as a dominant 
negative regulator of XBP-1s by occupying the binding sequences in target 
promoters; therefore degradation of XBP-1u is required for XBP-1s activity (Lee 
et al., 2003a). XBP-1u also accumulates during the recovery phase of ER stress 
and has been shown to inhibit XBP-1s nuclear entry (Yoshida et al., 2006). 
XBP-1u therefore acts to negatively regulate the spliced active form (XBP-1s) 
and this branch of the UPR.  
 
XBP-1 was first identified by its ability to bind to a conserved transcriptional 
element, the x-box, of the genes encoding MHC class II human leukocyte 
antigen (HLA) DPB and DRA (Liou et al., 1990). XBP-1 was found to bind 
preferentially to this promoter element, which is related to the cyclic AMP-
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response element (CRE), in additional genes (Clauss et al., 1996). In these 
XBP-1 cis-acting elements the ‘ACGT’ core sequence was shown to be highly 
conserved (Yamamoto et al., 2004) (Kanemoto et al., 2005). Recently, a ChIP-
on-chip analysis of XBP-1 binding sites in vivo confirmed the targets that 
contain ‘ACGT’ (unfolded protein response elements (UPREs)) but also 
identified related but distinct XBP-1 responsive sequence motifs (Acosta-Alvear 
et al., 2007). Genes containing the distinct binding motifs belonged to diverse 
functional categories including cell differentiation and DNA–damage pathways. 
This study also suggested that XBP-1 may regulate genes in a cell-type 
dependent manner, possibly by the recruitment of various accessory factors.  
 
Studies using knockout mice have shown that XBP-1 is essential for 
hepatogenesis, as XBP-1-/- embryos die at day 13.5-14.5 with severe liver 
hypoplasia (Reimold et al., 2000). In XBP-1-/- mice with a targeted expression 
of XBP-1 in the liver, defects are reported in the secretory exocrine glands, such 
as the salivary glands and the pancreas. These animals die early from a failure 
to secrete digestive enzymes from the acinar cells of the pancreas (Lee et al., 
2005). XBP-1 has also been implicated in cardiac myogenesis (Masaki et al., 
1999).  
 
Most recently XBP-1 has been found to be important in protecting the cell from 
the ER stress associated with activation of the innate immune system, auto-
immunity and inflammation (Todd et al., 2008). In addition a TLR mediated 
mechanism of XBP-1 activation in macrophages has been demonstrated which 
did not involve the induction of the complete ER-stress response (Martinon et 
al., 2010). However, the outcome of increased bacterial burden and decreased 
production of inflammatory cytokines when XBP-1 deficient mice are challenged 
with bacterial infection, does suggest a role for a specific predominantly XBP-1 
mediated UPR. Removal of XBP-1 also leads to disrupted ER morphology and 
increased larval lethality in C.elegans challenged with pathogenic bacteria 
(Richardson et al., 2010). Further, the risk of developing both types of 
inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis 
(UC) has been associated with several single-nucleotide polymorphisms (SNPs) 
within the XBP1 gene locus (Kaser et al., 2008). XBP-1 is also important in the 
development of both conventional and plasmacytoid dendritic cells (DCs) 
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(Iwakoshi et al., 2007). Spliced XBP-1 was also found in freshly isolated DCs 
and DC cell lines; indicating the UPR is required for DC function, possibly to 
facilitate antigen processing and cytokine production. In all these instances, 
XBP-1 promotes cellular survival, differentiation and function by regulating the 
folding capacity of the secretory apparatus to allow increased protein synthesis 
(Shaffer et al., 2004) (Sriburi et al., 2007). For this reason, XBP-1 is vital for the 
development of professional secretory cells including antibody-secreting plasma 
cells (see section 1.4.4) (Reimold et al., 2001) (Iwakoshi et al., 2003).  
 
Alongside its function in normal cell development, XBP-1 has also been shown 
to be necessary for cell survival under hypoxic conditions and tumour growth 
(Romero-Ramirez et al., 2004); indicating the importance of XBP-1 and the 
UPR in a variety of physiological stresses that induce ER stress (see section 
1.5.2). KSHV is known to infect B-cells and reactivate in response to hypoxia 
(see section 1.1.6) (Davis et al., 2001). Therefore, this thesis investigates 
further KSHV reactivation in reaction to the cellular stress associated with B-cell 
development and hypoxia (see sections 1.4 and 1.5). 
 
1.4 B-cell development  
B-cell development can be divided into two stages: the antigen-independent 
phase that occurs in the bone marrow, to produce mature B-cells (involving the 
pro-B-cell and pre-B-cell stages), and an antigen dependent differentiation 
phase that is completed in the periphery (resulting in memory or effector B-
cells) (see Figure 1-6) (reviewed in (Johnson et al., 2005b)). Each stage is 
influenced by external factors and is regulated by a complex transcription factor 
network (reviewed in (Schmidlin et al., 2009)). Pro-B-cells derive from 
pluripotent hematopoietic stem cells in the bone marrow, and are stimulated to 
proliferate by various factors, including stromal cell-derived growth factor-1 
(SDF-1) and IL-7, secreted by surrounding cells. Commitment to the B-cell 
lineage depends on several transcription factors, early B-cell factor, Pu.1, E2A 
and paired box protein 5 (PAX5) as well as microRNA expression (reviewed in 
(Busslinger, 2004)) (Chen et al., 2004).  
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Figure 1-6 B-cell development 
B-cell development occurs in both the bone marrow and peripheral lymphoid tissues such as the 
spleen. In the bone marrow, development progresses through the pro-B-cell, pre-B-cell and 
immature-B-cell stages. During this differentiation, rearrangements at the immunoglobulin locus 
result in the generation and surface expression of the pre-B-cell receptor (pre-BCR, which is 
comprised of an Ig heavy chain and surrogate light chains (VpreB or V5)) and finally a mature 
BCR (comprised of rearranged heavy- and light-chain genes) that is capable of binding antigen. 
At this immature stage of development, B cells undergo a selection process to prevent any 
further development of self-reactive cells. Both receptor editing and clonal deletion have a role 
at this stage. Cells successfully completing this checkpoint leave the bone marrow as 
transitional B cells, eventually maturing into mature follicular B cells (or marginal-zone B cells). 
Following an immune response, antigen-specific B cells develop into either plasma (antibody-
secreting) cells or memory B cells. Taken from (Cambier et al., 2007). 
 
B-lymphocytes are part of the adaptive immune system and provide protection 
against a variety of pathogens; by recognising a broad range of foreign proteins 
via a diverse B-cell receptor (BCR) repertoire. Diversity is generated early in 
development, firstly by random rearrangement of immunoglobulin heavy chain 
(IgH) locus, during the pro-B-cell stage. The process is known as V(D)J 
recombination and is catalysed by recombinase-activating genes (RAG1/2) and 
terminal deoxynucleotide transferase (TdT) (reviewed in (Bassing et al., 2002)). 
Successful recombination of IgH leads to pre-B-cells that express the pre-B-cell 
receptor (pre-BCR, which is comprised of an Igµ heavy chain and surrogate 
light chains (VpreB or Vλ5)). This step is necessary for B-cell maturation and 
allows clonal expansion and rearrangement of light gene (IgL) segments to form 
an immature BCR that can bind antigen (Ollila and Vihinen, 2005). At this stage, 
negative selection occurs through tolerance mechanisms including deletion, or 
receptor editing (reviewed in (Meffre and Wardemann, 2008) (von Boehmer and 
Melchers, 2010)). This ensures B-cells expressing self-reactive BCRs do not 
enter circulation thereby preventing autoimmunity and related diseases.  
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Naive B220+, IgM+ B-cells continue their maturation in the spleen, through a 
series of ‘transitional’ stages (T1 and T2) and another round of negative 
selection, resulting in possible anergy (Chung et al., 2003) (Cambier et al., 
2007).  T1 B-cells have yet to acquire the ability to re-circulate and are found in 
the bone marrow and spleen. T2 have entered the follicles and can re-circulate; 
they have also acquired cell surface IgD and CD23, but still carry markers of 
immaturity. At this point, in the murine system, a subset of B-cells, termed 
marginal zone (MZ) B-cells, is derived (reviewed in (Pillai et al., 2005)). In 
humans these cells circulate in a similar manner to memory cells and secrete 
‘natural antibodies’ without antigenic stimulation; whilst also responding to 
bacterial and self-antigens (see section 1.4.3) (Martin and Kearney, 2000) 
(Martin et al., 2001). These cells also have elevated levels of the transcription 
factor B-lymphocyte induced maturation protein-1 (BLIMP-1), allowing rapid 
differentiation to plasmablasts. Entry to the MZ B-cell subset in mice is based 
on low affinity BCR signalling and requires notch and NF-κB signalling (Pillai 
and Cariappa, 2009). However, in humans it still remains to be determined 
whether MZ B-cells are a separate B-cell subset or a specialised antigen-
specific branch of memory B-cells (see section 1.4.3).  
 
Another minority B-cell subset capable of secreting ‘natural antibodies’ are the 
B1 B-cells (reviewed in (Berland and Wortis, 2002) (Shapiro-Shelef and 
Calame, 2005)). B1 B-cells are also capable of responding to bacterial antigens 
and have a BCR repertoire that is biased towards recognition of T-cell 
independent type II antigens and self-antigens (Martin et al., 2001). These cells 
are predominantly found in the pleural and peritoneal cavities and the gut 
lamina propria. Although they secrete antibody in a BLIMP-1 dependent 
manner, they are different from the majority of conventional B-cells in various 
ways including cell surface markers and an ability to self-renew (Fairfax et al., 
2007). It is not known when B1 B-cells diverge from conventional B-cell 
development and in humans their existence is heavily debated.  
 
The majority of B-cells mature into naive follicular/B-2 conventional B-cells and 
will be the focus of this introduction. B2 B-cells circulate between the follicles in 
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the spleen, lymph nodes and bone marrow until they die or encounter their 
cognate antigen. 
 
1.4.1 B-cell activation 
 
The activation of antigen-specific B-cells requires two signals in order to prevent 
inappropriate activity: the first is BCR signalling; initiated by encountering 
antigen, usually presented by antigen-presenting cells (APCs). B-cells meet and 
respond to antigen through many different mechanisms depending on the 
cellular context and location in which antigen presentation occurs. This provides 
the greatest protection from pathogens for the host, as an appropriate response 
can be initiated to a particular antigen, for example cell-mediated presentation 
affords greater regulation and coordination of the immune response (reviewed 
in (Batista and Harwood, 2009)).  
 
B-cell activation is dependent on the overall binding strength or avidity for the 
antigen; this is increased by the formation of clusters of BCRs (BCR 
microclusters), to allow successful BCR stimulation (Harwood and Batista, 
2008). BCR signalling is propagated further by the spreading of B-cell surface, 
mediated by extension of lamellipodial protrusions, this allows the B-cell to 
engage with more antigen in receptor complexes (Fleire et al., 2006) (Harwood 
and Batista, 2008). BCR activation recruits a range of signalling molecules, 
including the kinases LYN and spleen tyrosine kinase (SYK), to form a 
‘signalosome’, which can trigger a variety of processes including BCR mediated 
internalisation of antigen (reviewed in (Harwood and Batista, 2008)). The 
antigen is then processed and presented on the cell surface in a complex with 
MHC II (Lanzavecchia, 1985) (Batista et al., 2001). This complex is recognised 
by the T-helper cell population that have been clonally expanded by recognition 
of the same antigen; in the formation of an immunological synapse (IS) with an 
APC (reviewed in (Friedl et al., 2005) (Klein and Dalla-Favera, 2008)). T-cell 
receptor (TCR) engagement with MHC II on the B-cell, via a second IS, 
provides the second signal required for B-cell proliferation and differentiation 
(Lanzavecchia, 1985). Co-stimulatory signals are also required to modulate the 
B-cell activation response, and occur between B-cell-surface receptors and 
ligands on T cells and/or APCs (reviewed in (Bishop and Hostager, 2001)). One 
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of the key interactions is between the tumour-necrosis factor (TNF)-receptor 
family member CD40, which is expressed by all B cells, and its ligand CD154 
expressed by T-helper cells. Upon activation B-cells can either differentiate to 
form extra-follicular plasmablasts, required for rapid antibody production and 
early protective immune responses or, with T-cell help, enter a germinal centre 
(GC) reaction. 
 
1.4.2 Germinal centres 
Activated proliferating B-cells can form a germinal centre (GC), which displaces 
resting B-cells within the follicles of peripheral lymphoid tissues, into a 
surrounding mantle zone. B-cells within this secondary follicle structure undergo 
affinity maturation, resulting in the production of both plasma cells, capable of 
producing high-affinity antibodies, and long-lived memory B cells, which provide 
protection against secondary antigen challenge (reviewed in (Schmidlin et al., 
2009) (Klein and Dalla-Favera, 2008) (Wolniak et al., 2004)). Rapidly 
proliferating cells known as centroblasts pack densely together to form the dark 
zone of the germinal centre. These cells undergo the process of somatic 
hypermutation (SHM), which modifies the genes encoding the immunoglobulin 
variable regions of the heavy and light chains (reviewed in (Liu and Schatz, 
2009)). This is achieved by introducing base pair mutations as well as small 
deletions and insertions into V(D)J recombination sites (Goossens et al., 1998). 
This leads to either an increased or decreased affinity for the given antigen. 
High affinity centroblasts then differentiate into non-dividing centrocytes which 
migrate to the light zone of the germinal centre. The light zone contains follicular 
dendritic cells (FDCs), T-cells and macrophages which aid the continued 
selection for enhanced binding to the antigen. At this stage, and at other times 
outside of the germinal centre, class switch recombination (CSR) may occur 
(Toellner et al., 1996). This allows the immunoglobulin isotype expressed by a 
B-cell to be changed from IgM or IgD to IgA, IgG or IgE; via non-homologous 
end-joining recombination between specific switch regions upstream of the 
heavy chain constant regions (reviewed in (Stavnezer et al., 2008)). This alters 
the function of an antibody without modifying the variable region. This process 
is linked to SHM; both require the enzyme activation induced cytidine 
deaminase (AID) to increase antibody diversity (reviewed in (Longerich et al., 
2006) (Hackney et al., 2009)). Uracil DNA-glycosidase (UNG) is also required 
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for CSR (Rada et al., 2002). Centrocytes and centroblasts cycle between the 
light and dark zones of the germinal centre, clonally expanding and undergoing 
further rounds of CSR and SHM, in a process known as affinity maturation. 
Eventually, a centrocyte is antigen selected to differentiate into a memory B-cell 
or a plasmablast (pre-antibody secreting plasma-cell) (Allen et al., 2004).  
 
The signals required for the differentiation of GC-B-cells are relatively unclear. 
Differentiation into a memory cells appears to randomly occur throughout the 
germinal centre reaction (Blink et al., 2005). In contrast post-GC differentiation 
into plasma cells is driven by a high affinity BCR (Phan et al., 2006). The 
process is however governed by transcription factors, and their regulation has 
been shown to control B-cell development. B-cell lymphoma-6 (BCL6) is the 
master transcriptional regulator of centroblasts and is expressed in some 
centrocytes (Cattoretti et al., 1995) (reviewed in (Klein and Dalla-Favera, 
2008)). B-cells that lack BCL-6 expression do not form germinal centres or 
undergo affinity maturation (Dent et al., 1997) (Ye et al., 1997). BCL-6 functions 
as a repressor and downregulates those genes involved in growth suppression 
and apoptosis, especially in response to genotoxic stress (Polo et al., 2004). 
This allows the cells of the germinal centre to rapidly proliferate and undergo 
the necessary processes of SHM and CSR (Shaffer et al., 2000) (Parekh et al., 
2007). BCL-6 also has a role in suppressing the genes required for T-cell 
dependent B-cell activation, preventing premature differentiation of cells 
(Shaffer et al., 2000). Finally, BCL6  (in combination with Spi-B, an Ets 
transcription factor) specifically blocks plasma cell differentiation by repression 
of positive-regulatory-domain-containing-1 (Prdm1), which encodes B-
lymphocyte induced maturation protein-1 (BLIMP-1) a repressor crucial for 
plasma cell development (see Figure 1-7) (Tunyaplin et al., 2004) (Schmidlin et 
al., 2008) (Shapiro-Shelef et al., 2003) (reviewed in (Crotty et al., 2010)). The 
metastasis-associated 1 family member 3 (MTA3) is required for BCL6-
mediated repression of BLIMP-1 (see Figure 1-7). Removal of this protein using 
siRNA leads to de-repression of BLIMP-1 and plasma cell differentiation. 
Interestingly, overexpression of BCL-6 in multiple myeloma (a tumour of plasma 
cells) results in MTA3 dependent de-differentiation, with cells becoming more 
GC-like (Fujita et al., 2004).   
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Figure 1-7 Transcription factors control of plasma cell development 
Transcriptional repression enforces mutually exclusive B-cell and plasma-cell gene-expression 
programmes. Several transcription factors — BCL6 (B-cell lymphoma 6), MTA3 (metastasis-
associated 1 family, member 3), MITF (microphthalmia-associated transcription factor) and 
PAX5 (paired box protein 5) — repress plasmacytic development by repressing BLIMP1 (B-
lymphocyte-induced maturation protein 1), XBP-1 (X-box-binding protein 1) and IRF4 
(interferon-regulatory factor 4). In plasma cells, BLIMP1 represses B-cell gene-expression 
programmes. This mutual repression prevents the unelicited formation of plasma cells in the 
germinal centre and prevents the reversion of plasma cells to a B-cell stage. BCR, B-cell 
receptor; TLR, Toll-like receptor. BCL-6, MTA3, PAX5 and MITF also regulate the expression of 
genes that are required for B-cell and germinal-centre functions, which are outlined in the pink 
box. BLIMP1, XBP1 and IRF4 induce the expression of genes that are required for plasma cells, 
which are outlined in the blue box. Taken from (Shapiro-Shelef and Calame, 2005).  
 
In order for GC-B-cells to growth arrest, interact with other cells and 
differentiate, BCL6 must be down regulated. BCR signalling has been shown to 
cause BCL6 degradation via the proteasome. However, BCR-mediated BCL6 
repression is not sufficient to induce plasma cell differentiation and many other 
signals are required to alter the B-cell transcriptional profile (Schliephake and 
Schimpl, 1996) (Shapiro-Shelef and Calame, 2005) (see section 1.4.4). B-cell 
engagement with T-cells, and consequent CD40 induced signalling, also inhibits 
BCL6 transcription by the upregulation of another transcription factor involved in 
plasma cell differentiation, IRF4 (see Figure 1-7) (Niu et al., 1998) (Basso et al., 
2004) (Falini et al., 2000) (Saito et al., 2007) (see section 1.4.4).  Cytokines play 
an important role in guiding the post-GC differentiation, for example the 
presence of IL-4 and IL-5 increases the potential for plasma cell development 
(Hasbold et al., 2004). Toll-like receptor (TLR) signalling also plays an important 
part in B-cell differentiation, with TLR-9-mediated activation of naive B-cells 
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triggering plasma cell development (Huggins et al., 2007). Finally, activation of 
signal transducer and activator-3 (STAT3), via IL-21, has been shown to initiate 
B-cell terminal differentiation via the upregulation of plasma cell genes, such as 
BLIMP-1 (Ettinger et al., 2008) (Diehl et al., 2008). Therefore although the exact 
cues for GC exit are unknown, BCL6 degradation terminates the GC 
transcriptional program, allowing changes in the transcription factor repertoire 
for post-GC differentiation into long-lived memory or plasma B-cells (see Figure 
1-7).  
 
1.4.3 Memory cells 
Memory B-cells are long-lived, non-dividing cells that can rapidly proliferate and 
differentiate into plasma cells in response to secondary encounter with the initial 
immunising antigen (reviewed in (Tangye and Tarlinton, 2009)). In addition, 
memory B-cells can respond to polyclonal stimulation through pattern 
recognition and T-cell help (Bernasconi et al., 2002). Memory B-cells also 
function to replenish the long-lived antibody-secreting plasma cells (reviewed in 
(McHeyzer-Williams and McHeyzer-Williams, 2005)). All memory B-cells are 
IgD-, are slightly larger than naive B-cells, express higher levels of co-
stimulatory and activation markers and the majority express CD27. Memory B-
cells can be divided in to various subsets based on the isotype expressed, 
which has implications for their role in immunity (reviewed in (Sanz et al., 
2008)). For example, IgM+ CD27+ B-cells exclusively act against 
polysaccharide T-independent pathogens and may represent the human 
counterpart of murine MZ-B-cells (see section 1.4) (reviewed in (Tangye and 
Tarlinton, 2009)). Another distinct subset expresses the inhibitory receptor Fc-
receptor like 4 (FCRL4), and is restricted to mucosal tissues and mesenteric 
lymph nodes (Ehrhardt et al., 2005). CD27- B-cells have also been detected in 
the spleen, tonsils and peripheral blood, however detailed functional analysis of 
these groups has yet to be undertaken (reviewed in (Tangye and Tarlinton, 
2009)). Various mechanisms facilitate the rapid response of memory cells to 
antigen and include strategic location and a high affinity for the antigen 
(reviewed in (Schmidlin et al., 2009) (Tangye and Tarlinton, 2009)). In addition, 
the mechanisms by which memory cells can persist for more than 50 years in 
humans remains a subject of intense study, but the high level expression of 
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anti-apoptotic factors is thought to have a role (Good et al., 2009) (reviewed in 
(Tangye and Tarlinton, 2009)). 
 
The development of memory B-cells requires the germinal centre reaction and 
memory cells have mutated IgV genes (Tarlinton, 2006). Despite this, the role of 
BCL6 in this process is not clear. BCL6 is thought to encourage memory B-cell 
development by blocking plasma cell differentiation. External stimuli have also 
been shown to be important in regulating memory B-cell differentiation by 
upregulating BCL6 expression, for example via STAT5 phosphorylation 
(Scheeren et al., 2005). However, memory B-cells can develop in BCL6 
deficient mice, in the absence of GCs (Toyama et al., 2002) and BCL6 over 
expression was shown to maintain the GC-B-cell phenotype, preventing 
memory B cell differentiation in vitro (Kuo et al., 2007). Therefore, the 
transcriptional control of B-cell differentiation is complex and involves the 
interplay between many transcription factors. PAX5 encodes the B-cell specific 
activator protein (BSAP), another transcriptional repressor essential for 
maintaining mature B-cell identity (Nutt et al., 1999) (see section 1.4); it 
therefore must also be downregulated to facilitate B-cell terminal differentiation. 
PAX5 is expressed in memory B-cells and when PAX5 expression is blocked, in 
B-cell lines, the plasma cell differentiation transcriptional program is upregulated 
(Nera et al., 2006). PAX5 is able to directly repress XBP-1 and Ig expression 
preventing plasma cell development (Reimold et al., 1996) (Singh and Birshtein, 
1996) (see Figure 1-7). Continued CD40 signalling has also been implicated in 
directing centrocytes towards memory B-cell differentiation (Arpin et al., 1995).  
 
1.4.4 Plasma cells and the UPR 
The effector cell of the B-cell lineage is the plasma cell, which produces large 
amounts of immunoglobulin required for both innate and adaptive immunity 
(reviewed in (Shapiro-Shelef and Calame, 2005) (Radbruch et al., 2006)). 
BLIMP-1 a five zinc-finger motif containing transcriptional repressor protein is 
the master regulator of plasma cell differentiation. BLIMP-1 functions to 
downregulate BCR signalling, arrest the cell cycle and inhibit the germinal 
centre reaction allowing plasma cell differentiation (Turner et al., 1994) (Lin et 
al., 1997) (Shaffer et al., 2002). This role was revealed in studies where 
exogenously supplied BLIMP-1 was sufficient to induce plasmablast 
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differentiation, while  BLIMP-1 conditional knock mice were unable to develop 
plasma cells (Turner et al., 1994) (Shapiro-Shelef et al., 2003). BLIMP-1 can 
directly repress BCL6 and PAX5 expression, which alleviates their repression of 
BLIMP-1 and XBP-1 respectively; amplifying BLIMP-1 expression and allowing 
Ig production (Shaffer et al., 2002) (Lin et al., 2002) (Tunyaplin et al., 2004) (see 
Figure 1-7). BLIMP-1 was subsequently shown to act upstream of the 
transcription factor XBP-1, which is required for plasma cell development 
(Shaffer et al., 2004) (Reimold et al., 2001) (see section 1.3.3.1). However, 
overexpression of XBP-1 in the BLIMP-1-/- background failed to restore 
expression of the marker of plasma cells, CD138 (syndecan-1) and IgM 
secretion (Shapiro-Shelef et al., 2003). In fact many of the genes upregulated 
during plasma cell differentiation are upregulated by XBP-1 and BLIMP-1 
(Shaffer et al., 2004).  
 
XBP-1 knock-out mice are embryonic lethal (see section 1.3.3.1) therefore, 
using the recombination activating gene-2 (RAG-2) blastocyst complementation 
system, chimeric mice were developed. These mice had expected numbers of 
B-cells that expressed B220+, IgM and IgD, and were able to proliferate in 
response to CD40 antibody and IL-4 or LPS stimulation (Reimold et al., 2001). 
These B-cells also express activation markers, undergo CSR and have a 
normal cytokine profile. However, the levels of Ig secretion are decreased and 
no antibody response was mounted after challenge with both T-cell dependent 
and independent antigen, leaving these mice susceptible to polyoma virus 
infection. Additionally, the B-cells from XBP-1 -/-, RAG-/- chimeric mice did not 
express CD138 (Reimold et al., 2001).  
 
XBP-1 is essential for the development of Ig secreting plasma cells because of 
its role in the UPR (see section 1.3.3.1) (Shaffer et al., 2004) (Reimold et al., 
2001) (Iwakoshi et al., 2003). Supplying exogenous XBP-1 to XBP-1 deficient 
B-cells allowed plasma cell differentiation and Ig secretion (Iwakoshi et al., 
2003). When XBP-1 is supplied to B-cell lymphoma cell lines that have 
transcriptional profiles representative of post-GC B-cells or plasmablasts, cells 
become more plasma cell-like (Shaffer et al., 2004) (Wilson et al., 2007).  Gene 
expression profiling of these cells reveals XBP-1 upregulates genes involved in 
ER expansion, cell size, lysosome content, mitochondrial mass, ribosome 
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production, protein synthesis and cellular growth; aspects required to facilitate 
the synthesis and secretion of a large amount of antibody (Lee et al., 2003b) 
(Shaffer et al., 2004). Interestingly, BCR signalling has been shown to 
transiently induce XBP-1 activity and upregulate the expression of several 
chaperones (Skalet et al., 2005). However, this does not lead to plasma cell 
differentiation but does indicate that in response to antigen the UPR can be 
primed, supporting the idea that the UPR is activated prior to antibody 
production (van Anken et al., 2003). Another model suggests that BLIMP-1 
mediated de-repression of Ig secretion leads to ER-stress and IRE-1α activity, 
which subsequently leads to expansion of the secretory apparatus (Tirosh et al., 
2005). Recent studies have shown that XBP-1 activation during B-cell terminal 
differentiation is a differentiation-dependent event (Hu et al., 2009). This occurs 
before the UPR is activated and is required after the plasmablast stage of 
development (Todd et al., 2009). Overall, it is clear that B-cell terminal 
differentiation requires the transcription factor machinery of the UPR to attain a 
professional secretory phenotype and produce antibody for the immune 
response.  
 
IRE-1α is critical for XBP-1 splicing and activity and therefore IRE-1α deficient 
mice display similar defects in plasma cell development (Zhang et al., 2005). 
This study also revealed that IRE-1α is required at an earlier stage in B-cell 
development as IRE-1α-/- B-cells did not progress past the pro-B-cell stage. 
IRE-1α activity is important for the expression of the enzymes required for Ig 
gene rearrangement (Zhang et al., 2005) (see section 1.4). ATF6 is cleaved and 
activated in response to B-cell activation suggesting that this axis of the UPR is 
also involved in plasma cell differentiation (Gass et al., 2002) (Gunn et al., 
2004). The remaining PERK-mediated branch of the UPR network does not 
appear to have a role in plasma cell development as LPS treatment of PERK-/- 
B-cells increased their Ig production and developed a specialised secretory 
phenotype (Zhang et al., 2005) (Gass et al., 2008). Plasma cell differentiation is, 
therefore, a biological condition that causes selective activation of the IRE-1α 
and ATF6 branches of the UPR (Wu and Kaufman, 2006) (Ma et al., 2010). 
However, the question remains as to how this is achieved. PERK activation may 
be attenuated by p58IPK, which is upregulated during the differentiation process, 
but these cells can still activate PERK in response to further ER stress (Yan et 
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al., 2002) (Rutkowski et al., 2007) (Gass et al., 2008). During plasma cell 
differentiation PERK is, therefore, not completely inactivated, suggesting that a 
threshold level of ER stress is required to activate PERK that may be higher 
than that of the other UPR branches. Despite PERK and IRE-1α having many 
similarities, this disparity could also be linked to the ability of the sensors to 
detect unfolded protein (Bertolotti et al., 2000) (Liu et al., 2000). However, this 
situation is not true of all professional secretory cells. For example, PERK 
activation is necessary for the function of pancreatic secretory cells. These cells 
must deal with periodic increases in the demand for protein synthesis in 
response to post-parandial increases in blood-glucose (Harding et al., 2001) 
(Zhang et al., 2002).  
 
The individual axes of the UPR are selectively engaged during physiological 
stress in a tissue specific manner. Regulation of UPR in these situations is 
unclear, but probably depends on the formation of regulatory complexes such 
as the ‘UPRosome’ as well as interplay between UPR and other signal 
transduction pathways (see section 1.3.3).  Consequently, it is important to 
consider the contributions of the XBP-1 and UPR in the context of the other 
known factors that are important for plasma cell differentiation. BLIMP-1 
(discussed above) and interferon regulatory factor-4 (IRF4) are the two major 
transcription factors involved in plasma-cell development. IRF4 is required for 
mature B-cell formation, and if IRF4 is conditionally knocked-out in GC-B-cells, 
a defect is also seen in plasma cell differentiation (Mittrucker et al., 1997) (Klein 
et al., 2006). LPS stimulation of these cells did not lead to antibody secretion 
and XBP-1 was not expressed. Further study revealed that IRF4 activity is 
upstream of BLIMP-1 effects (Sciammas et al., 2006). However, evidence also 
exists that the expression of these genes was independently regulated, at the 
terminal differentiation stage (Kallies et al., 2007). IRF4 is negatively regulated 
by MITF, a basic helix-loop-helix transcriptional repressor (see Figure 1-7) (Lin 
et al., 2004). Knock-down of MITF causes spontaneous B-cell activation and 
antibody secretion, indicating its involvement in plasma cell differentiation. 
 
Post-transcriptional gene regulation by microRNAs has also been implicated in 
the regulation of B-cell terminal differentiation. MicroRNA-155 (miR155) is 
upregulated by antigenic stimulation, and is important in B-cell responses to 
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thymus-dependent and -independent antigens (Rodriguez et al., 2007). 
Reduced extra-follicular and germinal centre responses were observed in the 
absence of miR-155, resulting in reduced IgG1 secretion and impaired affinity 
maturation (Vigorito et al., 2007). This defect was not due to SHM or CSR but 
was related to a defect in differentiation and survival of plasmablasts. A role for 
miR-155 in memory B-cell development was also identified. Amongst the many 
predicted target genes of miR-155, involved in various functions, the Ets 
domain-containing transcription factor Pu.1 was confirmed as a direct target. 
Pu.1 is required at early stages of B-cell development, however its role in 
terminal differentiation is unclear (McKercher et al., 1996) (Polli et al., 2005). 
Pu.1 is highly expressed in GC-B-cells and is downregulated in post-GC-B-cells 
(Cattoretti et al., 2006). Pu.1 downregulation by miR-155 may therefore be 
important in the output of the GC reaction, but this is yet to be confirmed. Since 
many other genes, including activation-induced cytidine deaminase (AID), were 
targeted by miR-155 the phenotypic outcome of miR-155 deletion is probably 
due to a combination of changes in gene expression (Teng et al., 2008).  
 
1.4.5 B-cell lymphomas 
Tumours corresponding to almost all stages of B-cell development have been 
described in humans, although the majority arise from GC-B-cells (reviewed in 
(Kuppers, 2005)). The unique physiology of centroblasts allows them to tolerate 
genotoxic stress (induced by SHM and CSR) and rapidly proliferate, while 
avoiding apoptosis and cell cycle arrest (see section 1.4.2). For these reasons 
GC-B-cells are potentially more susceptible to genetic alterations, such as 
chromosomal translocations and malignant transformation. Tumours maintain 
many of the characteristics of the cell type from which they are derived. This is 
clearly evident in B-cell neoplasia where distinctive morphology, 
immunophenotypes, immunoglobulin gene sequences and recently, gene 
expression signatures, facilitate classification by their cell of origin (reviewed in 
(Kuppers et al., 1999) (Shaffer et al., 2006) (Staudt and Dave, 2005)). This is in 
agreement with the model that malignant B-cells are blocked at otherwise 
transitory developmental stages (Greaves, 1986). For example, PEL expresses 
CD138 and IRF4, but XBP-1 is absent, an expression profile representative of a 
plasmablast cell. PEL cells are therefore blocked prior to terminal differentiation 
to antibody-secreting plasma cell (see section 1.1.8.2) (Jenner et al., 2003). 
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Therefore, identification of the particular stage of B-cell development from which 
the cancer was established is critical for understanding the pathogenesis of the 
disease, and may lead to the development of therapeutic strategies.  
 
1.4.6 B-cells and gamma-herpesviruses 
The interaction between KSHV and its primary in vivo target, the B-cell, is not 
well understood. This is primarily due to the fact that B-cells are relatively 
refractory to KSHV infection in vitro. However, EBV, the most the closely related 
gamma-herpesvirus to KSHV, readily infects and transforms resting B-cells in 
vitro. Subsequently, the relationship between EBV and human B-cells has been 
extensively studied (reviewed in (Thorley-Lawson, 2005)). EBV infects naive B-
cells in vivo and mimics certain aspects of B-cell differentiation to drive the 
infected cells towards a memory cell phenotype (Souza et al., 2005) (Thorley-
Lawson and Babcock, 1999). Establishment of latent EBV infection in the 
memory B-cell compartment allows lifelong persistence within the host. The 
information on EBV infection of B-cells allows one to infer possible similarities 
between the two viruses.  
 
Table 1-5 EBV expression programmes (adapted from (Thorley-Lawson, 2001)) 
Expression programme Proteins 
expressed 
Expression 
observed in 
Function 
Latency III Growth 
programme 
EBNA1-6 
LMP1 
LMP2A-B 
Activated B-cell 
LCLs 
Activates resting B-
cells to form 
lymphoblasts 
 
Latency II Default 
programme 
EBNA1 
LMP1 
LMP2A 
GC-B-cell  
Classical Hodgkin’s 
lymphoma 
Episome 
maintenance, 
survival and 
proliferation 
Latency I  EBNA-1 
LMP2A transcript 
 
Burkitt’s lymphoma Allows persistence 
Latency 0 Latency 
Programme 
 
None 
 
Memory B-cells Allows persistence 
 
Lytic 
replication 
 Ordered lytic 
cascade 
Plasma cells Produces infectious 
virions 
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EBV like all herpesviruses has a latent and a lytic phase to its life cycle. The 
latent phase can be further divided into three programmes by transcriptional 
profiling (see Table 1-5). Upon infection of a naive B-cell EBV expresses the set 
of latent genes associated with the growth programme (Latency III – see Table 
1-5). The expression of these viral gene products is sufficient to activate the B-
cell in a similar manner to antigen encounter (reviewed in (Thorley-Lawson, 
2005)). Activated B-cells then migrate to the follicle, and the EBV transcriptional 
profile changes to the default programme in order to drive the B-cell through the 
GC reaction (Latency II – see Table 1-5). LMP-1 causes Ig gene mutation while 
LMP-2 induces isotype switching and together they mimic signals caused by 
antigen encounter and T-cell help, allowing the EBV infected cell to avoid 
negative selection and survive the GC reaction (see section1.4.2) (Burkhardt et 
al., 1992) (Kilger et al., 1998). LMP-1 also inhibits BCL6 expression, signalling 
the B-cell to leave the GC and enter the memory cell pool (Panagopoulos et al., 
2004). Circulating EBV infected memory cells are associated with the latency 
programme (Latency 0/1 – see Table 1-5), where minimal viral proteins are 
expressed, allowing immune evasion and non-pathogenic persistence. EBV 
does not drive constant proliferation. Instead, a transient burst of proliferation is 
required to activate and differentiate cells into resting memory B-cells. However, 
in an immuno-suppressed environment, when errors occur in this process (i.e. 
cells do not exit the growth programme) tumours can develop (reviewed in 
(Thorley-Lawson, 2005)). 
 
EBV reactivation has been linked to plasma cell differentiation via the 
transcription factor XBP-1 (Laichalk and Thorley-Lawson, 2005) (Sun and 
Thorley-Lawson, 2007) (Bhende et al., 2007) (McDonald et al., 2010). Antibody 
secreting cells not only provide the ideal environment (i.e. expanded secretory 
apparatus) for herpesvirus production but also migrate to the mucosal 
epithelium, for example the tonsils; a perfect site for shedding virus into the 
saliva for dissemination.  
 
The stage of development of the B-cell targeted for KSHV infection in vivo is not 
known. Recent in vitro studies have indicated the possible requirement of an 
activated phenotype (Rappocciolo et al., 2008). However, cells of the KSHV 
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associated disease, PEL, represent plasmablast cells, a B-cell stage just prior 
to terminal differentiation (see sections 1.1.8.2 and 1.4). Whether KSHV adopts 
the EBV model of driving B-cell differentiation remains to be answered. Despite 
the potential for several KSHV latency programmes, only one gene expression 
profile is seen to predominate (see section 1.1.12). A connection between 
KSHV reactivation and plasma cell differentiation has however been reported 
and is investigated further in this thesis (Wilson et al., 2007) (Sun and Thorley-
Lawson, 2007).  
 
1.5 Hypoxia 
Oxygen is essential for the survival of complex organisms, and high or low 
levels can cause cellular stress (reviewed in (Brahimi-Horn and Pouyssegur, 
2007)).  In vivo, hypoxia is functionally defined as occurring whenever oxygen 
(O2) demand is greater than supply (reviewed in (Nizet and Johnson, 2009)). 
Hypoxia causes dramatic changes in cell physiology including cell cycle arrest, 
anaerobic glycolysis, increased expression of survival and proliferation factors 
and increased cell motility and invasion (Harris, 2002). Normal oxygen levels 
can be reduced as a result of tissue damage or other changes to perfusion, and 
is associated with various patho-physiological conditions including ischemic 
disorders, diabetes, inflammatory disease, psoriasis and cancer.  However, low 
oxygen conditions also occur during development and are found in normal 
physiology (see Table 1-6) (Ivanovic, 2009). For example, low oxygen levels 
found in lymph nodes are important in slowing down lymphocyte migration 
contributing to cell interaction time (Huang et al., 2007). The hypoxic 
microenvironment of the bone marrow is also crucial in protecting stem cells 
from damage caused by oxygen radicals, and may control the expression of 
genes associated with the self-renewing capacity for example NOTCH and 
telomerase (Parmar et al., 2007) (Gustafsson et al., 2005).  
 
Physiological oxygen tensions can vary between 2.5-9 % O2, depending on the 
organ and its perfusion, classifying many tissues as hypoxic from a normal 
atmospheric oxygen perspective (see Table 1-6). This highlights the non-
physiological conditions that are represented by cell culture at 21 % O2, 
regarded as normoxia (hyperoxia - (Ivanovic, 2009)); while hypoxia is routinely 
taken to be between 0.5-3 % O2 by volume in the air that perfuses the growth 
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medium. Anoxia is defined as the absence of physiologically available oxygen 
and can occur in areas of severe damage and acute inflammation (Nizet and 
Johnson, 2009).  Oxygen has a relatively short diffusion distance of only 100-
200 µm and therefore oxygen tensions rapidly reduce with distance from the 
oxygen supplying blood vessels. For this reason, hypoxia is a common feature 
of solid tumours and predicts a poor prognosis, the potential for metastasis is 
increased and the efficacy of treatment is decreased (Hockel and Vaupel, 2001) 
(Harris, 2002) (Maxwell, 2005). 
Table 1-6 Summary of oxygen tensions in mmHg and percentage oxygen content of various 
conditions.  
 
Condition Oxygen tension 
(mmHg) 
Oxygen levels 
( %) 
Reference 
Atmospheric/tissue culture 
 
160 21  
Upper Airway  
 
150 ~20 (Yee Koh et al., 2008) 
Lungs  104-150 13-20 (Brahimi-Horn and 
Pouyssegur, 2007) 
    
Arterial Blood 
 
95 ~12 (Arnett et al., 2003) 
 
Venous and Capillary blood 
 
40 5 (Arnett et al., 2003) 
 
Tissue levels (organ 
specific) 
 
20-70 
 
2.5-9 
 
(Nizet and Johnson, 
2009) 
 
Bone Marrow 
 
50 6.6 (Harrison et al., 2002) 
 
Thymus 10 ~1 (Braun et al., 2001) 
    
Lymphoid organs 
 
4-35 0.5-4.5 (Caldwell et al., 2001) 
 
Retina 
 
5 ~0.5 (Yee Koh et al., 2008) 
 
Hypoxia (HIF-1α 
stabilisation) 
 
10-22 1-3 (Koumenis and 
Wouters, 2006) 
 
Wounds and necrotic 
tissue 
<10 <1 (Nizet and Johnson, 
2009) 
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Pathology 
 
<10 <1 (Lewis et al., 1999) 
 
Anoxia 0 0  
 
1.5.1 Hypoxia inducible factor 
Hypoxia inducible factor (HIF) is the master regulator of the molecular adaptive 
response to hypoxia-induced cellular stress (reviewed in (Weidemann and 
Johnson, 2008) (Wenger, 2002)). HIF is known to act as a heterodimeric 
complex consisting of 120 kDa HIF- and a ~90 kDa HIF- subunit (Wang et 
al., 1995). Both subunits are members of the basic helix-loop-helix/Per-Arnt-Sim 
(bHLH/PAS) transcription factor family. HIF induces the transcriptional program 
essential for returning cells to homeostasis upon exposure to low oxygen 
conditions (Wang and Semenza, 1993a). This is achieved via HIF-mediated 
regulation of over a hundred genes involved in diverse processes including 
angiogenesis, anaerobic glycolysis, mitochondrial oxygen consumption and 
intracellular pH regulation (Wang et al., 1995) (Manalo et al., 2005) (Semenza 
et al., 1994) (Firth et al., 1994) (Fukuda et al., 2007) (Shimoda et al., 2006). 
Due to its functions, HIF also has a crucial role in tumour development and 
survival (Harris, 2002) (Semenza, 2010) (Maxwell, 2005).  
 
There are three isoforms of HIF-1β (aryl hydrocarbon receptor nuclear 
translocator-1 (Arnt1) 1, 2 and 3); there are also three HIF-α isoforms (HIF-1α, 
2α and 3α. HIF-1α and HIF-2α (also known as endothelial PAS domain protein 
1 (EPAS1)) have similar domain structure and are regulated in an analogous 
manner (Hu et al., 2003) (Wang et al., 2005b). Various studies have 
demonstrated both non-redundant and overlapping roles for these isoforms in a 
cell-type dependent manner and therefore further study is required to 
investigate the target gene specificity (Hu et al., 2007) (Wiesener et al., 2003) 
(reviewed in (Bardos and Ashcroft, 2005)). However, studies have revealed 
essential but different roles for HIF-1α and HIF-2α in embryonic development. 
Targeted disruption of HIF-1α or HIF-2α leads to lethality but at different stages 
and with variable phenotypes (reviewed in (Huang and Bunn, 2003)). Tissue-
specific deletion of HIF has indicated a role, not only in adaptation to hypoxia, 
but also for physiological function in many cell-types, including a role 
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haematopoietic differentiation, B-cell development and innate immune 
responses (Nguyen-Khac et al., 2006) (Kojima et al., 2002) (see section 1.5.3) 
(Nizet and Johnson, 2009). The role of the final HIF-α isoform, HIF-3α, is not 
completely clear. However, a product of alternative splicing of this gene 
removes the transactivation domain. The remaining N-terminal basic helix-loop-
helix and PAS domain containing protein (IPAS) can heterodimerise with HIF-1α 
inhibiting transactivation, providing a negative feedback system of HIF 
regulation (Makino et al., 2001) (Heidbreder et al., 2003). A natural antisense 
transcript of HIF-1α (aHIF) has also been identified and may contribute to the 
post-transcriptional regulation of HIF-1α (Uchida et al., 2004). 
 
HIF was discovered as the transcription factor responsible for the upregulation 
of the erythropoietin (EPO) gene under hypoxic conditions (Semenza et al., 
1991) (Semenza and Wang, 1992). HIF-α and HIF-β (Arnt) subunits are 
constitutively expressed but HIF-α subunits are rapidly degraded in the 
presence of oxygen (half-life of <5mins) (Huang et al., 1998) (Salceda and 
Caro, 1997). This process is regulated by a family of oxygen-, iron- and 2-
oxoglutarate-dependent prolyl hydroxylases (PHD1/2/3), which are themselves 
highly regulated by, among other factors, the presence of reactive oxygen 
species (ROS), intracellular calcium fluctuations, E3 ubiquitin ligases and HIF 
(Bruick and McKnight, 2001) (Berra et al., 2006) (Simon, 2006) (Berchner-
Pfannschmidt et al., 2004) (Nakayama and Ronai, 2004) (reviewed in (Schofield 
and Ratcliffe, 2005)). High concentrations of the immuneregulatory molecule 
nitric oxide (NO) are thought to positively regulate HIF-1α accumulation by 
inhibiting PHDs (Mateo et al., 2003).  
 
In the presence of oxygen HIF-conserved proline residues (Pro402 and Pro564) 
within the oxygen dependent degradation domain (ODD) are hydroxylated by 
PHDs (see Figure 1-8 A). As a consequence the von Hippel-Lindau tumor 
suppressor (VHL) E3-ligase complex is recruited, facilitating the 
polyubiquitination and proteasomal degradation of HIFα (see Figure 1-8 B) (Ohh 
et al., 2000) (Ivan et al., 2001) (Yu et al., 2001) (Jaakkola et al., 2001) (Safran 
and Kaelin, 2003).  
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Figure 1-8 Protein domains of HIF-1α and HIF-1β and regulation of HIF-1α 
(A) Functional domains and binding domains with co-factors are shown. Hydroxylation, 
acetylation and phosphorylation sites are indicated. bHLH, basic helix-loop-helix; ODD, oxygen-
dependent degradation domain; N-TAD and C-TAD, N- and C-terminal transactivation domain; 
NLS, nuclear localisation signal; PAS, Per-ARNT-Sim. Taken from (Dery et al., 2005). (B) Under 
normoxic conditions, hydroxylation of hypoxia-inducible factor 1 (HIF1) by prolyl hydroxylases 
(PHDs) occurs in an O2-dependent manner at amino acid residues 402 and 564. This results in 
polyubiquitylation of the HIF-1α protein by von Hippel–Lindau tumour suppressor protein (VHL) 
and ultimately in the degradation of HIF-1α by proteasomes. The asparaginyl hydroxylase factor 
inhibiting HIF (FIH) functions in conjunction with the prolyl hydroxylation, although in this case to 
hydroxylate an asparagine residue in the carboxy-terminal domain of HIF-1α. This blocks the 
association of HIF-1α with p300–CREB-binding protein (CBP; also known as CREBBP), which 
in turn inhibits transcriptional enhancement by the HIF complex (not shown). As all of these 
post-translational events depend on intracellular oxygen they are inhibited by oxygen 
deprivation. (C) Under hypoxic conditions, HIF-1α gene expression is upregulated through 
nuclear factor-κB (NF-κB) activation downstream of Toll-like receptors (TLRs). PHDs and FIH 
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are no longer able to hydroxylate HIF-1α. The unmodified form of HIF-1α in association with 
p300–CBP migrates to the nucleus to bind HIF-1β (also known as Arnt), forming a 
heterodimeric helix–loop–helix transcriptional regulator. The HIF complex binds to target 
promoters known as hypoxic-response elements (HREs). Adapted from (Nizet and Johnson, 
2009).  
 
The critical role played by VHL in the regulation of HIF-1α regulation is 
highlighted in VHL disease, where inactivation of VHL leads to the development 
of highly vascularised tumours of the kidney, retina and central nervous system 
(Kaelin, 2007). Therefore, VHL stability and its affinity for the components of the 
E3 ubiquitin ligase complex and HIF-1α are normally tightly regulated by various 
mechanisms. These include ubiquitylation and subsequent degradation 
mediated by ubiquitin carrier protein (UCP), a member of the E2 enzyme family 
(Jung et al., 2006) (reviewed in (Yee Koh et al., 2008)). VHL mediated 
degradation of HIF-1α is also dependent on localisation. HIF-1α has been show 
to accumulate and undergo degradation in different compartments in a cell-type 
dependent manner (Zheng et al., 2006). Also during acidosis, which occurs in 
hypoxic tissues, VHL nucleolar sequestration has been observed; adding the 
further complexity of pH conditions to VHL mediated HIF-1α control (Mekhail et 
al., 2004).  
 
Transcriptional activity of HIF-α is regulated by the oxygen-, iron- and 2-
oxoglutarate -dependent asparaginyl hydroxylase factor inhibiting HIF (FIH), 
which targets asparagine residues within the C-terminal transcriptional 
activation domain (C-TAD) of HIF (see Figure 1-8 A) (Lando et al., 2002b). This 
blocks any stabilised HIF from interacting with coactivators such as the p300-
CREB-binding protein, inhibiting co-activation of HIF responsive genes (see 
Figure 1-8 B) (Lando et al., 2002a) (Wenger, 2002) (reviewed in (Lisy and Peet, 
2008)). Under conditions of oxygen or iron deprivation, the prolyl and 
asparaginyl hydroxylases are unable to hydroxylate the HIFs, which are 
therefore no longer targeted for degradation (Jewell et al., 2001) (see Figure 1-8 
C). The level of HIF-1α stabilisation varies over the physiological range of 
oxygen tensions, and has been shown to be at its half maximal level between 
1.5-2 % O2 (Jiang et al., 1996b). Stabilised HIF-1 and the 48 % homologous 
HIF-2, heterodimerise with the HIF-1 subunit and bind to hypoxia response 
elements (HREs) (Jiang et al., 1996a). HREs have the core recognition 
sequence 5’-(T/A)CGTG-3’ (Semenza and Wang, 1992) and are present in the 
 98
promoter regions of HIF regulated genes for example, glucose transporter 1 
(GLUT1) and vascular endothelial growth factor (VEGF) (Firth et al., 1994) 
(Semenza et al., 1996) (Forsythe et al., 1996) (Harris, 2002). In addition, HIF-1α 
has also been reported to have a non-transcriptional role in promoting the 
differentiation of leukemic cells (reviewed in (Zhang and Chen, 2009)).  
 
This mechanism of HIF control by the oxygen-sensing mechanism of 
hydroxylation is the primary method of regulation. The HIF-mediated response 
is also negatively and positively regulated by a number of interactions with 
numerous coactivators or proteins that often lead to post-translational 
modifications. These interactions are not always dependent on hypoxia and 
may determine the genes targeted (reviewed in (Dery et al., 2005) (Bardos and 
Ashcroft, 2005) (Yee Koh et al., 2008) (Lisy and Peet, 2008)). The coactivator 
hepatocyte nuclear factor 4 (HNF4) is a liver and kidney specific transcription 
factor required for EPO transcription. HNF4 acts by binding to the EPO 
promoter at adjacent sites to the HRE and enhancing transcriptional activity of 
HIF-1α (Zhang et al., 1999). Post-translational modifications of HIF-1α include 
acetylation by the acetyltransferase ARD1, and sumoylation, both of which 
promote hydroxyl-proline independent VHL recruitment in normoxia or hypoxia, 
enhancing HIF-1α degradation (Jeong et al., 2002b) (Cheng et al., 2007). 
Conversely, S-nitrosylation of HIF-1α cysteine residues under normoxia 
prevents degradation and is thought to influence the interaction with p300 and 
therefore HIF-1α transcriptional activity (Li et al., 2007) (Yasinska and 
Sumbayev, 2003) (Cho et al., 2007).  Importantly, increased HIF-1α 
transcriptional activity is seen in response to MAPK dependent phosphorylation, 
linking the HIF-1α response to growth factor signalling (Richard et al., 1999) 
(Sang et al., 2003). In fact normoxic induction of HIF-1α occurs in response to a 
variety of cytokines and growth factors including TNF-α and insulin (Jiang et al., 
2001) (Hellwig-Burgel et al., 1999). The phosphatidylinositol 3-kinase-Akt (PI3K-
Akt) pathway has been implicated in upregulating HIF-1α translation in 
response to growth factors but also in regulation of HIF-1α degradation; its 
direct role in regulating the response to hypoxia is therefore not clear (reviewed 
in (Bardos and Ashcroft, 2005)). Glycogen synthase kinase 3 β (GSK3-β), 
which is inactivated by Akt, also leads to VHL-independent ubiquitination and 
degradation but this appears to depend on the level and duration of the hypoxia 
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experienced (Flugel et al., 2007) (reviewed in (Bardos and Ashcroft, 2005)). 
Analogously, the fork-head box transcription factor, FOXO4, negatively 
regulates HIF-1α and is inactivated by Akt (Tang and Lasky, 2003). 
 
The association of chaperone proteins, such as heat shock protein 90 (Hsp90), 
leads to increased HIF-1α stability by disrupting the interaction between HIF-1α 
and the receptor of activated protein C kinase (RACK1). This prevents the 
oxygen-independent recruitment of components of the E3 ligase complex and 
therefore HIF-1α degradation (Liu et al., 2007a) (reviewed in (Yee Koh et al., 
2008)). The RACK1-mediated pathway of HIF-1α regulation can also be 
modulated by calcium via Calcineurin A, which dephosphorylates RACK1 
preventing dimerisation and activity (Liu et al., 2007b). Hypoxia leads to an 
increase in free calcium in the cytoplasm due to an influx in extracellular 
calcium, combined with the release of calcium from the ER (Seta et al., 2004). 
Various calcium-dependent mechanisms of HIF-1α regulation have been 
proposed but this area remains complicated and requires further study 
(Berchner-Pfannschmidt et al., 2004) (reviewed in (Yee Koh et al., 2008)). 
Hypoxia also leads to the production of reactive oxygen species (ROS) by 
mitochondria, which can stabilise HIF-1α (Guzy et al., 2005) (Simon, 2006) 
(reviewed in (Dewhirst et al., 2008)). 
 
The importance of HIF-1α in tumour progression is highly significant and many 
cancer inducing mutations further enhance the HIF response (Semenza, 2010). 
HIF has two major roles in tumorigenesis: i) HIF is required for angiogenesis to 
facilitate blood supply to the growing tumour and ii) HIF mediates the ‘Warburg 
effect’, whereby tumour cells under normoxia have an increased rate of 
glycolysis compared to normal tissues. HIF is also involved in the increased 
proliferation, invasion, metastasis as well as apoptosis (reviewed in (Rankin and 
Giaccia, 2008)). Several tumour suppressor proteins p14ARF, PTEN and p53, 
which are deregulated in many human tumours, have been shown to negatively 
regulate HIF-1α (reviewed in (Bardos and Ashcroft, 2005)). Oncoproteins such 
as v-src have also been implicated in the induction of HIF-1α (Jiang et al., 
1997a). The central regulator of the inflammatory response, NF-κB has also 
been shown to increase HIF-1α mRNA production under hypoxic conditions 
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again linking the hypoxic response to cell function during inflammation (Frede et 
al., 2006) (see Figure 1-8 C).  
 
HIF-1α protein levels can be regulated by a vast number of mechanisms both 
dependent and independent of oxygen levels. The final major means of HIF-1α 
regulation is at the level of translation. Various growth factors, cytokines and 
oncoproteins have been shown to control HIF-1α protein translation (reviewed 
in (Yee Koh et al., 2008)). Activation of the PI3K mammalian target of 
rapamycin (mTOR) and MAPK leads to the formation of the eIF4F complex 
required for cap-dependent translation. Under hypoxia protein translation is 
much reduced in order to reduce the energy consumed under stress conditions 
(Liu et al., 2006) (see section 1.5.2). However, HIF-1α and proteins required for 
cellular survival continue to be translated despite the mechanism(s) for this 
being unclear (reviewed in (Yee Koh et al., 2008)). This may include the 
recruitment of the RNA binding protein, polypyrimidine tract-binding protein 
(PTB), to enhance translation (Galban et al., 2008).  
 
The HIF-1α mediated response therefore depends on a balance between HIF-
1α synthesis, degradation and activity, regulated by both oxygen dependent and 
independent mechanisms. This highlights the additional roles of HIF-1α outside 
of the hypoxic response. By having a large number of regulatory mechanisms, 
the HIF-1α response can be tailored to the conditions experienced, for example 
prolonged versus transient hypoxia.  
 
1.5.1.1 Hypoxia mimics 
Due to the dependence of PHDs and FIH prolyl hydroxylases on iron (Fe(II)) for 
activity, HIF stabilisation and ‘hypoxia’ can be mimicked by iron chelators such 
as desferoxamine and a range of metals including CO(II), Ni(II) and Mn(II) 
(Schofield and Ratcliffe, 2004) (Wang and Semenza, 1993b) (Goldberg et al., 
1988). The addition of compounds such as colbalt chloride inhibits PHDs which 
consequently leads to the stabilisation of HIF-α protein and the transactivation 
of HIF dependent genes (Schuster et al., 1989). However, the physiological 
relevance of hypoxia mimics is questionable as the response to hypoxia is not 
solely confined to the actions of HIF (reviewed in (Nakayama, 2009)). 
Numerous studies of gene expression profiles in response to hypoxia have 
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shown that HIF activation is not responsible for all the changes seen (reviewed 
in (Feldman et al., 2005)). The activity of major signalling pathways is altered 
rapidly and reversibly during hypoxia, predominantly in attempt to save energy 
and maintain cell viability. These pathways include the mTOR pathway, which is 
inactivated by hypoxia; mediating the inhibition of protein translation and in 
some instances apoptosis (Arsham et al., 2003) (Hamanaka et al., 2005). The 
NF-κB pathway is also activated by hypoxia and has a role in promoting cell 
survival and proliferation (Cummins et al., 2006). Recent work has shown that 
the expression of a selection of miRNAs is also regulated by hypoxia and 
contributes to the gene expression changes seen, possibly in a HIF-
independent manner (reviewed in (Kulshreshtha et al., 2008) (Ivan et al., 
2008)). The direct role for HIF-1α in the upregulation of miRNA expression has 
however been confirmed for some miRNA including miR-210. The targets of 
miR210 are still being uncovered, but include the receptor tyrosine kinase 
Ephrin-A3, important in the endothelial cell response to hypoxia (Fasanaro et 
al., 2008). Another important pathway activated by hypoxia is the ER stress 
pathway or UPR discussed further in section 1.5.2.  
 
Therefore in order to investigate the cellular response to hypoxia it is important 
to use the appropriate conditions. In some instances using hypoxia mimics 
should be considered as insufficient, as they do not induce the same complex 
cellular response as low oxygen ‘authentic hypoxia’ conditions. It is also 
important to consider the fact that hypoxia is a term given to a range of low 
oxygen tensions and does not specify the duration of exposure. The cellular 
response and gene expression pattern seen depends on both the severity and 
length of hypoxic exposure (reviewed in (Koumenis and Wouters, 2006)). It is 
therefore critical to obtain the most physiologically relevant hypoxia conditions 
to those that you wish to investigate (Ivanovic, 2009).  
 
1.5.2 Hypoxia and the UPR 
In a study by Romero-Ramirez et al. the global changes in gene expression 
under severe hypoxia were analysed and the UPR genes including those of the 
PERK and IRE-1/XBP-1 pathways were ‘mostly robustly induced’ (Romero-
Ramirez et al., 2004) (see section 1.3). Work by Koumenis and colleagues went 
onto show that cells cultured under hypoxic conditions, and transformed cells in 
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hypoxic regions of solid tumours, activate a translational control program known 
as the integrated stress response (ISR) (reviewed in (Koumenis and Wouters, 
2006) (Liu et al., 2006) (Moenner et al., 2007)). This response is partly 
mediated via the activation of PERK and its phosphorylation of eIF2-, causing 
hypoxia-induced translation attenuation which allows cellular adaptation to ER 
stress and cell survival (Koumenis et al., 2002). PERK therefore plays a key 
role in tumour development with PERK-/- tumours displaying slower growth 
rates and increased apoptosis (Bi et al., 2005). As mentioned previously, 
translational arrest in response to hypoxia is also mediated by the UPR 
independent mTOR pathway. Hypoxia inhibits mTOR function through multiple 
pathways reducing phosphorylation of its target proteins and preventing cap-
dependent translation initiation (Brugarolas et al., 2004) (reviewed in (Wouters 
and Koritzinsky, 2008)).  
 
The cell mounts a biphasic response in order to control mRNA translation, 
indicating the importance of this HIF-independent reaction to hypoxia (reviewed 
in (Wouters et al., 2005)). In fact, under severe hypoxia, the ATP demand for 
protein production is reduced by up to 7 %; aiding adaptation to the low oxygen 
and energy deficient conditions (Hochachka et al., 1996). However, during this 
general translational arrest certain genes, including HIF-1α, angiogenic factors 
and ATF4, are selectively translated and many contribute to hypoxia tolerance 
(Blais et al., 2006) (Blais et al., 2004). During hypoxia the translational 
machinery is redirected towards hypoxia-induced mRNA, an effect known as 
‘translational reprogramming’ (Ron and Walter, 2007). How this is achieved is 
still not completely understood, suggested mechanisms include internal 
ribosome entry site (IRES) elements which facilitate cap-independent 
translation as well an important role for miRNA (Hua et al., 2006). Importantly, 
the UPR, mTOR and HIF pathways do not act in complete independence, and a 
number of interactions have been observed; including negative feedback 
between the UPR and mTOR pathways, and transcriptional cooperation 
between the HIF and UPR mediated responses (reviewed in (Wouters and 
Koritzinsky, 2008)).  
 
Investigation of hypoxic regulation of XBP-1 has shown that low oxygen 
conditions increases the transcription of XBP-1 and also activates splicing. 
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Transformed cells deficient in XBP-1 are more sensitive to hypoxia-induced 
apoptosis, and tumour growth is strongly inhibited compared to wild type cells 
(Romero-Ramirez et al., 2004). These results indicate that XBP-1 has a crucial 
role, during hypoxia, in cell survival and the regulation of tumour expansion, and 
indicates that another mechanism exists to respond to hypoxia other than that 
mediated by HIFs. As yet hypoxic activation of ATF6, the third ER stress 
sensor, has not been demonstrated but is highly likely as many of its 
transcriptional targets are seen to be upregulated under hypoxic conditions.  
 
How the UPR is triggered by hypoxia however is still debated; the rapid 
inactivation of the translation initiation complex by PERK mediated 
phosphorylation of eIF2-α suggests that misfolded protein accumulates under 
low oxygen conditions (Koritzinsky et al., 2006). ER protein folding and 
maturation involved various steps including chaperones, oligosaccharide 
modification, isomerisation and di-sulphide bond formation. Oxygen provides 
the oxidative potential required for di-sulphide bond formation in yeast, 
however; whether oxygen acts as the crucial electron acceptor in the 
mammalian ER is yet to be confirmed (Tu and Weissman, 2002) (reviewed in 
(Tu and Weissman, 2004)). The UPR however is an extremely coordinated 
cellular response that facilitates the recovery or removal of cells undergoing ER 
stress and plays a crucial role during hypoxia (see section 1.3). Recently the 
UPR was also implicated in the upregulation of VEGF-A linking the UPR to 
angiogenesis, highlighting the importance of energy and oxygen supply for ER 
function (Ghosh et al., 2010). 
 
1.5.3 Hypoxia and B-cell development  
HIF-1α also has a role in B-cell physiology. This is perhaps not surprising as 
immune cells are exposed to low oxygen tensions as they develop in secondary 
lymphoid tissues, and migrate between the blood and different tissues (Caldwell 
et al., 2001) (reviewed in (Sitkovsky and Lukashev, 2005)). HIF-1α has also 
been shown to be stabilised in the microenvironments of the germinal centres 
(GCs) (Piovan et al., 2007), secondary lymphoid tissues and bone marrow 
possibly due to low oxygen availability (Parmar et al., 2007) (see section 1.5.1).  
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The importance of HIF-1α in B-cell development was highlighted in a study 
using HIF-1α knock out RAG2-/- chimeric mice. These mice display an increase 
in appearance of abnormal B-1-like peritoneal lymphocytes, expressing high 
levels of B220+.  An accumulation of autoantibodies were also seen in the 
serum of these mice as well as a disturbed maturation of the B-2 cell subset in 
the bone marrow (Kojima et al., 2002). Further studies have shown that the 
energy supply generated by HIF-1α mediated glycolysis is required for specific 
stages of B-cell development (Kojima et al., 2010). How HIF-1α is stabilised 
during B-cell development however is unclear, the microenvironment of the 
bone marrow has been reported as hypoxic while the insulin-like growth factor 
(IGF-1), which also has a role in promoting pro-B-cell development can also 
regulate HIF-1α (Taguchi et al., 2006). 
 
1.6 Aims of this thesis 
Understanding the relationship between the virus and its host is fundamental to 
virus biology, and importantly may provide new insights into the design of novel 
therapeutic treatments. The switch between latent and lytic KSHV infection is an 
aspect of the KSHV life-cycle that is not well understood. This thesis focuses on 
the physiologically relevant, cellular cues for KSHV reactivation and aims to 
investigate further the interactions between KSHV and B-cells. In particular, we 
aimed to further develop an in vitro cell-based system for investigating the 
molecular detail of KSHV lytic reactivation. We used this system to determine 
the mechanism for XBP-1s-induced KSHV reactivation and suggest that this 
virus-host interaction may be conserved among other related viruses. 
 
As hypoxia can activate the UPR and XBP-1 we hypothesised that the lytic 
reactivation of KSHV seen in response to hypoxia is caused by the presence of 
active XBP-1. In order to address this question we aimed to establish authentic 
‘low oxygen’ hypoxic tissue culture conditions that cause KSHV reactivation. We 
then dissect the roles of XBP-1s and HIF-1α in hypoxia-induced KSHV 
reactivation. Finally, we investigated further the role of XBP-1s in plasma cell 
differentiation of KSHV infected PEL cells. Focusing on gene expression 
changes induced during XBP-1s expression in PEL and the subsequent virus 
lytic replication cycle. 
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2 Materials and Methods 
 
2.1 Cell culture 
All cell culture work was carried out in class II biosafety cabinets using sterile 
technique. All culture plates and flasks were from Techno Plastic Products 
(TTP, Switzerland).  
 
B-cell lines used in this study are derived from B-cell tumours, some are 
infected with KSHV and/or EBV and were grown in complete medium, Roswell 
Park Memorial Institute (RPMI) - 1640 medium (GIBCO, Invitrogen, Paisley, 
UK) with 10 % foetal calf serum (FCS, BioSera) and 100 units/ml penicillin plus 
100 µg/ml streptomycin (P/S, GIBCO, Invitrogen, Paisley, UK). Cells were split 
1:10 to 1:20; depending on density and growth rate twice a week (Table 2-1). 
 
Table 2-1 B-cell lines used in this study 
Cell line B-cell tumour Viruses Reference 
BC-3 Primary effusion lymphoma KSHV (Arvanitakis et al., 1996) 
BCBL-1 Primary effusion lymphoma KSHV (Renne et al., 1996b) 
BCP-1 Primary effusion lymphoma KSHV (Boshoff et al., 1998) 
HBL-6 Primary effusion lymphoma KSHV/EBV (Gaidano et al., 1996) 
JSC-1 Primary effusion lymphoma KSHV/EBV (Cannon et al., 2000) 
JSC-1 
rKSHV.219 
Primary effusion lymphoma KSHV/EBV 
rKSHV.219
(Vieira and O'Hearn, 2004)
DEL Anablastic DLBCL  (Barbey et al., 1990) 
NCI-H292 Multiple myeloma  (Gazdar et al., 1986) 
Raji Burkitt’s Lymphoma EBV (Pulvertaft, 1964) 
Daudi Burkitt’s Lymphoma EBV  
Mutu Burkitt’s Lymphoma EBV  
 
HEK 293T and derived cell lines, were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, GIBCO, Invitrogen, Paisley, UK) with 15 % FCS and P/S. 
These cells were passaged three times a week and were split at either 1:4 or 
1:6. HeLa and Vero derived cell lines were cultured as above, however medium 
was supplemented with 10 % FCS (Table 2-2). 
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Table 2-2 Cell lines, not of B-cell origin, used in this study 
Cell line Description Reference 
HEK 293-T 293 cells containing the temperature sensitive gene 
encoding SV40 T-antigen 
(DuBridge et al., 
1987) 
rKSHV.219 HEK 
293-T  
Clone 9/Clone5 
293 cells containing the temperature sensitive gene 
encoding SV40 T-antigen 
infected with rKSHV.219 
(Wilson et al., 
2007) 
Vero rKSHV.219 Kidney epithelial cells extracted from African Green 
Monkey infected with rKSHV.219 
(Vieira and 
O'Hearn, 2004) 
HeLa Human cervical carcinoma cell line (Masters, 2002) 
 
Recombinant KSHV, rKSHV.219, which encodes GFP expressed from the 
human EF-1α promoter and DsRed expressed from by KSHV PAN promoter 
(Jeff Vieira, University of Washington (Vieira and O'Hearn, 2004)) infected cells 
were maintained with 2 µg/ml of puromycin dihydrochloride from S. alboniger 
(Sigma Aldrich, Dorset, UK). Cells were grown in a humidified incubator at 37°C 
with 5 % carbon dioxide (CO2) in 21 % atmospheric oxygen (O2) (Normoxia) or 
in a hypoxic chamber gassed regularly with a 5 % CO2 and 95 % nitrogen (N2) 
mix (Hypoxia) and placed within the standard incubator. Cylinders containing 
custom mixtures of O2, CO2, and N2 were purchased from BOC (London, UK). 
Oxygen levels of media were measured by the FOXY-R stainless steel 1/16" 
OD Fibre Optic Probe (Ocean Optics) (kindly supported by Tim Arnett, 
University College London, (Arnett et al., 2003; Orriss et al., 2009)). 
2.1.1 Freezing cells 
Cells were centrifuged at 325 x g for 5 minutes and resuspended at 5x106  
cells/ml in cold FCS containing 10 % dimethyl sulphoxide (DMSO, Sigma, 
Dorset, UK). Cells were aliquoted into cryovials (Nunc, USA) and gradually 
cooled to –80oC in an isopropanol-containing cryo-container (Nalgene, 
Rochester, NY, USA) overnight before being transferred to liquid nitrogen. 
 
2.1.2 Thawing cells 
Cells were removed from liquid nitrogen and thawed rapidly at 37oC. The 
contents of the cryotube were layered onto 10 ml of RPMI - 1640 or DMEM 
medium, with 10 % FCS and P/S depending on cell type (see section 2.1). Cells 
were then pelleted at 325 x g for 5 minutes. The cell pellet was washed with 
10 ml culture media. The cells were centrifuged for a further 5 minutes and 
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resuspended in a suitable volume of culture medium depending on the cell 
number, ascertained using a haemocytometer.  
 
2.1.3  Induction of KSHV lytic replication by drug treatment 
To activate protein kinase C and induce KSHV reactivation, 4x105 PEL or 
rKSHV.219 containing cells were cultured in medium containing 20 ng/µl, 12-O-
tetradecanoyl-phorbol 13-acetate (TPA) (Sigma Aldrich, Dorset, UK) overnight 
(Renne et al., 1996b). Sodium butyrate (NaBut, Sigma Aldrich, Dorset, UK) is a 
histone deacetylase inhibitor and leads to KSHV reactivation, cells were 
cultured in medium containing 2-3 mM NaBut overnight (Miller et al., 1996) 
(Miller et al., 1997). To induce an unfolded protein response (UPR) and the 
reactivation of KSHV via XBP-1s, 4x105 cells were cultured in medium 
containing 3-4 mM dithiothreitol (DTT) overnight (Wilson et al., 2007). All drugs 
were removed and replaced with fresh medium the following day, and images or 
samples taken accordingly. 
 
2.1.4  Deriving rKSHV.219 clonal cell populations - single colony 
selection 
Vero cells infected with the recombinant KSHV, rKSHV.219, were treated with 
3 mM NaBut (see section 2.1.3). This induced the KSHV lytic cycle as seen by 
an increase in DsRed-positive cells. Supernatants from these cells containing 
rKSHV.219 were harvested at 48 and 72 hours post NaBut treatment, passed 
through a 0.45 µm filter and stored at -80oC in 1 ml aliquots. This virus was then 
used to infect HEK 293T cells by spinoculation for 1 hour at 500 x g. 48 hours 
post infection the medium was removed and replaced with medium 
supplemented with 2 µg/ml puromycin (Sigma Aldrich, Dorset, UK). The 
medium was removed and replaced with fresh medium supplemented with 
2 µg/ml puromycin every 2-3 days until non-infected cells were no longer viable 
and GFP-positive single cell clones could be seen on the plate. These were 
then picked by suction pipetting and cultured individually in media with 2 µg/ml 
puromycin. The antibiotic-selected rKSHV.219 HEK 293T cell lines were then 
cultured normally in medium supplemented with 2 µg/ml puromycin and 
analysed for spontaneous lytic replication (DsRed expression) and reactivation 
in response to various stimuli. 
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2.2 Flow cytometry 
Ten thousand events were collected using a FACScan, FACsArray or LSR flow-
cytometers with Cellquest software (Becton Dickinson, Oxford, UK).  Data was 
analysed using Windows Multiple Document Interface Flow Cytometry 
Application (WinMDI, J. Trotter, http://facs.scripps.edu). 
 
2.2.1 Preparation of live cells for flow cytometry 
48 hours post infection cells were washed once with PBS, and incubated for 
1 minute with trypsin-EDTA (GIBCO, Invitrogen, Paisley, UK) at room 
temperature.  The trypsin was then quenched with DMEM supplemented with 
10 % FCS and P/S and transferred to sealed FACS tubes (Falcon).  The cells 
were pelleted, resuspended in PBS plus 3.7 % paraformaldehyde (TAAB) and 
kept on ice prior to analysis. 
 
2.3 Microscopy 
 
2.3.1 Confocal microscopy  
Images of GFP and DsRed fluorescence were gathered by laser scanning 
confocal microscopy (Zeiss Axiovert 100 TV) using Lasersharp 2000 (Bio-Rad). 
Cells were excited at 488 nm to image enhanced GFP fluorescence and 
separately excited at 568 nm to image DsRed expression with negligible GFP 
excitation and the equivalent intensity for each sample.  Imaging of live cells 
was achieved through replacing the growth medium with PBS.  No image 
enhancement was used.   
 
2.3.2 Light microscopy 
Cell were visualised using a Nikon Eclipse TS100 and images of GFP and RFP 
fluorescence were gathered using a digital camera Nikon E950. Imaging of live 
cells was achieved through growth medium. 
 
2.4  General Molecular biology Techniques 
 
2.4.1 Preparation of competent bacteria  
XL-1 Blue Escherichia coli (Stratagene, Leicester, UK) stored in the form of a 
glycerol stock were streaked on a 1.5 % Luria-Bertani agar plate, (LB, 10 g 
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trypton, 5 g yeast extract and 5 g sodium chloride plus 1.5 % agar-agar per litre 
of medium) containing 10 μg/ml tetracycline and incubated at 37oC for 16 hours. 
A single colony was used to inoculate 5 ml of LB-broth, supplemented with 
50 μg/ml tetracycline, and shaken at 37oC for 16 hours. This was added to 
500 ml LB-broth (as above composition without added agar) and shaken at 
37oC until the absorbance at 550 nm was 0.45-0.55 (around 3 hours). The 
culture was then put on ice to cool for 10 minutes. The bacteria were pelleted at 
3000 x g for 10 minutes at 4oC and resuspended in 15 ml of 100 mM calcium 
chloride (4oC). After incubation on ice for 30 minutes, the bacteria were 
centrifuged again and then resuspended in 2.5 ml of 100 mM calcium chloride 
containing 15 % glycerol by volume (4oC). The bacterial suspension was frozen 
on dry ice in 400 μl aliquots and stored at -80 oC. 
 
2.4.2  Introduction of plasmid DNA into E. coli by heat shock 
1-200 ng of plasmid was mixed with 50 μl of competent XL-1 Blue Escherichia 
coli (Stratagene, Leicester, UK) that have been thawed on ice and incubated on 
ice for 30 minutes. The cells were then heat shocked for 45 seconds at 42oC 
and immediately incubated on ice for 2 minutes. 450 μl of LB-broth was added 
to the heat shocked bacteria and incubated at 37oC for 1 hour with shaking at 
250 rpm. 100 μl of the culture was then plated on LB-agar plates containing 
50 μg/ml ampicillin and incubated upside down overnight at 37oC. 
 
2.4.3 Plasmid DNA midi-preps 
Midi preps of plasmid DNA were produced from 100 ml overnight liquid cultures 
of transformed XL-1 Blue Escherichia coli using the Plasmid Midi Kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. 
 
2.4.4 Plasmid DNA mini-preps 
Mini preps of plasmid DNA were produced from 5 ml overnight liquid cultures of 
XL-1 Blue Escherichia coli using the QIAprep Spin Miniprep Kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instructions. 
 
2.4.5 Molecular Cloning  
KOD Hot start Polymerase with proof-reading activity was purchased from 
Merck Chemicals Ltd., Nottingham, UK. Restriction endonucleases were 
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purchased from Promega, Southampton, UK or New England Biolabs, Hitchin, 
UK. Calf intestinal alkaline phosphatase and T4 DNA ligase were purchased 
from Promega, Southampton, UK.  All were used in accordance with the 
manufacturer’s specifications.   
 
2.4.5.1 Cloning using the pGEM-T-Easy vector system (Promega, 
Southampton, UK) 
The desired region was PCR-amplified using 1 unit of KOD Hot start 
polymerase (Merck Chemicals Ltd., Nottingham, UK) in a 50 μl reaction volume 
buffered with KOD Hot start polymerase 10 x buffer (Merck Chemicals Ltd., 
Nottingham, UK). PCR conditions involved 10-100 ng of template DNA and 
10 picomoles of each oligonucleotide primer.  In addition, the reaction was 
supplemented with a final concentration of 0.2 mM dNTPs (Merck Chemicals 
Ltd., Nottingham, UK) and 1.5 mM Mg++ (Merck Chemicals Ltd., Nottingham, 
UK).  Cycling conditions were used as manufacturer’s instructions. 
 
The desired PCR product is then purified using a Qiaquick gel extraction kit 
(Qiagen, Crawley, UK). Briefly 500 µl of QC buffer was added directly to PCR 
reaction mix, 10 µl of isopropanol was added and mixed well before all 650 µl 
were applied to the column. Manufacturer’s instructions for gel extraction were 
then followed and the PCR product was eluted in 32 µl. In order to allow cloning 
via the pGEM-T-Easy vector system the PCR product must have overhanging 
dATP ends. This was achieved via a 10 minute incubation with 1.5 units GoTaq 
polymerase and 1.6 µl of 5 nM dATPs in 8 µl of GoTaq buffer with MgCl2 and 
28 µl of PCR product at 72°C.  
 
The correct molecular weight product was then separated by electrophoresis 
and visualised using, 10 mg/ml ethidium bromide (Sigma Aldrich, Dorset, UK) 
stained, TAE buffered agarose gel (Sigma Aldrich, Dorset, UK) with a 
percentage between 1-3 % depending on size of expected product. The product 
was subsequently excised and extracted using the MinElute gel extraction 
system (Qiagen, Crawley, UK) in accordance with the manufacturer’s 
instructions.   
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The following ligation reaction was then used using the pGEM-T easy vector 
system (Promega, Southampton, UK).  Negative controls where PCR-amplified 
DNA is substituted with H2O were ligated in parallel. 
 
  5 µl 2X ligation buffer 
  1 µl T4 DNA ligase 
  0.5 µl pGEM-T-Easy linear DNA 
  3.5 µl MinElute extracted PCR product 
 
Ligation reactions were transformed as described in section 2.4.2 and positive 
colonies were identified by blue-white-screening, PCR-screening or restriction 
enzyme digest as desired. 
 
2.4.5.2 Subcloning 
Primers were designed to contain restriction endonuclease sites to subclone the 
gene of interest from pGEM-T easy vector into appropriate expression construct 
or lentiviral vector (Table 2-3) (see section 2.4.5.3). Vectors were digested 
overnight with appropriate restriction endonucleases as per manufacturer’s 
instructions and then treated with calf intestinal alkaline phosphatase (Promega, 
Southampton, UK) before being purified using the MinElute gel extraction 
system (Qiagen, Crawley, UK) in accordance with the manufacturer’s 
instructions. The pGEM-T vector containing gene of interest was checked by 
digestion overnight with appropriate restriction endonucleases. The insert, (i.e. 
gene of interest) is purified using the MinElute gel extraction system (Qiagen, 
Crawley, UK) and cloned into the appropriate expression vector (see section 
2.4.5.3). Ligations were carried out using the following ligation reaction.  
Negative controls are where PCR-amplified DNA is substituted with H2O were 
ligated in parallel. 
 
  5 µl 2X ligation buffer (Promega, Southampton, UK) 
  1 µl T4 DNA ligase (Promega, Southampton, UK) 
  1 µl Linear alkaline phosphatase treated vector 
  3 µl MinElute extracted PCR product 
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Ligation reactions were transformed as described in section 2.4.2 and positive 
colonies were identified by PCR-screening or restriction enzyme digest as 
desired. 
 
Table 2-3 DNA primers for cloning (Sigma Aldrich, Dorset, UK) 
Oligo Number Name Sequence 
1 HIF-1α fwd ggatccgagggcgccggcggcgcgaac 
2 HIF-1α rev gcggccgcgttaacttgatccaaagctc 
3 RTA prom fwd gcgctagcaattggaagcattctctct 
4 RTA prom rev gcagatctggaccgccgaagcttcttacc 
5 RTA DN fwd gcagatctatgaaagaatgttccaag 
6 RTA DN rev gcgcggccgccaccttcctcttcttcttgg 
gtagactctgatctacgtccag 
 
2.4.5.3 Lentivirus vector maps 
 
Figure 2-1 Lentivirus vector maps (see table in Appendix) 
Plasmids A is described in (Demaison et al., 2002) and plasmids B-F are modified versions of A. 
All plasmids contain integrative long terminal repeat regions (LTRs), a packaging signal (Ψ), a 
Rev response element (RRE) to promote mRNA nuclear export, a central polypurine tract 
(cPPT) for nuclear import and increased integration, a Spleen focus forming virus (SFFV) 
promoter and aa wood chuck hepatitus virus posttranscriptional regulatory element (WPRE) to 
promote mRNA maturation. Plasmid A was obtained from the laboratory of Professor Mary 
Collins and encodes eGFP under the SFFV promoter which can be substituted. Plasmids B and 
C encode puromycin resistance gene (PAc) and the hygromycin resistance gene (HPh) 
respectively. Plasmid D as internal ribosome entry site (IRES) to allow GFP to be expressed as 
a marker. Plasmid E has been modified to include an HA tag that is added to any cloned protein 
and finally plasmid F contains an addition Ubiquitin (Ub) promoter to allow dual expression.  
A 
 
B 
 
C 
 
D 
 
 
E 
 
F 
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2.4.5.4 Hypoxia Inducible Factor-1 α (HIF-1α) 
Lentiviral vector-genome expressing HIF-1α was generated by amplifying HIF-
1α using primers 1 and 2 (Table 2-3) and pCDNA3 HIF-1α (a kind gift from 
Peter Ratcliffe) as a template. The resulting 2.4 kb amplicon was cloned into 
pGEM-T-Easy vector (see section 2.4.5.1) (Promega, Southampton, UK) and 
sequence verified. The BamHI/NotI restricted HIF-1α insert was then subcloned 
into a modified version of the lentivirus vector pHR-SIN-CSGW (pCSGW), 
pSIN-HABN, kindly provided by Dr Edward Tsao, see section 2.4.5.3 allowing 
the expression of N-terminal HA-tagged HIF-1α (pSIN-HABN- HIF-1α/pSIN-HA- 
HIF-1α) (see table in Appendix).   
 
2.4.5.5 Luciferase reporter plasmids 
A wild-type and a mutant XBP-1 response element containing 4099 bp region of 
the ORF50 promoter, first exon, intron and the first 7 codons of the second exon 
was PCR amplified using primers 3 and 4 (Table 2-3) and 100 ng of template 
p50Redi previously described (Wilson et al., 2007) or a mutated version of this 
promoter pMUT50redi respectively. pMUT50redi was created by Sam Wilson 
using the QuickChange mutagenesis system (Stratagene, Leicester, UK) and 
the primers forward (5’-GCT TTT CAG GAG AGT TAG GTC GAC ACT GAG 
GAT GTG GAC AAG CTT CTG C-3’) and reverse (5’- GCA GAA GCT TGT 
CCA CAT CCT CAG TGT CGA CCT AAC TCT CCT GAA AAG C -3’) following 
manufacturer’s instructions (Dalton-Griffin et al., 2009). The PCR-products were 
then cloned into pGEM-T-Easy (see section 2.4.5.1).  The 4099 bp wild-type or 
mutant fragments were then digested with NheI and BglII and sub-cloned into 
pGL2-Basic vector (Promega, Southampton, UK), see section 2.4.5.2, to 
produce the reporter constructs p50LUC and p50MUTLUC respectively (see 
Figure 3-8) (see table in Appendix). 
 
2.4.5.6 RTA dominant negative (DNRTA) 
Lentiviral vector-genome expressing the C-terminal truncated, dominant 
negative form of RTA (Lukac et al., 1999) was generated by amplifying the first 
1590 bp of RTA using primers 5 and 6 (Table 2-3) and pSIN-BNHA-kRTA kindly 
provided by Dr Edward Tsao as a template. The resulting 1.5 kb amplicon was 
cloned into pGEM-T-Easy vector (see section 2.4.5.1) (Promega, Southampton, 
UK) and sequence verified.  The BglII/NotI restricted DNRTA insert was then 
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subcloned into a modified version of the pSIN-BNHA, kindly provided by Dr 
Edward Tsao, (see section 2.4.5.3) allowing the expression of C-terminal HA-
tagged DNRTA (pSIN-BNHA-DNRTA/pSIN-DNRTA). The BglII/NotI restricted 
DNRTA fragment was also subcloned into the dual promoter lentivirus vector 
(pDUAL-MEK-Cherry - provided by David Escors see section 2.4.5.3), to give 
pDUAL-DNRTA-Cherry(see table in Appendix). This vector expresses the gene 
of interest under the SFFV promoter and mCherry under the control of the 
ubiquitin promoter.   
 
2.4.6 Generation of lentiviral vectors encoding shRNAs 
The lentiviral vector expressing the short hairpin RNA (shRNA)-RTA, XBP-1 
and -GFP were produced previously (Wilson et al., 2007). The lentiviral vectors 
expressing shRNA to HIF-1α or Luciferase were generated using same 
methodology.  Briefly, the forward primer 7 and reverse primer 8, 9 or 10 (see 
Table 2-4) were used to PCR amplify a shRNA expression cassette using the 
plasmid pGemU61Linker previously described (Wilson et al., 2007).  This 
amplicon was cloned into the pGEM-T-Easy vector (see section 2.4.5.1), 
sequence verified, and subcloned (see section 2.4.5.2) via EcoRI restriction into 
antibiotic resistance modified versions of pCSGW namely the puromycin 
acetylase (PAc) encoding pHR-SIN-CSPW (pCSPW) or the hygromycin 
phosphotransferase (HPh) encoding pHR-SIN-CSHW (pCSHW) (see table in 
Appendix). shRNAs were sequenced using oligonucleotide 7 (Table 2-4) in their 
lentiviral vector context prior to use.   
 
Table 2-4 Oligonucleotides used to construct shRNA expression constructs (Sigma Aldrich, 
Dorset, UK) 
Oligo 
Number 
Name Sequence 
7 U6 fwd gggctgcagaaggtcgggcaggaagagggcctatttccc
8 HIF-1 α 1545 cgaaaaagatgaccagcaacttgaggaagtCGAAacctccccaag 
ctactggtcatcggtgtttcgtcctttccacaagatatataaag 
9 HIF-1α 1589 cgaaaaagaattcaagttggaattggtagaCGAAtccaccaactc 
caacctaaattcggtgtttcgtcctttccacaagatatataaag 
10 Luciferase 
1343 
cgaaaaaggtggctcccgctgaattggaatCGAAatcccaatcca
gcgagagccaccggtgtttcgtcctttccacaagatatataaag 
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2.4.7 DNA sequencing 
Cloning was confirmed by sequencing carried out either by Cogenics (Lark 
Technologies Incorporated, Essex, UK) or the University College London 
sequencing service. Results were then analysed using the program DNA 
dynamo.  
 
2.4.8 Expression plasmids  
The plasmid pXBPsIG was a generous gift from C. Tsantoulas, who generated 
pXBPsIG under the supervision of S. Wilson during an MSc project in the 
Kellam laboratory.  The pXBPsIG construct encodes XBP-1s tagged with a c-
terminal His-tag cloned in the IRES-Em vector. XBP-1s tagged with a c-terminal 
His-tag cloned in pCDNA3 (GIBCO, Invitrogen, Paisley, UK) was also supplied 
by S. Wilson. Another XBP-1s-expressing construct was generated by Edward 
Tsao, the Dual promoter lentivirus backbone pDUAL-XBP-1s-Cherry (provided 
by David Escors) (see table in Appendix).  
 
Positive control for HIF-1α expression, (pCDNA3- HIF-1α) was kindly donated 
by Peter Ratcliffe, University of Oxford (Raval et al., 2005)). A plasmid 
expressing viral RTA from the HCMV promoter (pCMVRTA) was supplied 
generously by Adrian Whitehouse, University of Leeds (Wilson et al., 2007). 
Finally, RTA-expressing pSIN-BNHA-kRTA and a GFP-expressing, control 
plasmid pSIN-BNHA-GFP/pSIN-GFP were supplied by Edward Tsao(see table 
in Appendix). 
 
2.4.9 Reporter plasmids 
The luciferase reporter plasmid pRpluc1-3087 contains a 3-kb sequence 
upstream of the RTA transcriptional start that drives the expression of firefly 
luciferase. Truncated RTA promoter pRpluc 1115-1327 contains the hypoxia 
response element 2, (HRE2) only. Truncated RTA promoter pRpluc1-550 
contains hypoxia response element 4, (HRE4) also identified as XBP-1 
response element (XRE) only. All luciferase plasmids outlined above were kind 
gifts from Erle Robertson, University of Pennsylvania. (Cai et al., 2006a) (see 
Figure 4-10) (see table in Appendix). 
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2.5 Transient transfection  
 
2.5.1 Transient transfection of HEK 293-T cells  
2x105 HEK 293-T cells were seeded per well of a six-well plate.  The following 
day the culture medium was removed and replaced with fresh medium.  The 
transfection was carried out using FuGENE-6 transfection reagent (Roche 
Applied Science, Burgess Hill, UK) as per the manufacturer’s instructions.  
Briefly, transfection mixes including 6 µl of FuGENE-6, 100 µl of Opti-MEM 
(GIBCO, Invitrogen, Paisley, UK) and varying amounts of DNA were incubated 
at room temperature for 30 minutes and then added drop wise to the cells. The 
amounts of Opti-MEM and FuGENE-6 were adjusted according to the well size 
and cell number by ratio. The medium containing the transfection mixture was 
removed the day after transfection and replaced with fresh medium.  48 hours 
post-transfection live cells were analysed by flow cytometry see section 2.2, RT 
PCR see section 2.7, western blot see section 2.8 or luciferase assay 2.9. 
 
2.6 Lentivirus production, transduction and titration 
 
2.6.1 Transient transfection of HEK 293-T cells for the production of 
lentivirus. 
Lentiviral vectors were produced as described in (Besnier et al., 2002).  HEK 
293-T cells were seeded so that 10 cm dishes were confluent on the day of 
transfection.  10 µl of FuGENE-6 (Roche Applied Science, Burgess Hill, UK) 
was added to 200 µl of Opti-MEM (Invitrogen, UK).  1 µg of p8.91, 1 µg of 
pMDG (both generous gifts from Didier Trono) and 1.5 µg of vector-genome 
encoding plasmid DNA were made up to 15 µl in H2O and added to the 
FuGENE-6 and Opti-MEM mixture.  The transfection mixture was incubated at 
room temperature for 30 minutes before being added drop wise to the confluent 
HEK 293-T cells in 8 ml DMEM medium with 10 % FCS and P/S.  
 
The HEK 293-T cells and the transfection reaction were incubated overnight at 
37oC and 10 % CO2. The lentiviral vector containing supernatants were 
harvested at 48, 72 and 96 hours post transfection, passed through a 0.45 µm 
filter and stored at -80 oC in 1 ml aliquots. 
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Virus was concentrated from the pooled supernatant collections using 
polyethylene glycol molecular weight 8000 (PEG – Sigma, Dorset UK)) 
treatment. 1/10th the volume of sterile 50 % PEG solution and 1/33rd the volume 
of 5 M sodium chloride (Sigma Aldrich, Dorset, UK) was added to the filtered 
supernatants, mixed well by inversion and stored at 4°C overnight (these are 
stable at 4°C at least a week). The virus collections were centrifuged at 
2000 x g at 4°C for 10 minutes the supernatant was then discarded carefully to 
avoid disturbing the pellet. The virus pellet was finally resuspended in media at 
a low volume by pipetting up and down several times. Concentrated virus was 
then aliquoted and stored at -80°C.  
 
2.6.2 Lentiviral vector titration of infectious units by GFP or RFP 
expression  
1x105 HEK 293-T cells were seeded per well of a 24-well plate and cultured 
overnight at 37oC and 10 % CO2 in 1ml of HEK 293-T medium (DMEM 
containing 10 % FCS, P/S). 1:3 serial dilutions of supernatant containing 
lentivirus were made using HEK 293-T medium.  100 µl of the diluted lentivirus 
containing supernatants and 100 µl of undiluted supernatant supplemented with 
15 µg/ml polybrene (Sigma Aldrich, Dorset, UK) were added to HEK 293-T cells 
in 0.9 ml of fresh medium. Cells were spinoculated for 1 hour at 500 x g. Cells 
were then incubated overnight at 37oC and 10 % CO2.  The cells were washed 
once with HEK 293-T medium and incubated for a further 36 hours. 
 
After incubation the HEK 293-T cells were trypsinised and the percentage of 
GFP- or RFP-expressing cells determined by flow cytometry (see section 2.2) 
relative to non-infected cells.  The percentage of GFP- or RFP-expressing cells 
were converted to infectious units by assuming a total of 2x105 cells at the time 
of infection.  Infectious units were plotted against µl of supernatant.  The 
absolute titre of the lentiviral vector was determined by extrapolating the 
infectious units per ml (IU/ml) using the straight-line equation of the above plot.  
 
2.6.3 Lentiviral vector titration of infectious units by antibiotic selection 
and colony counting 
1x105 HEK 293-T cells were seeded per well of a 24-well plate and cultured 
overnight at 37oC and 10 % CO2 in 1 ml of HEK 293-T medium (DMEM 
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containing 10 % FCS and P/S).  1:10 serial dilution of supernatant containing 
lentivirus were made so as 10 µl, 1 µl, 0.1 µl, 0.01 µl and 0.001 µl of lentivirus 
containing supernatants were mixed with HEK 293-T medium to a total volume 
of 100 µl.  The diluted lentiviral-vector containing supernatants were 
supplemented with 15 µg/ml polybrene (Sigma Aldrich, Dorset, UK) and added 
to HEK 293-T cells. Cells were spinoculated for 1 hour at 500 x g and then 
incubated overnight at 37oC and 10 % CO2.  The cells were then trypsinised 
and cultured in 5 cm dishes containing 5 ml of HEK 293-T medium containing 
the appropriate amount of antibiotic depending on the resistance encoded by 
the lentivirus (see section 2.6.6).  3 days after infection the plates were washed 
and placed in fresh HEK 293-T medium containing antibiotic. 14 days after 
infection visible antibiotic resistant colonies were counted and the infectious 
units extrapolated from the dilution containing approximately 10 colonies.  
 
2.6.4 Lentiviral transduction of suspension cells 
0.5x105 cells per well of a 24-well plate in 1 ml of the required amount of, 
lentivirus containing, HEK 293-T supernatant and RPMI culture medium 
supplemented with 15 µg/ml polybrene (Sigma Aldrich, Dorset, UK). Cells were 
spinoculated for 1 hour at 500 x g. The cells were then incubated for 6 hours or 
overnight at 37oC and 5 % CO2.  The cells were then pelleted and resuspended 
in fresh RPMI medium. 
 
2.6.5 Lentiviral transduction of adherent cells 
1 x105 cells were plated per well of a 24-well plate.  The following day the 
medium was removed and replaced with 1 ml of the required amount of, 
lentivirus containing, HEK 293-T supernatant supplemented with 15 µg/ml 
polybrene (Sigma Aldrich, Dorset, UK).and culture medium.  Cells were 
spinoculated for 1 hour at 500 x g. The cells were then incubated for 6 hours or 
overnight at 37oC.  The lentiviral vector containing, HEK 293-T supernatant and 
culture medium was then removed and replaced with fresh medium. 
 
2.6.6 Antibiotic selection following lentiviral vector transduction 
48 hours post infection (transduction see sections 2.6.4 and 2.6.5) the medium 
was removed and replaced with medium supplemented with 2 µg/ml puromycin 
dihydrochloride from S. alboniger (Sigma Aldrich, Dorset, UK) or 750 µg/ml 
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hygromycin B from S. hygroscopicus (GIBCO, Invitrogen, Paisley, UK) 
depending on the encoded resistance.  The medium was removed and replaced 
with fresh medium supplemented with appropriate antibiotic every 2-3 days until 
non-transduced cells, in parallel cultures, were no longer viable.  The antibiotic-
selected cells were then cultured normally in medium supplemented with 
respective antibiotic. 
 
2.7 RT PCR  
 
2.7.1 RNA extraction and DNase treatment  
Total RNA was purified from 8-10x105 cells resuspended in 1 ml of Trizol 
(GIBCO, Invitrogen, Paisley, UK). After an initial chloroform extraction step RNA 
was isolated using an RNeasy mini extraction kit (Qiagen, Crawley, UK) 
including an on-column DNase (Promega, Southampton, UK) digestion 
following the manufacturer’s instructions. RNA was quantified using a ND-1000 
spectrophotometer (Nanodrop Technologies, Rockland, DE). 
 
2.7.2 cDNA synthesis 
Reverse transcription reactions were carried out using Omniscript Reverse 
Transcriptase (Qiagen, Crawley, UK), in accordance with the manufacturer’s 
instructions and starting with 1-2 µg of total RNA.  
 
2.7.3 PCR to detect messenger RNA  
The desired region was PCR-amplified from the oligonucleotide dT (GIBCO, 
Invitrogen, Paisley, UK)-primed cDNA using 5 units of GoTaq polymerase 
(Promega, Southampton, UK) in a 50 μl reaction volume buffered with 5x 
GoTaq polymerase flexi buffer (Promega, Southampton, UK).  PCR conditions 
involved 20 picomoles of each oligonucleotide primer.  In addition, the reaction 
was supplemented with a final concentration of 0.2 mM dNTPs (Promega, 
Southampton, UK) and between 0.5 and 2 mM MgCl2 (Promega, Southampton, 
UK).   
 
Primers were designed to amplify a 300 bp region towards the 3’ end of the 
gene of interest. β-actin and GAPDH were detected using primers a and b or c 
and d respectively (Table 2-5). The PCR program used was as follows: hotstart 
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of 95°C for 2 minutes a PCR cycle consisting of 30 seconds, 60°C for 
30 seconds, and 72°C for 1 minute this was repeated 28 times. RTA was 
amplified from KSHV containing cells using primers i and j (Table 2-5) and the 
same cycling conditions as for β-actin above however with 35 cycles. ORF29a/b 
was amplified using the primers g and h (Table 2-5). The PCR reaction 
contained 1.8 mM MgCl2 and the same PCR cycle as above except with an 
annealing temperature 65°C and 35 cycles. All PCR programs finish with a final 
5 minutes extension at 72°C.  
 
The correct molecular weight product was separated and visualised using, 
10 mg/ml ethidium bromide (Sigma Aldrich, Dorset, UK) stained, agarose gel 
electrophoresis as before (see section 2.4.5.1). 
 
2.7.3.1 XBP1 PCR, Pst I digestion and resolution 
PCR amplification across the XBP-1 atypical splice junction was achieved using 
oligonucleotides e and f (Table 2-5). The desired region was PCR-amplified as 
above section 2.7.3., however with an annealing temperature of 58oC and with 
35 cycles. Following PCR amplification the 50 μl reaction was halved into 25 μl. 
Then 1 μl of H2O was added to one half while 20 units of Pst I was added to the 
other half of the reaction and incubated overnight at 37oC.  The restricted and 
non-restricted PCR products were resolved using agarose gel electrophoresis. 
The best separation was achieved using 3 % TBE buffered agarose gels, pre-
cooled to 4 oC.  The gels were resolved at 5 volts/cm in room temperature TBE 
buffer diluted 1:1 with H2O. 
 
Table 2-5 DNA primers for mRNA detection (Sigma Aldrich, Dorset, UK) 
Oligo  Name Sequence 
a Beta Actin fwd ctgtggcatccacgaaacta 
b Beta Actin rev acatctgctggaaggtggac 
c GAPDH fwd atggggaaggtgaaggtcgg 
d GAPDH rev tggtgaagacgccagtggac 
e XBP-1short fwd ccttgtagttgagaaccagg 
f XBP-1short rev cagaatgcccaacaggatatc 
g ORF29a/b fwd gcacgtagccaactccgtg 
h ORF29a/b rev gcaggaaactcgtggagcg 
i RTA fwd aatgcgttacgttgttgcag 
j RTA rev tcccaaagaggtaccaggtg 
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2.8 Immunoblotting  
Approximately 8x105 cells were lysed directly with 100 µl sample buffer (0.2 M 
Tris-HCl pH 6.8, 5.2 % sodium dodecyl sulphate (SDS), 20 % glycerol, 0.1 % 
bromophenol blue and 40 mg/ml DTT on day of use). Samples were then 
sonicated and boiled then centrifuged at 15,500 x g for 1 minute. Samples were 
aliquoted into 20 µl (load volume) and stored at -20°C. Protein concentration 
was normalised by cell number and by blotting for a housekeeping protein. 
Proteins were resolved by 10 % SDS poly-acrylamide gels using Bio-Rad 
(Hemel Hempstead, UK) apparatus and SDS PAGE running buffer (10x in 
5 litres: 50 g SDS, 150 g Tris, 720 g glycine. Separated proteins were then 
transferred using a semi-dry transfer blotter (Amersham Biosciences) and 
semiphor transfer buffer (25 mM Tris, 192 mM glycine, 20 % methanol) to a 
polyvinylidene difluoride membrane (PVDF, GE Healthcare, Little Chalfont, UK). 
Blotting conditions were 0.8 mA/cm2 for 1 hour.  
 
After blocking for 1 hr with 5 % non-fat dry milk in TBS (10x in 5 litres: 120.5 g 
Tris-base, 400 g NaCl, pH 7.6) containing 0.1 % TWEEN 20 (Sigma Aldrich, 
Dorset, UK) (TBST), the membrane was probed overnight at 4 °C with primary 
antibodies against HIF-1α (monoclonal BD Transduction Laboratories, San 
Jose, CA 1/200), RTA (polyclonal, Don Ganem, University of California and San 
Francisco (Lukac et al., 1998)1/20,000), BZLF-1: BZ-1 (Imperial College 
London, Dr. Paul Farrell (Bryant and Farrell, 2002)1/10,000), HIS (GE 
Healthcare Little Chalfont, UK 1/1000) or XBP-1(s) (monoclonal, Giovanna 
Roncador (Maestre et al., 2009) 1/100) in 1 % non-fat dry milk. Blots were 
washed 5 times with TBST at intervals of 5 minutes each before 1 hr incubation 
with the appropriate horseradish peroxidase (HRP) conjugated secondary 
antibodies (GE Healthcare, Little Chalfont, UK) in 1 % non-fat dry milk in TBST 
at room temperature.  The primary antibodies anti-HA (HRP-conjugated 1/3000) 
and β-actin (ABcam 1/40,000) as well as corresponding secondary antibody 
(1/2000) as required were incubated for 1 hour at room temperature 
respectively in TBST. All blots were washed 5 times with TBST at intervals of 
5 minutes each before developing. HRP-conjugated antibody was detected 
using ECL western blotting detection reagent (GE Healthcare, Little Chalfont, 
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UK). Chemiluminescence was measured by autoradiography using Hyperfilm 
ECL (GE Healthcare, Little Chalfont, UK).  
 
2.9 Luciferase promoter assays 
 
2.9.1.1  Bright Glo protocol 
HEK 293T cells were plated at a density of 2x104 in 96-well plates, the next day 
cells were transfected using 20 ng of the appropriate ORF50 reporter plasmids, 
section 2.4.9 (a kind gift from Erle Robertson, University of Pennsylvania, (Cai 
et al., 2006a) in combination with molar equivalent transcription factor 
expressing plasmid DNA, see section 2.5.1. After 48 hours, quantification of 
relative light units (RLU) was determined using the luciferase Bright Glo reagent 
in accordance with the manufacturer’s instructions (Promega, Southampton, 
UK) and a GloMax 96-microplate luminometer with single injector (Promega, 
Southampton, UK). All assays were performed in triplicate. Transfection 
efficiency was monitored by parallel transfection with a fluorescent protein and 
flow cytometry. The standard error of the mean for each triplicate represents the 
error for each experiment.  
 
2.9.1.2 Dual luciferase assay protocol 
As above with a few exceptions, reporter plasmids used were described in 
section 2.4.5.5, in addition 2 ng of Renilla Luciferase expression plasmid (phRL-
null) plasmid (a kind gift from Professor Gary Stein, University of 
Massachusetts) was transfected into every well to act as transfection control 
and used to normalise firefly luciferase data. After 48 hours, cells were 
harvested and lysates were measured for luciferase activity with a dual-
luciferase reporter assay kit (Promega, Southampton, UK) in accordance with 
manufacturer’s instructions. Raw values obtained from each experiment, 
performed in triplicate, were normalized to the Renilla value for each replicate. 
The standard error of the mean for each triplicate represents the error for each 
experiment.  
 
2.10 Virion DNA extraction and TaqMan PCR  
180 µl from 1 ml of supernatant containing approx 1-2x105 PEL cells in culture 
under normoxia or hypoxia were treated with DNase (Promega, Southampton, 
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UK), followed by the addition of 10 µg of salmon sperm DNA (ssDNA) as 
carrier. Virion DNA was extracted using the QIAamp DNA extraction kit 
(Qiagen, Crawley, UK). The amount of recovered DNA was used to normalise 
the DNA input of different samples for the calculation of viral load. KSHV 
ORF37 TaqMan PCR was performed as described previously with modification 
(Stamey et al., 2001).  Each 25 µl PCR contained 1x Platinum Quantitative PCR 
SuperMix-Uracil DNA Glycosylase (UDG) with ROX (GIBCO, Invitrogen, 
Paisley, UK), 300 nM each ORF37 primer, 150 nM ORF37 probe (Sigma 
Aldrich, Dorset, UK), and 5 µl sample DNA.  Following 2 minutes incubation at 
50°C for activation of the UDG, the sample is denatured for 3 minutes at 95°C. 
Fifty cycles of standard quantitative PCR were performed consisting of 95°C for 
15 seconds and 60°C for 50 seconds. Amplification was carried out with an ABI 
Prism 7000 sequence detection system (Applied Biosystems).  Each PCR run 
also contained a standard dilution curve of ORF37 and no template negative 
controls.  All samples were run in duplicate reactions.   
 
2.11 Whole Human Genome Oligo Microarray analysis 
 
2.11.1 RNA extraction 
RNA was extracted as in section 2.7.1. RNA integrity was measured using RNA 
6000 Series II Nano Kit and 2100 Bioanalyzer Series C (Agilent Technologies, 
West Lothian, UK), according to manufacturer’s instructions. RNA samples 
used for analysis had an RNA integrity number (RIN number) of >9.0; indicating 
high-quality RNA with minimal degradation products. All chips were analyzed 
using 2100 Expert software version B.02.04 (Agilent Technologies, West 
Lothian, UK). 
 
2.11.2   Labelling, hybridisation and analysis 
Agilent Whole Human Genome Oligo Microarrays (G4112A) which contains 
44,000 60-mer oligonucleotide probes representing 41,000 unique genes and 
transcripts were used for the gene expression experiments. Probe labelling and 
hybridization were carried out following the manufacturer's specified protocols 
(Two-colour Microarray-Based Gene Expression Analysis Protocol, Agilent 
Technologies, West Lothian, UK). Briefly, amplification and labelling of 500 ng 
of total RNA and was performed using Cy5 for sample RNA and Cy3 for the 
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universal human reference RNA (Stratagene, Leicester, UK). Hybridization was 
performed for 17 hours at 65°C and arrays were scanned on an Agilent DNA 
microarray scanner (Agilent Technologies, West Lothian, UK). Images were 
analysed and the data was extracted, background subtracted and normalised 
using the standard procedures of Agilent Feature Extraction software (v9.5.3.1) 
(Agilent Technologies, West Lothian, UK). Intensities for each sample relative to 
the reference were obtained from the feature extraction file by background 
subtraction and scale normalisation using R and BioConductor (Gentleman et 
al., 2004). For detailed analysis methods, performed by Dr Dan Frampton; see 
results sections 3.2.6 and 5.2.5. 
 
2.12 Statistics 
Performed by Dr Dan Frampton 
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3 Establishing a model for lytic reactivation - 
rKSHV.219 HEK 293T cells 
 
3.1 Introduction 
 
KSHV establishes life-long persistent latent infection of its host; however, 
reactivation and lytic replication is necessary for transmission and dissemination 
of the virus as well as tumourigenesis (Whitby et al., 1995) (Staskus et al., 
1997) (Song et al., 2004) (Grundhoff and Ganem, 2004). This is highlighted by 
the reported reduced risk of developing Kaposi Sarcoma (KS) after treatment 
with ganciclovir; an anti-herpetic that is only effective against lytic virus (Martin 
et al., 1999). Lytic gene products have also been linked to the pathology seen in 
KSHV associated diseases, for example ORF74 which encodes a viral G-
protein coupled receptor and induces production of the cytokine, VEGF, leading 
to cell proliferation and angiogenesis (Bais et al., 1998) (Liu et al., 2001) 
(Jenner and Boshoff, 2002) (see section 1.1.12). 
 
The reactivation of KSHV from latency can be induced in vitro by various factors 
including the chemical inducer, 12-O-tetradecanoyl-phorbol 13-acetate (TPA) 
(Renne et al., 1996b) (Yu et al., 1999) (see section 1.1.14) However, such 
predominantly non-physiological inducers provide limited insight into the cellular 
cues that induce KSHV lytic replication in KS, PEL and MCD. The viral protein 
regulator of transcription activation (RTA), encoded by open reading frame 50 
(ORF50), is both necessary (Xu et al., 2005) (Lukac et al., 1999) and sufficient 
(Gradoville et al., 2000) for inducing KSHV lytic replication. RTA can also auto-
activate the ORF50 promoter leading to a substantial amplification of any 
stimulus that induces RTA expression (Deng et al., 2000).  Despite this 
knowledge, what activates the switch from latency to lytic replication is still 
poorly understood. Therefore, determining the physiological triggers that induce 
RTA expression is critical for understanding the control of KSHV reactivation in 
asymptomatic infection and disease.  
 
In this chapter we characterise a system for monitoring KSHV reactivation and 
employ this method to investigate a physiological trigger of lytic replication. 
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Recombinant KSHV systems, that contain a GFP expression cassette as a 
marker of infection, have been engineered partly to overcome the problem of 
KSHV propagation and dilution in vitro (Bechtel et al., 2003) (Zhou et al., 2002) 
(Vieira et al., 2001). Recent advances have added a DsRed expression 
cassette under the control of the KSHV lytic Polyadenylated nuclear RNA (PAN) 
promoter to produce the recombinant virus, rKSHV.219 (Figure 3-1 B) (Vieira 
and O'Hearn, 2004). The viral PAN promoter is transactivated specifically by 
RTA and therefore DsRed expression directly infers lytic replication. In the 
Vieira study the rKSHV.219 virus established latent infection and could be 
induced to reactivate in all cell lines tested (Vieira and O'Hearn, 2004). This 
system, therefore, is a simple way of monitoring KSHV reactivation in response 
to stimuli. The rKSHV.219 Vero and rKSHV.219 JSC-1 cell lines were 
generously supplied by the laboratory of Jeff Vieira. 
 
HEK 293T cells were infected with rKSHV.219 and characterised. Using the cell 
lines generated we further establish the role of the transcription factor, X-box 
binding protein-1 (XBP-1), as an inducer of the KSHV lytic cycle (Wilson et al., 
2007) (Sun and Thorley-Lawson, 2007) (Yu et al., 2007a). XBP-1, is a basic 
leucine zipper transcription factor essential for the induction of the unfolded 
protein response (UPR), which is triggered by a variety of different cellular 
stresses, including the ER-stress induced by B-cell terminal differentiation into 
plasma cells (see section 1.3.3.1) (Schroder and Kaufman, 2005) (Reimold et 
al., 2001). We show that XBP-1s activated by non-physiological triggers, such 
as dithiothreitol (DTT), can induce KSHV reactivation (Wilson et al., 2007). This 
chapter also defines the mechanism by which XBP-1s induces reactivation of 
KSHV, and explores the possibility of a similar mechanism in related 
Rhadinoviruses. Finally, using the rKSHV.219 infected HEK 293T clonal cell 
lines and gene expression profiling we attempt to reveal other cellular regulators 
of KSHV lytic replication. 
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3.2 Results 
 
3.2.1 rKSHV.219 infection of HEK 293T cells  
The rKSHV.219 infected Vero cell line was obtained from the laboratory of Jeff 
Vieira. However, this kidney epithelial cell line derived from African green 
monkey (AGM) was not optimal for my work. This is predominantly due to the 
lack of infection by lentiviruses, a mechanism for gene delivery well established 
in the laboratory. Lentivirus infection is blocked by members of the tripartite 
motif (TRIMs) family of proteins, endogenous restriction factors expressed by 
AGM cells (Stremlau et al., 2004) (Keckesova et al., 2004). We therefore used 
the Vero cell line only for the initial production of recombinant rKSHV.219 virus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Generating rKSHV.219 HEK 293T cell lines 
(A) Flow diagram summarising the method used to generate rKSHV.219 infected HEK 293T 
clonal cell lines. (B) Schematic diagram of the KSHV genome showing expansion of the 4.8 kb 
BamHI fragment used to make the recombinant rKSHV.219 virus, and the structure and 
insertion site of the RFP/GFP/PURO construct. The cassette is inserted between ORFK9 and 
ORF57 in a predicted non-coding region. The BamHI and HindIII sites of the 4.8 kb fragment 
 128
are indicated. Adapted from (Vieira and O'Hearn, 2004). (C) Photomicrographs of two 
morphologically distinct rKSHV.219 infected HEK 293T clonal cell lines with different levels of 
spontaneous reactivation. Typical fields of EF1α-GFP and PAN-DsRed fluorescence of each 
cell line are shown magnified at x20.  
 
The method of generating stable rKSHV.219 infected HEK 293T cell lines is 
briefly summarised below and in Figure 3-1 A.  Sodium butyrate was used to 
induce lytic reactivation in the original rKSHV.219 containing Vero cell line as 
described previously (Miller et al., 1997; Miller et al., 1996) (Vieira and O'Hearn, 
2004). Infectious rKSHV.219 virus was collected in the cell-free culture medium 
of these cells and used to infect HEK 293T cells by spinoculation. HEK 293T 
cells are derived from human embryonic kidney (HEK) and were chosen for this 
system because they are permissive to infection, can be easily transfected and 
contain the SV40 large T antigen; to provide efficient and prolonged expression 
from plasmids containing an SV40 origin of replication. 48 hours after infection 
puromycin was used to select rKSHV.219 infected, GFP-positive HEK 293T 
single cell clones, which were expanded for further analysis. The clones 
obtained had mixed phenotypes, varying in morphology and in the amount of 
spontaneous lytic reactivation, represented by level of DsRed expression driven 
from the PAN promoter (Figure 3-1 B). Two examples of the rKSHV.219 
infected HEK 293T cell lines generated are shown in Figure 3-1 C. The 
rKSHV.219 infected HEK 293T cell line, Clone 5, is an example of a clonal cell 
line that appears to clump and has a significant amount of spontaneous lytic 
replication. The cells of another clone, Clone 9, resemble regular HEK 293T cell 
morphology and represent a predominantly latent KSHV infection, with a 
spontaneous lytic population of approximately 1 %.  
 
3.2.2 Characterisation of rKSHV.219 HEK 293T cell line – Clone 9 
 
3.2.2.1 Response to various stimuli reported to reactivate latent KSHV 
In order to characterise the rKSHV.219 infected HEK 293T cell lines generated 
and their potential use as a system to monitor the switch from latent to lytic 
KSHV replication, we studied their response to various factors known to induce 
reactivation. Starting with Clone 9, which displays a predominant latent infection 
with around a 1-3 % level of spontaneous lytic replication in untreated samples, 
similar to what is observed in the disease states of KS and PEL (Figure 3-2 A).  
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Figure 3-2 Treatment of Clone 9 cells with known inducers of KSHV reactivation 
Photomicrographs of HEK 293T cells harbouring recombinant KSHV, rKSHV.219 (rKSHV.219 
HEK 293Ts – Clone 9) 48 hours post-treatment. Typical fields of EF1α-GFP and PAN-DsRed 
fluorescence of each treatment magnified at x20 are shown. (A) Spontaneous levels of 
reactivation shown in untreated Clone 9 cells. Reactivation as demonstrated by DsRed 
expression in response to 3 mM sodium butyrate (NaBut) (B), 4 mM dithiothreitol (DTT) (C), 
20 ng/µl TPA (D) or transfected with 1 µg pXBPsIG (E).  
 
Treatment of Clone 9 cells with either 3 mM sodium butyrate (NaBut) or 4 mM 
DTT for 16 hours overnight led to significant reactivation of rKSHV.219, as 
measured by DsRed expression from the PAN lytic promoter 48 hours after 
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treatment (Figure 3-2 B and C). 48 hours after treatment with 20 ng/µl TPA low 
levels of DsRed expression were seen compared to untreated controls (Figure 
3-2 D). Finally, overexpression of XBP-1 in its spliced active form induced 
KSHV reactivation as we have previously reported (Figure 3-2 E) (Wilson et al., 
2007). Altogether this data shows that the rKSHV.219 infected HEK 293T cell 
line, Clone 9, faithfully represents a latent KSHV infection and responds to 
known triggers of lytic reactivation.  
 
3.2.2.2 Dose dependent rKSHV.219 reactivation in response to DTT 
To further analyse the rKSHV.219 infected HEK 293T cell line, Clone 9, the 
response to DTT, a known inducer of the UPR, over a range of concentrations 
was investigated. DTT is a reducing reagent that alters the redox environment 
of the endoplasmic reticulum (ER), and prevents the formation of di-sulphide 
linkages leading to the accumulation of misfolded proteins in the ER. Clone 9 
cells were cultured in the presence of increasing concentrations of DTT for 
16 hours first and then in fresh media for a further 48 hours before 
photomicrographs were taken, and the cells were prepared for FACs analysis. 
In response to DTT-induced stress Clone 9 cells displayed a dose dependent 
level of DsRed expression (Figure 3-3 A). The level of spontaneous lytic 
reactivation of Clone 9 cells was also measured in untreated control samples by 
FACsArray and was found to be below 3 % DsRed-positive (Figure 3-3 B).  
 
Approximately 5 % of Clone 9 cells were driven into the KSHV lytic cycle after 
treatment with 4 mM DTT (Figure 3-3 B). To reach a final concentration of 4 mM 
DTT, 24 µl of DMSO containing DTT is added to 2 ml of media, this 
corresponds to 1.2 % of the total culture volume. This level of DMSO does not 
cause reactivation over and above the level of spontaneous reactivation 1-3 % 
measured by FACsArray (Figure 3-3 C). However the addition of larger volumes 
of DMSO, such as 45 µl (or 2.25 % of the total culture volume), causes levels of 
DsRed expression greater than background, and are therefore avoided (Figure 
3-3 C). Higher concentrations of above 4 mM DTT appear to be toxic as fewer 
GFP-positive cells can be seen in these samples (Figure 3-3 A). Therefore in 
order to induce KSHV reactivation in Clone 9 cells specifically via DTT-induced 
UPR, without toxicity, the optimal concentration of DTT to be used is 3-4 mM. 
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When comparisons are made between the percentages of DsRed-expressing 
cells determined by FACsArray with the levels seen by microscopy of the same 
cells, we can see that the FACsArray underestimates DsRed levels compared 
to the fluorescent microscope (Figure 3-3 A and B).  
Figure 3-3 DTT titration on Clone 9 cells 
(A) Photomicrographs of rKSHV.219 infected HEK 293T clonal cell line – Clone 9, 48 hours 
post-treatment with a range of DTT concentrations. Typical fields of EF1α-GFP and PAN-DsRed 
fluorescence of each condition magnified at x20 are shown. (B) Activity of the PAN lytic 
promoter in the cultures seen in the photomicrographs (A) were measured by flow cytometry 
and displayed as the percentage of DsRed-positive cells. Clone 9 cells displayed a dose 
dependent level of Ds-Red expression in response to DTT. (C) The percentage of DsRed-
positive Clone 9 cells in response to a range of volumes of DMSO were measured by FACs. 
Volumes of DMSO below 40 µl do not induce DsRed expression above 2.5 %. Error bars 
represent the standard error of the mean of triplicate experiments. The percentage of DsRed 
cells resulting from 4mM DTT treatment is significantly different to those resulting from the 
equivalent amount of DMSO treatment p<0.0274  (D) The potential difference between the 
percentage of DsRed positive cells detected by the confocal microscope (squares) and FACs 
analysis (triangles). Clone 9 cells treated with NaBut were counted by automatic software before 
FACs analysis.  
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3.2.2.3 DsRed expression is dependent on RTA in Clone 9 cells  
We have shown that the rKSHV.219 infected HEK 293T cell line, Clone 9, 
expresses DsRed in response to various known triggers of KSHV reactivation 
(section 3.2.2.1 and 3.2.2.2). In rKSHV.219 recombinant virus, DsRed 
expression is driven by the PAN lytic promoter, which is transactivated by RTA; 
an immediate early viral protein both necessary and sufficient for lytic replication 
(Vieira and O'Hearn, 2004) (Lukac et al., 1998). To confirm that in Clone 9 cells 
DsRed expression is dependent of RTA we took advantage of shRNA 
technology. Previously in the laboratory, a short hairpin RNA (shRNA) was 
designed to target RTA and shown to be effective at reducing the number of 
cells expressing RTA protein. An irrelevant control shRNA targeting GFP was 
also designed and shown to have no effect on RTA protein levels. Lentivirus 
expressing shRNA-RTA or control shRNA-GFP was used to transduce Clone 9 
cells at an MOI 5. 48 hours post-transduction Clone 9 cells were then cultured 
in the presence or absence of 4 mM DTT overnight. Media was then replaced 
the next day and the DsRed expression was observed by confocal microscopy 
24 hours later. Treatment of non-transduced Clone 9 cells with 4 mM DTT led to 
an increase in DsRed expression compared to control untreated cells (Figure 
3-4 A). As expected GFP expression was noticeably lower in Clone 9 cells 
transduced with shRNA-GFP (Figure 3-4 B). DTT treatment of shRNA-GFP-
expressing Clone 9 cells led to increased DsRed expression similar to non-
transduced DTT treated samples (Figure 3-4 B). However, in the presence of 
shRNA-RTA DsRed expression was markedly reduced in response to DTT 
treatment compared to the non-transduced and shGFP transduced, DTT treated 
samples (Figure 3-4 C and A). 
 
Additionally, non-transduced Clone 9 cells or Clone 9 cells expressing shRNA-
RTA were cultured in the presence or absence of 3 mM NaBut. As expected, 
NaBut treatment of Clone 9 cells led to an increase in DsRed expression which 
was blocked by the presence of shRNA-RTA (Figure 3-4 D). Therefore, the 
DsRed expression detected in Clone 9 cells was directly due to KSHV 
reactivation, the presence of RTA and transactivation of the PAN lytic promoter. 
Importantly, we also demonstrate that shRNA mediated knock down of gene 
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expression is an effective way of dissecting the role of different proteins in 
Clone 9 cells.  
 
 
Figure 3-4 RTA dependence of DsRed expression in Clone 9 cells 
rKSHV.219 HEK 293Ts – Clone 9 cells were transduced with lentivirus expressing shRNA-GFP 
or shRNA-RTA at MOI 5 and 48 hours later stimulated to induce the KSHV lytic cycle with 4 mM 
DTT or 3 mM sodium butyrate (NaBut) treatment. After 48 hours cells were analysed using 
confocal microscopy. Typical fields singly excited with 488-nm light to detect cells expressing 
GFP from the EF1  promoter (green) or 568 nm light to detect cells expressing DsRed from the 
KSHV lytic cycle PAN promoter (red) are shown magnified at x60. (A) Non-transduced Clone 9 
cells treated with DTT have increased DsRed expression. (B) DsRed expression in response to 
DTT is also seen in the presence of shRNA-GFP. (C) DTT-induced DsRed expression is 
blocked by the presence of shRNA-RTA. (D) NaBut treated non-transduced Clone 9 cells have 
increased levels of DsRed expression relative to untreated controls which is blocked by the 
presence of shRNA-RTA.  
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3.2.3 Utilising the rKSHV.219 HEK 293T cell model for reactivation 
Having characterised and established the rKSHV.219 infected HEK 293T cell 
line, Clone 9, we wished to use this model to further investigate the role of XBP-
1s in the reactivation of KSHV (Wilson et al., 2007). 
 
3.2.3.1 Effective knock down of XBP-1s protein using shRNA  
It was previously observed that treatment of PEL cells with the drug DTT led to 
XBP-1 activation (XBP-1s). Also full KSHV lytic replication was induced by the 
overexpression of XBP-1s in latently infected cells (Wilson et al., 2007).  To 
determine the direct involvement of endogenous XBP-1s in KSHV reactivation 
we therefore sort to remove XBP-1 from the rKSHV.219 system and monitor 
reactivation. A shRNA to target XBP-1 was previously designed (Figure 3-5 A) 
(Wilson et al., 2007). We showed that this hairpin was effective at reducing 
exogenous XBP-1s protein levels in HEK 293Ts cells stably expressing shRNA-
XBP-1 (Figure 3-5 B). XBP-1 protein levels were unaffected by the presence of 
the control, shRNA-GFP (Figure 3-5 B). This validated a shRNA to XBP-1s, 
which we can use to study the function of XBP-1s in the induction of KSHV lytic 
replication.  
 
 
 
Figure 3-5 Validation of shRNA-XBP-1 
(A) Sequences and probable structures of shRNAs targeting GFP or XBP-1 respectively. (B) 
shRNA ability to knock down target protein levels was demonstrated by co-transfection of HEK 
293T cells with 1 µg of C-terminal domain (CTD) HIS tagged XBP-1s-expressing plasmid (CTD 
HIS XBP-1s) and 3 µg of relevant/irrelevant control hairpins in a pGEMT backbone. Western 
blot using anti-HIS for HIS-tagged XBP-1 detection. β-actin acts as a loading control.   
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3.2.3.2 Endogenous XBP-1s results in rKSHV.219 reactivation from 
latency in Clone 9 cells 
Using shRNA to XBP-1 and rKSHV.219 HEK 293T, Clone 9 cells, we 
investigated whether DTT-mediated endogenous IRE1 activity results in 
induction of KSHV lytic replication through XBP-1s. Since Clone 9 cells enter the 
lytic cycle after exposure to 4 mM DTT, we first looked to see if this DTT 
treatment also led to the induction of XBP-1s processing, consistent with the 
data derived in PEL cells (see section 3.2.2.2.) (Wilson et al., 2007).  XBP-1 
transcript splice status was monitored using a modified version of an RT PCR 
assay developed by Heather Harding, (Calfon et al., 2002) (Figure 3-6 A). 
Minimal XBP-1 spliced transcript is present in Clone 9 cells maintained in 
growth medium without DTT treatment (Figure 3-6 B). A 4 mM DTT overnight 
treatment of Clone 9 cells resulted in the detection of a strong band 
representing spliced XBP-1 that could not be seen in untreated controls (Figure 
3-6 B).  
 
 
Figure 3-6 DTT induces XBP-1 splicing in Clone 9 cells  
(A) Schematic representation of XBP-1 mRNA processing. Nucleotides are numbered relative to 
translation initiation. The PstI restriction site located in the intronic region is lost during a splicing 
event. Unspliced XBP-1 is therefore digested by PstI whereas spliced XBP-1s is resistant to 
digestion by PstI (B) RT PCR amplification across the XBP-1 intron produces a 249 base pair 
amplicon from XBP-1u mRNA and a 223 base amplicon from XBP-s mRNA. Pst I digests only 
the XBP-1u amplicon resulting in two bands, whereas XBP-1s results in a single band (Wilson 
et al., 2007). RT PCR amplification from the total mRNA of Clone 9 cells untreated or treated 
with DTT. A band corresponding to spliced XBP-1 is seen in DTT treated Clone 9 cells, a 
slower-migrating non-Pst I digestible PCR hybrid between the XBP-1s and XBP-1u products is 
visible in this lane as previously described (Wilson et al., 2007). RT PCR for β-actin on the 
same RNA was used to normalise cDNA input (data not shown). 
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Figure 3-7 Endogenous XBP-1s induces rKSHV.219 reactivation in Clone 9 cells 
(A) HEK 293T cells harbouring recombinant KSHV, rKSHV.219 (Clone 9 cells), were stimulated 
to induce the KSHV lytic cycle by 4 mM DTT treatment overnight. At 48 hours post-treatment, 
cells were analyzed using confocal microscopy as described in Figure 3-3. Clone 9 cells were 
also transduced at an MOI 5 with lentiviral vectors expressing shRNA XBP-1 (B), shRNA GFP 
(C), or shRNA-RTA (D) and treated with DTT as described above. (E) Activity of the PAN lytic 
promoter in the cultures seen in the confocal images (A-C) were measured by flow cytometry 
and displayed as the percentage of DsRed-positive cells. Columns represent mean of three 
independent experiments and error bars represent the standard error of the mean. 
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As seen before in section 3.2.2.2, increased DsRed expression indicating KSHV 
lytic cycle initiation was detected 48 hours after DTT treatment of non-
transduced Clone 9 cells  (Figure 3-7 A). The percentage of DsRed-positive 
non-transduced Clone 9 cells after DTT treatment as determined by FACsArray 
was 4.7 % (Figure 3-7 E). However, the photomicrograph of the same cells 
shows that the proportion of DsRed-positive cells was again underestimated by 
the FACsArray (Figure 3-7 A).  
 
Importantly, the reactivation seen in Clone 9 cells in response to DTT is blocked 
by the presence of a shRNA specific for XBP-1 but not by an irrelevant shRNA 
targeted to GFP. This is clearly visible when photomicrographs of DTT treated 
shRNA-XBP-1-expressing Clone 9 cells (Figure 3-7 B) are compared to DTT 
treated, non-transduced or shRNA-GFP-expressing cells (Figure 3-7 A or C). 
The percentage of DsRed-positive cells in DTT treated shRNA-GFP transduced 
samples was quantified by FACsArray as 3.7 % which was reduced to 0.89 %, 
background levels, in shRNA-XBP-1-expressing Clone 9 cells after DTT 
treatment (Figure 3-7 E).  As a further control for transduction, as well as DTT 
induction of the lytic cycle via RTA expression, shRNA-RTA was included in the 
experiment. As seen previously the presence of shRNA to RTA led to the 
reduction of DsRed expression in Clone 9 cells after DTT treatment (Figure 
3-7 D). This data provides evidence that endogenous activation of XBP-1 by 
DTT-induced UPR can specifically cause KSHV reactivation from latency. 
 
3.2.4 The ORF50 promoter and XBP-1 response elements 
 
3.2.4.1 The KSHV ORF50 promoter contains a novel XBP-1 responsive 
element 
We demonstrated that the highly active plasma cell transcription factor XBP-1 is 
a lytic switch trigger for KSHV using rKSHV.219 HEK 293T, Clone 9 cells. 
Previously, we showed that only expression of the spliced active isoform of 
XBP-1 (XBP-1s) in PEL cell lines robustly increased the expression of RTA, and 
this was sufficient to initiate the full lytic cycle (Wilson et al., 2007). The direct 
action of XBP-1s on the RTA promoter was also mapped to the 200 base pairs 
preceding the RTA start codon (Wilson et al., 2007). Examination of the targets 
for XBP-1 binding previously identified by chromatin immunoprecipitation (ChIP) 
 138
(Acosta-Alvear et al., 2007), revealed a potential XBP-1 response elements 
(XRE) in the ORF50 promoter with an ‘ACGT’ core containing motif (Figure 3-8 
A). To assess the relevance of this we determined the effect of XBP-1s 
expression on a luciferase reporter gene cloned downstream of the wild type 
ORF50 promoter and an ORF50 promoter sequence containing a mutant 
putative XRE in transient transfection assays (Figure 3-8 A). Both the wild type 
and mutant promoters responded to overexpressed RTA (Figure 3-8 B). 
Overexpression of XBP-1s was able to activate transcription from the wild type 
promoter with a 10 fold increase in activity with respect to empty vector control 
(pIG). However, XBP-1s overexpression failed to transactivate the mutant 
ORF50 promoter (Figure 3-8). This data identifies a functional XBP-1 response 
element 76 base pairs upstream of the starting methionine in the ORF50 
promoter. This element was previously identified as a weak HIF-1α response 
element 4 (HRE4) in the ORF50 promoter (Cai et al., 2006a) and we propose 
this element should be renamed XRE (Dalton-Griffin et al., 2009). 
 
Figure 3-8 A novel XBP-1s response element (XRE) in the ORF50 promoter 
(A) A schematic representation of the ORF50 promoter and coding region included in the 
luciferase reporter, showing the location of the predominant hypoxia response element (HRE2) 
as well as the newly identified XBP-1 response element (XRE), previously identified as the 
putative HRE4. Adapted from (Cai et al., 2006a). Numbers in brackets indicate the response 
element start sites relative to KSHV genome sequence (NC_003409). The wild type sequence 
of both HRE2 and XRE are shown with the core ‘ACGT’ sequence element highlighted in grey.  
LUCRTA 
 139
The mutated sequence of the XRE is indicated underneath with mutated nucleotides indicated 
by (•). (B) HEK 293T cells were transfected with a Renilla-expressing control plasmid (phRL-
null) plus the Firefly luciferase reporter plasmid, with either the wild type (p50LUC - black bars) 
or the mutant (pMUT50LUC - white bars) ORF50 promoter sequence together with pIG 
(control), RTA-expressing (pCMV-RTA) or XBP-1s-expressing (pXBPsIG). Firefly luciferase 
activity was determined 48 hours post-transfection and normalised to Renilla luciferase (phRL-
null) activity and plotted as a fold change relative to empty vector control pIG. Columns 
represent mean of three independent experiments and error bars represent the standard error 
of the mean.  
 
3.2.4.2 Establishing the ORF50 promoter regions for other 
Rhadinoviruses 
Having established a mechanism of KSHV reactivation that is linked to B-cell 
terminal differentiation, we were keen to assess whether the mechanism was 
potentially conserved among other Rhadinoviruses and their hosts. This 
seemed plausible due to the fact that the UPR is highly conserved from yeast to 
mammals and RTA is highly homologous across Rhadinoviruses (Ron and 
Walter, 2007) (Damania et al., 2004).  To address this we attempted to identify 
potential XREs in the ORF50 promoter regions of several Rhadinoviruses. The 
RTA transcripts of Rhadinoviruses have also been shown to have similar 
structures, consisting of a small first exon followed by an intron and a second 
larger exon (Lukac et al., 1999) (Sun et al., 1998) (DeWire et al., 2002) (Wu et 
al., 2000b). Due to the small size of the first exon it is often missing from 
annotations and deposited sequences. We therefore sort to determine the 
correct start sites for the RTA coding regions of different Rhadinoviruses before 
searching for potential XREs.  
 
This was achieved by using the KSHV ORF50 intronic sequence as a template 
to BLAST against published Rhadinoviruses complete genome sequences 
within the NCBI sequence database. When significant matches were found the 
first exon could easily be identified by searching for the nearest and smallest 
open reading frame upstream of this putative intron. All prospective transcripts 
were checked for functional splicing elements by identifying splice donor and 
acceptor sites. Schematic diagrams of the full ORF50 transcripts for KSHV, 
Macaca mulatta Rhadinovirus (RRV), Ateline herpesvirus (HVA), Herpesvirus 
Saimiri (HVS) and Murine herpesvirus 4 (MHV 68) are shown (Figure 3-9).  
Numbering refers to the genomic sequences with accession numbers indicated.  
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Figure 3-9 ORF50 promoter regions for other Rhadinoviruses 
Schematics denote first exon, intron and second exon of RTA homologues. Numbering relates 
to genome position as given by the NCBI sequence database. All transcripts are spliced 
efficiently.  
 
3.2.4.3 Identifying the potential XBP-1 response elements in other 
Rhadinovirus ORF50 promoters 
A genome wide search for genes regulated by the transcription factor XBP-1 
revealed that XBP-1 is involved in various functionally distinct processes and 
acts through different motifs or response elements (Acosta-Alvear et al., 2007). 
Using this information, we identified a functional XRE in the KSHV ORF50 
promoter (see section 3.2.4.1) (Dalton-Griffin et al., 2009). Next, we examined 
the first 500 nucleotides upstream of the transcriptional start site of ORF50 in 
several Rhadinoviruses for similar, potential XBP-1 binding sites as predicted by 
Acosta-Alvear (Figure 3-10 A).  XREs are indicated by the presence of the core 
sequences, ‘ACGT’, ‘CGTG’ and ‘ACGC/A’ (Figure 3-10 B) (Acosta-Alvear et 
al., 2007).  A sequence logo was created to apply weight to each nucleotide 
found within a potential XBP-1 binding site, providing a consensus sequence for 
XREs in the Rhadinovirus ORF50 promoter (Figure 3-10 C). This analysis 
identifies potential XREs present within the promoter regions of ORF50 from 
several Rhadinoviruses; further work is required to determine their functionality.  
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ACGCTAGGGTCTCCCCACCCAACCCCCATAGGACCCAGCTACAGCTTATCCTCCACTAAATACCAGGCAGCTACCGG 
CAGCCATGACACCGTGAACTTCCTGATGTCTCCTAAAACTAACCCCGAAACAGAGCTAAATACCAATGACTGTCACC 
TACTGAAAGCTCCATGAGTAAACTAAATACTTTATCCCACACTAACCAGTTAAATACAGAGCAAGTTGTTTACGCCC 
TGGCAATGAAAGCTCCATAGTCAAGCTAAATGCTATCATCAACTAACTAGTTAAATACCATGCAGTTGTTTCCACCC 
TCAAGGTCCATTTTTGAACACATTATCCCACAATGTGCTGCAGTCTGCAAGAAATAATAGCCTCCCACTTTTATGGA 
 
CGACTCATTAAGCCCCGCCCAGAAACCAGTAGCTGGGTGGCAATGACACGTCCCCTTTAAAAAGTCAACCTTACTCC 
CCTACCCCAAGCCACGCCCCCGTACTATTAGACCAGGGTGAGTAACCACGCTATCCTTTAAAAACCCATACGTGGAG 
CCTAAACACACCCACCGCTGACTAAGCTAAATGCCCTAAAGCATTTAAAGGGAAGACTTTACATAGTGTACCACCAC 
ATAGACACGCCTACCTCATTAATAAGCTAAATGCCCTGAAGCATTTAAAAGGAAGAATTTACATAGTGTACAATCAC 
AATCTGGTAGCTCCTCCTACATGAGTCATGAAATGTCCCTTCAAAGGCTGAGGAGAGAGCACAACTCTTTTCAATCT 
 
GCAAGGGGTAGTCTGTTGTGAGAATACTGTCCAGGCAGCCACAAAAATG Human herpesvirus 8 type M, complete genome NC_003409.1 
TTTGTAAGGTAAACAGCTCGTGTATATTTCAGACGCCTGTCATAAAATG Macaca mulatta rhadinovirus, complete genome AY528864.1 
TCTTCACAAACTTGGAATCTTACCTTTTAACTCCACAAATACAACAATG Ateline herpesvirus 3 complete genome AF083424.1 
TCTGCACAAACTTGAGATCTTACAGCTGAGCTCTTAAGCAACAACAATG Saimiriine herpesvirus 2 complete genome X64346.1 
ACACTCAAAAATACAACTCCTGCACTACGAGGGAATTTCTGCAGCGATG Murid herpesvirus 4 complete genome AF105037.1 
 
GAC ACGT CCC Human herpesvirus 8 type M, NC_003409.1 
ACA CCGT GAA 
GCC ACGC CCC 
ACC ACGC TAT Macaca mulatta rhadinovirus, AY528864.1 
CAT ACGT GGA 
AGC TCGT GTA 
CAG ACGC CTG 
TTT ACGC CCC Ateline herpesvirus 3 AF083424.1 
GAC ACGC CTA Saimiriine herpesvirus 2 X64346.1 
ACT ACGA GGG Murid herpesvirus 4 AF105037.1 
 
A 
B 
C 
Figure 3-10 Potential XBP-1 response elements in the first 
500 nucleotides upstream from the translation start site of 
selected Rhadinovirus ORF50 promoters  
(A) Manual alignment of the first 500 bp of the promoter 
regions of the ORF50 genes of Human herpesvirus 8, Macaca 
mulatta Rhadinovirus, Ateline herpesvirus 3, Saimiriine 
herpesvirus 2 and Murid herpesvirus 4, by anchorage to the 
starting ATG in each case. Potential XBP-1 binding sites are 
highlighted. (B) Representation of the XBP-1 core binding 
sites and surrounding sequences identified within the 
promoter regions. (C) Sequence logo of consensus XBP-1 
response element, size of letter determines how often that 
nucleotide is seen at that position within the elements. 
Created at http://weblogo.berkeley.edu/logo.cgi 
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3.2.5 Characterisation of rKSHV.219 HEK 293T cell line – Clone 5 
Infection of HEK 293T cells with rKSHV.219 gave rise to a number of cell clones 
that were morphologically different and varied in the amount of spontaneous 
DsRed expression. One of these clones, Clone 5, appeared to form cell clumps 
as well as display higher levels of spontaneous DsRed expression compared to 
those seen in Clone 9 cells. We therefore sort to characterise Clone 5 cells in 
relation to Clone 9 cells to find a possible explanation for the augmented level of 
reactivation.  
 
3.2.5.1 The response of Clone 5 cells to DTT treatment  
Clone 9 cells were previously shown to respond to DTT treatment with a dose 
dependent level of reactivation (see section 3.2.2.2). In order to characterise 
Clone 5 cells we also assessed the DsRed expression in response to DTT. 
Clone 5 and Clone 9 cells were cultured for 16 hours, overnight, in the presence 
or absence of 3 mM DTT. DTT was removed the following day and the level of 
DsRed expression was recorded by light microscopy a further 24 hours later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11 DTT treatment of Clone 5 cells 
Photomicrographs of rKSHV.219 infected HEK 293T clonal cell lines – (A) Clone 9 or (B) 
Clone 5 taken 48 hours after 3 mM DTT treatment overnight. Two typical fields of EF1α-GFP 
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and PAN-DsRed fluorescence of each condition untreated or treated with 3 mM DTT for each 
cell line magnified at x20 are shown. Clone 5 cells display more spontaneous DsRed 
expression. DsRed expression increases in response to DTT in both Clone 5 and Clone 9 cells. 
 
As demonstrated in section 3.2.2.2, DTT treatment of Clone 9 cells induces 
DsRed expression greater than the spontaneous levels seen in untreated 
controls (Figure 3-11 A). The higher level of spontaneous DsRed expression 
observed in Clone 5 cells can be seen when comparing untreated Clone 5 cells 
in Figure 3-11 B with those of untreated Clone 9 cells in Figure 3-11 A. DsRed 
expression in Clone 5 cells was also further increased in response to DTT 
treatment (Figure 3-11 B). Together, this shows that Clone 5 cells have an 
enhanced level of spontaneous DsRed expression compared to what is 
observed for Clone 9 cells, and that DTT treatment further induced DsRed 
expression in both cell lines.  
 
The difference in morphology between Clone 9 and Clone 5 cells is seen most 
clearly when DTT treated samples from Figure 3-11 A and B are compared.  
Clone 9 cells retained the evenly spaced, spindle-like morphology of HEK 293T 
cells whereas Clone 5 cells had a tendency to form large clumps. This 
phenotype was less easily seen when cells were more confluent.  
 
3.2.5.2 XBP-1 activity and the high level of rKSHV.219 reactivation in 
Clone 5 cells 
DTT is a known inducer of the UPR and a major component of this response is 
the transcription factor XBP-1. We have shown that XBP-1 is activated by a 
splicing event that can be induced by DTT treatment, and results in KSHV 
reactivation (see section 3.2.3.2) (Wilson et al., 2007). Also exogenous 
expression of XBP-1s in the rKSHV.219 HEK 293T cell line, Clone 9, drives 
DsRed expression which corresponds directly to reactivation (see section 
3.2.2.1). We therefore wanted to determine if the higher spontaneous DsRed 
expression observed in Clone 5 cells was perhaps due to an augmented XBP-1 
activity compared to Clone 9. Semi-quantitative RT PCR for the presence of 
XBP-1 transcript shows that both Clone 9 and 5 cell lines have similar 
undetectable resting levels of XBP-1s. After overnight DTT treatment the level 
of XBP-1s transcript in Clone 9 and Clone 5 cells increased to similar levels 
(see section 3.2.3.2) (Figure 3-12 A). Therefore untreated and DTT treated 
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Clone 5 cells do not have significantly higher levels of active XBP-1s transcript 
than Clone 9 cells. The increased spontaneous DsRed expression seen in 
Clone 5 cells is therefore not due to increased levels of XBP-1s.  
 
In parallel samples obtained 48 hours after DTT treatment, we monitored the 
relative levels of rKSHV.219 lytic induction using RT PCR for the spliced late 
lytic gene ORF29a/b (Renne et al., 1998). In untreated Clone 9 cells, where 
spontaneous reactivation is less than 1 %, ORF29a/b was undetectable (Figure 
3-12 B). After DTT treatment a slight increase in lytic transcript can be seen 
confirming the ability of DTT to induce KSHV reactivation in Clone 9 cells 
(Figure 3-12 B). In agreement with the increased level of spontaneous DsRed 
expression in Clone 5 cells, ORF29a/b transcript was detected in resting cells 
(Figure 3-12 B). DTT treatment of Clone 5 cells significantly induced ORF29a/b 
transcript, and to levels greater than those in Clone 9 cells after DTT treatment 
(Figure 3-12 B). RT PCR for β-actin was used to normalise for cDNA input and 
provides semi-quantitative data for both XBP-1 and ORF29a/b RT PCR (Figure 
3-12 C).  Together, these data show that higher levels of DsRed expression 
observed in Clone 5 compared to Clone 9 cells correlate with higher levels of 
lytic reactivation, as measured by ORF29a/b transcript, and which is not linked 
to higher levels of XBP-1 splicing in these cells.  
 
Figure 3-12 XBP-1 splice status of Clone 5 cells 
(A) RT PCR amplification from the total mRNA of Clone 5 and Clone 9 cells; untreated or 
treated with DTT. PstI non-restricted bands of amplified XBP-1s product are visible in the DTT 
treated samples only, and at similar levels. (B) A 300bp product was amplified from RNA 
samples taken 48 hours after DTT treatment with gene specific primers for the spliced lytic 
transcript, ORF29 a/b.  PCR product is seen in untreated Clone 5 and in samples with XBP-1s 
after DTT treatment corresponding to the induction of KSHV lytic cycle and the DsRed seen in 
Figure 3-11. (C) RT PCR for β actin on the same RNA was used to normalise cDNA input. 
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3.2.5.3 DsRed expression is dependent on RTA in Clone 5 cells 
To further conclude that the higher levels of spontaneous and DTT-induced 
DsRed expression in Clone 5 cells were due to increased RTA expression and 
lytic replication; cells were transduced with lentivirus expressing shRNA-GFP or 
shRNA-RTA at an MOI 5. 48 hours after transduction, cells were cultured in the 
presence or absence of 4 mM DTT for 16 hours to induce the lytic cycle. Cells 
were then cultured in fresh media for 48 hours before representative 
photomicrographs of the cells were taken and cells were sampled for both 
western blot analysis and RNA extraction followed by cDNA synthesis.  
 
Expression of shRNA-RTA in Clone 5 cells alone led to a reduction in the 
spontaneous DsRed expression seen when compared to Clone 5 cells 
transduced with the control shRNA targeted to GFP (Figure 3-13 A and B). After 
lytic cycle induction with DTT, DsRed expression was increased in Clone 5 cells 
transduced with shRNA-GFP as expected (see section 3.2.5.1) (Figure 3-13 A). 
Although DsRed expression did increase after DTT treatment of Clone 5 cells 
expressing shRNA-RTA, this was clearly repressed in contrast to the shRNA-
GFP-expressing DTT treated sample (Figure 3-13 B and A). Western blot 
analysis for RTA expression also reveals low levels in resting Clone 5 cells that 
are robustly increased in response to DTT treatment (Figure 3-13 C). Therefore, 
RTA is required for the DsRed expression following addition of DTT to Clone 5 
cells. 
 
To confirm that lytic cycle induction goes beyond RTA expression in Clone 5 
cells, we looked at lytic gene ORF29a/b expression in these samples, and in 
samples treated in an identical way but with Sodium Butyrate as the inducing 
agent (Figure 3-13 D). The semi-quantitative RT PCR reveals that the known 
triggers of KSHV reactivation, DTT and NaBut, increased the presence of the 
spliced ORF29a/b transcript in the control shRNA-GFP-expressing Clone 5 
cells. In the presence of shRNA-RTA the levels of RTA induced by DTT and 
NaBut exposure should be effectively reduced and therefore should impair lytic 
replication initiation. Levels of ORF29a/b transcript were marginally increased in 
DTT or NaBut treated Clone 5 cell samples transduced with shRNA-RTA but 
were lower than those seen in samples expressing irrelevant control shRNA 
(Figure 3-13 D). Input levels of cDNA were normalised using RT PCR for β-actin 
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(Figure 3-13 D). The DsRed expression in Clone 5 cells faithfully represents 
lytic reactivation of the rKSHV.219 in these cells, and the presence of RTA is 
required for both the spontaneous and induced levels of DsRed seen.  
 
Figure 3-13 RTA dependence of DsRed expression in Clone 5 cells 
rKSHV.219 HEK 293Ts, Clone 5 cells were transduced with lentivirus expressing (A) shRNA-
GFP or (B) shRNA-RTA at an MOI 5 and 48 hr later stimulated to induce the KSHV lytic cycle 
with 4 mM DTT treatment. After 48 hours cells photomicrographs were taken. Two typical fields 
of EF1α-GFP and PAN-DsRed fluorescence of each shRNA-expressing cell line untreated or 
treated with 4 mM DTT magnified at x20 are shown. (A) shRNA-GFP-expressing Clone 5 cells 
treated with DTT have increased DsRed expression. (B) Spontaneous and DTT-induced DsRed 
expression in blocked by the presence of shRNA-RTA. (C) Western blot analysis of whole cell 
lysates of the Clone 5 cells untreated or treated with DTT with polyclonal rabbit anti-RTA. RTA 
is present in untreated Clone 5 cells representing the high spontaneous lytic replication seen in 
this cell line and is further induced by DTT treatment. β-actin acts as a loading control. (D) RT 
PCR amplification of ORF29a/b from the total mRNA of Clone 5 cells expressing shRNA-GFP or 
shRNA-RTA, untreated or treated with DTT or 3 mM Sodium Butyrate (NaBut). Lower levels of 
ORF29a/b transcript are seen in shRNA-RTA-expressing samples. RT PCR for β actin on the 
same RNA was used to normalise cDNA input. 
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3.2.6 A comparison of the gene expression profiles of Clone 5 and 
Clone 9 cells. 
We have observed a greater level of spontaneous lytic reactivation in Clone 5 
cells compared to Clone 9 cells (section 3.2.5). Increased levels of XBP-1s in 
resting cells could not account for this phenotype (section 3.2.5.2). We have 
also shown that, in Clone 5 and Clone 9 cells, RTA expression is necessary for 
lytic replication. In this section, we aimed to identify cellular genes with 
differential expression between Clone 9 and Clone 5 cells that could be 
responsible for the difference in lytic replication observed. To this end we 
compared the gene expression profiles of untreated Clone 9 and Clone 5 cells. 
To specifically determine those differential genes that were independent of 
increased lytic reactivation in Clone 5 cells, we also compared the gene 
expression profile of Clone 5 cells transduced with lentivirus encoding shRNA 
targeting RTA or GFP as control, at an MOI 8. We have seen in section 3.2.5.3 
that the expression of shRNA-RTA effectively suppresses KSHV lytic replication 
in Clone 5 cells. 6 hours post-transduction the cells were washed once and 
resuspended in fresh medium.  24 hours later these cells were transduced a 
second time with lentivirus encoding shRNA targeting RTA or GFP as control at 
an MOI 8 and again washed 6 hours post-transduction. 72 hours post-
transduction, the cells were pelleted and resuspended in TRIzol reagent. 
Samples of Clone 9 and Clone 5 cells non-transduced or transduced with 
control vectors were also resuspended in TRIzol reagent.  Total RNA was 
purified from all samples and the quality and quantity assessed using an Agilent 
bioanalyzer. From this, mRNA was labelled according to the materials and 
methods (see section 2.11.2). Labelled cDNA was mixed with Cy3-labelled 
reference RNA and hybridised to Agilent Whole Human Genome Oligo 
Microarrays. A common reference RNA mixture was used to enable comparison 
across the whole sample set.   
 
Intensities for each sample relative to the reference were obtained from the 
feature extraction file by background subtraction and scale normalisation using 
R and BioConductor (Gentleman et al., 2004). Differentially expressed genes 
were identified by constructing linear models using the Limma BioConductor 
library (Smyth, 2005). The samples were split into three groups: Clone 9 (CL9), 
Clone 5 (CL5), which includes Clone 5 cells expressing the control short-hairpin 
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GFP (CL5shGFP) and finally, the short-hairpin RTA-expressing Clone 5 cells 
(CL5shRTA). Fold changes for two comparisons (CL9/CL5 and 
CL5shRTA/CL5) were calculated and used to construct lists of significantly 
differentially expressed genes (Benjamini-Hochberg adjusted p-value < 0.01).  
Probes with mean intensities across all 10 samples less than twice the 
background level were removed (1/2log2RG< 7). 
 
Figure 3-14 Understanding the difference between Clone 9 and Clone 5 cells 
Diagrams representing the scenarios that could account for the difference in lytic replication 
seen between Clone 9 and Clone 5 cells. (A) Genes upregulated (yellow) in this first comparison 
between Clone 9 (CL9) and Clone 5 (CL5) cells represent potential repressors of KSHV lytic 
cycle, whereas downregulated (blue) genes are potential inducers. (B) Genes upregulated 
(yellow) in this first comparison between shRNA to RTA-expressing Clone 5 (shRTACL5) and 
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Clone 5 (CL5) cells represent those genes that are suppressed by KSHV lytic RTA whereas 
downregulated (blue) genes are induced by RTA.  
 
As described earlier in the chapter, we observe less spontaneous lytic 
replication in Clone 9 cells than in the Clone 5 cells. Thus either Clone 9 cells 
express a repressor of lytic replication that is suppressed in Clone 5 cells or 
Clone 5 cells express an inducer of the lytic cycle that is not expressed in 
Clone 9 cells (Figure 3-14 A). A comparison of these two samples reveals 383 
genes that are differentially expressed between Clone 9 and Clone 5 cells 
(CL9/CL5 list). Of these, 80 genes are upregulated (yellow) in Clone 9 
compared to Clone 5 cells and could represent potential repressors of KSHV 
reactivation. The remaining 303 genes are downregulated (blue) in Clone 9 
compared to Clone 5 cells and could represent potential inducers of KSHV 
reactivation (Figure 3-14 A).  However, a number of these genes could have 
differential expression due to the presence of RTA and the KSHV lytic cycle in 
Clone 5 cells.   
 
Looking directly at the effect of RTA and the lytic cycle on gene expression we 
compared Clone 5 cells expressing shRNA-RTA to un-transduced Clone 5 cells 
and Clone 5 cells expressing shRNA-GFP control (shRTACL5/CL5 list). 78 
genes were upregulated (yellow) and 117 genes were downregulated (blue) in 
the absence of RTA (Figure 3-14 B). These differentially expressed genes are 
dependent on the RTA-induced lytic environment in Clone 5 cells and can 
therefore be regarded as false positives. Without further investigation it is not 
possible to determine whether the level of these genes change the replication 
state or are altered by the replication state itself.  These genes were used to 
filter the genes in the CL9/CL5 list in order to obtain those genes that represent 
the potential inducers or repressors of KSHV lytic replication that are 
independent of the lytic cycle in Clone 5 cells (Figure 3-15 A).  
 
Our analysis of the differences between the gene expression profiles of Clone 9 
and Clone 5 cells led to the identification of several possible scenarios in which 
potential repressors or inducers could be identified (Figure 3-14). By translating 
these scenarios into comparisons between the samples we were able to 
characterise differentially expressed genes by how they may regulate RTA 
expression and therefore control KSHV reactivation (Figure 3-15 A and B).  
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Figure 3-15 Constructing a gene list 
(A) Diagrammatic representation of the comparisons being made between Clone 9 (CL9) 
samples to Clone (CL5) and shRNA-RTA-expressing Clone 5 cells (shRTACL5) to CL5 cells. 
For each comparison genes can be upregulated (↑), downregulated (↓) or neither (-). (B) Genes 
that are upregulated or downregulated in both comparisons RTA regulation groups 1 and 3 (↑↑ 
and ↓↓) or in groups 2 and 4 (opposite genes) were removed from the final gene list as their 
expression is dependent on RTA and lytic cycle. The final gene list is therefore composed of 
genes that fall into RTA regulation groups 5 and 6 (unique genes) highlighted by the red box. 
(C) Representations of the heatmap gene expression patterns expected based on RTA 
regulation group criteria. Group 5: CL9 up compared to CL5 and shRTACL5 similar to CL5, 
potential repressors of KSHV lytic replication and Group 6: CL9 down compared to CL5 and 
shRTACL5 similar to CL5, potential inducers of KSHV lytic replication.  
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Genes found to be upregulated in both comparisons or downregulated in both 
comparisons, members of RTA regulation groups 1 and 3, were removed from 
the analysis. These genes are dependent on RTA and KSHV lytic replication as 
discussed above. Those genes that fall into the RTA regulation groups 2 and 4, 
have opposite gene expression levels, ‘opposite genes’, and are also regulated 
by RTA expression, possibly directly, but in a complex way. For example, genes 
present in group 2 are the potential inducers of KSHV lytic cycle that are 
suppressed by RTA possibly indicating a negative feedback interaction. RTA 
regulation groups 5 and 6 represent ‘unique genes’, these genes are 
differentially expressed in CL9 and CL5 and are independent of RTA; as their 
expression is not changed in the presence of shRNA-RTA (Figure 3-15 B). 
Some of these cellular genes are likely potential repressors (Group 5) and 
inducers (Group 6) of KSHV lytic replication. Therefore genes in RTA regulation 
groups 5 and 6 were included in the final list of differentially expressed genes. 
This is outlined in Figure 3-15 B, the final gene list being constructed from the 
genes in red boxes.  
 
The final filtered gene list was then split into two lists of upregulated and 
downregulated genes. The Ensembl BioMart server was used to convert the 
Agilent probe identifiers to Entrez Gene IDs using the BioConductor BioMart 
package (Durinck et al., 2005).  These were then uploaded to the functional 
annotation clustering tool on the DAVID website (http://david.abcc.ncifcrf.gov/) 
to identify significantly over-represented functional groups within each list 
(Benjamini-Hochberg adjusted p-value < 0.05) (Huang da et al., 2009) (Dennis 
et al., 2003). The broad annotation clusters created by DAVID were kept but 
sub-clusters that had Benjamini-Hochberg adjusted p-values greater than 0.05 
were removed, yielding 4 annotation clusters consisting of 72 genes.  All of 
these genes were downregulated in Clone 9 compared to Clone 5 cells and 
represent potential inducers of the lytic cycle (Figure 3-16 B). These genes 
were present in one or more of the four broad functional groups, nervous 
system development – 27 genes, anatomical structure morphogenesis – 27 
genes, cell differentiation – 35 genes and plasma membrane part – 38 genes. 
The 69 genes that were upregulated in Clone 9 compared to Clone 5 cells, and 
therefore represent potential repressors of KSHV lytic replication, did not cluster 
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into over-represented functional groups, therefore all genes are shown in the 
heatmap (Figure 3-16 A).  
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Figure 3-16 Heatmap representation of differentially expressed genes between Clone 9 and 
Clone 5 cells 
(A) Heatmap of all genes significantly upregulated in Clone 9 compared to Clone 5 after RTA 
and lytic cycle dependent genes were removed – Potential repressors (B) Heatmap of 
significantly over-represented functional groups within the downregulated gene lists after RTA 
and lytic cycle dependent genes were removed – Potential inducers. Each column represents 
one sample and each row one gene. Gene expression is shown as a pseudo-coloured 
representation of log(2) expression ratio with yellow being above and blue below the 
row/column median level of expression (set to 0) as shown by the scale. DAVID was used to 
annotate the downregulated genes into broad functional groups colour coded to right of 
heatmap.  
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From the potential repressors and inducers identified we could then select, 
using the heatmap (Figure 3-16), those genes that best represent the 
expression criteria set out by the RTA regulation groups (Figure 3-15 C) and 
focus on these genes as potential regulators of KSHV lytic replication (Figure 
3-17). The genes that could potentially be involved in the repression of KSHV 
lytic cycle and most closely fit the criteria of RTA regulation group 5 are given in 
the table A while potential inducers are listed in the table B (see Figure 3-17).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-17 Table of potential repressors and inducers of KSHV reactivation 
Genes that most obviously satisfy the individual regulation group criteria were selected. (A) 
Potential repressors of KSHV lytic replication are upregulated in Clone 9 compared to Clone 5 
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cells and are not affected by RTA expression. (B) Potential inducers of KSHV lytic replication. 
All are downregulated in Clone 9 compared to Clone 5 cells and are not affected by RTA 
expression.  
 
Of those genes identified as potential repressors several candidates are worthy 
of selection for further investigation based on previous studies (Figure 3-17 
Table A). Candidates include two genes that are involved in the regulation of 
the NF-κB pathway. This pathway is activated in latently infected cells by the 
KSHV v-FLIP protein (see section 1.1.12.4). When PEL cells were treated with 
Bay11-7082, a pharmacological inhibitor of NF-κB, increased KSHV lytic 
replication was seen, indicating a role for the NF-κB pathway in maintaining 
latency (Brown et al., 2003). NF-κB has also been shown to negatively regulate 
RTA expression by antagonising the coactivator RBP-Jk (Izumiya et al., 2009). 
However NF-κB is highly active in cells undergoing lytic replication and 
therefore if p65 does act to inhibit reactivation then this must be overcome 
during the lytic cycle. Indeed the dependence on NF-κB activity for KSHV lytic 
replication is cell type dependent, with primary infected endothelial cells 
behaving like PEL cells, but infected human fibroblasts showing no increase in 
KSHV reactivation when the NF-κB pathway is inhibited (Grossmann and 
Ganem, 2008).  
 
The two genes highlighted by this microarray study as potential KSHV lytic 
cycle repressors are the nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta (NFKBIZ) and the transcription repressor, 
forkhead box P1 (FOXP1).  The full-length form of FOXP1 has been shown to 
inhibit the transcription of NF-κB responsive genes; however truncated forms of 
the protein have been associated with NF-κB activity in some DLCBLs and 
follicular lymphomas (FLs) (Green et al., 2009). This suggests that truncated 
forms of FOXP1 act as dominant negatives, inhibiting the function of FOXP1 
and allow NF-κB to function.  Further study would require identification of the 
isoform expressed in Clone 9 cells and its effect on NF-κB activity. If a truncated 
form is found then its introduction into Clone 5 cells should show an increase in 
NF-κB activity and a decrease in the lytic replication observed. It would also be 
interesting to ascertain which form of FOXP-1 is present in PEL cells and 
whether this contributes to the increased NF-κB activity seen.  
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NFKBIZ is a known inhibitor of the NF-κB pathway therefore its contribution to 
the repression of KSHV lytic cycle is unclear. However, in the context of the 
infected cell environment with increased NF-κB activity through vFLIP, a 
complex mechanism of regulation is expected and may require inhibitors to 
balance the pathway (Yamazaki et al., 2001). In fact NF-κB is known to induce 
its own inhibitors leading to a negative feedback mechanism of regulation 
(Brown et al., 1993). Further investigation is required in order to determine the 
exact role of NFKBIZ in KSHV reactivation possibly via regulation of the NF-κB 
pathway.  
 
Another of the genes highlighted as a potential repressor of KSHV lytic 
replication and independent of RTA expression is the human Argonaute protein, 
eukaryotic translation initiation factor 2C, 1 (EIF2C1/hAgo2) (reviewed in 
(Carmell et al., 2002)). This protein is required for short interfering RNA 
mediated post-transcriptional gene silencing in mammalian cells (Doi et al., 
2003). Recent studies have identified several KSHV microRNAs that are 
involved in providing fine control over KSHV reactivation (Bellare and Ganem, 
2009) (Lei et al., 2010) (Lu et al., 2010) (reviewed in section 1.1.12.7). The 
functions of these viral microRNAs rely on the same machinery as the host 
cellular miRNA and therefore any perturbations in this pathway may affect the 
control of KSHV lytic replication. Further investigation into the role of EIF2C1 in 
maintaining KSHV latency through the processing of KSHV miRNAs is required 
but is technically difficult.  
 
Finally two dual specific phosphatases, DUSP3 and DUSP26 were identified as 
potential repressors of KSHV reactivation by the microarray analysis. The 
proteins encoded by these genes negatively regulate members of the mitogen-
activated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38), by 
dephosphorylating both the phosphoserine/threonine and phosphotyrosine 
residues. These proteins have distinct substrate specificities for the various 
MAP kinases and have different tissue distribution and subcellular localization. 
DUSP3 inhibits JNK activity while DUSP26 can inactivate p38 (Arnoldussen et 
al., 2008) (Yu et al., 2007c). Recently the MAPKs, MEK/ERK, JNK and p38 
have been shown to have a role in KSHV primary infection as well as in 
reactivation (Pan et al., 2006) (Cohen et al., 2006) (Xie et al., 2008) (Ford et al., 
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2006). In response to TPA, ERK and p38 activity is enhanced and induces 
KSHV reactivation via the transcriptional activator AP-1 which binds the RTA 
promoter directly. Inhibition of ERK, JNK and p38 pathways resulted in reduced 
TPA-induced reactivation (Xie et al., 2008). The reduced expression of a 
negative regulator of MAPK activity, such as the DUSPs, may therefore lead to 
the increased spontaneous reactivation seen in Clone 5 cells. Further study to 
confirm this hypothesis is required, including overexpression of these proteins in 
Clone 5 cells, which should reduce the level of DsRed seen in resting cells 
compared to control.  
 
Of the genes identified as potential inducers of KSHV lytic replication only 
cyclin D1 (CCND1) could be selected based on previous studies, for further 
investigation, (Figure 3-17 B).  The G1-S phase transition of the cell cycle is 
controlled by cyclin dependent kinases 4 and 6 (cdks) in combination with D-
type cyclins. DNA is replicated during this stage of the cell cycle including KSHV 
progeny virus DNA and viral DNA tethered as an episome to the host 
chromosome. Recently a study using TPA as an inducer of KSHV lytic 
replication reported a 30 % increase in virus production when BCBL-1 cells 
were synchronised and TPA-induced during S-phase (McAllister et al., 2005). 
KSHV encodes a homologue of cellular cyclin D, v-cyc, which is thought to be 
important in driving cell proliferation but may also be important in preparing the 
cell for viral DNA replication during lytic reactivation (Bryan et al., 2006) (see 
section 1.1.12.3). Therefore deregulated cyclin D expression in Clone 5 cells 
may lead to a larger number of the cells in the S-phase of the cell-cycle, with a 
concomitant increase in spontaneous lytic replication. In order to further 
investigate this hypothesis, it would be important to look at the cell cycle profile 
of Clone 5 cells as well as determine the effect of overexpressing cellular 
cyclin D on the level of lytic reactivation in Clone 9 cells.  
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3.3 Discussion 
 
KSHV has been shown to infect more than 20 cell types in vitro, predominantly 
establishing latent infection (Renne et al., 1998) (Blackbourn et al., 2000b) 
(Bechtel et al., 2003). KSHV infected cell lines, therefore, provide valuable tools 
for the study of factors that can induce the switch between latent and lytic 
phases of the life cycle. However, until recently, the assays available for 
monitoring KSHV lytic replication were limited to measuring virus production 
and the detection of viral gene products by PCR or western blotting. These 
techniques require destruction of cell cultures and/or vast amounts of 
processing, delaying any investigation into KSHV reactivation. It is also difficult 
to observe subtle changes in reactivation levels using these assays because 
the entire population is assessed. Therefore, any small but physiologically 
relevant changes may be masked by the spontaneous reactivation levels 
present or diluted out by the sheer number of cells.  In this chapter we have 
developed and characterised a system based on the Vieira Laboratory’s 
recombinant virus, rKSHV.219, to facilitate further investigation into the cellular 
regulators of KSHV reactivation (Figure 3-1). Using fluorescent markers, the 
rKSHV.219 system allows the rapid identification of latently infected cells by 
GFP expression. Initiation of lytic replication in these cells is further indicated by 
the co-expression of DsRed fluorescence. 
 
Before using this system to reveal potential activators of KSHV lytic replication 
we tested the response of rKSHV.219 infected HEK-293T cells to known 
inducers of KSHV reactivation (Figure 3-2, Figure 3-3 and Figure 3-11). The 
response of Clone 9 to the phorbol ester, TPA, was weak but has been seen in 
other studies (Bechtel et al., 2003) (Vieira and O'Hearn, 2004). It has also been 
reported that cells synchronised in S-phase of the cell cycle respond better to 
TPA-induced reactivation (McAllister et al., 2005). However, the lytic cycle was 
stimulated in response to all other inducers; confirming that the rKSHV.219 
infected HEK-293T cell lines generated did represent authentic KSHV infected 
cell lines.  
 
While carrying out these experiments it was evident that, in the same sample, 
the level of DsRed expression seen by microscopy was consistently greater 
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than that detected by FACsArray. The data generated by FACsArray did 
provide the same conclusions as the microscope i.e. the number of DsRed-
positive cells increase on induction of KSHV reactivation, but the percentages 
given each time were an underestimate. On further investigation we discovered 
that the FACsArray, which does not detect GFP fluorescence essential for this 
system, was unable to detect all cells expressing DsRed. DsRed has a maximal 
absorbance of 561 nm and maximal emission range from 525 - 675 nm.  The 
FACsArray has a filter which can detect wavelengths between 564 - 606 nm, 
while the excitation wavelength was set at 532 nm. This was therefore not an 
optimal set up for the detection of cells expressing varying levels of DsRed. The 
confocal microscope however was set at an excitation wavelength of 568 nm 
and was therefore able to excite and visualise a greater number of DsRed-
expressing cells. Direct comparison showed that the microscope detected at 
least 3-fold more DsRed-expressing cells than the FACsArray (Figure 3-3 D). 
Despite this we have demonstrated that the rKSHV.219 infected HEK 293T 
cells act as a robust sensor for KSHV lytic replication, and can be used for the 
study of physiological inducers of reactivation. 
 
The rKSHV.219 system’s ability to report KSHV lytic reactivation is reliant on 
DsRed expression driven by the PAN lytic promoter. Studies by Vieira et.al. 
have shown that ectopic expression of RTA leads to DsRed expression and 
infectious virus production in rKSHV.219 infected cell lines, and that all DsRed-
positive cells express lytic antigens (Vieira and O'Hearn, 2004).  To ensure that 
the DsRed fluorescent expression we saw in the rKSHV.219 HEK 293T cell 
lines was exclusively caused by the presence of RTA we used RNA 
interference. Expression of shRNA to RTA, but not GFP, in rKSHV.219 HEK 
293Ts reduced DsRed expression as well as the expression of the lytic 
transcript ORF29a/b in response to known inducers of KSHV reactivation 
(Figure 3-4 and Figure 3-13). We were therefore confident that the rKSHV.219 
HEK 293T cell systems established respond, as expected, to challenges known 
to induce KSHV lytic cycle and that DsRed fluorescence was directly dependent 
on RTA expression.  
 
By creating and characterising a range of clonal cell lines, derived from the 
rKSHV.219 infection of HEK-293T cells, we hoped to use the system to isolate 
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additional cellular processes involved in KSHV reactivation. DsRed expression 
in these cells results from three rounds of signal amplification, first the direct 
activation of RTA by the cellular gene, secondly the auto-activation of the RTA 
promoter by RTA itself and finally RTA activation of the PAN promoter. This 
renders the rKSHV.219 reporter system highly sensitive to KSHV lytic 
replication. The difference in DsRed expression seen between clonal cell lines, 
for example between Clone 5 and Clone 9 cells, is therefore significant and can 
be investigated. By microarray analysis we hoped to explain the difference in 
the degree of spontaneous reactivation occurring in these two cell lines (see 
section 3.2.6). This analysis provided several candidates for potential inducers 
and repressors of KSHV lytic replication however, further investigation is 
required to confirm these associations. This work shows that the rKSHV.219 
system is not only valuable as a reporter system but has the potential to identify 
novel virus-host interactions when different phenotypes are observed. 
 
Using the characterised rKSHV.219 HEK 293T cell, Clone 9, system we also 
provided further evidence that KSHV lytic replication is initiated by the cellular 
stress induced basic leucine zipper transcription factor, XBP-1s (Wilson et al., 
2007). By RNA interference we were able to inhibit the ability of endogenous 
XBP-1s to induce reactivation (Figure 3-7). Recent studies that have employed 
genome-wide screens in an attempt to systematically identify cellular signals 
involved in KSHV reactivation have also revealed XBP-1 (Yu et al., 2007b) 
(Bryan et al., 2006). XBP-1s is an important mediator of the unfolded protein 
response (UPR) and is activated by several physiological conditions including 
B-cell receptor ligation and importantly hypoxia investigated in chapter 4 (Yan et 
al., 2008) (Skalet et al., 2005) (Thuerauf et al., 2006) (Feldman et al., 2005) 
(Koumenis and Wouters, 2006). XBP-1 is also a necessary transcription factor 
for the terminal differentiation of B-cells to plasma cells (Reimold et al., 2001) 
(Iwakoshi et al., 2003).  
 
PEL cells are latently infected with KSHV and phenotypically resemble 
plasmablast cells, a B-cell stage prior to antibody-secreting plasma cell (Jenner 
et al., 2003) (Klein et al., 2003) (Tarte et al., 2003). KSHV infected PEL cells 
predominantly express XBP-1u but when XBP-1s is exogenously supplied the 
KSHV lytic cycle is activated (Wilson et al., 2007) (Yu et al., 2007b). In addition, 
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the morphology and gene expression profiles of these cells reveals a phenotype 
that closely resembles plasma cells, investigated further in chapter 5  (Wilson et 
al., 2007) (Shaffer et al., 2004). This data and the evidence provided in chapter 
3 suggest that plasma cell differentiation and XBP-1s expression can act as a 
cellular cue for the induction of the KSHV lytic cycle. By preparing the infected 
B-cell for protein production, XBP-1s provides an ideal environment for lytic 
replication. This raises the possibility that in KSHV infected B-cells latency is 
maintained until plasma cell differentiation; which through XBP-1s causes 
reactivation of KSHV. If this occurs in the reticulated epithelium of the oral cavity 
and the lymphoid tissue of the Waldeyers ring, KSHV could be shed from 
infected plasma cells along with antibodies into the saliva (Cattani et al., 1999) 
(Koelle et al., 1997). KSHV reactivation from latency in B-cells is probably 
responsible for initiating the waves of transient viraemia reported in the saliva of 
KSHV positive individuals, and is important in viral transmission (Pauk et al., 
2000). 
 
Understanding whether XBP-1s directly transactivates the ORF50 promoter or 
activation results from indirect interactions or downstream effects of XBP-1s 
overexpression, is central to understanding the role of XBP-1s in KSHV 
reactivation. We were able to show that the mechanism for XBP-1s induced 
reactivation is direct transactivation of the ORF50 promoter via a XBP-1s 
responsive element ‘ACGT’ (Figure 3-8). This reporter experiment was carried 
out in virus-free HEK 293T cells therefore, due to absence of endogenous RTA, 
auto-activation of the ORF50 promoter is not seen (Deng et al., 2000). The 
ability of XBP-1s to induce RTA expression is still observed but this activity 
would be enhanced in the presence of endogenous RTA. The precise 
mechanism of XBP-1s transactivation of the ORF50 promoter is still not fully 
clear, as it is not yet known whether XBP-1 binds as a homodimer or as a 
heterodimer with another bZIP containing partner for example ATF-6 (Newman 
and Keating, 2003). It is also not known how plasma cell differentiation affects 
the epigenetic modifications that are known to influence the switch from latency 
to lytic replication, for example ORF50 promoter demethylation (Chen et al., 
2001) (Gwack et al., 2001) (Lu et al., 2010) (reviewed in (Pantry and 
Medveczky, 2009)).  
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A recent study demonstrated the ability of mouse XBP-1s to act on the KSHV 
RTA promoter (Yu et al., 2007a). This not only supports our findings but also 
indicates that XBP-1 and the response elements it recognises are potentially 
conserved amongst species. In fact alignment of the human and mouse XBP-1 
DNA sequences reveals 77 % similarity (data not shown). It has also recently 
been observed that XBP-1s is associated with reactivation of EBV, the most 
closely related human virus to KSHV (Sun and Thorley-Lawson, 2007) (Bhende 
et al., 2007) (McDonald et al., 2010). We therefore reasoned that the 
mechanism of XBP-1s reactivation may be exploited by other viruses in the 
same genus as KSHV. To address this hypothesis we carried out ORF50 
promoter analysis for potential XBP-1 binding elements, indentified by Acosta-
Alvear, on several Rhadinoviruses (Acosta-Alvear et al., 2007). The 
RTA/ORF50 proteins of gamma-2-herpesviruses have been shown to have 
significant homology and the ability to act on each other’s promoters (Damania 
et al., 2004), providing further evidence that methods for ORF50 transactivation 
may be conserved. We also used this information to identify the accurate 
promoter regions for each virus studied (Figure 3-9). Once the first exon and the 
starting ATG was determined for each Rhadinovirus selected, we scanned the 
preceding 500 bp for any of the core sequences shown to be recognised by 
XBP-1s in previous ChIP analysis (Acosta-Alvear et al., 2007). This examination 
resulted in the potential consensus sequence ‘(A/C/T), C, G, (C/T/A)’ for XBP-1 
binding and transactivation of the ORF50 promoter (Figure 3-10). To confirm 
the functionality of the elements identified, XBP-1 from each infected species 
would need to be cloned and tested on the respective virus ORF50 promoter 
region, cloned upstream of a reporter such as luciferase (see Figure 3-8). If 
confirmed this would indicate that the plasma cell differentiation induced 
reactivation strategy may be employed by other B-cell tropic gamma-
herpesviruses.  
 
Other physiological triggers of the switch from latency to lytic phases have since 
been identified including activation of the Toll-like receptors (TLRs) (see section 
1.1.14). Specifically, TLR 7/8 have been shown to induce KSHV lytic replication 
in PEL cells, linking innate immunity to reactivation (Gregory et al., 2009). This 
mechanism can be translated into a physiological scenario in which a B-cell 
latently infected with KSHV encounters a secondary pathogen that activates 
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TLR 7/8 and induces KSHV reactivation. Another physiological stimulus of 
KSHV reactivation was identified by a gain-of-function kinome screen. Pim-1 
and 3 kinases were shown to phosphorylate LANA, negating its repressive 
effect on lytic replication (Varjosalo et al., 2008) (Cheng et al., 2009b) (Garber 
et al., 2002) (Lan et al., 2004). These kinases are shown to be upregulated by 
the cytokines present in the microenvironment of KSHV associated tumours 
(Bachmann and Moroy, 2005) (Ensoli et al., 2001b). Some of these cytokines, 
for example interferon-γ (IFNγ), have been shown to induce KSHV reactivation; 
possibly identifying a method of cytokine induced reactivation (Chang et al., 
2000). Another relevant inducer of KSHV reactivation is the physiological stress 
hypoxia (Davis et al., 2001).  In fact the response element identified in this 
chapter as XBP-1 responsive was previously identified as the hypoxiaresponse 
element (HRE), HRE4 (Cai et al., 2006a). We therefore explore the mechanism 
of action and the physiological significance of hypoxia in KSHV reactivation 
further in chapter 4.  
 
It is clear than many cellular processes regulate KSHV reactivation, and many 
more are yet to be discovered. Information on how every process acts 
individually and in combination to balance latency and lytic replication; aids are 
understanding of virus-host interactions and continues to emphasise how 
diverse and complex they can be. To expand this knowledge further in depth 
and systems biology based study involving genome screening techniques is 
required. This will be made easier by the development of model systems such 
as the rKSHV.219 virus for monitoring reactivation.  
 
.         
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4 The role of HIF-1α and XBP-1s in hypoxia-induced 
reactivation 
 
4.1 Introduction 
 
Hypoxia, acting through the transcription factor hypoxia inducible factor -1 alpha 
(HIF-1α) is a cellular stress demonstrated to induce the KSHV lytic cycle (Davis 
et al., 2001) (see section 1.5). Under normoxic conditions the HIF-α subunits 
are constitutively expressed but rapidly degraded (Huang et al., 1998) (Salceda 
and Caro, 1997). Under hypoxia the HIF-1α subunits are stabilised, accumulate 
and dimerise with the HIF-1β subunit (Jiang et al., 1996a). The basic helix-loop-
helix transcription factor, HIF-1α acts on promoters via hypoxic response 
elements (HREs) to upregulate genes involved in angiogenesis and anaerobic 
glycolysis (Wang et al., 1995) (see section 1.5.1). The hypoxia response is 
therefore crucial for solid tumour cell survival (Harris, 2002). ORF50 is hypoxia 
inducible, with its promoter containing seven putative HREs (Haque et al., 
2003), of which three respond to HIF-1α (Cai et al., 2006a). Hypoxia-induced 
HIF-1α is therefore a relevant biological activator of KSHV lytic replication. 
Reportedly, however, HIF-1α is stabilised and sequestered to the nucleus in all 
PEL cells although, importantly, no lytic replication is induced (Cai et al., 
2006a).  
 
HIF-1α is also important in normal mammalian physiology with a particular role 
in normal B-cell physiology. Indicative of hypoxia, HIF-1α is stabilised in the 
microenvironments of the germinal centres (GC), other secondary lymphoid 
tissues and bone marrow, raising the possibility that KSHV infected B-cells 
encountering these environments may induce viral lytic replication (Piovan et 
al., 2007) (Parmar et al., 2007). HIF-1α is important in normal B-cell physiology; 
HIF-1α knock out RAG2-/- chimeric mice display an increase in appearance of 
abnormal B-1-like peritoneal lymphocytes with an associated increase in the 
level of autoimmunity and a disturbed maturation of the B-2 cell subset in the 
bone marrow (Kojima et al., 2002). Concomitantly, XBP-1 alongside its function 
in normal B-cell development has also been shown to be necessary for tumour 
growth (Romero-Ramirez et al., 2004) and is activated under hypoxia (Thuerauf 
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et al., 2006). Together, therefore, XBP-1 and HIF-1α are both lytic cycle triggers 
for KSHV, with these two pathways intersecting at normal B-cell development, 
the response to cellular stress and promotion of tumour survival.  
 
In chapter 3 we identified a novel and active binding site for XBP-1 in the 
ORF50 promoter containing the core sequence ‘ACGT’; intriguingly this 
sequence is identical to the core sequence of HIF-1α binding HREs (Semenza 
et al., 1996). This exact response element was previously identified as the 
hypoxiaresponse element (HRE), HRE4 in the ORF50 promoter (Cai et al., 
2006a). In this chapter, due to the presence of both stress inducible factors 
under hypoxia and their involvement in normal B-cell biology, we investigate 
further their roles in KSHV reactivation in response to hypoxia.  
 
 
 166
4.2 Results 
 
4.2.1 Establishing hypoxic culture conditions 
In order to determine the involvement of the two transcription factors HIF-1α 
and XBP-1s in hypoxia-induced KSHV reactivation, it was essential to establish 
hypoxic tissue culture conditions. Cells are cultured normally prior to the 
experiment (see section 2.1) and on the first day of the experiment split to a 
density (60-70 % confluent) that will allow them to remain viable up to 72 hours. 
Experimental cultures are set up in parallel; one is maintained at 21 % 
atmospheric oxygen (normoxia) and 5 % carbon dioxide (normoxia), in a 
standard humidified incubator. The second culture is sealed inside an air tight 
container (hypoxia chamber) and flushed by gassing with a mixture of 5 % CO2 
and 95 % N2 mix (hypoxia) (Figure 4-1 A, section 2.1). Oxygen levels in the 
culture medium were found consistently to be between 1-3 % using a FOXY-R 
stainless steel 1/16" OD Fibre Optic Probe (Ocean Optics).  
 
 
Figure 4-1 Establishing hypoxia culture conditions 
(A) Hypoxic culture conditions were obtained by placing cultures in the air-tight container shown 
and flushing the container with 5 % CO2 and 95 % N2. The container is then sealed and placed 
within a humidified incubator. (B) Western blot analysis with anti-HIF-1α antibody (BD 
Transduction Labs) of whole cell lysates of HEK 293T cells transfected with pCDNA3-HIF-1α 
(HIF-1α  lane) or empty control (vector control lane) cultured in normoxia (Normoxia; 21 %O2) or 
exposed to 48 hours of hypoxia (Hypoxia; <3 % O2). HIF-1α is expressed in pCDNA3- HIF-1α 
transfected samples and endogenous HIF-1α is stabilised only under hypoxic cultures relative to 
normoxic cultures.  
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To confirm that the conditions established are indeed hypoxic, we monitored the 
stabilisation of HIF-1α in HEK 293T cells by western blot. HIF-1α is 
accumulated and readily detected in HEK 293T cells transfected with empty 
vector and cultured under these hypoxic conditions at 48 hours, compared to 
normoxic controls (Figure 4-1 B). HIF-1α is also detected in HEK 293T cells 
transfected with a plasmid expressing HIF-1α under normoxia. Overexpression 
of HIF-1α under hypoxic conditions leads to a further accumulation due to the 
presence of endogenous HIF-1α (Figure 4-1 B). These data show that we are 
able to achieve sustained hypoxic culture conditions and these are sufficient to 
cause HIF-1α stabilisation. 
 
4.2.2 The rKSHV.219 HEK 293T cell model and hypoxia-induced 
reactivation  
 
4.2.2.1  Hypoxic suppresses DsRed expression in rKSHV.219 infected 
HEK 293T cells – Clone 9 
Using the rKSHV.219 HEK 293T cell model for reactivation, previously 
established in chapter 3, we determined the level of KSHV reactivation by 
monitoring DsRed expression in response to hypoxic conditions. 48 hours 
hypoxia treatment was unable to induce DsRed expression from the PAN 
promoter in Clone 9 cells, compared to normoxic controls (data not shown). 
Hypoxia also did not induce DsRed expression in Clone 9 cells transfected with 
empty vector control, pCDNA3, (Figure 4-2 A and E). In addition we observed a 
reduction in the number of cells expressing DsRed after NaBut treatment (a 
stimulus known to cause reactivation; see section 3.2.2.1) under hypoxic 
conditions compared to normoxia (Figure 4-2 B and F). Transfection of Clone 9 
cells with the RTA-expressing plasmid, pCMV-RTA, resulted in a large 
proportion of the cells expressing DsRed under normoxia; however, under 
hypoxia the level of DsRed expression and the number of DsRed-positive RTA-
expressing cells were markedly reduced (Figure 4-2 C and G). Overexpression 
of HIF-1α in Clone 9 cells under normoxic conditions induced DsRed expression 
in a number of the cells; however, under hypoxia DsRed expression again was 
evidently reduced in these cells (Figure 4-2 D and H). We also determined 
DsRed expression by FACs analysis. It is clear that the number of cells 
expressing DsRed detected by the FACsArray does not correspond to the 
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number of DsRed-positive cells seen by the microscope (Figure 4-2), explained 
in chapter 3. However, the patterns of expression of DsRed reported by the 
FACsArray followed the same trend whereby hypoxia decreases DsRed 
expression even when RTA is expressed.    
 
Figure 4-2 Hypoxia suppresses DsRed expression in Clone 9 cells 
HEK 293T cells harbouring recombinant KSHV, rKSHV.219 (rKSHV.219 HEK 293Ts – Clone 9) 
were transfected with 1 µg empty vector (pCDNA3) (A and E) or stimulated to induce the KSHV 
lytic cycle by 3 mM sodium butyrate (NaBut) treatment (B and F) or transfected with 1 µg 
pCMV-RTA (C and G) or 1 µg pCDNA3- HIF-1α (D and H) and grown under normoxic (21 %O2) 
or hypoxic (<3 % O2) culture conditions. After 48 hours cells were analysed using confocal 
microscopy. Typical fields singly excited with 488-nm light to detect cells expressing GFP from 
the EF1  promoter (green) or 568 nm light to detect cells expressing DsRed from the KSHV 
lytic cycle PAN promoter (red) are shown magnified at x60. Clone 9 cells unstimulated or 
stimulated to reactivate express lower levels of DsRed under hypoxia compared to normoxic 
controls.  
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Figure 4-3 Flow cytometry analysis of Clone 9 cells after hypoxia treatment 
DsRed expression of the same samples was quantified by flow cytometry. Flow cytometry 
results reflect the pattern of reactivation but underestimates the number of DsRed cells  
detected by confocal microscopy. 
 
Previously, we have shown that XBP-1s induces the lytic cycle and DsRed 
expression from the PAN lytic promoter; see section 3.2.2.1. When XBP-1s was 
supplied to Clone 9 cells under normoxic conditions at 48 hours around 5 % of 
the cells, measured by FACsArray, are DsRed-positive (black bars Figure 4-4). 
After 48 hours under hypoxic conditions only 1 % of the Clone 9 cells 
expressing XBP-1s are DsRed-positive; a level similar to background levels of 
spontaneous PAN lytic promoter activity (grey bars Figure 4-4). After 24 hours 
in hypoxia and then a recovery period of 24 hours in normoxia (reoxygenation), 
9 % of Clone 9 cells transfected with XBP-1s expressed DsRed (white bars 
Figure 4-4). Therefore, under conditions of 48 hours hypoxia Clone 9 cells are 
not induced to express DsRed from the PAN lytic promoter and the response to 
NaBut, RTA, HIF-1α and XBP-1s is reduced compared to parallel normoxic 
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cultures. Subjecting Clone 9 cells to hypoxic conditions followed by normoxia 
(reoxygenation), however, leads to DsRed expression and enhanced PAN lytic 
promoter activity induced by XBP-1s. 
 
Figure 4-4 Graphical representation of FACs analysis of Clone 9 cells exposed to hypoxia 
Clone 9 cells untransfected or transfected with 1 µg empty pCDNA3 or pCDNA3-XBP-1s were 
exposed to 48 hours of normoxia (black bars), hypoxia (grey bars) or 24 hours hypoxia followed 
by 24 hours normoxia (reoxygenation – white bars). Activity of the PAN lytic promoter in these 
cultures was measured by flow cytometry and displayed as the percentage of DsRed-positive 
cells in the culture. Reoxygenation of samples reveals the affect of hypoxia-induced reactivation 
and allows fluorescence of DsRed from the PAN lytic promoter. Columns represent mean of 
three independent experiments and error bars represent the standard error of the mean. 
 
4.2.2.2 Exposure to 72 hours hypoxia or reoxygenation induces 
rKSHV.219 reactivation in Clone 9 cells  
48 hours exposure to continued hypoxia was unable to induce DsRed 
expression from the PAN promoter in Clone 9 cells. However, increasing the 
length of hypoxic exposure to 72 hours led to increased DsRed expression 
compared to parallel cultures maintained at 21 % O2 (normoxia) (Figure 4-5 A 
and B). The number of DsRed-expressing Clone 9 cells further increased when 
cells were cultured for 48 hours under hypoxic conditions then reoxygenated 
and grown under normoxic conditions for a further 24 hours before analysis 
(Figure 4-5 C). Western blot analysis was used to determine the presence of 
RTA in DsRed-expressing Clone 9. Under normoxic conditions RTA was not 
detected at 24 and 72 hours (Figure 4-6 A). Hypoxia readily induces RTA 
expression at 72 hours but not at 24 hours in Clone 9 cells (Figure 4-6 A). After 
48 hours hypoxia followed by 24 hours normoxia (reoxygenation) RTA levels 
were reduced compared to 72 hours continuous hypoxia but higher than in 
normoxic controls (Figure 4-6 A).  
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Figure 4-5 Clone 9 cells express DsRed in response to 72 hours hypoxia or reoxygenation 
Photomicrographs of rKSHV.219 HEK 293T cells (Clone 9) grown under (A) normoxic ( 21 %O2) 
or (B) hypoxic (<3 % O2) culture conditions for 72 hours or (C) for 48 hours under hypoxia and 
then returned to normoxic conditions for 24 hours (reoxygenation). Two typical fields of phase, 
EF1α-GFP and PAN-DsRed fluorescence of each treatment are shown magnified at x20. 
Hypoxic and reoxygenated cultures show DsRed expression greater than parallel normoxic 
cultures at 72 hours.  
 
Enhanced DsRed expression was seen in Clone 9 cells transfected with XBP-
1s and subjected to reoxygenation (Figure 4-4). Due to the role of XBP-1 and 
KSHV reactivation previously established (see section 3.2.3) we assayed XBP-
1 transcript splice status in these cells by RT PCR. Minimal XBP-1 spliced 
transcript is present in Clone 9 cells after 24 or 72 hours culture under normoxic 
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conditions (Figure 4-6 B). After 72 hours hypoxic treatment of Clone 9 cells, a 
strong band of spliced XBP-1 can be seen relative to 24 hours hypoxia and 
normoxic controls (Figure 4-6 B). When Clone 9 cells were subjected to a  24 
hour period of normoxia after 48 hours hypoxia (reoxygenation) normal control 
levels of minimal XBP-1s are detected by RT PCR (Figure 4-6 B). Therefore, 
hypoxia can induce both RTA and XBP-1s but only after prolonged (72 hours) 
hypoxia treatment.  
 
Figure 4-6 rKSHV.219 reactivation and XBP-1 splice status in Clone 9 cells in response to 
hypoxia or reoxygenation 
(A) Western blot analysis with polyclonal rabbit anti-RTA of whole cell lysates of Clone 9 cells 
cultured in normoxia (N; 21 %O2), hypoxia (H; <3 % O2) for 24 or 72 hours or reoxygenated for 
24 hours after 48 hours hypoxic exposure (R). RTA is induced by hypoxia at 72 hours and is 
present at a lower level in reoxygenated samples compared to cells under normoxia. β-actin 
acts as a loading control. (B) RT PCR amplification across the XBP-1 intron produces a 249 
base pair amplicon from XBP-1u mRNA and a 223 base amplicon from XBP-s mRNA. Pst I 
digests only the XBP-1u amplicon resulting in two bands, whereas XBP-1s results in a single 
band (Wilson et al., 2007). RT PCR amplification from the total mRNA of Clone 9 cells cultured 
under normoxia (N; 21 %O2), hypoxia (H; <3 % O2) for 24 or 72 hours or reoxygenated for 24 
hours after 48 hours hypoxic exposure (R) shows that XBP-1s is produced after 72 hours of 
hypoxia but is absent in reoxygenated samples and in cells under normoxia. In the 72 hours 
hypoxia sample a slower-migrating non-Pst I digestible PCR hybrid between the XBP-1s and 
XBP-1u products is visible similar to that previously described (Wilson et al., 2007). RT PCR for 
β-actin on the same RNA was used to normalise cDNA input (data not shown). 
  
 
4.2.3 The rKSHV.219 JSC-1 cell model for hypoxia-induced reactivation  
 
4.2.3.1 Exposure to 72 hours hypoxia or reoxygenation induces 
rKSHV.219 reactivation in rKSHV.219 JSC-1 cells  
A more relevant model for KSHV reactivation in response to hypoxic treatment 
is to use the PEL cell line rKSHV.219 JSC-1 (a kind gift from the lab of Jeff 
Vieira); which contains an identical rKSHV.219 to the HEK 293T cells used in 
the previous sections. rKSHV.219 JSC-1 cells were exposed to the established 
hypoxic conditions. After 72 hours hypoxic treatment DsRed expression from 
the PAN lytic promoter was marginally increased above normoxic controls 
(Figure 4-7 B). As seen with the Clone 9 cells, a recovery period of 24 hours in 
normoxic conditions after 48 hours of hypoxia led to an increase in DsRed-
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positive cells as seen by microscopy. This was quantified by FACsArray 
analysis to around 8 % of the cells (Figure 4-7 A and B). Therefore the 
rKSHV.219 JSC-1 model for reactivation responds to the hypoxic culture 
conditions in the same way as Clone 9 cells, although possibly to a lesser 
extent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7 rKSHV.219 JSC-1 cells express DsRed in response to 72 hours hypoxia or 
reoxygenation 
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Photomicrographs of the PEL cell line rKSHV.219 JSC-1 grown under normoxic (21 %O2) or 
hypoxic (<3 % O2) culture conditions for (A) 48 or (B) 72 hours or for 48 hours under hypoxia 
and then returned to normoxic conditions for 24 hours (reoxygenation). Typical fields of phase, 
EF1α-GFP and PAN-DsRed fluorescence of each treatment are shown magnified at x20. 72 hr 
hypoxic treated and reoxygenated cultures show DsRed expression greater than 48 hr hypoxic 
cultures and parallel normoxic cultures at 72 hours. (C) The activity of the PAN lytic promoter in 
the 72 hour cultures above was measured by flow cytometry and displayed as the percentage of 
DsRed-positive cells in the culture. Reoxygenation of samples reveals the affect of hypoxia-
induced reactivation and allows fluorescence of DsRed from the PAN lytic promoter. Columns 
represent mean of nine independent experiments and error bars represent the standard error of 
the mean.  
 
4.2.4 Determining the role of HIF-1 and XBP-1 in hypoxia-induced 
reactivation 
 
4.2.4.1 Hypoxia stabilises HIF-1α and activates XBP-1 in PEL 
Hypoxia is able to induce both HIF-1α stabilisation and XBP-1 splicing, and both 
transcription factors can transactivate the ORF50 promoter through ‘ACGT’ core 
containing XREs and HREs respectively (see section 3.2.4.1). Therefore, we 
examined the ability of hypoxia to induce both transcription factors in PEL. HIF-
1α is stabilised and activated at oxygen concentrations below 3 % in a variety of 
cell lines (Koumenis and Wouters, 2006). Under conditions of acute hypoxia (<3 
% O2) HIF-1α is stabilised and readily detected in the PEL cell line rKSHV.219 
JSC-1 (Figure 4-8 A). Levels of HIF-1α are increased by 48 hours of hypoxia 
compared to cells cultured in normoxia and are robustly expressed after 72 
hours of hypoxic treatment (Figure 4-8 A). We note, however, that in our hands 
PEL do not consistently express detectable HIF-1α under normoxia in contrast 
to work carried out by Cai et. al (Cai et al., 2007). We have previously shown 
that XBP-1 is present in PEL as the unspliced, inactive transcript which can be 
activated to the spliced bZIP-containing transcript by the reducing agent DTT 
(Wilson et al., 2007). We have seen an increase in XBP-1 spliced transcript 
after 72 hours hypoxia treatment in rKSHV.219 HEK 293T cells, Clone 9 (see 
section 4.2.2.2). XBP-1 has also been shown to be activated by hypoxia in 
cardiac myocytes (Thuerauf et al., 2006). Consistent with these data, exposure 
of rKSHV.219 JSC-1 cells to hypoxia leads to significant conversion of XBP-1 to 
the spliced, active form (XBP-1s) (Figure 4-8 B). Therefore hypoxia induces 
both HIF-1α and XBP-1s transcription factors in PEL.  
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Figure 4-8 Hypoxia-induced HIF-1α stabilisation and XBP-1 splicing in PEL 
(A) Western blot analysis of whole cell lysates of the PEL cell line rKSHV.219 JSC-1 cultured in 
normoxia (N; 21 %O2) or exposed to 48 or 72 hours of hypoxia (H; <3 % O2) with anti-HIF-1α 
antibody (BD Transduction Labs). HIF-1α is stabilised in rKSHV.219 JSC-1 cells in response to 
hypoxia at 48 and 72 hours compared to normoxia, β-actin acts as loading control. (B) RT PCR 
amplification from the total mRNA of the rKSHV.219 JSC-1 cell line cultured under normoxia (N; 
21 %O2) or exposed to hypoxia (H; <3 % O2) for 48 or 72 hours shows that XBP-1s is produced 
after 72 hours of hypoxia but is absent in cells under normoxia. In the 72 hours hypoxia sample 
a slower-migrating non-Pst I digestible PCR hybrid between the XBP-1s and XBP-1u products is 
visible similar to that previously described (Wilson et al., 2007). RT PCR for β-actin on the same 
RNA was used to normalise cDNA input (data not shown). 
 
 
4.2.4.2 Hypoxia induces the KSHV lytic cycle in PEL 
The effect of hypoxia and hypoxia mimics, such as cobalt chloride, on KSHV 
lytic cycle induction has been demonstrated (Cai et al., 2006a; Davis et al., 
2001; Haque et al., 2003). We have also shown that low oxygen conditions 
induce XBP-1s and RTA expression in rKSHV.219 HEK 293Ts, Clone 9 
(4.2.2.2). We therefore investigated whether KSHV reactivation is seen in PEL 
under the same low oxygen conditions. Under normoxia RTA is not significantly 
expressed rKSHV.219 JSC-1 (Figure 4-9 A), wild-type JSC-1 or HBL-6 cells 
(Figure 4-9 D). RTA expression is readily induced in all PEL cell lines tested in 
response to hypoxia treatment (Figure 4-9 A and D). RT PCR for the spliced 
KSHV lytic cycle transcript ORF29a/b shows that KSHV enters the full lytic 
cycle (Figure 4-9 B) and ORF37 qPCR for extracellular KSHV viral genome 
confirms production of virus in response to hypoxia in both PEL cell lines JSC-1 
and HBL-6 (Figure 4-9 C).  Therefore RTA induced by low oxygen conditions is 
able to induce the full lytic cycle of KSHV in PEL. 
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Figure 4-9 Hypoxia leads to the induction of the full KSHV lytic cycle in PEL 
(A) Western blot analysis of whole cell lysates of the PEL cell line rKSHV.219 JSC-1 cultured in 
normoxia (N; 21 %O2) or exposed to 48 or 72 hours of hypoxia (H; <3 % O2) with polyclonal 
rabbit anti-RTA. RTA is induced by hypoxia at 48 hours and further increased at 72 hours 
exposure compared to cells under normoxia. β-actin acts as a loading control. (B) Total cellular 
RNA was isolated from rKSHV.219 JSC-1 cultured under normoxic or hypoxic conditions for 48 
and 72hours. RT PCR and gene specific primers for the spliced lytic transcript, ORF29a/b, were 
used to amplify a 300bp product from cDNA.  PCR product is seen only in samples exposed to 
hypoxia (H; <3 % O2). RT PCR for β-actin on the same RNA was used to normalise cDNA input. 
(C) qPCR for ORF37 from KSHV virion DNA extracted from the supernatants of JSC-1 and 
HBL-6 cells cultured for 72 hours in normoxia (N; 21 %O2, black bars) or Hypoxia (H; <3 % O2’ 
white bars). Copy number is determined using an ORF37 standard curve and normalised for 
total DNA input. Hypoxia leads to a significant increase in virus copies present in the 
supernatant. (D) Western blots for HIF-1α and RTA of whole cell lysates of the corresponding 
cells to the supernatants used in C. At 48 hours - shows samples are HIF-1α-positive and RTA 
is induced. 
 
4.2.4.3 The RTA promoter has the potential to respond to HIF-1α and 
XBP-1s 
The RTA promoter can be induced by the transcription factors XBP-1s and HIF-
1α (Cai et al., 2006a) (Figure 4-10 A). The response elements of these 
transcription factors also contain essentially the same core sequence ‘ACGT’. 
We therefore determined if ‘ACGT’ elements present in the OR50 promoter 
could respond to both transcription factors. A series of truncated constructs of 
the RTA promoter fused to a luciferase reporter were used to isolate HRE2 from 
XRE (HRE4) (Figure 4-10 B). Expression of RTA efficiently induced luciferase 
activity from the full-length and truncated ORF50 promoters (Figure 4-10 C). 
HIF-1α was also able to drive luciferase expression from the full-length 
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promoter as well as the HRE-containing truncated promoters as previously seen 
(Cai et al., 2006a). However, XBP-1s is able to activate expression of luciferase 
from the full-length ORF50 reporter and the XRE- (HRE-4)-containing promoter 
only. Therefore, the RTA promoter of KSHV can be transactivated by both HIF-
1α and XBP-1s and both factors act through ACGT binding sites.  
 
Figure 4-10 The KSHV RTA promoter responds to both XBP-1 and HIF-1α  
(A) A schematic of the predicted hypoxia-responsive elements (HREs) in the KSHV RTA 
promoter region (adapted from (Cai et al., 2006a)).  (B) Schematic of reporter plasmids 
pRpluc1-3087 containing a 3-kb sequence upstream of the RTA transcriptional start that drives 
the expression of firefly luciferase (Cai et al., 2006a) as well as truncated promoters named 
pRpluc 1115-1327 (HRE2 only) and pRpluc1-550 XRE (HRE4) only. (C) A fixed amount of the 
reporter plasmids were transfected into HEK 293T cells together with pIG (empty vector control 
- ↓), RTA-expressing (pCMVRTA – black bars), XBP-1s-expressing (pXBPsIG – striped bars) or 
HIF-1α-expressing (pHIF-1αIG – white bars) plasmids normalised by plasmid copy number. 
Promoter activity levels are expressed as the log of relative light units (logRLU) relative to the 
reporter plus pIG control plasmid. Columns represent the mean of three independent 
experiments and error bars represent standard error of the mean. HIF-1α acts on all reporters 
containing HRE2 and XRE (no significant difference 95% CFI) while XBP-1s acts on the full-
length and XRE only promoter but not HRE2 only. Activity of XBP-1s on the HRE2 only 
promoter found to be significantly different to it’s activity on the XRE only promoter p<0.001.  
 
4.2.4.4 XBP-1s contributes to the RTA induction by hypoxia 
As both HIF-1α and XBP-1s are activated by hypoxia at similar times to RTA 
induction, we wished to determine if one transcription factor was dominant for 
inducing KSHV lytic reactivation under hypoxia. We used the short hairpin 
LUC 
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interfering RNA (shRNA) to XBP-1 previously described in section 3.2.3.1 and 
produced shRNAs to HIF-1α. These hairpins led to a reduction in HIF-1α protein 
levels when HIF-1α protein was overexpressed in HEK 293Ts cells (Figure 
4-11). The shRNA targeted to the nucleotide region 1545 of HIF-1α mRNA 
sequence (NM_001530) acted more efficiently to reduce HIF-1α protein levels 
than shRNA targeting the nucleotide region around 1589, and therefore the 
former was used in further experiments and named shHIF-1α.  
 
Figure 4-11 Production of shRNA to HIF-1α 
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(A) Sequences and probable structures of shRNAs targeting two different regions of HIF-1α 
mRNA. Numbering corresponds to sequence (NM_001530). (B) shRNA ability to knock down 
target protein levels was demonstrated by co-transfection of HEK 293T cells with 1µg of target 
expressing plasmid (pCDNA3-HIF-1α) and 3 µg of relevant/irrelevant control hairpins in a 
pGEMT backbone. Western blot for target protein using anti-HIF-1α (BD transduction labs) 
reveal both shRNA targeting HIF-1α are able to reduce target protein level substantially 
compared to the irrelevant control shRNA. β-actin acts as a loading control. shRNA 1545 HIF-
1α was used for further experiments.  
 
 
Figure 4-12 XBP-1s involvement in RTA induction by hypoxia 
(A) Clone 9  (B) rKSHV.219 JSC-1, (C) JSC-1 and (D) HBL-6 cells stably transduced with 
lentiviruses containing shRNA to XBP-1, HIF-1α and irrelevant control independently were 
cultured in normoxia (N-21 %O2) or hypoxia (H- <3 % O2) for 72 hours. Western blot analysis of 
whole cell lysates was performed for HIF-1α indicating its upregulation in hypoxic samples and 
attenuated expression in those cells expressing the shRNA to HIF-1α. The same samples 
probed with anti-RTA show the induction of RTA in response to hypoxia which is reduced in the 
presence of shRNA to HIF-1α or XBP-1s. β-actin acts as a loading control. 
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The cell line rKSHV.219 HEK 293T, Clone 9  (Figure 4-12 A) or the PEL cell 
lines rKSHV.219 JSC-1 (Figure 4-12 B), JSC-1 (Figure 4-12 C) and HBL-6 
(Figure 4-12 D) were transduced with lentivirus expressing hairpins targeting 
XBP-1, HIF-1α or a control with an input equivalent to a MOI 5 on HEK 293-T 
cells. Stable cell lines were then produced and maintained using puromycin 
selection. Cells were exposed to hypoxia or normoxia for 72 hours before being 
sampled. Western blot analysis shows that decreasing the levels of HIF-1α 
under hypoxia clearly results in attenuated RTA induction (Figure 4-12). The 
shRNA to XBP-1s also led to a reduction in RTA expression under the same 
hypoxic conditions (Figure 4-12). The presence of shRNA does not interfere 
with the processing of XBP-1 mRNA (data not shown). These data suggest that 
both HIF-1α and XBP-1s contribute to the lytic cycle induction of KSHV under 
hypoxia.  
 
4.2.4.5 HIF-1α overexpression under normoxia does not lead to RTA 
induction in PEL 
Due to the stabilisation of HIF-1α in PEL and KS lesions (Cai et al., 2006b; 
Carroll et al., 2006), we wanted to determine the contribution of HIF-1α to KSHV 
lytic cycle induction under normoxia. We transduced the PEL cell lines JSC-1, 
HBL-6 and BC-3 with lentivirus expressing HIF-1α, XBP-1s or empty vector at 
an input equivalent to a MOI 5 on HEK 293-T cells.   
 
Overexpression of HIF-1α from the lentivirus vector led to HIF-1α protein 
expression in all PEL cell lines (Figure 4-13 A). Previously, HIF-1α 
overexpression resulted in transactivation of the ORF50 promoter in HEK 293T 
cells and DsRed expression from the PAN lytic promoter in rKSHV.219 HEK 
293T cells (Figure 4-13 B and section 4.2.2.1). However, RTA was only induced 
in PEL cells overexpressing XBP-1s under normoxia (Figure 4-13 B). The 
overexpression of HIF-1α in PEL did not reactivate KSHV under normoxia. 
Therefore, only XBP-1s is able to reactivate KSHV in PEL cells under conditions 
of normoxia and hypoxia. 
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Figure 4-13 Overexpression of HIF-1α in PEL under normoxia 
(A) Whole cell lysate RTA western blot of JSC-1, HBL-6 and BC3 cells transduced with empty 
vector (pIG) or HIF-1α-expressing (pSIN-HA-HIF-1α)) or XBP-1s-expressing (pXBPsIG) at an 
input equivalent to a MOI 5 on HEK 293-T cells. RTA is induced only in the presence of XBP-1s 
expression (pXBPsIG) under normoxia. (B) Anti-HIF-1α western blot of whole cell lysates of 
JSC-1, HBL-6 and BC3 cells transduced with lentivirus expressing HIF-1α. β-actin acts as a 
loading control. 
 
4.2.4.6 Co-expression of HIF-1α and XBP-1s under normoxia in PEL 
To determine whether normoxic expression of HIF-1α required the presence of 
XBP-1s in order to induce RTA expression in PEL, we overexpressed both 
proteins simultaneously in the PEL cell line JSC-1.  
 
As seen before, HIF-1α overexpression in JSC-1 did not induce RTA expression 
under normoxia (Figure 4-13). Expression of HIF-1α in conjunction with XBP-1s 
did not increase the level of RTA protein over and above the level induced in 
the presence of XBP-1s alone (Figure 4-14 A). Expression of both XBP-1s and 
HIF-1α in HEK 293Ts led to a 3.2 fold increase in the expression of luciferase 
from a full-length ORF50 promoter (Figure 4-14 B). XBP-1s and HIF-1α, when 
expressed individually, caused a 2.2 and 2.6 fold increase in RTA promoter 
activity respectively (Figure 4-14 B). The presence of XBP-1s therefore does 
not allow HIF-1α to induce KSHV lytic reactivation under normoxia. 
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Figure 4-14 Co-expression of HIF-1α and XBP-1s under normoxia 
(A) Whole cell lysate anti-HIF-1α and RTA western blot of JSC-1 cells transduced with empty vector 
(pIG), HIF-1α-expressing (pSIN-HA- HIF-1α), XBP-1s-expressing (pXBPsIG) at an input equivalent to 
a MOI 5 on HEK 293-T cells or both pSIN-HA- HIF-1α and pXBPsIG.  RTA is induced only in the 
presence of XBP-1s expression (pXBPsIG) under normoxia and is not further induced when both 
XBP-1s and HIF-1α are expressed. β-actin acts as a loading control. (B) HEK 293T cells were 
transfected with a Renilla-expressing control plasmid (phRL-null) plus the ORF50 promoter Firefly 
luciferase reporter plasmid (pRpluc1-3087+s) together with pIG (control) or RTA-expressing 
(pCMVRTA) or XBP-1s-expressing (pXBPsIG), or HIF-1α-expressing (pSIN-HA- HIF-1α) or the last 
two plasmids in combination. Firefly luciferase activity was determined 48 hours post-transfection 
and normalised to Renilla luciferase (phRL-null) activity and plotted as a fold change relative to 
empty vector control pIG. Columns represent the mean of three independent experiments and error 
bars represent standard error of the mean. No significant difference was found when plasmids were 
used in combination to the 95% confidence level.  
 
4.2.5 Hypoxia induces EBV BZLF-1 expression in both BL and PEL 
It has been previously demonstrated that hypoxic culture of B95-8 cells, a 
marmoset B-cell line transformed with EBV, induced BZLF-1 expression and 
lytic replication (Jiang et al., 2006). Burkitt’s Lymphoma (BL) is an EBV 
associated B-cell lymphoma, we therefore took BL derived cell lines and 
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monitored the expression of BZLF-1 in response to the same hypoxic 
conditions. BZLF-1 expression is dramatically up regulated in response to low 
oxygen conditions in both Mutu and Daudi cell lines compared to normoxic 
controls. No EBV reactivation is seen in Raji cells where EBV is known to be 
defective (Figure 4-15 A). The PEL cell line JSC-1 is co-infected with EBV, 
therefore we looked for BZLF-1 expression in the same samples that had 
displayed KSHV reactivation under hypoxic conditions (see section 4.2.4.4).  
BZLF-1 was strongly induced in all hypoxic samples including those stably 
transduced with control shRNA-GFP or shRNA to HIF-1α (Figure 4-15 A).  In 
JSC-1 samples expressing shRNA to XBP-1s, BZLF-1 can be seen by western 
blot under normoxic conditions and is further accumulated after hypoxic 
treatment (Figure 4-15 A).  The EBV present in PEL cells is also induced into 
the lytic cycle by hypoxia, this appears however to be independent of HIF-1α, 
while the role of XBP-1s remains complicated.  
Figure 4-15 EBV reactivation in response to hypoxia 
(A) Western blot analysis of whole cell lysates of the BL cell lines Raji, Mutu and Daudi were cultured 
in normoxia (N; 21 %O2) or exposed to 72 hours of hypoxia (H; <3 % O2) with anti-HIF-1α antibody 
(BD transduction labs). HIF-1α is stabilised in all cell lines in response to hypoxia at 72 hours 
compared to normoxia. BZLF-1 western blot analysis of the same samples shows BZLF-1 is robustly 
upregulated in all hypoxic treated samples compared to normoxic samples except in the EBV 
defective Raji cell line. β-actin acts as loading control. (B) JSC-1 cells stably transduced 
independently with lentiviruses containing shRNA to XBP-1, HIF-1α and irrelevant control, GFP, were 
cultured in normoxia (N-21 %O2) or hypoxia (H- <3 % O2) for 72 hours. Western blot analysis of 
whole cell lysates was performed for BZLF-1 indicating its upregulation in all hypoxic samples 
(except for EBV defective Raji cell samples) relative to normoxic parallel cultures. β-actin acts as a 
loading control. 
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4.3 Discussion 
 
Here we have established a role of both transcription factors XBP-1s and HIF-
1α in hypoxia-induced KSHV reactivation. Hypoxia was previously identified as 
an inducer of KSHV lytic replication (Davis et al., 2001), and HREs, required for 
the transcription factor activity of HIF-1α, are present within the promoter 
regions of KSHV viral genes including ORF50/RTA (Haque et al., 2003). 
However, studies of RTA promoter activity in response to HIF-1α over 
expression (Haque et al., 2003) (Jiang et al., 1997b) or hypoxia mimics show 
minimal or cell type specific activation by HIF-1α under otherwise normoxic 
culture conditions. Under low oxygen conditions however the RTA promoter is 
active. Hypoxia mimics such as cobalt chloride and desferoxamine are iron 
chelators which act to prevent HIF-1α degradation and are often used in KSHV 
RTA induction studies (Wang and Semenza, 1993b) (Carroll et al., 2006) 
(Haque et al., 2003). Whilst this may lead to the expression of HIF-1α 
dependent genes (Costa-Giomi et al., 1990; Wang and Semenza, 1993b) 
hypoxia mimics do not accurately represent conditions of low oxygen (authentic 
hypoxia - see section 1.5.1.1). Combining previous studies together, data 
suggests that either HIF-1α is not sufficient for the induction of KSHV lytic cycle 
or that authentic hypoxia is required, possibly causing the induction of other 
factors that may promote KSHV reactivation. 
 
HIF-1α is the major transcriptional activator under hypoxic conditions and is 
known to regulate over 100 genes involved in the cellular response to stress 
induced by low oxygen levels (Semenza and Wang, 1992) (Manalo et al., 
2005). However, HIF-1α independent responses to hypoxia have been reported 
and generally include processes that require oxygen or energy consumption, for 
example protein folding (Wykoff et al., 2000) (Tu et al., 2000) (Tu and 
Weissman, 2002). The accumulation of misfolded protein under hypoxic 
conditions leads to the activation of the unfolded protein response (UPR) in a 
HIF-1α independent manner (Koumenis et al., 2002) (Ameri et al., 2004) 
(Koumenis and Wouters, 2006). XBP-1 is a major component of the UPR and is 
able to induce KSHV reactivation (see chapter 3) (Wilson et al., 2007) (Yu et al., 
2007a). Therefore, to establish the combined effects of XBP-1s and HIF-1α on 
KSHV reactivation under hypoxia true, low oxygen, hypoxia conditions are 
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essential (Feldman et al., 2005) (Romero-Ramirez et al., 2004). Fundamentally 
the HIF-1α-independent hypoxia-induced responses are absent in studies that 
employ hypoxia mimics or HIF-1α overexpression as a surrogate for hypoxic 
conditions. Using established techniques we were able to achieve 
physiologically relevant, low oxygen, hypoxic culture conditions that led to the 
accumulation of HIF-1α for our study (Figure 4-1).  
 
When rKSHV.219 HEK 293T cells, Clone 9, were exposed to these hypoxic 
conditions for 48 hours, DsRed expression was not induced (Figure 4-2 A and 
E). This suggested that these hypoxic conditions do not induce KSHV lytic 
reactivation in contrast to previously published results (Davis et al., 2001). 
However, known lytic cycle inducers such as, NaBut, RTA and XBP-1s also did 
not induce DsRed expression when introduced under hypoxia (Figure 4-2). The 
fact that the model system does not respond to known triggers of reactivation 
under hypoxic conditions suggests that hypoxia may affect the RTA driven 
expression of DsRed from the PAN lytic promoter. This could be for two major 
reasons; firstly translational arrest is induced by hypoxia (see section 1.5.2). 
This is a complex process which consists of two effector pathways; the first is 
via activation of PERK, an ER kinase, which phosphorylates and inactivates the 
translation initiation factor, eIF2α, blocking translation (Koumenis et al., 2002). 
The second is via disruption of the eIF4F cap-binding protein complex after 
prolonged hypoxic exposure (Koritzinsky et al., 2006). Therefore RTA and/or 
DsRed translation may be blocked under hypoxic conditions. 
 
The second explanation, for the absence of DsRed in response to hypoxia, is 
the requirement of molecular oxygen in the final maturation stage of fluorescent 
proteins. DsRed initially undergoes the same maturation process as GFP; the 
three steps are cyclisation of the main chain, dehydration and finally oxidation to 
form a fully mature fluorescent protein (Heim et al., 1994). However, DsRed 
requires a further oxidation step responsible for the red shift in fluorescence 
(Gross et al., 2000). Therefore, DsRed requires two oxygen dependent steps to 
fluoresce and is particularly sensitive to hypoxia. Heim et.al. demonstrated that 
fluorescence gradually developed when oxygen was introduced to GFP-
expressing bacteria grown anaerobically, importantly, this was independent of 
new protein synthesis (Heim et al., 1994). Further to this, Gross et.al. showed 
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that the conversion of green fluorescent DsRed to red fluorescent DsRed 
requires molecular oxygen (Gross et al., 2000).  Therefore, under hypoxic 
conditions, even if RTA and consequently DsRed protein were synthesised, 
fluorescence may not occur due to the absence of oxygen and a failure of the 
chromophore to mature.  
 
We favour oxygen dependent fluorescence as the explanation as to why DsRed 
expression is not seen in Clone 9 cells after 48 hours hypoxic treatment; as 
returning hypoxic cultures to oxygen conditions (reoxygenation) resulted in rapid 
DsRed expression (Figure 4-5 and Figure 4-7). Weak DsRed expression is 
seen in Clone 9 and r219.KSHV JSC-1 cells after 72 hours hypoxia treatment 
indicating hypoxic induction of DsRed expression but the lack of sufficient 
oxygen to allow maturation of all the fluorescent protein produced (Figure 4-5 
and Figure 4-7). The presence of RTA protein in cells under hypoxia but not 
under normoxic conditions argues against translational arrest of RTA and 
DsRed protein production, although we did not assay for DsRed protein 
production (Figure 4-5). Together this data shows that the conditions 
established do represent true hypoxic conditions that lead to KSHV reactivation, 
but this could and should not be monitored by PAN specific DsRed expression. 
Further study therefore focused on the presence of RTA as a measure of 
reactivation. Results also show that the length of hypoxic exposure time is 
important as XBP-1s, HIF-1α and RTA are robustly upregulated at 72 hours and 
not at 24 (Figure 4-5 and Figure 4-8).  
 
Experiments were carried out using rKSHV.219 HEK 293T cells, Clone 9, and a 
range of PEL cell lines in order to address the role of HIF-1α and XBP-1s in 
KSHV reactivation. Previous studies displaying the ability of HIF-1α to activate 
transcription from ORF50 promoter-reporters show cell type specific results. 
HIF-1α overexpression under normoxia in HEK 293 cells was shown to increase 
RTA promoter activity substantially more than in BJAB cells (Cai et al., 2006a). 
In contrast overexpression of HIF-1α in Hep3B cells only weakly induced the 
ORF50 promoter and RTA expression in the absence of hypoxia (Haque et al., 
2003), a situation more akin to that found in KSHV infected endothelial cells 
(Carroll et al., 2006). Indeed, overexpression of HIF-1αunder normoxia in PEL 
cell lines failed to induce RTA expression, whereas XBP1s overexpression 
 187
efficiently initiates the KSHV lytic cycle (Figure 4-13 and Figure 4-14) (Wilson et 
al., 2007). In contrast HIF-1α was able to induce RTA promoter activity under 
normoxia in HEK 293T cells but in the absence of virus (Figure 4-10). Together 
this suggests a role for KSHV in maintaining latency through the control or 
suppression of HIF-1α activity on the ORF50 promoter under normoxia.  
 
Under normoxic culture conditions KSHV LANA mediates degradation of the 
Von Hippel-Lindau factor (VHL), the master regulator of HIF stability, thereby 
stabilising HIF-1α upon KSHV infection (Cai et al., 2006b). HIF-1α mRNA is 
induced in KSHV infected endothelial cells and HIF-1 protein is abundantly 
expressed in KS lesions, where it is nuclear localised (Carroll et al., 2006). HIF-
1α induces the upregulation of cytokines for neoangiogenesis and the growth of 
target endothelial cells and is therefore able to contribute to the high 
vascularisation and location of KS lesions in the relatively hypoxic environment 
of the skin (Bedogni et al., 2005), particularly on the lower extremities of those 
with poor circulation, the elderly and diabetes patients (Ensoli et al., 2001a) 
(Laor and Schwartz, 1979). LANA, via its N-terminal domain also mediates HIF-
1α nuclear accumulation in PEL cell lines (Cai et al., 2007). Additionally, B-cells 
are exposed to low oxygen tensions as they develop in secondary lymphoid 
tissues and migrate between the blood and different tissues, possibly 
contributing to the HIF-1α accumulation in PEL (Caldwell et al., 2001).  
 
Despite the nuclear accumulation and stabilisation of HIF-1 in PEL, infected 
endothelial cells and KS lesions very little KSHV lytic replication is observed, 
typical of the infected cells being predominantly latent. The nuclear 
accumulation of HIF-1α in response to KSHV latent infection and hypoxia are 
spatially distinct. This suggests that accumulation in nuclear compartments 
under normoxia does not result in the induction of RTA and that redistribution of 
HIF-1α under hypoxia is required for the induction of the lytic cycle (Cai et al., 
2007) (Zheng et al., 2006). Alternatively, KSHV associated HIF-1α accumulation 
could prime infected cells so that when exposed to hypoxia the nuclear 
stabilised HIF-1α is further activated, for example by phosphorylation (Richard 
et al., 1999), resulting in lytic reactivation (Carroll et al., 2006). This 
‘superinduction’ of HIF-1α in response to hypoxia has been observed through 
the increased activity of HIF-1α by v-SRC (Jiang et al., 1997a). Interestingly, not 
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all studies, including ours, are able to visualise stabilised HIF-1α consistently in 
normoxic PEL; suggesting that levels may be very low or transient and therefore 
insufficient for transactivation. However, VEGF, a HIF-1α responsive gene is 
upregulated in a KSHV LANA-induced, HIF-1α dependent way under normoxia 
(Carroll et al., 2006) (Cai et al., 2007) indicating that HIF-1α can be 
transcriptionally active under latent normoxic infection. It is possible an 
additional factor(s) activated by hypoxia and absent during latent KSHV 
infection are necessary for HIF-1mediated lytic induction. Overexpression of 
XBP-1s in conjunction with HIF-1under normoxia resulted in no further 
accumulation of RTA over and above that seen with XBP-1s alone (Figure 
4-14), indicating that XBP-1s is not the additional factor required by HIF-1to 
induce KSHV lytic cycle under hypoxia.  
 
It is likely that the architecture of the hypoxia-induced transcriptional complex 
assembled on the RTA promoter contains other factors. High cell density, 
through nutritional starvation, can lead to the upregulation of hypoxia-inducible 
genes, for example carbonic anhydrase 9 (CA9), in a HIF-1α independent way 
under normoxia and an enhanced upregulation in a HIF-1 dependent way 
under hypoxia; an effect mediated by the transcription factor Ets-1 (Salnikow et 
al., 2008). Ets-1 has been reported to induce KSHV lytic replication directly and 
is important for TPA-induced reactivation (Yu et al., 2007b). Ets-1 and other Ets 
family members have also been identified as potential coactivators of XBP-1s 
leading to the possibility of an HIF-1α, Ets, XBP-1 complex being formed on the 
ORF50 promoter (Acosta-Alvear et al., 2007). HIF-1α responsive genes such as 
VEGF and GLUT-1 can also be induced differentially by hypoglycaemia, a 
metabolic insult that often occurs in parallel but also independently of hypoxia 
(Stein et al., 1995). Further, it has been documented that the HIF-1α binding 
site consists of the HRE as well as the HIF-1α ancillary sequence (HAS), a 
required cis-acting element for transcriptional activation under hypoxia 
(Forsythe et al., 1996). Also, HAS binding factors may be distinct for VEGF 
compared to other hypoxia inducible genes (Kimura et al., 2001).  
 
PEL cell lines have minimal KSHV lytic induction and contain inactive XBP-1u 
and nuclear HIF-1α, both of which can be rapidly activated by relevant stresses 
leading to lytic replication  (Wilson et al., 2007) (Cai et al., 2006b). Why XBP-1 
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is inactive and nuclear accumulation of HIF-1α fails to induce the KSHV lytic 
cycle in PEL cells is not known. However, both transcription factors play 
important and varied roles at different stages of normal B-cell differentiation. 
XBP-1s, as part of the physiological UPR is critical for plasma cell differentiation 
(Reimold et al., 1996) (Reimold et al., 2001) (Iwakoshi et al., 2003). In an 
analogous way B-cells also experience hypoxic microenvironments and HIF-1α 
stabilisation in normal physiology (Caldwell et al., 2001). HIF-1α is expressed in 
the microenvironments of the germinal centres (GCs) (Piovan et al., 2007), 
secondary lymphoid tissues and bone marrow (Parmar et al., 2007). In the GC 
environment HIF-1α has been shown to upregulate the chemokine receptor 
CXCR4 and its ligand CXCL12 (Ceradini et al., 2004). This is required for the 
correct homing of a circulating normal B-cell and can lead to metastasis in 
malignant cases. In fact PEL express CXCR4 on their surface and home to the 
CXCL12 expressing mesothelium; possibly giving rise to the body cavity based 
presentation of PEL (Foussat et al., 2001). Interestingly, XBP-1s has also been 
shown to be induced by B-cell receptor (BCR) cross linking; an event that 
occurs within the GC (Skalet et al., 2005). Additionally, HIF-1α deficient 
chimeric mice display a distortion in the number of B-2 lymphocytes in the bone 
marrow as well as an accumulation of peritoneal B-1 cells and autoimmunity 
(Kojima et al., 2002). This places HIF-1α and XBP-1s with a role in normal B-
cell biology as well as being usurped in reactivation of KSHV through shared 
response elements in the ORF50 promoter. It is possible that antigen stimulated 
cells of the HIF-1α-positive germinal centre provide the cues for the KSHV lytic 
cycle induction in primary infection; whereas terminal differentiation of B-cells to 
plasma cells at the activation of XBP-1 provide the lytic cues during life-long 
persistent oral shedding. 
 
The co-involvement of HIF-1α and XBP-1s may also be of significance in other 
herpesviruses. Epstein Barr virus (EBV), the most closely related human 
herpesvirus to KSHV, is also induced into its lytic cycle by hypoxic treatment 
(Figure 4-15) (Jiang et al., 2006). XBP-1s has also been implicated as an EBV 
lytic cycle inducer, although most likely in the presence of other co-activators 
such as protein kinase D (Bhende et al., 2007) (Sun and Thorley-Lawson, 2007) 
(McDonald et al., 2010). In the murine herpesvirus 4 (MuHV-4), a related 
Rhadinovirus, ORF50 is also upregulated in response to hypoxia (Polcicova et 
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al., 2008) although a response to XBP-1s has not been reported. Similar to 
KSHV LANA, the EBV latent membrane protein 1 (LMP-1) has been reported to 
upregulate HIF-1α (Kondo et al., 2006; Wakisaka et al., 2004). Together, these 
data suggest that gamma herpesviruses have evolved the ability to respond to 
cellular stress transcription factors and that these same factors are crucial for 
normal B-cell development, where their expression during differentiation may 
facilitate controlled KSHV lytic cycle activation. 
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5 Separating plasma cell differentiation from KSHV 
reactivation 
 
5.1 Introduction 
 
The interactions between virus and host are numerous and complex; however, 
certain cellular pathways are often manipulated by many viruses (Fossum et al., 
2009). These key pathways are crucial, usually enabling the virus to replicate 
and persist. The UPR is an example of a host response targeted by several 
viruses (see section 1.3). The manufacture of viral proteins increases the load 
on the host folding apparatus triggering ER-stress pathways. The ways in which 
viruses modify the UPR are not completely understood; in some cases viruses 
encode proteins to act directly for example, the human cytomegalovirus US11 
protein (He, 2006).  
 
The data in chapter 3 shows that KSHV reactivation is directly linked to the UPR 
via XBP-1s, and in chapter 4 we show that KSHV can also reactivate in 
response to hypoxia, another ER-stress inducing condition. Whether KSHV 
modulates the UPR during reactivation is unclear; however, from gene 
expression profiling of PEL cells latently infected with KSHV we can see that the 
UPR is only partially active in these cells (Jenner et al., 2003) (Klein et al., 
2003). This profile identifies PEL cells as plasmablast-like, representing a late 
stage of B-cell differentiation prior to plasma cells, having active ATF6 and 
unspliced XBP-1 (Jenner et al., 2003) (see sections 1.1.8.2 and 1.4.4). 
However,  IRE-1 is functional in PEL cells (Wilson et al., 2007) and therefore it 
is not clear whether another UPR defect, insufficient ER stress (van Anken et 
al., 2003) or latent KSHV is responsible for the lack of active XBP-1.  
 
As previously introduced, XBP-1 is essential for plasma cell differentiation to 
facilitate the production of vast amounts of antibody (Reimold et al., 2001) 
(Iwakoshi et al., 2003) (see section 1.4.4). PEL cells do not secrete 
immunoglobulin and many do not express surface immunoglobulin (Nador et al., 
1996). Supplying XBP-1s to PEL cells results in KSHV reactivation and 
importantly, the induction of gene expression changes relating to plasma cell 
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differentiation (Wilson et al., 2007) (Shaffer et al., 2004). The UPR that occurs 
during B-cell terminal differentiation or indeed the differentiation of any 
professional secretory cell can be termed ‘physiological UPR’ (Iwakoshi et al., 
2003) (see section 1.4.4). This specific UPR may be comprised of one or more 
branches of the pathway. However, the cellular changes involved provide the 
ideal environment of an expanded secretory system in the absence of 
translational arrest, for the production of herpes virions. KSHV reactivation and 
B-cell differentiation are therefore firmly connected. 
 
The aim of this chapter was therefore two-fold: firstly, to further understand the 
interactions between KSHV and its host cell during XBP-1s-induced reactivation 
and secondly, to explore the final stages of B-cell development, as PEL cells 
provide the correct transcriptional environment i.e. BCL-6- and BLIMP-1+ for 
this. However, plasma cell differentiation requires XBP-1s and we have 
established that this transcription factor leads to KSHV reactivation. We 
therefore needed to remove the impact of the reactivating virus in order to 
observe the changes that occur solely during plasma cell differentiation. This we 
attempted by preventing the reactivation of KSHV and supplying XBP-1s to PEL 
cells. KSHV lytic replication is dependent on the presence of the immediate 
early, RTA protein (Lukac et al., 1999) (Xu et al., 2005), in this chapter we 
therefore employ both shRNA and dominant negative techniques to target RTA 
and prevent KSHV reactivation.  
 
Gene expression changes resulting from XBP-1s expression in PEL cells that 
are unable to reactivate should represent changes that occur during the 
terminal differentiation of B-cells. Removing these differentially expressed 
genes from the changes seen when XBP-1s is supplied to PEL cells, with no 
block to reactivation, should provide information about the virus-host interface.  
 
 193
5.2 Results 
 
5.2.1 Characterisation of shRNA-RTA-expressing JSC-1 50P-2 cell line  
A short hairpin RNA was previously designed, by Sam Wilson, to target the 3’ 
region of RTA (Figure 5-1 B) and cloned into a lentivirus backbone. JSC-1 cells 
were transduced and selected, to generate stable shRNA-RTA-expressing 
clonal cell lines. RTA expression in response to TPA treatment of these cell 
lines was measured by staining and FACs analysis. The cell line JSC-1 50P-2 
was determined to have the lowest number of cells expressing RTA. Consistent 
with the accepted role of KSHV RTA, the block prevented subsequent lytic gene 
expression and virion production (Sam Wilson – unpublished data).  
 
Figure 5-1 Characterisation of shRNA-RTA-expressing JSC-1 50P-2 cell line 
(A) Western blot analysis of whole cell lysates of the KSHV negative cell line CRFK and the PEL 
cell lines, parental JSC-1 and JSC-1 stably expressing shRNA-RTA (JSC-1 50P-2); treated or 
untreated with 20 ng/µl TPA. Samples taken 48 hours after treatment are blotted with polyclonal 
rabbit anti-RTA. RTA is induced by TPA treatment of the parental JSC-1 cells only. β-actin acts 
as a loading control. (B) Sequence and probable structure of the shRNA targeting the 3’ region 
(73546 – 73569) of RTA mRNA. Numbering corresponds to KSHV genomic sequence (gi:  
18845965). (C) RT PCR amplification of RTA from the total mRNA of parental JSC-1 and JSC-1 
50P2 cells, untreated or treated with TPA.  Two ten-fold dilutions of cDNA are shown for each 
sample. Similar levels of RTA transcript are seen in the parental and shRNA-expressing JSC-1 
samples. RT PCR for GAPDH on the same RNA was used to normalise cDNA input and three 
ten-fold dilutions of cDNA are shown for each sample. 
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To ensure that shRNA-RTA expression is maintained, JSC-1 50P-2 cells were 
thawed and cultured under puromycin selection for one week. Parental JSC-1 
or JSC-1 50P-2 cells were then cultured in the presence of 20 ng/µl TPA 
overnight to induce the KSHV lytic cycle. 48 hours after treatment RTA 
expression was monitored by RT PCR and western blot analysis. No RTA 
protein was detected by western blot in the untreated or TPA treated JSC-1 
50P-2 cell line samples (Figure 5-1 A). In comparison an increase in RTA 
expression was seen in the parental JSC-1 cells in response to the lytic cycle 
inducer TPA, compared to untreated controls (Figure 5-1 A). However, semi-
quantitative RT PCR showed similar levels of RTA transcript in the TPA treated 
samples of both the parental and shRNA-RTA-expressing cell lines (Figure 5-1 
C). This data indicates that shRNA-RTA expression is maintained in the JSC-1 
50P-2 cells and acts to block RTA translation rather than induce transcript 
degradation.  
 
5.2.2 Exogenous XBP-1s induces KSHV lytic cycle in the presence of 
shRNA-RTA 
We have shown that KSHV reactivation and plasma cell differentiation are 
linked by the transcription factor XBP-1s; see chapter 3 (Wilson et al., 2007). 
We wanted to ascertain the interactions between virus and host when XBP-1s is 
supplied to PEL cells. In order to separate differentiation from reactivation we 
attempted to prevent XBP-1s-induced reactivation with shRNA targeting RTA. 
We, therefore, transduced shRNA-RTA-expressing JSC-1 50P-2 cells or the 
parental JSC-1 cells with XBP-1s-expressing lentivirus or empty control at an 
input equivalent to an MOI 5 on HEK 293-T cells. TPA treatment was 
performed, as above, as a control and the resulting KSHV lytic replication in 
each sample was monitored 48 hours later. RTA protein was expressed in both 
the TPA treated and XBP-1s-expressing JSC-1 parental cell samples as 
expected (Figure 5-2 A). As in section 5.2.1, RTA protein was not seen in TPA 
treated JSC-1 50P-2 cells; however, a weak band corresponding to RTA could 
be seen in the XBP-1s-expressing sample (Figure 5-2 A). The level of 
overexpressed XBP-1s in the parental cell line was similar to that of the shRNA-
RTA-expressing cell line, as determined by western blot (Figure 5-2 A). RTA 
protein was not detected in either cell line in the non-transduced samples, or 
samples transduced with empty vector control (Figure 5-2 A). 
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To confirm that the absence of RTA protein does prevent KSHV lytic cycle 
induction we analysed the expression of a spliced early lytic gene ORF29a/b by 
RT PCR. ORF29a/b transcript was present at low levels in parental JSC-1 cells 
transduced with empty vector control (Figure 5-2 B).  However, far higher levels 
of ORF29a/b mRNA were detected in the parental JSC-1 samples treated with 
TPA or transduced with XBP-1s (Figure 5-2 B). In the JSC-1 50P-2 samples 
ORF29a/b was only amplified from the sample transduced with XBP-1s (Figure 
5-2 B). This suggests that when RTA is absent in TPA treated JSC-1 50P-2 
cells KSHV lytic replication is not induced. Unfortunately, the shRNA-RTA 
expressed by the stable JSC-1 50P-2 cell line is not able to prevent reactivation 
in all cells in response to exogenous XBP-1s.  
 
Figure 5-2 JSC-1 50P-2 express RTA in response to exogenous XBP-1s 
(A) Whole cell lysate anti-RTA and XBP-1s western blot of parental JSC-1 cells and JSC-1 
stably expressing shRNA-RTA (JSC-1 50P-2) either non-transduced (Neg), transduced with 
empty vector (pIG) or XBP-1s-expressing vector (pXBPsIG) at an input equivalent to an MOI 5 
on HEK 293-T cells or treated with TPA. RTA is induced in the parental JSC-1 cells after TPA 
treatment and in XBP-1s-expressing samples.  Weak RTA expression is detected only in the 
JSC-1 50P-2 sample transduced with XBP-1s. XBP-1s is expressed to similar levels in both cell 
lines transduced with pXBPsIG. β-actin acts as a loading control. (B) Total cellular RNA was 
isolated from parallel cultures of the samples in A. RT PCR and gene specific primers for the 
spliced lytic transcript, ORF29a/b, were used to amplify a 300bp product from cDNA.  PCR 
product is seen in both TPA treated and XBP-1s-expressing parental JSC-1 samples. A slightly 
reduced level of ORF29a/b transcript is also seen in the JSC-1 50P-2 cells containing shRNA-
RTA transduced with XBP-1s.  RT PCR for β-actin on the same RNA was used to normalise 
cDNA input. 
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5.2.3 DTT treatment causes splicing of endogenous XBP-1 and cell death 
in JSC-1 cells 
It has previously been shown that DTT treatment of PEL cells causes XBP-1 
splicing (Wilson et al., 2007). We wanted to determine whether this endogenous 
level of XBP-1s would induce KSHV reactivation in PEL, which could then be 
blocked by shRNA targeted to RTA. We therefore cultured parental JSC-1 and 
the shRNA-RTA-expressing JSC-1 50P-2 in the presence of 3 mM DTT for 
1 hour. At this point samples were taken to monitor XBP-1s splice status by 
RT PCR. Similar levels of increased XBP-1 spliced transcript were present in 
both the parental JSC-1 and the JSC-1 50P-2 cell lines compared to untreated 
controls (Figure 5-3 A). 48 hours after the 1 hour DTT treatment, samples were 
taken to monitor KSHV reactivation by RT PCR for the spliced lytic transcript of 
ORF29a/b. DTT led to significant cell death 4-6 hours after treatment of both the 
parental JSC-1 and the JSC-1 50P-2 cell lines. Lytic transcript was therefore 
only detected in the positive control TPA treated sample of the parental JSC-1 
cell line (Figure 5-3 B). DTT therefore cannot be used to investigate the ability 
of endogenous XBP-1s to activate KSHV RTA expression in response to ER-
stress in JSC-1 cells. Therefore, we attempted to remove the residual RTA 
activity in JSC-1 50P2 cells.  
 
Figure 5-3 JSC-1 cell response to DTT 
(A) RT PCR amplification across the XBP-1 intron produces a 249 base pair amplicon from 
XBP-1u mRNA and a 223 base amplicon from XBP-s mRNA. Pst I digests only the XBP-1u 
amplicon resulting in two bands, whereas XBP-1s results in a single band (Wilson et al., 2007). 
RT PCR amplification from the total mRNA parental JSC-1 cells and JSC-1 stably expressing 
shRNA-RTA (JSC-1 50P-2) treated or untreated with 3 mM DTT shows that XBP-1s is produced 
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after 1 hour treatment. XBP-1 remains unspliced in samples not treated with DTT. In the DTT 
treated samples a slower-migrating non-Pst I digestible PCR hybrid between the XBP-1s and 
XBP-1u products is visible similar to previously described (Wilson et al., 2007). β-actin on the 
same RNA was used to normalise cDNA input (data not shown). (B) A 300bp product was 
amplified from RNA samples taken 48 hours after DTT treatment with gene specific primers for 
the spliced lytic transcript, ORF29a/b.  PCR product is seen only in the parental JSC-1 samples 
after TPA treatment. ORF29a/b transcript is not seen in the DTT treated XBP-1s-positive 
samples as this treatment was toxic after 4-6 hours.  RT PCR for β actin on the same RNA was 
used to normalise cDNA input (data not shown). 
 
5.2.4 Generating a dominant negative form of RTA 
The KSHV RTA protein contains a potent carboxy-terminal transactivation 
domain (Figure 5-4 A). A truncated mutant created by deletion of the C-terminal 
161 amino acids of RTA, does not cause transcriptional activation (Lukac et al., 
1999).  Through multimerisation with wild-type RTA the C-terminally truncated 
RTA functions as an RTA specific dominant negative inhibitor of transactivation 
(Bu et al., 2007). Since shRNA targeted to RTA was unable to completely block 
KSHV reactivation induced by ectopic XBP-1s we wanted to determine if a 
dominant negative RTA could be used instead. We therefore designed primers 
to PCR the first 530 amino acids of RTA, and that would add a nuclear 
localisation signal to the C-terminus of these amino acids (Figure 5-4 B). PCR 
amplification, using wild-type RTA as a template, provided a truncated 
fragment. This was cloned into a HA-tagged lentivirus vector (see materials and 
methods 2.4.5.6) and transduced into HEK 293T cells where it was detectably 
expressed at a lower molecular weight to full-length RTA (data not shown).  
 
Figure 5-4 Generating a dominant negative form of RTA 
(A) Domain map of full-length ORF50/RTA, depicting structural and functional regions. 
Numbering refers to amino acid positions. Abbreviations: NLS, Nuclear localisation sequence. 
(B) Deletion of the RTA activation domain results in a dominant negative. Schematic 
representing the carboxy-terminal truncated dominant negative RTA.  
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5.2.4.1 Dominant negative RTA can reduce transactivation of the RTA 
promoter by full-length RTA 
We used a luciferase reporter assay to examine the ability of the mutant, 
dominant negative RTA to interfere with the activity of wild-type RTA. A full-
length RTA promoter luciferase construct (p50LUC) was co-transfected into 
HeLa cells with equal amounts of either wild-type RTA alone or in combination 
with dominant negative RTA- or a GFP-expressing control plasmid. The 
luciferase activity obtained from transactivation by wild-type RTA alone was 
taken as 100 % activation of the system (Figure 5-5). Co-expression of a control 
plasmid in addition to wild-type RTA led to a slight reduction in this activity 
(Figure 5-5). However, expression of dominant negative RTA with wild-type 
RTA reduced luciferase activity by around 50 % (Figure 5-5). Therefore, the C-
terminal truncated RTA mutant generated inhibits the transactivation ability of 
wild-type RTA when expressed at the same time as full-length RTA and in equal 
amounts.  
 
Figure 5-5 Dominant negative RTA activity 
HeLa cells were transfected with a Renilla-expressing control plasmid (phRL-null) plus the 
ORF50 promoter Firefly luciferase reporter plasmid (p50LUC) with either wild-type RTA 
(pCMVRTA) alone or in combination with vector expressing GFP control (pSIN-GFP) or 
expressing dominant negative RTA (pSIN-DNRTA). Firefly luciferase activity was determined 48 
hours post-transfection and normalised to Renilla luciferase (phRL-null) activity. Wild-type RTA 
was able to transactivate the RTA promoter and luciferase expression. The activity of full-length 
RTA on the promoter was plotted as 100%. GFP co-expression reduced the activity of full-
length RTA minimally. However, the presence of dominant negative RTA reduced this activity to 
approximately 50 % (p<0.05 95% CFI). Columns represent the mean of three independent 
experiments and error bars represent standard error of the mean. 
 
5.2.4.2 Dominant negative RTA is unable to block DTT-induced 
rKSHV.219 reactivation in Clone 5 cells 
To test the ability of dominant negative RTA to block the activity of endogenous 
RTA we used rKSHV.219 HEK 293T, Clone 5 cells.  We have previously shown 
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that DTT treatment of these cells induces XBP-1s and KSHV reactivation which 
is dependent on RTA; see section 3.2.5. We therefore transfected Clone 5 cells 
with 8 µg of lentivirus vector expressing dominant negative RTA- or GFP-
expressing control. After 48 hours cells were treated with 3 mM DTT or 
remained untreated overnight. Following a further 48 hours, cells were sampled 
for western blot and RT PCR analysis of the KSHV lytic cycle. The level of 
DsRed-positive cells increased in all DTT treated samples to similar levels (data 
not shown). Full-length RTA protein was detectable in all Clone 5 cell samples 
treated with DTT, and was not seen in untreated samples (Figure 5-6 A). Similar 
levels of dominant negative RTA were present in both untreated and DTT 
treated samples (Figure 5-6 A).  
 
Figure 5-6 DTT treatment of Clone 5 cells expressing dominant negative RTA 
(A) Anti-RTA western blot of the Clone 5 whole cell lysates either untransfected (Neg), 
transfected with 8 µg GFP-expressing vector (pSIN-GFP) or 8 µg dominant negative expressing 
vector (pSIN-DNRTA); left untreated or treated overnight with 3 mM DTT. Full-length RTA 
protein was detected only in DTT treated samples indicating KSHV reactivation in these 
samples. The expression of dominant negative RTA can be seen running at a lower molecular 
weight than full-length RTA in all samples transfected with pSIN- DNRTA. β-actin acts as a 
loading control. (B) Total cellular RNA was isolated from parallel cultures of the samples in A. 
RT PCR and gene specific primers for the spliced lytic transcript, ORF29a/b, were used to 
amplify a 300bp product from cDNA. PCR product is seen in all DTT treated Clone 5 cell 
samples including the sample expressing dominant negative RTA.  RT PCR for β-actin on the 
same RNA was used to normalise cDNA input. 
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If the dominant negative is acting to inhibit the action of RTA then the KSHV 
lytic cycle should be blocked. We therefore looked by RT PCR for the spliced 
lytic transcript ORF29a/b after DTT treatment of Clone 5 cells in the presence of 
dominant negative RTA. The semi-quantitative PCR revealed similar levels of 
lytic transcript in the untransfected and dominant negative RTA transfected 
samples (Figure 5-6 B). Slightly higher levels of ORF29a/b were seen in the 
GFP-expressing Clone 5 cells (Figure 5-6 B). These results suggest that 
overexpression of dominant negative RTA is not able to block KSHV 
reactivation in response to DTT in rKSHV.219 HEK 293T cells.  
 
5.2.4.3 Exogenous XBP-1s induces KSHV lytic cycle in JSC-1 expressing 
dominant negative RTA 
 
Figure 5-7 XBP-1s overexpression in JSC-1 cells expressing dominant negative RTA 
(A) Whole cell lysate anti-RTA and XBP-1s western blot of JSC-1 cells either transduced with 
empty vector (pDUAL-Cherry) or dominant negative-expressing vector (pDUAL-DNRTA-Cherry) 
at an input equivalent to a MOI 5 on HEK 293-T cells, in combination with either empty vector 
(pDUAL-Cherry) or XBP-1s-expressing vector (pDUAL-XBP-1s-Cherry) at an input equivalent to 
a MOI 2 on HEK 293-T cells. RTA is induced in the XBP-1s-expressing samples regardless of 
the presence of dominant negative RTA, which can be seen at a lower molecular weight. β-actin 
acts as a loading control. (B) Total cellular RNA was isolated from parallel cultures of the 
samples in A. RT PCR and gene specific primers for the spliced lytic transcript, ORF29a/b, were 
used to amplify a 300bp product from cDNA.  A feint band of ORF29a/b transcript is also seen 
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in the samples transduced with pDUAL-Cherry. However, a strong PCR product is seen in both 
XBP-1s-expressing JSC-1 samples including cells expressing dominant negative RTA.  RT PCR 
for β-actin on the same RNA was used to normalise cDNA input. 
 
We wanted to assess the ability of dominant negative RTA to prevent 
reactivation in the PEL cell model. JSC-1 cells were transduced with an empty 
or dominant negative RTA-expressing lentivirus at an input equivalent to an 
MOI 5 on HEK 293-T cells, in combination with either empty or XBP-1s-
expressing lentivirus at an input equivalent to a MOI 2 on HEK 293-T cells. After 
48 hours western blot analysis confirmed that ectopic expression of XBP-1s in 
JSC-1 cells induces RTA expression in the presence or absence of dominant 
negative RTA (Figure 5-7 A). It should be noted however that the dominant 
negative RTA was expressed at lower levels in JSC-1 cells.  
 
RT PCR for the lytic gene ORF29a/b revealed transcript at levels comparable to 
TPA-induced reactivation in all samples expressing XBP-1s (Figure 5-7 B and 
data not shown). The dominant negative RTA generated by truncation of the 
full-length RTA, is unable to inhibit the reactivation caused by the presence of 
exogenous XBP-1s in JSC-1 cells.  
 
5.2.5 Separating plasma cell differentiation from KSHV reactivation using 
gene expression profiling 
We have so far determined that although shRNA-RTA can effectively block 
KSHV reactivation by the known inducer TPA, it cannot stop the induction of the 
lytic cycle by XBP-1s. The dominant negative RTA generated can inhibit the 
transactivation of the ORF50 promoter by full-length RTA, but is unable to 
prevent reactivation in response to XBP-1s. We therefore do not have a method 
for comparing XBP-1s in PEL cells to PEL cells blocked for RTA activity and 
KSHV lytic cycle. As an alternative we used a KSHV negative cell line that 
resembles a post germinal centre stage of B-cell development, DEL, as the 
control cell line.   
 
Tumours are known to resemble the cell-type from which they arise, which is 
particularly true of B-cell lymphomas that can be classified by morphology, 
immunophenotypes and Ig gene sequences (Kuppers et al., 1999) (see section 
1.4.5). Recent analysis of the gene expression profiles of a range of B-cell 
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lymphoma cell lines demonstrated clustering that depends on the type of 
tumour and stage of B-cell development they derive from (Jenner et al., 2003). 
A major branch point was shown to separate pre-GC and GC-B-cells from post 
GC derived cells, which is further divided into PEL and plasma cells. One of the 
shortest tree distances joins DEL cells, in the post-GC branch of this major 
cluster, to the next branch composed of PEL cells, which are of a plasmablast 
origin (Jenner et al., 2003). This analysis indicates that the gene expression 
profile of DEL is closely related to PEL, second only to plasma cells. Therefore, 
the KSHV negative cell line DEL was used in this experiment as an alternative 
to preventing lytic replication in JSC-1 cells. Comparison with JSC-1 cells acts 
as a control for the effect of KSHV because the response of DEL cells should 
be similar to that of the closely related PEL cells. 
 
2.5x105 JSC-1 or DEL cells were transduced in triplicate experiments with 
pDUAL-XBP-1s-Cherry or pDUAL-Cherry lentivirus at an input equivalent to a 
MOI 8 (as determined on HEK 293-T cells). Previous studies have shown that 
gene expression profiles of empty vector controls are indistinguishable from that 
of untransduced controls (Wilson et al., 2007). 6 hours post-transduction the 
cells were washed once and resuspended in fresh medium. 72 hours post-
transduction, the cells were pelleted and resuspended in TRIzol reagent.  Total 
RNA was purified from all samples and the quality and quantity assessed using 
an Agilent bioanalyzer. From this, mRNA was labelled according to the 
materials and methods (see section 2.11.2). Labelled cDNA was mixed with 
Cy3-labelled reference RNA and hybridised to the Agilent Whole Human 
Genome Oligo Microarrays. A common reference RNA mixture was used to 
enable comparison across the whole sample set.  Array analysis was performed 
in collaboration with Dan Frampton.  
 
To identify the changes in gene expression in response to XBP-1s expression in 
JSC-1 and DEL, the M- (expression ratio of sample/reference) and A- 
(expression level of sample gene) values were calculated for the full dataset of 
12 arrays after applying background correction and scale-normalisation using R 
and BioConductor (Gentleman et al., 2004).  Using the BioConductor Limma 
package a linear model was created using cell type (JSC-1 or DEL) and XBP-1s 
(overexpressed or empty vector) as factors (Smyth, 2005).  By creating 
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appropriate design and contrast matrices, an empirical Bayes method was used 
to construct a list of 687 genes found to be significantly differentially expressed. 
Of these genes 556 were upregulated and 131 were downregulated in response 
to overexpression of XBP-1s in both cell types (Benjamini-Hochberg adjusted p-
value < 0.05) (Figure 5-8). Probes with mean intensities across all samples less 
than twice the background level were removed (1/2log2RG< 7), as they were 
close to background noise levels.  
 
To identify JSC-1-specific changes in gene expression, a similar analysis was 
performed using the 6 JSC-1 arrays (3 wild-type samples and 3 expressing-
XBP-1s) and a second gene list created. Those genes found in both lists or only 
the first were cell type independent and classified as ‘XBP1-responsive’ genes.  
366 differentially expressed genes were found solely in the second list and were 
classified as ‘JSC-1-specific’ genes. These genes could represent cell type 
dependent gene expression responses to XBP-1s or changes caused by XBP-
1s-induced KSHV lytic replication (Figure 5-9). Both the ‘XBP-1 responsive’ 
genes represented by the first list and the remaining ‘JSC-1 specific’ genes from 
the second list were split into up- and downregulated genes and analysed for 
functional enrichment using the online DAVID database, applying a Benjamini-
Hochberg adjusted p-value cut-off of 0.05 as before; see section 3.2.6 (Huang 
da et al., 2009) (Dennis et al., 2003). 
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Figure 5-8 Gene expression changes in response to XBP-1s 
Heatmap of significantly over-represented functional groups; consisting of upregulated or 
downregulated genes in both DEL and JSC-1 cells in response to XBP-1s overexpression. Each 
column represents one sample and each row one gene. Gene expression is shown as a 
pseudo-coloured representation of log(2) expression ratio with yellow being above and blue 
below the row/column median level of expression (set to 0) as shown by the scale. DAVID was 
used to annotate the genes into broad functional groups colour coded to right of heatmap.  
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Figure 5-9 JSC-1 cell dependent gene expression changes in response to XBP-1s 
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Heatmap of significantly over-represented functional groups consisting of upregulated or 
downregulated genes found only in the JSC-1 cell response to XBP-1s overexpression. Each 
column represents one sample and each row one gene. Gene expression is shown as a 
pseudo-coloured representation of log(2) expression ratio with yellow being above and blue 
below the row/column median level of expression (set to 0) as shown by the scale. DAVID was 
used to annotate the genes into broad functional groups colour coded to right of heatmap.  
 
Functional over-representation analysis of those genes significantly up- or 
downregulated in the comparison of XBP-1s overexpressing JSC-1 or DEL cells 
yielded 8 major significant annotation clusters including 229 genes; with 218 of 
those genes being upregulated and many belonging to more than one functional 
group (see Figure 5-8). Unsurprisingly, due to the known function of XBP-1s in 
the UPR; see section 1.3.3.1, the functions of these over-represented groups 
were related to the ER – 135 genes, Golgi – 79 genes, protein transport – 136 
genes, protein folding – 27 genes, cell redox homeostasis – 16 genes, among 
others shown on the heatmap (Figure 5-8). The majority of these genes are 
involved in the secretory pathway and are important for preparing the cell for the 
production of large amounts of protein. These include genes encoding for 
proteins involved in targeting protein to the ER, the signal recognition proteins 
(SRPs) -19, -54 and -72. Proteins that are important for the next step of the 
secretory pathway, translocation of ER-targeted protein across the ER 
membrane into the lumen, are also upregulated including; signal sequence 
receptors (SSRs), SPR receptors, translocation associated membrane protein 
(TRAM1) as well as KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor-2 (KDELR2). Signal peptidase complexes (SPCs) are also 
found to be upregulated; these are required to cleave the signal peptide 
sequence from translocated proteins. A vast proportion of the genes shown to 
be upregulated in this comparison encode proteins required for protein folding in 
the ER including; several DnaJ/Hsp40-like proteins (DnaJb9, DnaJb11, 
DnaJc3), Hspa5/BiP, ERprotein44 (TXNDC4), FK506 binding protein-2 
(FKBP2), peptidylprolyl isomerase B (PPIB), protein disulfide isomerase-
associated-5 (PDIA5), ER oxidoreductins (ERO-1LB) as well as the hypoxia 
upregulated-1 (HYOU1) protein. Genes involved in the removal of misfolded 
protein from the ER by degradation pathways were also found including; ER 
degradation enhancer, mannosidase alpha-like-1 (EDEM), cAMP responsive 
element binding protein - 3 (CREB3) and homocysteine-inducible, endoplasmic 
reticulum stress-inducible ubiquitin-like domain member-1 (HERPUD1). 
Glycosylation is an important post-translation modification required by many 
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proteins for complete maturation and exit from the ER; for this reason several 
genes involved in glycosylation were upregulated in response to XBP-1 
overexpression. These include members of the solute carrier family, dolichyl-
diphosphooligosaccharide-protein glycosyltransferase (DDOST), mannosidase 
(MAN1A2) and ribophorin-I (RPN1). The remaining group of genes found to be 
induced by XBP-1 overexpression were those involved in ER-Golgi or 
endosomal trafficking which includes; members of the SEC24 related gene 
family, golgi transport-1 homolog B (GOLT1B), archain-1 (ARCN1), vesicle 
docking protein p115 (VDP), golgi SNAP receptor complex member-2 
(GOSR2), coatomer protein complex, subunit epsilon (COPE), golgi reassembly 
stacking protein-2 (GORASP2), pallidin homolog (PLDN), golgi autoantigen 
(GOLGB1), lectin, mannose-binding-1 (LMAN1) and member RAS oncogene 
family (RAB1A). 
 
Several genes including DnaJc3 (P58IPK), DnaJb9 (ERdj4), DnaJb11 (HEDJ), 
EDEM, protein disulfide isomerases, and SERP-1 (RAMP4) were previously 
shown to be directly upregulated by XBP-1, and contribute to the general 
transcriptional changes seen when XBP-1 is supplied to fibroblasts or 
plasmablast like cells (Lee et al., 2003b) (Sriburi et al., 2007) (Wilson et al., 
2007). This consistency with our data suggests that here we are observing 
typical XBP-1 response at the level of the whole transcriptome.  Many of these 
genes were also identified during a similar study where gene expression 
changes of the cell line Raji were monitored in response to XBP-1s (Shaffer et 
al., 2004). This study also examined the gene expression profile of wild-type 
mature mouse B-cells in contrast with XBP-1 and BLIMP-1 deficient cells 
stimulated to differentiate by lipopolysaccharide (LPS) treatment. This 
confirmed that the changes seen due to ectopic expression of XBP-1s are 
comparable to the differentiation seen in response to a physiological trigger of 
B-cell terminal differentiation (Shaffer et al., 2004). Further study is required to 
determine if PEL and DEL cells overexpressing XBP-1s do become more 
‘plasma cell like’. An increase in size and granularity of the cells was observed 
by FACs analysis, seen previously by Wilson et.al. (data not shown) (Wilson et 
al., 2007). However, further tests such as those carried out by Shaffer et.al. on 
Raji cells supplied with XBP-1s, including staining of the ER and measuring 
mitochondrial respiration, would aid further characterisation of cell phenotype 
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(Shaffer et al., 2004). Whether all the genes identified in this study are directly 
regulated by XBP-1s and the precise temporal regulation of gene expression 
will also require further study. 
 
Although the genes identified by the DEL/JSC-1, XBP-1s overexpression 
comparison are dominated by those genes involved in the secretory pathway 
several genes that, so far, have not been implicated directly in the response to 
ER stress were also shown to be upregulated. These genes include 
glutaredoxin (GLRX), a thioltransferase dehydrogenase/reductase (SDR family) 
member-1 (DHOURS1) and the cyclin-dependent kinase inhibitor-1B (p27, 
Kip1). GLRX is an enzyme that catalyses deglutathionylation, a post-
translational modification, which depends on the oxidative environment of the 
cell, and is important for sulfhydryl homeostasis and signal transduction 
(Gallogly and Mieyal, 2007). DHOURS1 is a member of a large protein family of 
NAD(P)(H)-dependent oxidoreductases and is therefore also involved in 
maintaining redox homeostasis (Wu et al., 2001b). Recently, a novel role for 
XBP-1 in the cellular response to oxidative stress has been reported, 
suggesting that these genes may be directly regulated by XBP-1 (Liu et al., 
2009). XBP-1 dependent upregulation of the cell-cycle inhibitor p27 has not 
been reported; however, a reduction of p27 levels is associated with B-cell 
activation, which is then restored during the G1 cell-cycle arrest associated with 
B-cell terminal differentiation (reviewed in (Chen-Kiang, 2003)). PEL cells are 
also known to have a high level of p27 (see section 1.1.12.3). The identification 
of genes with no characterised role in the UPR and plasma cell differentiation 
indicates the potential for conserved functions of XBP-1s outside of the 
secretory pathway as suggested by a recent study by Acosta-Alvear and 
colleagues. In this study XBP-1s was shown to regulate, alongside its core 
group of ER function genes, genes involved in myogenesis as well as DNA 
damage and repair pathways; via a range of different sequence motifs (Acosta-
Alvear et al., 2007).   
 
A relatively small number of genes were downregulated in response to the 
expression of XBP-1s in both JSC-1 and DEL cells; this was to be expected as 
spliced XBP-1 is known to function as a transcriptional activator. Of the genes 
that were downregulated insulin receptor substrate (IRS1) was identified, this 
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may be linked to the repression of insulin signalling and increased insulin 
resistance associated with ER-stress (Ozcan et al., 2004).  
 
Of those genes found to be significantly differentially expressed only in the JSC-
1 comparison, 146 genes were upregulated and 220 were downregulated in a 
cell-type dependent manner. 94 of these genes, that may represent cellular 
genes modified by KSHV lytic gene expression in response to XBP-1 
expression, were present in significant functionally enriched groups (see Figure 
5-9). These groups were concerned functionally with the nucleus – 84 genes, 
chromatin assembly – 19 genes, DNA binding – 22 genes, citrullination (a 
common histone modification) – 10 genes and the cell cycle – 28 genes.  
 
Due to the reported activity of the KSHV encoded SOX (shut off and 
endonuclease), a rapid and extensive shut off of host protein production is 
expected during KSHV lytic replication (Glaunsinger et al., 2005) (Glaunsinger 
and Ganem, 2004b). However, further microarray studies have since revealed 
that selective host transcripts can avoid SOX mediated degradation 
(Glaunsinger and Ganem, 2004a) (Chandriani and Ganem, 2007). In this study 
a dramatic downregulation of host transcripts is not seen and we believe this 
maybe due to the context of KSHV lytic replication. This appropriate induction of 
the KSHV lytic cycle in the B-cell environment does not result in the same 
extensive downregulation of host gene expression seen in the KSHV infection 
of TIME cells, although some similarities are seen (Chandriani and Ganem, 
2007). This may be due to the activation of KSHV lytic replication, from latency, 
in the highly adapted and specialised environment of the plasma cell. In this 
physiologically relevant situation many of the transcripts are associated with ER 
stress and are refractory to translational arrest; potentially providing resistant to 
SOX degradation. In fact one of the genes shown to be upregulated in JSC-1 
cells by XBP-1s-induced KSHV reactivation is the stress inducible cold inducible 
RNA binding protein (CIRBP). This protein is induced in response to a variety of 
cellular stresses, including hypoxia, and is important in promoting translation 
and stabilisation of mRNA; possibly providing a mechanism by which host 
transcripts can avoid SOX degradation (Lleonart, 2010). Further investigation 
into how KSHV moderates the host shut off to allow the accumulation of viral 
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transcripts is also required, and may indicate a potential mechanism for host 
transcript escape.  
 
Interferon inducible transcripts 2',5'-oligoadenylate synthetase 1 (OAS1) and 
tripartite motif-containing protein 32 (TRIM 32) were also upregulated in the 
JSC-1 expressing XBP-1s analysis. Selective interferon induced genes were 
shown to escape SOX-mediated shut off in previous studies (Chandriani and 
Ganem, 2007). These genes in the absence of XBP-1s were already more 
highly expressed in JSC-1 cells compared to DEL; possibly because of the 
presence of KSHV in JSC-1 cells.  
 
The dual specificity phosphatase-16 (DUSP-16) gene was also identified here 
as an upregulated gene during XBP-1s-induced KSHV reactivation in JSC-1.  
Previously, a related family member DUSP-5 was shown to be upregulated by 
KSHV lytic replication and evade SOX degradation (Chandriani and Ganem, 
2007). This gene family is involved in the regulation of MAPK signalling, and 
members were identified earlier in this thesis as potential repressors of KSHV 
lytic replication by inhibiting JNK and p38 activity (see chapter 3 – reviewed in 
(Keyse, 2008)). The potential repressive action of DUSP-16 on reactivation is 
evident here due to an observed downregulation of the AP-1 pathway. Several 
of the AP-1 constituent proteins Jun, JunB, JunD, FOS and Maf are 
downregulated in response to XBP-1s overexpression in JSC-1 cells, as well as 
the stress inducible activator of the JNK pathway the growth arrest and DNA-
damage-inducible- 45 beta (GADD45B) (Lopez-Bergami et al., 2010) 
(Liebermann and Hoffman, 2008) . During plasma cell development BLIMP-1 is 
known to upregulate the expression of pro-apoptotic GADD45, and plasma cells 
undergo rapid apoptosis if the correct survival signals are not provided 
(reviewed in (Shapiro-Shelef and Calame, 2005)). The control of the pro-
apoptotic function of JUN is cell-type dependent, specific to the JUN binding 
partners available, and can be affected by both internal and external stimuli; 
including mitogenic and stress signals (reviewed in (Lopez-Bergami et al., 
2010)). Therefore, the proposed downregulation of a potential apoptotic 
pathway during KSHV reactivation in differentiating B-cells suggested by the 
data presented here; indicates a potential mechanism for KSHV to maintain cell 
survival. The lytic protein vGPCR is associated with inducing cell proliferation 
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and oncogenesis is also known to activate the JNK pathway and induce 
transcription from AP-1 containing promoters (Bais et al., 1998) (Arvanitakis et 
al., 1997). Despite this, the highly controlled AP1 pathway terminal effector 
molecules are significantly downregulated in this analysis; possibly by the direct 
action of KSHV lytic replication in the environment of plasma cell differentiation, 
this therefore warrants further investigation.  
 
Active JUN is also involved in the transcription of genes that regulate the cell 
cycle including cyclins D, A and E, but also cell cycle inhibitors. KSHV encodes 
a viral homologue of cyclin D during latency in order to drive cell proliferation 
(see section 1.1.12.3). During lytic replication the viral protein K-bZIP induces 
cell cycle arrest at the G1/S boundary, via upregulation of p21 and inhibition of 
both E2F proteins and cdk2/cyclinA/E complexes (Wu et al., 2003) (Izumiya et 
al., 2003b) (see section 1.1.13). However, this may also depend on the 
proliferation state of the host cell; for example, as B-cells terminally differentiate 
into plasma cells they enter G1-arrest and no longer divide (reviewed in (Chen-
Kiang, 2003)). BLIMP-1 is known to downregulate the transcription factor E2F-
1, which plays a major role in G1/S transition. Previous studies have shown that 
BCBL-1 cells synchronised in S-phase led to increased virus production when 
stimulated by TPA compared to non-synchronised cells (McAllister et al., 2005). 
This study suggests that the cell cycle is important in KSHV lytic replication and 
may be a particular target for viral lytic products. XBP-1s-induced reactivation of 
KSHV in JSC-1 cells led to a decrease in expression of two members of the 
E2F gene family (E2F2 and E2F7) as well as cyclin E (CCNE), suggesting a cell 
cycle block in G1 that is not seen in DEL cells. It would be interesting to 
investigate further the role of KSHV in manipulating the cell cycle during 
reactivation in PEL cells.  
 
Related to this, the largest group of genes shown to be downregulated in JSC-1 
cells expressing XBP-1s was the histone gene family. Histones are required 
during S-phase to package newly synthesised DNA into nucleosomes, the 
expression of histones are temporally restricted to the G1/S phase transition 
(reviewed in (Stein et al., 2006)). The alteration of chromatin structure has been 
identified as an important event in regulating KSHV gene expression and 
replication (reviewed in (Pantry and Medveczky, 2009)). However, this is 
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focused around epigenetic modification of histones for example histone 
acetylation which facilitates KSHV reactivation. Nucleosome positioning can 
also be altered and is required for KSHV genome replication. The depletion of 
histones as a mechanism of KSHV gene expression control has not been 
reported, however, our analysis indicates a possible KSHV or JSC-1 specific 
downregulation of histone encoding genes in response to XBP-1s 
overexpression.  
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5.3 Discussion 
 
The aim of this investigation is to further understand the interactions between 
KSHV and the host cell during XBP-1s-induced reactivation, and secondly to 
explore the final stages of B-cell development. This, however, involved 
separating the two events that occur when XBP-1s is supplied to PEL cells, 
namely, plasma cell differentiation and KSHV lytic replication. The results 
obtained in this chapter have demonstrated that preventing RTA driven KSHV 
lytic replication is challenging and requires further development.  
 
To dissect the role of KSHV lytic replication in PEL cells supplied with XBP-1s 
we attempted to block reactivation by targeting RTA. Previous studies had 
developed a JSC-1 cell line stably expressing shRNA-RTA that following TPA-
treatment displayed an 80 % reduction in the population of cells expressing 
RTA.  In this study we confirmed, by western blot analysis, that after TPA 
treatment detectable levels of RTA protein were not seen in JSC-1 cells 
expressing shRNA-RTA targeted to an invariant region of RTA sequence (JSC-
1 50P-2 cells). By RT PCR analysis of the RTA transcript we showed that this 
shRNA acts as a miRNA, to block translation, and the JSC-1 50P-2 clonal cell 
line has maintained KSHV infection. RTA transcript in both JSC-1 and JSC-1 
50P-2 cells is, as expected, was upregulated in response to TPA treatment, 
however, RTA protein is only detected in the absence of shRNA-RTA (see 
Figure 5-1).  
 
This study requires RTA activity to be blocked in response to the physiological 
induction of KSHV reactivation by XBP-1s (Wilson et al., 2007). When XBP-1s 
was overexpressed in JSC-1 50P-2 cells a low level of RTA protein was 
detected by western blot. This is in contrast to the complete block to RTA 
production seen in JSC-1 50P-2 cells treated with TPA (see Figure 5-2 A). The 
ability of XBP-1s but not TPA to induce RTA expression in JSC-1 50P-2 cells is 
interesting, and the reasons for this are unclear. In chapter 3 we demonstrated 
that XBP-1s is able to directly bind to and transactivate the RTA promoter, 
whereas TPA induction occurs via the indirect action of PKC and the AP-1 
pathway (see section 1.1.14) (Dalton-Griffin et al., 2009). XBP-1s induction of 
KSHV reactivation therefore appears to be more efficient. Despite low levels of 
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RTA protein seen in XBP-1s-expressing JSC-1 50P-2 cells, semi-quantitative 
RT PCR analysis of ORF29a/b indicates that the lytic replication seen in both 
JSC-1 and JSC-1 50P-2 is at similar levels (see Figure 5-2 B).  Therefore, the 
shRNA-RTA-expressing PEL cell line system could not be used to investigate 
the action of XBP-1s in PEL in the absence of KSHV reactivation.  
 
We were unable to determine whether shRNA-RTA could prevent reactivation in 
response to endogenous levels of XBP-1s due to the hypersensitivity of PEL to 
DTT treatment. PEL cells have a partially active ‘physiological’ UPR, however 
when this system is overwhelmed by the accumulation of large amounts of 
unfolded protein due to DTT or the proteasome inhibitor, bortezomib, cell death 
is induced (An et al., 2004). This analysis confirmed that XBP-1 is spliced in 
both PEL cell lines in response to DTT, however, this out of context activation  
cannot prevent cell death (see Figure 5-3) (Wilson et al., 2007).  
 
Results obtained using the JSC-1 50P-2 cell line revealed that it was unsuitable 
for this study, as XBP-1s retains its ability to reactivate KSHV in the presence of 
shRNA-RTA. We therefore, attempted to develop and characterise a dominant 
negative form of RTA, described previously (Lukac et al., 1999). Although, 
expression of C-terminally truncated dominant negative RTA protein was able to 
reduce activity of full-length RTA in luciferase assay studies (see Figure 5-5), it 
could not prevent XBP-1s-mediated induction of the KSHV lytic cycle in either 
Clone 5 or JSC-1 cells (see Figure 5-6 B and Figure 5-7 B). These results 
indicate that the dominant negative RTA created is functional and able to inhibit 
RTA promoter transactivation by full-length RTA; however, this effect is not 
seen in KSHV infected systems. This is possibly due to the absence of RTA 
auto-regulation in the luciferase assay system. In this assay the amount of full-
length and truncated RTA are equal and limited by the transfected input DNA. 
At this ratio, the dominant negative protein is able to either hetero-multimerise 
with the full-length RTA preventing its activity or homo-multimerise and 
effectively out-compete wild-type RTA for promoter binding (Lukac et al., 1999) 
(Bu et al., 2007). However, in Clone 5 or JSC-1 cells insufficient dominant 
negative RTA can be supplied to counteract the large amounts of RTA 
produced on induction, due to the positive feedback regulation of the ORF50 
promoter. Unfortunately, the target sequence of the shRNA-RTA is present in 
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the dominant negative truncated form of RTA; therefore, analysis of the 
combined approaches on preventing KSHV reactivation could not be assessed.  
 
We therefore pursued the comparison of the response to XBP-1s 
overexpression in the non-infected cell line DEL with that of KSHV infected PEL 
cells. This revealed a common gene list, with functions predominantly 
concerned with the secretory pathway (see Figure 5-8). This was expected due 
to the already well defined role for XBP-1 in preparing the cell for high-level 
immunoglobulin secretion during plasma cell development; see section 1.4.4 
(Reimold et al., 2001) (Lee et al., 2003b) (Yoshida et al., 2003) (Shaffer et al., 
2004). Interestingly, the upregulation of DnaJc3 (P58IPK) is observed in both 
DEL and JSC-1 cells. This gene encodes an inhibitor of PERK and potentially 
explains how the UPR is selectively activated to increase the protein folding 
capacity, while avoiding translational arrest and ER-stress induced apoptosis 
during plasma cell differentiation (Yan et al., 2002) (see section 1.4.4).  
 
This investigation provides an appropriate insight into the role of XBP-1 in 
plasma cell differentiation. A previous, similar study utilised the germinal centre 
derived, EBV infected cell line Raji, which does not provide the correct cellular 
transcriptional environment, namely BCL-6- and BLIMP-1+, for the expression of 
XBP-1s. BLIMP-1 alongside XBP-1 is considered a master regulator of plasma 
cell differentiation and acts upstream of XBP-1 (Shaffer et al., 2002) (Shapiro-
Shelef et al., 2003) (Shaffer et al., 2004). For this reason the BLIMP-1 
dependent, XBP-1 independent genes, for example syndecan-1, were not 
reported by this study; as the expression of these genes is not significantly 
changed by XBP-1s expression in the already BLIMP-1 expressing DEL and 
PEL cell lines. Also, PEL cells have a partially active UPR, where ATF-6 is 
active and the XBP-1 branch is inactive (see section 1.4.4). PEL cells are 
trapped in a proliferating plasmablastic state prior to immunoglobulin secretion 
and therefore may not authentically represent the situation of a normal 
terminally differentiating B-cell. For example, ATF-6 has recently been shown to 
upregulated late during plasma cell differentiation and has many overlapping 
transcriptional targets with XBP-1s (Ma et al., 2010). Therefore many ATF-6 
regulated genes may not appear in the normal temporal order in this analysis as 
they may already be upregulated in PEL (see section 1.3.3.1). To confirm that 
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the results seen are representative of normal plasma cell differentiation further 
study is required.  
 
We could also investigate the role played by lytic KSHV during XBP-1s-induced 
B-cell differentiation. By determining the differentially expressed genes that 
were seen only in the JSC-1 analysis a list of potential novel candidates for 
KSHV host gene regulation was identified, providing prospective insights into 
KSHV biology (see section 5.2.5 and Figure 5-9). The functional annotations of 
these genes were related to processes concerned with cell proliferation and cell 
cycle. Previous gene expression analysis between KSHV negative lymphoma 
and PEL identified similar results, with many genes associated with the MAPK 
pathway being upregulated in KSHV positive PEL (Fan et al., 2005).  
 
The host cell response seen to KSHV lytic replication will be highly dependent 
on the cell-type infected. For example the host response to KSHV reactivation 
in PEL may be very different to that in endothelial cells; as indicated by the lack 
of dramatic host shut-off seen in this study compared to that of KSHV infected 
TIME cells (Glaunsinger et al., 2005). Cell-type specific patterns of cellular 
genes were previously observed during a study of host gene induction in 
response to KSHV infection of endothelial, fibroblasts and B-cells (Naranatt et 
al., 2004). These differences will depend on the KSHV viral genes expressed as 
well as the biology and outcome of infection in these cell types. Differences in 
the host response would also be expected between studies examining changes 
seen on initial KSHV infection and those caused by reactivation.  The 
transcriptional response to XBP-1s has also been shown to be cell-type 
dependent when secretory cells were compared to non-secretory cell types 
(Acosta-Alvear et al., 2007). However, many genes in this study and in previous 
studies overlap with our data suggesting a conserved host response to XBP-1s 
expression and KSHV reactivation.  
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6 General Discussion 
The balance between latent and lytic replication is an important characteristic of 
herpesvirus biology and is necessary for persistent infection of the host. This is 
achieved by careful adaptation to the host, to facilitate exploitation of pre-
existing cellular pathways in order to promote each stage of the virus life cycle. 
Latency is maintained by a variety of mechanisms employed by the virus to 
prevent detection by the host immune system (see section 1.1.12.). However, 
lytic replication is required to allow virus propagation within the host, and 
transmission to new hosts. Therefore, the switch between these phases must 
be tightly controlled to facilitate reactivation only in response to appropriate 
stimuli in the correct environment. In KSHV the expression of RTA, the ‘lytic 
switch’ protein, is highly regulated to provide the required level of life cycle 
phase control.  
 
KSHV infects B-cells and we have demonstrated that reactivation is linked to 
plasma cell differentiation (Wilson et al., 2007). This is achieved by the direct 
activation of RTA by XBP-1s, a key transcription factor of the UPR (see 
chapter 3) (Dalton-Griffin et al., 2009). KSHV exploits the expansion of 
secretory apparatus in the absence of translational arrest, the physiological 
UPR that is associated with the terminal differentiation of B-cells to plasma 
cells. This situation provides an appropriate cellular environment for KSHV 
reactivation that assists efficient lytic replication and virion production at a 
suitable site for transmission, the lymphoid tissue of the oral mucosa.  
 
Importantly, this mechanism of lytic reactivation appears to be conserved 
across herpesviruses, with a similar mechanism proposed, in this work, for 
other Rhadinoviruses, and for EBV by others (Laichalk and Thorley-Lawson, 
2005) (Sun and Thorley-Lawson, 2007) (Bhende et al., 2007) (McDonald et al., 
2010).  Recently, reactivation from latency of the murine gamma-herpesvirus 68 
(MHV68) was associated with plasma cell differentiation (Collins et al., 2009). 
Using the same system the MHV68 latency associated protein, M2, was shown 
to be capable of driving plasma cell differentiation. One proposed mechanism of 
M2-induced reactivation is the upregulation of BLIMP-1, the master regulator of 
plasma cell differentiation. Studies, again using the mouse model MHV68, have 
shown that BLIMP-1 is important for ‘episodic’ reactivation, as B-cells terminally 
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differentiate, and this is required to establish and ‘renew latency reservoirs’ for 
maintenance as well as a sustained humoral response (Siegel et al., 2010). 
These findings not only highlight the importance of this process in gamma-
herpesvirus replication but also that it can be controlled by the virus itself (Liang 
et al., 2009). No M2 or ‘reactivation conditioner’ homologue has been identified 
in KSHV, however, a gene product with conserved function could explain why 
PEL cells are blocked at the plasmablast stage of B-cell differentiation.  
However, our data provides an indication that lytic replication of KSHV has an 
effect on the cellular gene expression profile during plasma cell differentiation, 
suggesting that KSHV manipulates this process further to achieve effective 
reactivation.  
 
The UPR is a stress response that in the context of plasma cell differentiation 
acts in a physiological manner to allow the cell to function as a factory for 
antibody production. However, the UPR can also be activated in response to a 
variety of other cellular insults that lead to the accumulation of misfolded 
proteins, for example hypoxia (see section 1.3). It is therefore possible that 
many other cellular stresses may induce KSHV reactivation, by inducing XBP-
1s or related ‘stress’ transcription factors’, and this warrants further 
investigation.  
 
Here we have shown that the RTA promoter contains response elements to the 
cellular stress inducible factors XBP-1s and HIF-1α, and responds directly to 
both. These transcription factors have been shown to have important and 
overlapping roles in both the response to cellular stress and normal 
development. It would be interesting to explore further the degree of overlap in 
their regulation of gene expression, as they share a response element core 
sequence ‘ACGT’. This could lead to the possible identification of other 
convergent roles for these two stress-inducible factors.  
 
The virus-host interactions outlined in this study are fundamental to KSHV 
biology and may be used to identify and explain potential therapeutic strategies 
for KSHV-associated disease.  
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Appendix 
 
Name Protein Marker/Tag Source 
pCDNA3 HIF-1α HIF-1 α None Kind gift from Peter Ratcliffe 
(Raval et al., 2005) 
pSIN-HABN-HIF-1 
α/ 
pSIN-HA-HIF-1 α 
HIF-1 α NTD HA Tag Backbone provided by Ed 
Tsao. HIF-1 α subcloned by 
candidate 
p50LUC 4099bp of the 
ORF50 promoter 
including the first 
exon, intron and 
first seven codons 
of second exon  
Luciferase reporter 
construct 
Derived from DsRed reporter 
constructs from Sam Wilson 
(Wilson et al., 2007) 
p50MUTLUC Mutated version 
of above see 
Figure 3-8 
Luciferase reporter 
construct 
As above 
pSIN-BNHA-
DNRTA/ 
pSIN-DNRTA 
C terminal 
truncated RTA 
(dominant 
negative) 
CTD-HA Tag Backbone provided by Ed 
Tsao. RTA truncated by 
PCR and  subcloned by 
candidate 
pDUAL-DNRTA-
Cherry 
C terminal 
truncated RTA 
(dominant 
negative) 
mCherry Backbone provided by David 
Escors. RTA truncated by 
PCR and  subcloned by 
candidate 
pHR-SIN-CSPW shRNA 
(-HIF-1α/-RTA/-
XBP-1/-GFP) 
Puromycin 
acetylase 
Backbone modified from 
CSGW by Sam Wilson. 
shRNA designed and cloned 
into EcoR1 site by candidate 
pHR-SIN-CSHW shRNA 
(-HIF-1α/-RTA/-
XBP-1/-GFP) 
Hygromycin 
phosphotransferase
Backbone modified from 
CSGW by Sam Wilson. 
shRNA designed and cloned 
into EcoR1 site by candidate 
pXBPsIG XBP-1s eGFP/ His Tag Generous gift of C. 
Tsantoulas generated under 
supervision of Sam Wilson 
(Wilson et al., 2007). 
CTDHIS XBP-1s XBP-1s His Tag Kind gift from Sam Wilson 
pDUAL-XBP-1s -
Cherry 
XBP-1s mCherry Kind gift from Ed Tsao 
pCMV RTA RTA None Generously supplied by 
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Adrian Whitehouse (Wilson 
et al., 2007) 
pSIN-BNHA-kRTA FL RTA HA Tag Kind gift from Ed Tsao 
pSIN-BNHA-
GFP/pSIN-GFP 
GFP HA Tag Kind gift from Ed Tsao 
pRpluc1-3087+s 3kb sequence 
upstream of RTA 
transcriptional 
start site and 1kb 
splice sequence 
of RTA  
Luciferase reporter 
construct 
Kind gift from Erle Robinson 
(Cai et al., 2006a) 
pRpluc1115-1327 Contains the RTA 
promoter 
sequence 
containing HRE2 
only 
Luciferase reporter 
construct 
Kind gift from Erle Robinson 
(Cai et al., 2006a) 
pRpluc1-550 Contains the RTA 
promoter 
sequence 
containing 
HRE4/XRE only 
Luciferase reporter 
construct 
Kind gift from Erle Robinson 
(Cai et al., 2006a) 
 
